ࡱ> | c d e f g h i j k l m n o p q r s t u v w x y z {  \pL Ba==?'8X@"1Arial1Arial1Arial1Arial1Arial1<Arial @ @  @ @  @ @  @ @  @ @  @ @  @ @  @ @  @ @  @ @  @ @  @ @  @ @  @ @  @ @  @ @ , @ @ * @ @  @ @ + @ @ )@ @ X@ @  `&patent_peptides" |"DRAVP_IDSequenceSequence_LengthNameSourceTarget_Organism Patent_Type Patent_NoPublication_Date Family_Info Patent_TitleCommentAbstract Other_link Connectives DRAVPa1672EAQSQEVKNW MTETLLVQNA N%Sequence 2 from Patent US 20090281041 Homo sapiensHIVPatent ApplicationUS 2009/0281041 A1 2009-11-12CA 2725227 A1##WO 2009/137532 A1##AU 2009/244400 A1##US 2009/0281041 A1##AU 2009/244400 A2##EP 2283033 A1##JP 2011522796 A##US 8324153 B2##AU 2009/244400 B2##US 2013/0059776 A1##US 8933019 B2#Antiviral Cell-Penetrating PeptidesNo cooments found in patentdDisclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.Anti-HIV DRAVPa1673AQEVKNWMTETLLVA%Sequence 3 from Patent US 20090281041Synthetic construct DRAVPa1671KRKKRRHR&Sequence 94 from Patent US 20090258815 Herpes viruseUS 2009/0258815 A1 2009-10-15TWO 2007/099993 A1##JP 2007230903 A##US 2009/0258815 A1##JP 4831410 B2##US 8138146 B2%Antiviral Peptide and Antiviral AgentDisclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.Anti-Herpes viruse DRAVPa1670 KKEKKKSKK&Sequence 93 from Patent US 20090258815 DRAVPa1669PQSRKKLR&Sequence 92 from Patent US 20090258815 DRAVPa1668KHRKHPG&Sequence 91 from Patent US 20090258815Saccharomyces cerevisiae DRAVPa1667KTRKHRG&Sequence 90 from Patent US 20090258815 DRAVPa1666 IKYFKKFPKD&Sequence 89 from Patent US 20090258815 DRAVPa1665 SKRVAKRKL&Sequence 88 from Patent US 20090258815 DRAVPa1664PQPKKKP&Sequence 87 from Patent US 20090258815 DRAVPa1663PPQKKIKS&Sequence 86 from Patent US 20090258815 DRAVPa1662PLLKKIKQ&Sequence 85 from Patent US 20090258815 DRAVPa1661 EEDGPQKKKRRL&Sequence 84 from Patent US 20090258815Polyomavirus sp. DRAVPa1660PNKKKRK&Sequence 83 from Patent US 20090258815Simian virus 40 DRAVPa1659APTKRKGS&Sequence 82 from Patent US 20090258815 DRAVPa1658VSRKRPR&Sequence 81 from Patent US 20090258815 DRAVPa1657PKKARED&Sequence 80 from Patent US 20090258815 DRAVPa1656 MNKIPIKDLLNPG&Sequence 79 from Patent US 20090258815 DRAVPa1655KRPAEDMEEEQAFKRSR&Sequence 78 from Patent US 20090258815 DRAVPa1654 PAAKRVKLD&Sequence 77 from Patent US 20090258815 DRAVPa1653YNNQSSNFGPMKGGN&Sequence 76 from Patent US 20090258815 DRAVPa1652KRKKEMANKSAPEAKKKK&Sequence 75 from Patent US 20090258815 Gallus gallus DRAVPa1651KRPAATKKAGQAKKKK&Sequence 74 from Patent US 20090258815 Xenopus sp. DRAVPa1649 EYLSRKGKLEL&Sequence 72 from Patent US 20090258815Agrobacterium tumefaciens DRAVPa1650PKRPRDRHDGELGGRKRARG&Sequence 73 from Patent US 20090258815 DRAVPa1647PRGRRQPIPKARQP&Sequence 70 from Patent US 20090258815Hepatitis C virus DRAVPa1648KRSAEGGNPPKPLKKLR&Sequence 71 from Patent US 20090258815 DRAVPa1645KVNSRKRRKEVPGPNGATEED&Sequence 68 from Patent US 20090258815 Rattus sp. DRAVPa1646PRRGPR&Sequence 69 from Patent US 20090258815 DRAVPa1643 VNEAFETLKRC&Sequence 66 from Patent US 20090258815 DRAVPa1644MPTEERVRKRKESNRESARRSRYRKAAHLK&Sequence 67 from Patent US 20090258815Zea mays DRAVPa1642 CKRKTTNADRRKA&Sequence 65 from Patent US 20090258815 DRAVPa1640LKRKLQR&Sequence 63 from Patent US 20090258815avian neuroretina DRAVPa1641RRKGKEK&Sequence 64 from Patent US 20090258815 DRAVPa1638RKRRTKK&Sequence 61 from Patent US 20090258815Arabidopsis sp. DRAVPa1639 SDKKVRSRLIECA&Sequence 62 from Patent US 20090258815Thermoplasma acidophilum DRAVPa1636 REKKEKEQKEKCA&Sequence 59 from Patent US 20090258815 DRAVPa1637< LEKKVKKKFDWCA&Sequence 60 from Patent US 20090258815 DRAVPa1635GRKRKKRT&Sequence 58 from Patent US 20090258815 DRAVPa1633RIRKKLR&Sequence 56 from Patent US 20090258815 Mus musculus DRAVPa1634KRAAEDDEDDDVDTKKQK&Sequence 57 from Patent US 20090258815 DRAVPa1631RKRKKMPASQRSKRRKT&Sequence 54 from Patent US 20090258815 DRAVPa1632RAIKRRPGLDFDDDGEGNSKFLR&Sequence 55 from Patent US 20090258815 DRAVPa1630KKQTTLAFKPIKKGKKR&Sequence 53 from Patent US 20090258815 DRAVPa1629RKEWLTNFMEDRRQRKL&Sequence 52 from Patent US 20090258815 DRAVPa1628KKSKKGRQEALERLKKA&Sequence 51 from Patent US 20090258815 DRAVPa1627KRMRNRIAASKCRKRKL&Sequence 50 from Patent US 20090258815 DRAVPa1626RRERNKMAAAKCRNRRR&Sequence 49 from Patent US 20090258815 DRAVPa1625RKCLQAGMNLEARKTKK&Sequence 48 from Patent US 20090258815 DRAVPa1624 PAKRARRGYK&Sequence 47 from Patent US 20090258815canine parvovirus DRAVPa1623RRSMKRK&Sequence 46 from Patent US 20090258815 DRAVPa1622RKRKK&Sequence 45 from Patent US 20090258815 DRAVPa1621KRPRP&Sequence 44 from Patent US 20090258815 adenovirus DRAVPa1620 LKDVRKRKLGPGH&Sequence 43 from Patent US 20090258815epstein-barr virus DRAVPa1619 YKRPCKRSFIRFI&Sequence 42 from Patent US 20090258815 DRAVPa1618 PPRKKRTVV&Sequence 41 from Patent US 20090258815 DRAVPa1617RKRR&Sequence 40 from Patent US 20090258815 DRAVPa1616PRRRK&Sequence 39 from Patent US 20090258815 DRAVPa1615KRPMNAFIVWAQAARRK&Sequence 38 from Patent US 20090258815 DRAVPa1614RPRRK&Sequence 37 from Patent US 20090258815 DRAVPa1613KRPMNAFIVWSRDQRRK&Sequence 36 from Patent US 20090258815 DRAVPa1612MPKTRRRPRRSQRKRPPT&Sequence 35 from Patent US 20090258815 DRAVPa1611 RQARRNRRRRWR&Sequence 34 from Patent US 20090258815 DRAVPa1610 RKKRRQRRR&Sequence 33 from Patent US 20090258815 DRAVPa1609 APKRKSGVSKC&Sequence 32 from Patent US 20090258815 DRAVPa1608KDCVINKHHRNRCQYCRLQR&Sequence 31 from Patent US 20090258815 DRAVPa1607 PPRIYPQLPSAPT&Sequence 30 from Patent US 20090258815Borna disease virus DRAVPa1606PRPRKIPR&Sequence 29 from Patent US 20090258815 DRAVPa1605KKKKKEEEGEGKKK&Sequence 28 from Patent US 20090258815 DRAVPa1604KVTKRKHDNEGSGSKRPK&Sequence 27 from Patent US 20090258815 DRAVPa1603 KKKRRSREK&Sequence 26 from Patent US 20090258815Drosophila sp. DRAVPa1602 KKKKRKREK&Sequence 25 from Patent US 20090258815 DRAVPa1601CYGSKNTGAKKRKIDDA&Sequence 24 from Patent US 20090258815 DRAVPa1600 PYLNKRKGKP&Sequence 23 from Patent US 20090258815 DRAVPa1599 PPVKRERTS&Sequence 22 from Patent US 20090258815 DRAVPa1598RKRRR&Sequence 21 from Patent US 20090258815 DRAVPa1597RGRRRRQR&Sequence 20 from Patent US 20090258815 DRAVPa1596KAKRQR&Sequence 19 from Patent US 20090258815avian reticuloendothelios DRAVPa1595GKKRSKA&Sequence 18 from Patent US 20090258815 DRAVPa1594PKKKRKV&Sequence 17 from Patent US 20090258815 Simian virus DRAVPa1593KRPACTLKPECVQQLLVCSQEAKK&Sequence 16 from Patent US 20090258815 DRAVPa1592RVHPYQR&Sequence 15 from Patent US 20090258815 DRAVPa1591RRMKWKK&Sequence 14 from Patent US 20090258815 DRAVPa1590RKKKRKVLALKAGLDI&Sequence 13 from Patent US 20090258815 DRAVPa1589YGRKKRRQRRRLPPLERLTLD&Sequence 12 from Patent US 20090258815 DRAVPa1588LPPLERLTLDRQARRNRRRRWR&Sequence 11 from Patent US 20090258815 DRAVPa1587RQARRNRRRRWRLPPLERLTLD&Sequence 10 from Patent US 20090258815 DRAVPa1586 LSAQLYSSLSLD%Sequence 9 from Patent US 20090258815Human T-cell lymphotropic DRAVPa1585 LPPDLRLTLD%Sequence 8 from Patent US 20090258815Human immunodeficiency virus DRAVPa1584 LALKLAGLDI%Sequence 7 from Patent US 20090258815 DRAVPa1583 LPPLERLTLD%Sequence 6 from Patent US 20090258815 DRAVPa1582 YGRKKRRQRRR%Sequence 5 from Patent US 20090258815 DRAVPa1581RKKKRKV%Sequence 4 from Patent US 20090258815 DRAVPa1580%Sequence 3 from Patent US 20090258815 DRAVPa1579%Sequence 2 from Patent US 20090258815 DRAVPa1578%Sequence 1 from Patent US 20090258815 DRAVPa1577 RLLLRLLYGY&Sequence 27 from Patent US 20090215699US 2009/0215699 A1 2009-08-27CCA 2592888 A1##WO 2006/072579 A1##EP 1838333 A1##US 2009/02156< 99 A1*Pharmaceutically Active Antiviral PeptidesAThe inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects. DRAVPa1575 RLLLRYLLGY&Sequence 25 from Patent US 20090215699 DRAVPa1576 RLLLRLYLGY&Sequence 26 from Patent US 20090215699 DRAVPa1574 RLLYRLLLGY&Sequence 24 from Patent US 20090215699 DRAVPa1572 RYLLRLLLGY&Sequence 22 from Patent US 20090215699 DRAVPa1573 RLYLRLLLGY&Sequence 23 from Patent US 20090215699 DRAVPa1571 RLLLRLLWGY&Sequence 21 from Patent US 20090215699 DRAVPa1568 RLLWRLLLGY&Sequence 18 from Patent US 20090215699 DRAVPa1569 RLLLRWLLGY&Sequence 19 from Patent US 20090215699 DRAVPa1570 RLLLRLWLGY&Sequence 20 from Patent US 20090215699 DRAVPa1565 RLLLRLLIGY&Sequence 15 from Patent US 20090215699 DRAVPa1566 RWLLRLLLGY&Sequence 16 from Patent US 20090215699 DRAVPa1567 RLWLRLLLGY&Sequence 17 from Patent US 20090215699 DRAVPa1562 RLLLRLVLGY&Sequence 12 from Patent US 20090215699 DRAVPa1563 RLLLRLILGY&Sequence 13 from Patent US 20090215699 DRAVPa1564 RLLLRLLVGY&Sequence 14 from Patent US 20090215699 DRAVPa1559 RLLIRLLLGY%Sequence 9 from Patent US 20090215699 DRAVPa1560 RLLLRVLLGY&Sequence 10 from Patent US 20090215699 DRAVPa1561 RLLLRILLGY&Sequence 11 from Patent US 20090215699 DRAVPa1557 RLILRLLLGY%Sequence 7 from Patent US 20090215699 DRAVPa1558 RLLVRLLLGY%Sequence 8 from Patent US 20090215699 DRAVPa1554 RVLLRLLLGY%Sequence 4 from Patent US 20090215699 DRAVPa1555 RILLRLLLGY%Sequence 5 from Patent US 20090215699 DRAVPa1556 RLVLRLLLGY%Sequence 6 from Patent US 20090215699 DRAVPa1553 RLLLRLLLGY%Sequence 3 from Patent US 20090215699 DRAVPa1552SGSWLRDDWDWECTVLTDDKTWLQSKL&Sequence 91 from Patent US 20090105151HCVUS 2009/0105151 A1 2009-04-23GWO 2009/014615 A2##US 2009/0105151 A1##WO 2009/014615 A3##US 8728793 B2BAmphipathic Alpha-Helical Peptide Compositions as Antiviral AgentsThe peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV89), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses.The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.Anti-HCV DRAVPa1551SGSWLRDDWDWECTVLTDDKTWLQSKLDYKD&Sequence 90 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV88), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1550SGSWLRDVWDWICTVLTDFKTWLQSKLDYKD&Sequence 89 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV87), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1549ELGFQPGLKVAQHLAYPVPDVP&Sequence 88 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infec< tion, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV86), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1548LCLAGRGLQEAEGLLLELLSEHHPLLDV&Sequence 87 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV85), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1547 SWLRDVWDWIC&Sequence 86 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV84), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1546 DVWDWICTVLTD&Sequence 85 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV83), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1545 LRDVWDWICT&Sequence 84 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV82), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1544LRDVWDWICTVLTDFKT&Sequence 83 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV81), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1543IEQGMMLAEQFKQKALGLLQTASRHAEV&Sequence 81 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV80), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1542DVRCHARKAVAHINSVWKD&Sequence 80 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV79), CMV, EBV, < etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1541QDVLKEVKAAASKVKANLLSVEE&Sequence 79 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV78), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1540SGSWLRDVWDWICTVLTDFKTWLQSKLDYK&Sequence 77 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV77), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1539SWLRDIWDWVCTVLSDF&Sequence 76 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV76), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1538SWLYDIVNWVCTVLADF&Sequence 75 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV75), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1537SWLWDVWDWVLHVLSDF&Sequence 74 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV74), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1536SWLHDIWDWVCIVLSDF&Sequence 73 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV73), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1535SWLRTIWDWVCSVLADF&Sequence 72 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV72), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1534SWLRIIWDWVCSWSDFK&Sequence 71 from Patent US 20090105151The peptide effects viral envelope disruption, which serves<  to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV71), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1533SWLRDIWEWVLSILTDF&Sequence 70 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV70), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1532SWLRDVWDWVCTILTDF&Sequence 69 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV69), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1531SWLRDVWDWICTVLTDF&Sequence 68 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV68), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1530SWLRDIWDWVCTVLSD&Sequence 67 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV67), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1529SWLYDIVNWVCTVLAD&Sequence 66 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV66), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1528SWLWDVWDWVLHVLSD&Sequence 65 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV65), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1527SWLHDIWDWVCIVLSD&Sequence 64 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV64< ), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1526SWLRTIWDWVCSVLAD&Sequence 63 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV63), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1525SWLRIIWDWVCSWSDF&Sequence 62 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV62), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1524SWLRDIWEWVLSILTD&Sequence 61 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV61), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1523SWLRDVWDWVCTILTD&Sequence 60 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV60), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1522SWLRDVWDWICTVLTD&Sequence 59 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV59), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1521SWLRDIWDWVCTVLS&Sequence 58 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV58), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1520SWLYDIVNWVCTVLA&Sequence 57 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV57), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1519SWLWDVWDWVLHVLS&Sequence 56 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral<  infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV56), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1518SWLHDIWDWVCIVLS&Sequence 55 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV55), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1517SWLRTIWDWVCSVLA&Sequence 54 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV54), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1516SWLRIIWDWVCSWSD&Sequence 53 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV53), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1515SWLRDIWEWVLSILT&Sequence 52 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV52), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1514SWLRDVWDWVCTILT&Sequence 51 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV51), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1513SWLRDVWDWICTVLT&Sequence 50 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV50), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1512GSWLRDIWDWVCTVLSDFRVWLKSKL&Sequence 49 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV49), CMV, EBV, etc< .), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1511GSWLYDIVNWVCTVLADFKLWLGAKI&Sequence 48 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV48), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1510GSWLWDVWDWVLHVLSDFKTCLKAKF&Sequence 47 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV47), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1509GSWLHDIWDWVCIVLSDFKTWLSAKI&Sequence 46 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV46), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1508GSWLRTIWDWVCSVLADFKAWLSAKI&Sequence 45 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV45), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1507GSWLRIIWDWVCSWSDFKTWLSAKI&Sequence 44 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV44), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1506GSWLRDIWEWVLSILTDFKNWLSAKL&Sequence 43 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV43), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1505GSWLRDVWDWVCTILTDFKNWLTSKL&Sequence 42 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV42), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1504GSWLRDVWDWICTVLTDFKTWLQSKL&Sequence 41 from Patent US 20090105151The peptid< e effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV41), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1503SGSWLRDIWDWVCTVLSDFRVWLKSKL&Sequence 40 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV40), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1502SGSWLYDIVNWVCTVLADFKLWLGAKI&Sequence 39 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV39), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1501SGSWLWDVWDWVLHVLSDFKTCLKAKF&Sequence 38 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV38), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1500SGSWLHDIWDWVCIVLSDFKTWLSAKI&Sequence 37 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV37), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1499SGSWLRTIWDWVCSVLADFKAWLSAKI&Sequence 36 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV36), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1498SGSWLRIIWDWVCSWSDFKTWLSAKI&Sequence 35 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV35), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1497SGSWLRDIWEWVLSILTDFKNWLSAKL&Sequence 34 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more o< f the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV34), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1496SGSWLRDVWDWVCTILTDFKNWLTSKL&Sequence 33 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV33), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1495SGSWLRDVWDWICTVLTDFKTWLQSKL&Sequence 32 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV32), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1494SGSLRDIWDWICEVLSDFKTWLKA&Sequence 31 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV31), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1493SWLRDIWDWVCTVLSDFRVWLKSKL&Sequence 30 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV30), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1492SWLYDIVNWVCTVLADFKLWLGAKI&Sequence 29 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV29), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1491SWLWDVWDWVLHVLSDFKTCLKAKF&Sequence 28 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV28), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1490SWLHDIWDWVCIVLSDFKTWLSAKI&Sequence 27 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV27), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), < togaviruses, flaviviruses and hepadnaviruses. DRAVPa1489SWLRTIWDWVCSVLADFKAWLSAKI&Sequence 26 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV26), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1488SWLRIIWDWVCSWSDFKTWLSAKI&Sequence 25 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV25), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1487SWLRDIWEWVLSILTDFKNWLSAKL&Sequence 24 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV24), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1486SWLRDVWDWVCTILTDFKNWLTSKL&Sequence 23 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV23), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1485SWLRDVWDWICTVLTDFKTWLQSKL&Sequence 22 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV22), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1484WLRDIWDWVCTVLSDFRVWLKSKL&Sequence 21 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV21), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1483WLYDIVNWVCTVLADFKLWLGAKI&Sequence 20 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV20), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1482WLWDVWDWVLHVLSDFKTCLKAKF&Sequence 19 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit vir< al replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV19), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1481WLHDIWDWVCIVLSDFKTWLSAKI&Sequence 18 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV18), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1480WLRTIWDWVCSVLADFKAWLSAKI&Sequence 17 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV17), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1479WLRIIWDWVCSVVSDFKTWLSAKI&Sequence 16 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV16), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1478WLRDIWEWVLSILTDFKNWLSAKL&Sequence 15 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV15), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1477WLRDVWDWVCTILTDFKNWLTSKL&Sequence 14 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV14), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1476WLRDVWDWICTVLTDFKTWLQSKL&Sequence 13 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV13), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1475LRDIWDWICEVLSDFKTWLKA&Sequence 12 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., H< SV1, HSV12), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1474SWLRDIWDWICEVL&Sequence 11 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV11), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPe01079 DRAVPa1472SWLYDIVNWVCTVC%Sequence 9 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV9), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1473SWLRDIWDWVCTVC&Sequence 10 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV10), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1470SWLHDIWDWVCIVC%Sequence 7 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV7), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1471SWLWDVWDWVLHVL%Sequence 8 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV8), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1468SWLRIIWDWVCSWC%Sequence 5 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV5), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1469SWLRTIWDWVCSVC%Sequence 6 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV6), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1466SWLRDVWDWVCTIL%Sequence 3 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral < infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV3), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1467SWLRDIWEWVLSIL%Sequence 4 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV4), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1465SWLRDVWDWICTVL%Sequence 2 from Patent US 20090105151The peptide effects viral envelope disruption, which serves to inhibit viral infection, inhibit viral replication, reduce viral load and reduce infectivity. And It may be used to treat disease caused by one or more of the following viruses: poxvirus, baculovirus, paramyxoviruses, arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV2), CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coronaviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses and hepadnaviruses. DRAVPa1464 PGDVYANGLVA&Sequence 32 from Patent US 20050130884HSVUS 2005/0130884 A1 2005-06-16WO 2001/057072 A2##CA 2399676 A1##AU 2001/036700 A##WO 2001/057072 A3##EP 1272510 A2##JP 2003522185 A##US 2005/0130884 A1##AU 784264 B2##EP 1272510 B1##AT 374208 T##DE 60130641 D1##ES 2293977 T3##US 7DPharmacologically active antiviral peptides and methods of their useThe peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.Anti-HSV DRAVPa1462RRKKAAVA&Sequence 30 from Patent US 20050130884 DRAVPa1463 PGYAGAVVNDL&Sequence 31 from Patent US 20050130884 DRAVPa1461 RRKKAAVAVVP&Sequence 29 from Patent US 20050130884 DRAVPa1460RRKKAAVAVVPAVL&Sequence 28 from Patent US 20050130884 DRAVPa1458RRKKLLAP&Sequence 26 from Patent US 20050130884 DRAVPa1459RRKKAAVALLPAVLLAL&Sequence 27 from Patent US 20050130884 DRAVPe01188 DRAVPa1457 RRKKLLALLAP&Sequence 25 from Patent US 20050130884 DRAVPa1456RRKKPAVLLALLAP&Sequence 24 from Patent US 20050130884 DRAVPe01196 DRAVPa1455RRKKALLPAVLLALLAP&Sequence 23 from Patent US 20050130884 DRAVPe01193 DRAVPa1453 RRKKPAVLLA&Sequence 20 from Patent US 20050130884 DRAVPa1454RRKKPAVLLALLALLA&Sequence 22 from Patent US 20050130884 DRAVPa1452RRKKAVAVAVPAVLLALLAP&Sequence 19 from Patent US 20050130884 DRAVPa1451 RRKKAAVALLP&Sequence 18 from Patent US 20050130884 DRAVPe01190 DRAVPa1449RRKK&Sequence 16 from Patent US 20050130884 DRAVPa1450RRKKLAALPLVLAAPLAVLA&Sequence 17 from Patent US 20050130884 DRAVPa1448DPKGDPKGVTVTVTVTVTGKGDPKPD&Sequence 13 from Patent US 20050130884 DRAVPa1447GWTLNSAGYLLGKINLKALAALAKKIL&Sequence 12 from Patent US 20050130884 DRAVPa1446YGRKKRRQRRRPGDVYANGLVA&Sequence 11 from Patent US 20050130884UThe peptide shows antiviral activity against a wide range of enveloped and non< -enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=67 M). DRAVPa1445YGRKKRRQRRRPGYAGAVVNDL&Sequence 10 from Patent US 20050130884UThe peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=26 M). DRAVPa1443RQIKIWFPNRRMKWKK%Sequence 8 from Patent US 20050130884TThe peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=7 M). DRAVPa1444RQIKIFFPNRRMKFKK%Sequence 9 from Patent US 20050130884UThe peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=40 M). DRAVPa1442RQIKIWFPNRRMKWKKPGYAGAVVNDL%Sequence 7 from Patent US 20050130884WThe peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=9-12 M). DRAVPa1441KLALKLALKALKAALKLA%Sequence 5 from Patent US 20050130884UThe peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=11 M). DRAVPa1440 RRKKPAVLLALLA%Sequence 4 from Patent US 20050130884 DRAVPa1439RRKKAAVALLAVLLALLAPP%Sequence 3 from Patent US 20050130884 DRAVPa1437)QQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ&Sequence 48 from Patent US 20040091855US 2004/00< 91855 A1 2004-05-13dMethod for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefromGThe peptide shows antiviral activity against HIV IIIB.(IC50=0.89 g/ml),Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers. DRAVPa1438RRKKAAVALLPAVLLALLAP%Sequence 1 from Patent US 20050130884XThe peptide shows antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of such enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesiculovirus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, human papilloma virus (HPV) and adenoviruses.The peptide shows antiviral activity against HSV by blocking virus entry(IC50=15-26 M). DRAVPe01185 DRAVPa14363QARQLLSGIVQQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ&Sequence 47 from Patent US 20040091855GThe peptide shows antiviral activity against HIV IIIB.(IC50=0.61 g/ml) DRAVPa1434)QQQNNLLRAIEAQQHLLQLTVWGIKQLAARILAVERYLKDQ&Sequence 45 from Patent US 20040091855No comments found in patent DRAVPa1435)QQQNNLLRAIEAQQHALQLTVWGIKQLQARILAVERYLKDQ&Sequence 46 from Patent US 20040091855 DRAVPa1433)QQQNNLLRAIEAQQHLLQLTVWGIAQLQARILAVERYLKDQ&Sequence 44 from Patent US 20040091855 DRAVPa1432)QQQNNLLRAIEAQQHLLQLTVFGIKQLQARILAVERYLKDQ&Sequence 43 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=1.34 g/ml, IC90=3.81 g/ml) DRAVPa14301QARQLVSGLVQQQNNILRALEATQHLVQLLVWGVKQLQARVLALERYIK&Sequence 41 from Patent US 20040091855ZThe peptide shows antiviral activity against HIV IIIB.(IC50=3.892 g/ml, IC90=14.53 g/ml) DRAVPa14311QIRQLLSGIVQQQNNLLRAIEAIQHLLQLIVWGIKQLQARILAVERYLK&Sequence 42 from Patent US 20040091855[The peptide shows antiviral activity against HIV IIIB.(IC50=13.605 g/ml, IC90=33.56 g/ml) DRAVPa14293QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGVKQLQARILAVERYLKDQ&Sequence 40 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=0.41 g/ml, IC90=1.84 g/ml) DRAVPa14273QARQLLSGIVQQQNNLLRAIEATQHAVQALVWGVKQLQARVLALERYIKDQ&Sequence 38 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=0.18 g/ml, IC90=0.88 g/ml) DRAVPa14283QARQLVSGLVQQQNNILRALEAQQHALQATVWGIKQLQARVLALERYIKDQ&Sequence 39 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=0.26 g/ml, IC90=1.20 g/ml) DRAVPa14261QARQLVSGLVQQQNNILRALEATQHAVQALVWGVRQLQARVLALERYIK&Sequence 37 from Patent US 20040091855GThe peptide shows antiviral activity against HIV IIIB.(IC50<0.78 g/ml) DRAVPa14251QIRQLLSGIVQQQNNLLRAIEAIQHALQAIVWGIKQLQARILAVERYLK&Sequence 36 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=0.73 g/ml, IC90=3.03 g/ml) DRAVPa14233QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLKDQ&Sequence 34 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=0.19 g/ml, IC90=0.62 g/ml) DRAVPa14241QARQLVSGLVQQQNNILRALEATQHAVQALVWGVKQLQARVLALERYIK&Sequence 35 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=0.14 g/ml, IC90=0.69 g/ml) DRAVPa1422$WMEWDREINNYTSLIHSLIEES< QNQQEKNEQELLEL&Sequence 33 from Patent US 20040091855 DRAVPe01974 DRAVPa14201QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVFGIRQLQARILAVERYLK&Sequence 31 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=0.93 g/ml, IC90=3.06 g/ml) DRAVPa14211QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLK&Sequence 32 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=0.59 g/ml, IC90=1.90 g/ml) DRAVPa1419)QQQNNLLRAIEAQQHLLQLTVAGIKQLQARILAVERYLKDQ&Sequence 30 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=0.37 g/ml, IC90=1.00 g/ml) DRAVPa1418)QQQNNLLRAIEAQQHLLQLTAWGIKQLQARILAVERYLKDQ&Sequence 29 from Patent US 20040091855XThe peptide shows antiviral activity against HIV IIIB.(IC50=2.81 g/ml, IC90=5.86 g/ml) DRAVPa1416)QQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ&Sequence 27 from Patent US 20040091855YThe peptide shows antiviral activity against HIV IIIB.(IC50=4.69 g/ml, IC90=23.24 g/ml) DRAVPa1417"RAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ&Sequence 28 from Patent US 20040091855 DRAVPa1415-SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ&Sequence 26 from Patent US 20040091855 DRAVPa14133QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ&Sequence 24 from Patent US 20040091855ZThe peptide shows antiviral activity against HIV IIIB.(IC50=3.73 g/ml, IC90=12.301 g/ml) DRAVPa1414$SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL&Sequence 25 from Patent US 20040091855 DRAVPa14121QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK&Sequence 23 from Patent US 20040091855 DRAVPa1410*QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL&Sequence 21 from Patent US 20040091855 DRAVPa1411/QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERY&Sequence 22 from Patent US 20040091855 DRAVPa1409$LTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG&Sequence 20 from Patent US 20040091855 DRAVPa1407&TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGI&Sequence 18 from Patent US 20040091855 DRAVPa1408,TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQAR&Sequence 19 from Patent US 20040091855 DRAVPa1406%TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG&Sequence 17 from Patent US 20040091855 DRAVPa1404#TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV&Sequence 15 from Patent US 20040091855 DRAVPa1405$TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVW&Sequence 16 from Patent US 20040091855 DRAVPa1403"TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT&Sequence 14 from Patent US 20040091855 DRAVPa1401#MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT&Sequence 12 from Patent US 20040091855 DRAVPa1402$MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV&Sequence 13 from Patent US 20040091855 DRAVPa1400$SMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT&Sequence 11 from Patent US 20040091855 DRAVPa1399$RSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL&Sequence 10 from Patent US 20040091855 DRAVPa13972GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI%Sequence 8 from Patent US 20040091855 DRAVPa1398$ARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQ%Sequence 9 from Patent US 20040091855 DRAVPa1396(GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV%Sequence 7 from Patent US 20040091855 DRAVPa1394$GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLL%Sequence 5 from Patent US 20040091855 DRAVPa1395&GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL%Sequence 6 from Patent US 20040091855 DRAVPa13936GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI%Sequence 4 from Patent US 20040091855 DRAVPa1391&NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ%Sequence 2 from Patent US 20040091855 DRAVPa1392+GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT%Sequence 3 from Patent US 20040091855 DRAVPa1389$YQEWERKVDFLEENITALLEEAQIQQEKNMYELQKL)Sequence 80 from Patent US 20100261876 A1US 2010/0261876 A1 2010-10-14CA 2700354 A1##WO 2009/042194 A2##WO 2009/042194 A3##MX 2010003179 A##EP 2201028 A2##KR 20100080812 A##US 2010/0261876 A1##CN 101874038 A##JP 2010540528 A##BR PI0817697 A2=Novel Methods of Synthesis for Therapeutic Antiviral PeptidesProvided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides. DRAVPa1390;TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQLLGI%Sequence 1 from Patent US 20040091855 DRAVP< a1386 EALLRALQE)Sequence 77 from Patent US 20100261876 A1 DRAVPa1387'WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF)Sequence 78 from Patent US 20100261876 A1 DRAVPe00254 DRAVPa1388'YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT)Sequence 79 from Patent US 20100261876 A1 DRAVPa1383 AARIEALLRALQE)Sequence 74 from Patent US 20100261876 A1 DRAVPa1384 ARIEALLRALQE)Sequence 75 from Patent US 20100261876 A1 DRAVPa1385 RIEALLRALQE)Sequence 76 from Patent US 20100261876 A1 DRAVPa1380TTWEAWDRAIAEYA)Sequence 71 from Patent US 20100261876 A1 DRAVPa1381 TYWEAWDRAIAEY)Sequence 72 from Patent US 20100261876 A1 DRAVPa1382EL)Sequence 73 from Patent US 20100261876 A1 DRAVPa1377TTWEAWDRAIAEYAARI)Sequence 68 from Patent US 20100261876 A1 DRAVPa1378TTWEAWDRAIAEYAAR)Sequence 69 from Patent US 20100261876 A1 DRAVPa1379TTWEAWDRAIAEYAA)Sequence 70 from Patent US 20100261876 A1 DRAVPa1374TTWEAWDRAIAEYAARIEALLR)Sequence 65 from Patent US 20100261876 A1 DRAVPa1375TTWEAWDRAIAEYAARIEALL)Sequence 66 from Patent US 20100261876 A1 DRAVPa1376TTWEAWDRAIAEYAARIEA)Sequence 67 from Patent US 20100261876 A1 DRAVPa1371 EQQEKNEAALREL)Sequence 62 from Patent US 20100261876 A1 DRAVPa1372TTWEAWDRAIAEYAARIEALLRALQ)Sequence 63 from Patent US 20100261876 A1 DRAVPa1373TTWEAWDRAIAEYAARIEALLRAL)Sequence 64 from Patent US 20100261876 A1 DRAVPa1368RIEALLRALQEQQEKNEAALRE)Sequence 59 from Patent US 20100261876 A1 DRAVPa1369QEQQEKNEAALREL)Sequence 60 from Patent US 20100261876 A1 DRAVPa1370LQEQQEKNEAALREL)Sequence 61 from Patent US 20100261876 A1 DRAVPa1365AIAEYAARIEALLRAAQEQQEKLEAALREL)Sequence 56 from Patent US 20100261876 A1 DRAVPa1366%TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRE)Sequence 57 from Patent US 20100261876 A1 DRAVPa1367AARIEALLRALQEQQEKNEAALRE)Sequence 58 from Patent US 20100261876 A1 DRAVPa1362EYAARIEALLRAAQEQQEKLEAALREL)Sequence 53 from Patent US 20100261876 A1 DRAVPa1363AEYAARIEALLRAAQEQQEKLEAALREL)Sequence 54 from Patent US 20100261876 A1 DRAVPa1364IAEYAARIEALLRAAQEQQEKLEAALREL)Sequence 55 from Patent US 20100261876 A1 DRAVPa1359ALLRAAQEQQEKLEAALRE)Sequence 50 from Patent US 20100261876 A1 DRAVPa1360ALLRAAQEQQEKLEAALREL)Sequence 51 from Patent US 20100261876 A1/The peptide was modified with amide C-terminus. DRAVPa1361YAARIEALLRAAQEQQEKLEAALREL)Sequence 52 from Patent US 20100261876 A1 DRAVPa1357LRAAQEQQEKLEAALRE)Sequence 48 from Patent US 20100261876 A1 DRAVPa1358LRAALQEQQEKLEAALREL)Sequence 49 from Patent US 20100261876 A1 DRAVPa1354AEYAARIEALLRAAQE)Sequence 45 from Patent US 20100261876 A1 DRAVPa1355IAEYAARIEALLRAAQE)Sequence 46 from Patent US 20100261876 A1 DRAVPa1356AIAEYAARIEALLRAAQE)Sequence 47 from Patent US 20100261876 A1 DRAVPa1351 QQEKLEAALRE)Sequence 42 from Patent US 20100261876 A1 DRAVPa1352 QQEKLEAALREL)Sequence 43 from Patent US 20100261876 A1 DRAVPa1353EYAARIEALLRAAQE)Sequence 44 from Patent US 20100261876 A1 DRAVPa1348AIAEYAARIEALLRALQEQQEKNEAALREL)Sequence 39 from Patent US 20100261876 A1 DRAVPa1349TTWEAWDRAIAEYAARIEALLRALQE)Sequence 40 from Patent US 20100261876 A1 DRAVPa1350YAARIEALLRAAQE)Sequence 41 from Patent US 20100261876 A1 DRAVPa1345EYAARIEALLRALQEQQEKNEAALREL)Sequence 36 from Patent US 20100261876 A1 DRAVPa1346AEYAARIEALLRALQEQQEKNEAALREL)Sequence 37 from Patent US 20100261876 A1 DRAVPa1347IAEYAARIEALLRALQEQQEKNEAALREL)Sequence 38 from Patent US 20100261876 A1 DRAVPa1342ALLRALQEQQEKNEAALRE)Sequence 33 from Patent US 20100261876 A1 DRAVPa1343ALLRALQEQQEKNEAALREL)Sequence 34 from Patent US 20100261876 A1 DRAVPa1344YAARIEALLRALQEQQEKNEAALREL)Sequence 35 from Patent US 20100261876 A1 DRAVPa1339LRALQEQQEKNEAALRE)Sequence 30 from Patent US 20100261876 A1 DRAVPa1340LRALQEQQEKNEAALREL)Sequence 31 from Patent US 20100261876 A1 DRAVPa1341TTWEAWDRAIAEYAARIE)Sequence 32 from Patent US 20100261876 A10The peptide was modified with acetyl N-terminus. DRAVPa1336TTWEAWDR)Sequence 27 from Patent US 20100261876 A1 DRAVPa1337AIAEYAARIEALLRALQE)Sequence 28 from Patent US 20100261876 A1 DRAVPa1338TTWEAWDRAIAEYAARIEAL)Sequence 29 from Patent US 20100261876 A1 DRAVPa< 1333AEYAARIEALLRALQE)Sequence 24 from Patent US 20100261876 A1 DRAVPa1334 TTWEAWDRA)Sequence 25 from Patent US 20100261876 A1 DRAVPa1335IAEYAARIEALLRALQE)Sequence 26 from Patent US 20100261876 A1 DRAVPa1330 TTWEAWDRAIA)Sequence 21 from Patent US 20100261876 A1 DRAVPa1331EYAARIEALLRALQE)Sequence 22 from Patent US 20100261876 A1 DRAVPa1332 TTWEAWDRAI)Sequence 23 from Patent US 20100261876 A1 DRAVPa1327YAARIEALLRALQE)Sequence 18 from Patent US 20100261876 A1 DRAVPa1328 QQEKNEAALRE)Sequence 19 from Patent US 20100261876 A1 DRAVPa1329 QQEKNEAALREL)Sequence 20 from Patent US 20100261876 A1 DRAVPa1325&TTWEAWDRAIAEYAARIEALLRAAQEQQEKIEAALREL)Sequence 15 from Patent US 20100261876 A1 DRAVPa1326 TTWEAWDRAIAE)Sequence 17 from Patent US 20100261876 A1 DRAVPa1322&TTWEAWDRAIAEYAARIEALIRAIQEQQEKLEAALREL)Sequence 12 from Patent US 20100261876 A1 DRAVPa1323&TTWEAWDRAIAEYAARIEALIRALQEQQEKIEAALREL)Sequence 13 from Patent US 20100261876 A1 DRAVPa1324&TTWEAWDRAIAEYAARIEALLRAIQEQQEKNEAALREL)Sequence 14 from Patent US 20100261876 A1 DRAVPa1319&TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALREL(Sequence 9 from Patent US 20100261876 A1dThe peptide shows antiviral activity against HIV-IIIB(IC50<0.10 g/ml) and HIV-Res(IC50<0.10 g/ml). DRAVPa1320&TTWEAWDRAIAEYAARIEALLRAAQEQQEKLEAALREL)Sequence 10 from Patent US 20100261876 A1 DRAVPa1321&TTWEAWDRAIAEYAARIEALIRALQEQQEKLEAALREL)Sequence 11 from Patent US 20100261876 A1 DRAVPa1316&TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAALREL(Sequence 6 from Patent US 20100261876 A1dThe peptide shows antiviral activity against HIV-IIIB(IC50<0.10 g/ml) and HIV-Res(IC50>0.10 g/ml). DRAVPe00262 DRAVPa1317&TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL(Sequence 7 from Patent US 20100261876 A1 DRAVPe00265 DRAVPa1318&TTWEAWDRAIAEYAARIEALLRAAQEQQEKNEAALREL(Sequence 8 from Patent US 20100261876 A1GThe peptide shows antiviral activity against HIV-IIIB(IC50<0.10 g/ml). DRAVPa1314(Sequence 4 from Patent US 20100261876 A1 DRAVPa1315&TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL(Sequence 5 from Patent US 20100261876 A1 DRAVPe00792 DRAVPa1311@WNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF(Sequence 1 from Patent US 20100261876 A1 DRAVPa1312$YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF(Sequence 2 from Patent US 20100261876 A1 DRAVPe00520 DRAVPa1313$MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL(Sequence 3 from Patent US 20100261876 A1 DRAVPe00255 DRAVPa1309 TYICEVEDQKEE$Sequence 10 from Patent US 5447915 AGranted Patent US 5447915 A 1995-09-05[CA 2077088 A1##WO 1991/013088 A1##US 5115098 A##EP 0517792 A1##JP H05503535 A##US 5447915 A%Terminally blocked antiviral peptidesThis invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds. DRAVPa1310XPXLX$Sequence 11 from Patent US 5447915 AxX residues at position 1 and 5 are any amino acid, and can vary from 0 residues to about 100 residues at reach position. DRAVPa1308LKIEDSDTYICEVEDQKEE#Sequence 9 from Patent US 5447915 A DRAVPa1306KWLDAFYKDVAKELEKAF#Sequence 7 from Patent US 5447915 A DRAVPa1307IKILGNQGSTLTKGPYSK#Sequence 8 from Patent US 5447915 A DRAVPa1304ACYCRIPACIAGERRYGTCIYQGRLWAFCC#Sequence 5 from Patent US 5447915 A DRAVPe00299 DRAVPa1305DWLKAFYDKVAEKLKEAF#Sequence 6 from Patent US 5447915 A DRAVPe01095 DRAVPa1303ASTTTNYT#Sequence 4 from Patent US 5447915 A DRAVPa1301TKPKTKPR#Sequence 2 from Patent US 5447915 A DRAVPa1302AKTKPRQQ#Sequence 3 from Patent US 5447915 A DRAVPa1299GTHPSSSAGLKNDLLEN"Sequence 58 from Patent US 56< 16327influenza virus US 5616327 A 1997-04-01|CA 2108263 A1##WO 1992/022575 A1##EP 0590055 A1##JP H06508623 A##US 5616327 A##EP 0590055 B1##DE 69223406 D1##DE 69223406 T29M-protein peptides of influenza virus as antiviral agentsPeptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.Anti-influenza virus DRAVPa1300TKPKTKPK#Sequence 1 from Patent US 5447915 A DRAVPa1297KREITFHGAKEISLS"Sequence 56 from Patent US 5616327 DRAVPa1298EQIADSQHRSHRQMV"Sequence 57 from Patent US 5616327 DRAVPa1295 LTVPSERGLQRRR"Sequence 54 from Patent US 5616327 DRAVPa1296ALNGNGDPNNMDKAVKLY"Sequence 55 from Patent US 5616327 DRAVPa1293CXTCEQIADSQHXSHRQMV"Sequence 52 from Patent US 5616327;The 'X' at position 2 and 13 represent NMe-Ala and NMe-Arg. DRAVPa1294CXTCEQIADSQHXSHXQMV"Sequence 53 from Patent US 5616327YThe 'X' at position 2 represents NMe-Ala and 'X' at position 13 and 16 indicates NMe-Arg. DRAVPa1291CATCEQIADSQHXSHRQMV"Sequence 50 from Patent US 5616327*The 'X' at position 13 represents Nme-Arg. DRAVPa1292CATCEQIADSQHRSHXQMV"Sequence 51 from Patent US 5616327*The 'X' at position 16 represents NMe-Arg. DRAVPa1289"Sequence 48 from Patent US 5616327UThe 'X' at position 2 represents D-Ala and 'X' at position 13 and 16 indicates D-Arg. DRAVPa1290CXTCEQIADSQHRSHRQMV"Sequence 49 from Patent US 5616327)The 'X' at position 2 represents NMe-Ala. DRAVPa1288"Sequence 47 from Patent US 56163277The 'X' at position 2 and 13 represent D-Ala and D-Arg. DRAVPa1286"Sequence 45 from Patent US 5616327(The 'X' at position 13 represents D-Arg. DRAVPa1287"Sequence 46 from Patent US 5616327(The 'X' at position 16 represents D-Arg. DRAVPa1284CATCEQIADSQHRSHRQMI"Sequence 43 from Patent US 5616327 DRAVPa1285"Sequence 44 from Patent US 5616327'The 'X' at position 2 represents D-Ala. DRAVPa1282CATCEQIADSQHRSHRNMV"Sequence 41 from Patent US 5616327 DRAVPa1283CATCEQIADSQHRSHRQML"Sequence 42 from Patent US 5616327 DRAVPa1280CATCEQIADSNHRSHRQMV"Sequence 39 from Patent US 5616327 DRAVPa1281CATCEQIADSQHRTHRQMV"Sequence 40 from Patent US 5616327 DRAVPa1278CATCEQIAESQHRSHRQMV"Sequence 37 from Patent US 5616327 DRAVPa1279CATCEQIADTQHRSHRQMV"Sequence 38 from Patent US 5616327 DRAVPa1276CATCEQLADSQHRSHRQMV"Sequence 35 from Patent US 5616327 DRAVPa1277CATCEQVADSQHRSHRQMV"Sequence 36 from Patent US 5616327 DRAVPa1274CATCDQIADSQHRSHRQMV"Sequence 33 from Patent US 5616327 DRAVPa1275CATCENIADSQHRSHRQMV"Sequence 34 from Patent US 5616327 DRAVPa1272CATCEQIADSQHKSHKQMV"Sequence 31 from Patent US 5616327 DRAVPa1273CASCEQIADSQHRSHRQMV"Sequence 32 from Patent US 5616327 DRAVPa1270CATCEQIADSQHKSHRQMV"Sequence 29 from Patent US 5616327 DRAVPa1271CATCEQIADSQHRSHKQMV"Sequence 30 from Patent US 5616327 DRAVPa1268CATCEQIADSQHRSHRQAV"Sequence 27 from Patent US 5616327 DRAVPa1269CATCEQIADSQHRSHRQMA"Sequence 28 from Patent US 5616327 DRAVPa1267CATCEQIADSQHRSHRAMV"Sequence 26 from Patent US 5616327 DRAVPa1265CATCEQIADSQHRAHRQMV"Sequence 24 from Patent US 5616327 DRAVPa1266CATCEQIADSQHRSHAQMV"Sequence 25 from Patent US 5616327 DRAVPa1263CATCEQIADSAHRSHRQMV"Sequence 22 from Patent US 5616327 DRAVPa1264CATCEQIADSQHASHRQMV"Sequence 23 from Patent US 5616327 DRAVPa1261CATCEQIAASQHRSHRQMV"Sequence 20 from Patent US 5616327 DRAVPa1262CATCEQIADAQHRSHRQMV"Sequence 21 from Patent US 5616327 DRAVPa1259CATCEAIADSQHRSHRQMV"Sequence 18 from Patent US 5616327 DRAVPa1260CATCEQAADSQHRSHRQMV"Sequence 19 from Patent US 5616327 DRAVPa1257CAACEQIADSQHRSHRQMV"Sequence 16 from Patent US 5616327 DRAVPa1258CATCAQIADSQHRSHRQMV"Sequence 17 from Patent US 5616327 DRAVPa1256CATCEQIADSQHRSH< RQMV"Sequence 15 from Patent US 5616327 DRAVPa1255"Sequence 14 from Patent US 5616327EThe peptide was modified with acetyl N-terminus and amide C-terminus. DRAVPa1254CATCEQIADSQHRHRQMV"Sequence 13 from Patent US 5616327 DRAVPa1253"Sequence 12 from Patent US 5616327 DRAVPa1252CACEQIADSQHRSHRQMV"Sequence 11 from Patent US 5616327 DRAVPa1251CTCEQIADSQHRSHRQMV"Sequence 10 from Patent US 5616327 DRAVPa1250CATCADSQHRSHRQMV!Sequence 9 from Patent US 5616327 DRAVPa1249CATCIADSQHRSHRQMV!Sequence 8 from Patent US 5616327 DRAVPa1248CATCQIADSQHRSHRQMV!Sequence 7 from Patent US 5616327 DRAVPa1247CATCEQIADSQHRSH!Sequence 6 from Patent US 5616327 DRAVPa1246CATCEQIADSQHRSHR!Sequence 5 from Patent US 5616327 DRAVPa1245CATCEQIADSQHRSHRQ!Sequence 4 from Patent US 5616327 DRAVPa1244CATCEQIADSQHRSHRQM!Sequence 3 from Patent US 5616327 DRAVPa1243!Sequence 2 from Patent US 5616327 DRAVPa1242!Sequence 1 from Patent US 5616327 DRAVPa1241 APGDEPAPP$Sequence 12 from Patent US 5859187 A US 5859187 A 1999-01-12IT 9019881 D0##GB 9007137 D0##CA 2011884 A1##DE 4010593 A1##FR 2645157 A1##GB 2230011 A##JP H0341094 A##IT 9019881 A1##US 5120639 A##GB 2230011 B##IT 1241092 B##FR 2645157 B1##US 5859187 AAntiviral peptidesDThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=115 M).Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents. DRAVPa1240EETRRMLHRAFDTLA$Sequence 11 from Patent US 5859187 AEThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=32.5 M). DRAVPa1239 AGATAEETA$Sequence 10 from Patent US 5859187 AEThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=88.5 M). DRAVPa1238GATAEETA#Sequence 9 from Patent US 5859187 ADThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=240 M). DRAVPa1237 AGATAEETAA#Sequence 8 from Patent US 5859187 AEThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=56.6 M). DRAVPa1236 AGATAEETAY#Sequence 7 from Patent US 5859187 AEThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=37.5 M). DRAVPa1235 AAAPGDEPAPP#Sequence 6 from Patent US 5859187 ACThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=90 M). DRAVPa1234 AAPGDEPAPP#Sequence 5 from Patent US 5859187 ADThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=152 M). DRAVPa1233#Sequence 4 from Patent US 5859187 ADThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=188 M). DRAVPa1232 APGDEPAPPY#Sequence 3 from Patent US 5859187 ADThe peptide inhibits HSV by UL42 of HSV DNA polymerase(IC50=161 M). DRAVPa1231QVNEKINQSLAFIRKSDELLHNVNAGKST&Sequence 232 from Patent US 6228983 B1 US 6228983 B1 2001-05-08WO 1996/019495 A1##CA 2208420 A1##AU 1996/044734 A##EP 0793675 A1##KR 987000333 A##EP 0793675 A4##AU 714695 B2##US 6013263 A##NZ 300002 A##US 6054265 A##US 6060065 A##US 6068973 A##US 6093794 A##US 62VHuman respiratory syncytial virus peptides with antifusogenic and antiviral activities'The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides. DRAVPa1230ISQVNEKINQSLAFIRKSDELLHNVNAGKST&Sequence 231 from Patent US 6228983 B1 DRAVPa1229FDASISQVNEKINQSLA< FIRKSDEL&Sequence 230 from Patent US 6228983 B1 DRAVPa1228FDASISQVNEKINQSLAFIRKSDELLH&Sequence 229 from Patent US 6228983 B1 DRAVPa1227FDASISQVNEKINQSLAFIRKSDELLHNV&Sequence 228 from Patent US 6228983 B1 DRAVPa1226FDASISQVNEKINQSLAFIRKSDELLHNVNA&Sequence 227 from Patent US 6228983 B1 DRAVPa1225#DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT&Sequence 226 from Patent US 6228983 B1 DRAVPe00912 DRAVPa1224#FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST&Sequence 225 from Patent US 6228983 B1 DRAVPe00911 DRAVPa1223#EFDASISQVNEKINQSLAFIRKSDELLHNVNAGKS&Sequence 224 from Patent US 6228983 B1 DRAVPe00910 DRAVPa1222#DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK&Sequence 223 from Patent US 6228983 B1 DRAVPe00909 DRAVPa1221#SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG&Sequence 222 from Patent US 6228983 B1 DRAVPe00908 DRAVPa1220#PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA&Sequence 221 from Patent US 6228983 B1 DRAVPe00907 DRAVPa1219#FPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN&Sequence 220 from Patent US 6228983 B1 DRAVPe00906 DRAVPa1218#VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV&Sequence 219 from Patent US 6228983 B1 DRAVPe00905 DRAVPa1217#LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHN&Sequence 218 from Patent US 6228983 B1 DRAVPe00904 DRAVPa1216#PLVFPSDEFDASISQVNEKINQSLAFIRKSDELLH&Sequence 217 from Patent US 6228983 B1 DRAVPe00903 DRAVPa1215#DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL&Sequence 216 from Patent US 6228983 B1 DRAVPe00902 DRAVPa1214#YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL&Sequence 215 from Patent US 6228983 B1 DRAVPe00901 DRAVPa1213#FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE&Sequence 214 from Patent US 6228983 B1 DRAVPe00900 DRAVPa1212#INFYDPLVFPSDEFDASISQVNEKINQSLAFIRKS&Sequence 213 from Patent US 6228983 B1 DRAVPe00898 DRAVPa1211#IINFYDPLVFPSDEFDASISQVNEKINQSLAFIRK&Sequence 212 from Patent US 6228983 B1 DRAVPe00897 DRAVPa1210DEFDASISQVNEKINQSLAFIRKSDELL&Sequence 211 from Patent US 6228983 B1 DRAVPa1209#VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV&Sequence 210 from Patent US 6228983 B1 DRAVPa12089PGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTSTGPCRTCMTT&Sequence 209 from Patent US 6228983 B1 DRAVPa1207.PLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSP&Sequence 208 from Patent US 6228983 B1 DRAVPa1206%SENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDLLNF&Sequence 207 from Patent US 6228983 B1 DRAVPa1205#SSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDL&Sequence 206 from Patent US 6228983 B1 DRAVPa1204-LQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHED&Sequence 205 from Patent US 6228983 B1 DRAVPa1203#LLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSI&Sequence 204 from Patent US 6228983 B1 DRAVPa1202-ASRKCRAKFKQLLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDS&Sequence 203 from Patent US 6228983 B1 DRAVPa1201-SELEIKRYKNRVASRKCRAKFQLLQHYREVAAAKSSENDRLRLLL&Sequence 202 from Patent US 6228983 B1 DRAVPa1200?MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWG&Sequence 201 from Patent US 6228983 B1 DRAVPa1199$LSNLLQISNNSDEWLEALEIEHEKWKLTQWQSYEQF&Sequence 200 from Patent US 6228983 B1 DRAVPa1198$LLDNFESTWEQSKELWEQQEISIQNLHKSALQEYWN&Sequence 199 from Patent US 6228983 B1 DRAVPa1197$YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNSF&Sequence 198 from Patent US 6228983 B1 DRAVPa1196$YTSLIHSLIEESQNQQEKNEQELLELDKWASPWNWF&Sequence 197 from Patent US 6228983 B1 DRAVPa1195$YTSLIHSLIEESQNQQEKNEQELLELDKPASLWNWF&Sequence 196 from Patent US 6228983 B1 DRAVPa1194$YTSLIHSLIEESQNQQEKNEQELLEFDKWASLWNWF&Sequence 195 from Patent US 6228983 B1 DRAVPa1193$YTSLIHSLIEESQNQQEKLEQELLELDKWASLWNWF&Sequence 194 from Patent US 6228983 B1 DRAVPa1192$YTSLIHSLIEESQNLQEKNEQELLELDKWASLWNWF&Sequence 193 from Patent US 6228983 B1 DRAVPa1191$YTSLIHSLIEESQNQQEKNEQELLELDKWASLFNFF&Sequence 192 from Patent US 6228983 B1 DRAVPa1190$YTSLIQSLIEESQNQQEKNEQQLLELDKWASLWNWF&Sequence 191 from Patent US 6228983 B1 DRAVPa1189$YTSLIHSLIEESQNQQEKNEQQLLELDKWASLWNWF&Sequence 190 from Patent US 6228983 B1 DRAVPa1188$YTSLIHSLIEESQNQQEKNEQELLELDKWASLANAA&Sequence 189 from Patent US 6228983 B1 DRAVPa1187$YTSLIHSLIQQSQNQQQKNQQQLLQLDKWASLWNWF&Sequence 188 from Patent US 6228983 B1 DRAVPa1186$YTSLIHSLIQESQNQQEKNEQELLELDKWASLWNWF&Sequence 187 from Patent US 6228983 B1 DRAVPa1185$YTSLIHSLIEQSQNQQEK< NEQELLELDKWASLWNWF&Sequence 186 from Patent US 6228983 B1 DRAVPa1184$YTSLIHSLIEESQNQQEKNEQELLELNKWASLWNWF&Sequence 185 from Patent US 6228983 B1 DRAVPa1183$YTSLIHSLIEESQQQQEKNEQELLELDKWASLWNWF&Sequence 184 from Patent US 6228983 B1 DRAVPa1182$YTSLIQSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 183 from Patent US 6228983 B1 DRAVPa1181$YTSLIHSLIEESQNQQEKNQQELLQLDKWASLWNWF&Sequence 182 from Patent US 6228983 B1 DRAVPa1180$YTSLIHSLIEESQNQQEKNEQELLQLDKWASLWNWF&Sequence 181 from Patent US 6228983 B1 DRAVPa1179&Sequence 180 from Patent US 6228983 B1 DRAVPa1178$YTSLIHSLIEESQNQQEKNEQELLELDKWASLANWF&Sequence 179 from Patent US 6228983 B1 DRAVPa1177$YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNAF&Sequence 178 from Patent US 6228983 B1 DRAVPa1176'CGGYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 177 from Patent US 6228983 B1 DRAVPa1175 LELKKWASLWNWF&Sequence 176 from Patent US 6228983 B1 DRAVPa1174 LKLDKWASLWNWF&Sequence 175 from Patent US 6228983 B1 DRAVPa1173 LELDKAASLWNWF&Sequence 174 from Patent US 6228983 B1 DRAVPa1172 LELDKWASAWNWF&Sequence 173 from Patent US 6228983 B1 DRAVPa1171 LELDKWASLWNWA&Sequence 172 from Patent US 6228983 B1 DRAVPa1170 LELDKWASLWNAF&Sequence 171 from Patent US 6228983 B1 DRAVPa1169 LELDKWASLFNFF&Sequence 170 from Patent US 6228983 B1 DRAVPa1168 LELDKWASLANAF&Sequence 169 from Patent US 6228983 B1 DRAVPa1167CLELDKWASLWNFFC&Sequence 168 from Patent US 6228983 B1 DRAVPa1166CLELDKWASLANWFC&Sequence 167 from Patent US 6228983 B1 DRAVPa1165CLELDKWASLWNWFC&Sequence 166 from Patent US 6228983 B1 DRAVPa1164FWNWLSAWKDLELYPGSLELDKWASLWNWF&Sequence 165 from Patent US 6228983 B1 DRAVPa1163#RMKQLEDKVEELLSKNYHLENELELDKWASLWNWF&Sequence 164 from Patent US 6228983 B1 DRAVPa1162FWNWLSAWKDLELKSLLEEVKDELQKMR&Sequence 163 from Patent US 6228983 B1 DRAVPa1161RMKQLEDKVEELLSKLELDKWASLWNWF&Sequence 162 from Patent US 6228983 B1 DRAVPa1160EAAAREAAAREAAARLELDKWASLWNWF&Sequence 161 from Patent US 6228983 B1 DRAVPa11591YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWLIKIFI&Sequence 160 from Patent US 6228983 B1 DRAVPa1158#WMEWDREINNYTSLIGSLIEESQNQQEKNEQELLE&Sequence 159 from Patent US 6228983 B1 DRAVPa11579NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEEQNQQEKNEQELLELDKWASLWNWF&Sequence 158 from Patent US 6228983 B1 DRAVPa1156$TSITLQVRLPLLTRLLNTQIYRVDSISYNIQNREWY&Sequence 157 from Patent US 6228983 B1HPIV3 Anti-HPIV3 DRAVPa1155$YSELTNIFGDNIGSLQEKGIKLQGIASLYRTNITEI&Sequence 156 from Patent US 6228983 B1 DRAVPa1154#DQQIKQYKRLLDRLIIPLYDGLRQKDVIVSNQESN&Sequence 155 from Patent US 6228983 B1 DRAVPa1153RMKQLEDKVEELLSKLEWIRRSNQKLDSI&Sequence 154 from Patent US 6228983 B1 DRAVPa1152#IDISIELNKAKSDLEESKEWIKKSNQKLDSIGNWH&Sequence 153 from Patent US 6228983 B1 DRAVPa1151 EWIRRSNQKLDSI&Sequence 152 from Patent US 6228983 B1 DRAVPa1150LKEAIRDTNKAVQSVQSSIGNLIVAIKS&Sequence 151 from Patent US 6228983 B1 DRAVPa1149AVQSVQSSIGNLIVAIKSVQDYVNKEIV&Sequence 150 from Patent US 6228983 B1 DRAVPa1148IRDTNKAVQSVQSSIGNLIVAIKSVQDY&Sequence 149 from Patent US 6228983 B1 DRAVPa1147#AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA&Sequence 148 from Patent US 6228983 B1 DRAVPa1146#AAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSS&Sequence 147 from Patent US 6228983 B1 DRAVPa1145ATSAQITAAVALVEAKQARSDIEKLKEA&Sequence 146 from Patent US 6228983 B1 DRAVPa1144&Sequence 145 from Patent US 6228983 B1 DRAVPa1143!ASISQVNEKINQSLAFIRKSDELLHNVNAGKST&Sequence 144 from Patent US 6228983 B1 DRAVPa1142!FDASISQVNEKINQSLAFIRKSDELLHNVNAGK&Sequence 143 from Patent US 6228983 B1 DRAVPa1141SLAFIRKSDELLHNVNAGKST&Sequence 142 from Patent US 6228983 B1 DRAVPa1140FDASISQVNEKINQSLAFI&Sequence 141 from Patent US 6228983 B1 DRAVPa1139AFIRKSDELLHNVNAGKST&Sequence 140 from Patent US 6228983 B1 DRAVPa1138RMKQLEDKVEELLSKLAFIRKSDELLHNV&Sequence 139 from Patent US 6228983 B1 DRAVPa1137#PIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR&Sequence 138 from Patent US 6228983 B1 DRAVPa1136$SISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVS&Sequence 137 from Patent US 6228983 B1RSV`The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolec< ular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 g/ml).Anti-RSV DRAVPa1135NDQKKLMSNNVQIVRQQSYSIMSIIKEE&Sequence 136 from Patent US 6228983 B1`The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>500 g/ml). DRAVPa1134#VLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSK&Sequence 135 from Patent US 6228983 B1`The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50=328 g/ml). DRAVPa1133%ASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGV&Sequence 134 from Patent US 6228983 B1 DRAVPa1132LLSTNKAVVSLSNGVSVLTSKVLDLKNY&Sequence 133 from Patent US 6228983 B1 DRAVPa1131VLHLEGEVNKIKSALLSTNKAVVSLSNG&Sequence 132 from Patent US 6228983 B1 DRAVPa1130&Sequence 131 from Patent US 6228983 B1 DRAVPa1129VVSLSNGVSVLTSKVLDLKNYIDKQLL&Sequence 130 from Patent US 6228983 B1 DRAVPa1128$AVSKGYLSALRTGWYTSVITIELSNIKENKXNGTDA&Sequence 129 from Patent US 6228983 B1X represents U,the standard designation for C-abu,a modified cysteine.The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50>100 g/ml). DRAVPa1127#KENKXNGTDAKVKLIKQELDKYKNAVTELQLLMQS&Sequence 128 from Patent US 6228983 B1 DRAVPa1126#SNIKENKXNGTDAKVKLIKQELDKYKNAVTELQLL&Sequence 127 from Patent US 6228983 B1 DRAVPa1125#SVITIELSNIKENKXNGTDAKVKLIKQELDKYKNA&Sequence 126 from Patent US 6228983 B1 DRAVPa1124#TSVITIELSNIKENKXNGTDAKVKLIKQELDKYKN&Sequence 125 from Patent US 6228983 B1 DRAVPa1123#YTSVITIELSNIKENKXNGTDAKVKLIKQELDKYK&Sequence 124 from Patent US 6228983 B1 DRAVPa1122 AFIRKSDELLHNV&Sequence 123 from Patent US 6228983 B1_The N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group.The antiviral activity of peptide on RSV(IC50=26 g/ml). DRAVPa1121VSKGYSALRTGWYTSVITIELSNIKEN&Sequence 122 from Patent US 6228983 B1aThe N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group. The antiviral activity of peptide on RSV(IC50=165 g/ml). DRAVPa1120*IELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 121 from Patent US 6228983 B1aThe N teminal may be modified with an amino group,a hydrophobic group, an acetyl group, a 9-fluorenylmethoxycarbonyl group, or a macromolecular carrier group, and the C terminal may be modified with a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecular carrier group. The antiviral activity of peptide on RSV(IC50>500 g/ml). DRAVPa1119/TWQEWERKVDFLEENITALLEEAQIQQEKNMYELQKLNSWDVFGNWF&Sequence 120 from Patent US 6228983 B1SIVAnti-SIV DRAVPa1118"LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK&Sequence 119 from Patent US 6228983 B1 DRAVPa1117#PDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLED&Sequence 118 from Patent US 6228983 B1 DRAVPe00936 DRAVPa11168YTPNDITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT&Sequence 10< 1 from Patent US 6228983 B1 DRAVPa1115FGTIALGVATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIVP&Sequence 100 from Patent US 6228983 B1 DRAVPa11145GEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT%Sequence 99 from Patent US 6228983 B1 DRAVPa11136ASGVAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLL%Sequence 98 from Patent US 6228983 B1 DRAVPa1112.YTSVITIELSNIKENKCNGAKVKLIKQELDKYKNAVTELQLLMQST%Sequence 97 from Patent US 6228983 B1 DRAVPa1111%Sequence 89 from Patent US 6228983 B1 DRAVPa1110IEKTNEKFHQIEKEFSEVEGRIQDLEKY%Sequence 88 from Patent US 6228983 B1 DRAVPa1109EQKLISEEDLLEKRREQLKHKLEQLRNS%Sequence 87 from Patent US 6228983 B1 DRAVPa1108IARLEEKVKTLKAQNSELASTANMLREQ%Sequence 86 from Patent US 6228983 B1 DRAVPa1107TDTLQAETDQLEDEKSALQTEIANLLKE%Sequence 85 from Patent US 6228983 B1 DRAVPa1106MKQLEDKVEELLSKNYHLENEVARLKKL%Sequence 84 from Patent US 6228983 B1 DRAVPa1105%Sequence 83 from Patent US 6228983 B1MeVAnti-MeV DRAVPa1104"SLERLDVGTNLGNAIAKLEAKELLESSDQILRSM%Sequence 82 from Patent US 6228983 B1 DRAVPa1103"PISLERLDVGTNLGNAIAKLEAKELLESSDQILR%Sequence 81 from Patent US 6228983 B1 DRAVPa1102"PPISLERLDVGTNLGNAIAKLEAKELLESSDQIL%Sequence 80 from Patent US 6228983 B1 DRAVPa1101"GPPISLERLDVGTNLGNAIAKLEAKELLESSDQI%Sequence 79 from Patent US 6228983 B1 DRAVPa1100"LGPPISLERLDVGTNLGNAIAKLEAKELLESSDQ%Sequence 78 from Patent US 6228983 B1 DRAVPa1099"DLGPPISLERLDVGTNLGNAIAKLEAKELLESSD%Sequence 77 from Patent US 6228983 B1 DRAVPa1098"IDLGPPISLERLDVGTNLGNAIAKLEAKELLESS%Sequence 76 from Patent US 6228983 B1 DRAVPa1097"RIDLGPPISLERLDVGTNLGNAIAKLEAKELLES%Sequence 75 from Patent US 6228983 B1 DRAVPa1096"HRIDLGPPISLERLDVGTNLGNAIAKLEAKELLE%Sequence 74 from Patent US 6228983 B1 DRAVPa1095"LHRIDLGPPISLERLDVGTNLGNAIAKLEAKELL%Sequence 73 from Patent US 6228983 B1 DRAVPa1094#FLEENITALLEEAQIQQEKNMYELQKLNSWDVFGN%Sequence 72 from Patent US 6228983 B1 DRAVPa1093#DFLEENITALLEEAQIQQEKNMYELQKLNSWDVFG%Sequence 71 from Patent US 6228983 B1 DRAVPa1092#VDFLEENITALLEEAQIQQEKNMYELQKLNSWDVF%Sequence 70 from Patent US 6228983 B1 DRAVPa1091#KVDFLEENITALLEEAQIQQEKNMYELQKLNSWDV%Sequence 69 from Patent US 6228983 B1 DRAVPa1090#RKVDFLEENITALLEEAQIQQEKNMYELQKLNSWD%Sequence 68 from Patent US 6228983 B1 DRAVPa1089#ERKVDFLEENITALLEEAQIQQEKNMYELQKLNSW%Sequence 67 from Patent US 6228983 B1 DRAVPa1088#WERKVDFLEENITALLEEAQIQQEKNMYELQKLNS%Sequence 66 from Patent US 6228983 B1 DRAVPa1087#EWERKVDFLEENITALLEEAQIQQEKNMYELQKLN%Sequence 65 from Patent US 6228983 B1 DRAVPa1086#QEWERKVDFLEENITALLEEAQIQQEKNMYELQKL%Sequence 64 from Patent US 6228983 B1 DRAVPa1085#WQEWERKVDFLEENITALLEEAQIQQEKNMYELQK%Sequence 63 from Patent US 6228983 B1 DRAVPa1084#AIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV%Sequence 62 from Patent US 6228983 B1 DRAVPa1083#LKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNK%Sequence 61 from Patent US 6228983 B1 DRAVPa1082#KLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVN%Sequence 60 from Patent US 6228983 B1 DRAVPa1081#SDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQ%Sequence 59 from Patent US 6228983 B1 DRAVPa1080#RSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSV%Sequence 58 from Patent US 6228983 B1 DRAVPa1079#ARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKS%Sequence 57 from Patent US 6228983 B1 DRAVPa1078#QARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIK%Sequence 56 from Patent US 6228983 B1 DRAVPa1077#KQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAI%Sequence 55 from Patent US 6228983 B1 DRAVPa1076%Sequence 54 from Patent US 6228983 B1 DRAVPa1075#EAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIV%Sequence 53 from Patent US 6228983 B1 DRAVPa1074#VEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLI%Sequence 52 from Patent US 6228983 B1 DRAVPa1073#LVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNL%Sequence 51 from Patent US 6228983 B1 DRAVPa1072#AVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSI%Sequence 50 from Patent US 6228983 B1 DRAVPa1071#TAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQS%Sequence 49 from Patent US 6228983 B1 DRAVPa1070#ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT%Sequence 48 from Patent US 6228983 B1 DRAVPe00935 DRAVPa1069#IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST%Sequence 47 from Patent US 6228983 B1 DRAVPe00934 DRAVPa1068#SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS< %Sequence 46 from Patent US 6228983 B1 DRAVPe00933 DRAVPa1067#ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS%Sequence 45 from Patent US 6228983 B1 DRAVPe00932 DRAVPa1066#DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ%Sequence 44 from Patent US 6228983 B1 DRAVPe00931 DRAVPa1065#IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH%Sequence 43 from Patent US 6228983 B1 DRAVPe00929 DRAVPa1064#PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW%Sequence 42 from Patent US 6228983 B1 DRAVPe00928 DRAVPa1063#DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN%Sequence 41 from Patent US 6228983 B1 DRAVPe00927 DRAVPa1062#LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG%Sequence 40 from Patent US 6228983 B1 DRAVPe00926 DRAVPa1061#ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI%Sequence 39 from Patent US 6228983 B1 DRAVPe00925 DRAVPa1060#VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS%Sequence 38 from Patent US 6228983 B1 DRAVPe00924 DRAVPa1059#SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD%Sequence 37 from Patent US 6228983 B1 DRAVPe00923 DRAVPa1058#NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL%Sequence 36 from Patent US 6228983 B1 DRAVPe00922 DRAVPa1057#NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK%Sequence 35 from Patent US 6228983 B1 DRAVPe00921 DRAVPa1056#LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ%Sequence 34 from Patent US 6228983 B1 DRAVPe00920 DRAVPa1055#TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN%Sequence 33 from Patent US 6228983 B1 DRAVPe00919 DRAVPa1054!ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ%Sequence 32 from Patent US 6228983 B1 DRAVPa1053!IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK%Sequence 31 from Patent US 6228983 B1 DRAVPa1052!KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID%Sequence 30 from Patent US 6228983 B1 DRAVPa1051!NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI%Sequence 29 from Patent US 6228983 B1 DRAVPa1050!VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY%Sequence 28 from Patent US 6228983 B1 DRAVPa1049!EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN%Sequence 27 from Patent US 6228983 B1 DRAVPa1048!GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK%Sequence 26 from Patent US 6228983 B1 DRAVPa1047!LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD%Sequence 25 from Patent US 6228983 B1 DRAVPa1046!KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS%Sequence 24 from Patent US 6228983 B1 DRAVPa1045!SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT%Sequence 23 from Patent US 6228983 B1 DRAVPa1044!VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL%Sequence 22 from Patent US 6228983 B1 DRAVPa1043!AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV%Sequence 21 from Patent US 6228983 B1 DRAVPa1042!VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS%Sequence 20 from Patent US 6228983 B1 DRAVPa1041"ALGVATSAQITAAVALVEAKQARSDIEKLKEAIR%Sequence 19 from Patent US 6228983 B1 DRAVPa1040#ITLNNSVALDPIDISIELNKAKSDLEESKEWIRRS%Sequence 18 from Patent US 6228983 B1 DRAVPe00918 DRAVPa1039%FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL%Sequence 17 from Patent US 6228983 B1 DRAVPa10380YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST%Sequence 16 from Patent US 6228983 B1 DRAVPa1037&QQLLDVVKRQQEMLRLTVWGTKNLQARVTAIEKYLKDQ%Sequence 10 from Patent US 6228983 B1 DRAVPa1036LQARILAVERYLKDQQQ$Sequence 9 from Patent US 6228983 B1 DRAVPa1035)CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ$Sequence 8 from Patent US 6228983 B1 DRAVPa1034$LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL$Sequence 7 from Patent US 6228983 B1 DRAVPa1033$LEANISKSLEQAQIQQEKNMYELQKLNSWDIFGNWF$Sequence 6 from Patent US 6228983 B1 DRAVPa1032$YTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWF$Sequence 5 from Patent US 6228983 B1 DRAVPa1031$YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF$Sequence 4 from Patent US 6228983 B1 DRAVPa1030$YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF$Sequence 3 from Patent US 6228983 B1 DRAVPa1029$SSESFTLLEQWNNWKLQLAEQWLEQINEKHYLEDIS$Sequence 2 from Patent US 6228983 B1 DRAVPa1028$Sequence 1 from Patent US 6228983 B1 DRAVPa1027%Sequence 44 from Patent US 7432045 B22HSV,HIV,Influenza A Virus,H5 Avian Influenza Virus US 7432045 B2 2008-10-07GWO 2005/060541 A2##US 2005/0203024 A1##WO 2005/060541 A3##US 7432045 B2@Method of inhibiting influenza infection with antiviral peptides The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular st< omatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.AAnti-HSV,Anti-HIV,Influenza A Virus,H5 Avian Anti-influenza virus DRAVPa1026%Sequence 43 from Patent US 7432045 B2 DRAVPa1025 GRKKRRQXXRC%Sequence 42 from Patent US 7432045 B2RThe 'X' at position 8 and 9 represents Norleucine.The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV). DRAVPa1024%Sequence 41 from Patent US 7432045 B2 DRAVPa1023 GRXXRRQRRRC%Sequence 40 from Patent US 7432045 B2RThe 'X' at position 3 and 4 represents Norleucine.The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV). DRAVPa1022 GRKKRRQRRRC%Sequence 39 from Patent US 7432045 B2 DRAVPe01935 DRAVPa1021%Sequence 38 from Patent US 7432045 B2 DRAVPa1020 GRKKRRQRRR%Sequence 37 from Patent US 7432045 B2 DRAVPe01573 DRAVPa1019%Sequence 36 from Patent US 7432045 B2 DRAVPa1018%Sequence 35 from Patent US 7432045 B2 DRAVPa1017LAVLAPGRKKRRQRRRC%Sequence 34 from Patent US 7432045 B2 DRAVPa1016LVLAAPLAVLAPGRKKRRQRRRC%Sequence 33 from Patent US 7432045 B2 DRAVPa1015LAALPLVLAAPLAVLAPGRKKRRQRRRC%Sequence 32 from Patent US 7432045 B2 DRAVPa1014YGRKKRRQRRRPLAALPLVLAAPLAVLA%Sequence 31 from Patent US 7432045 B2 DRAVPa1013GRKKRRQRRRPLAALPLVLAAPLAVLA%Sequence 30 from Patent US 7432045 B2 DRAVPa1012%Sequence 29 from Patent US 7432045 B2 DRAVPa1011%Sequence 28 from Patent US 7432045 B2 DRAVPa1010%Sequence 27 from Patent US 7432045 B2 DRAVPa1009%Sequence 26 from Patent US 7432045 B2 DRAVPa1008%Sequence 25 from Patent US 7432045 B2 DRAVPa1007%Sequence 24 from Patent US 7432045 B2 DRAVPa1006%Sequence 23 from Patent US 7432045 B2 DRAVPa1005%Sequence 22 from Patent US 7432045 B2 DRAVPa1004%Sequence 21 from Patent US 7432045 B2 DRAVPa1003%Sequence 20 from Patent US 7432045 B2 DRAVPa1002%Sequence 19 from Patent US 7432045 B2 DRAVPa1001%Sequence 18 from Patent US 7432045 B2 DRAVPa1000%Sequence 17 from Patent US 7432045 B2 DRAVPa0999%Sequence 16 from Patent US 7432045 B2 DRAVPa0998%Sequence 13 from Patent US 7432045 B2 DRAVPa0997%Sequence 12 from Patent US 7432045 B2 DRAVPa0996%Sequence 11 from Patent US 7432045 B2YThe antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV< ), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=67 m). DRAVPa0995%Sequence 10 from Patent US 7432045 B2The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=26 m) and antifree virus activity(IC50=8 m). DRAVPa0994$Sequence 9 from Patent US 7432045 B2The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=40 m) and antifree virus activity(IC50=34 m). DRAVPa0993$Sequence 8 from Patent US 7432045 B2XThe antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=7 m). DRAVPa0992$Sequence 7 from Patent US 7432045 B2The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=9-12 m) and antifree virus activity(IC50=6 m). DRAVPa0991$Sequence 6 from Patent US 7432045 B2YThe antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=23 m). DRAVPa0990$Sequence 5 from Patent US 7432045 B2The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped vir< uses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=11 m) and antifree virus activity(IC50=4.5 m). DRAVPa0989$Sequence 4 from Patent US 7432045 B2 DRAVPa0988$Sequence 3 from Patent US 7432045 B2 DRAVPa0987$Sequence 2 from Patent US 7432045 B2The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=15 m) and antifree virus activity(IC50=21 m). DRAVPa0986$Sequence 1 from Patent US 7432045 B2\The antiviral peptide showS antiviral activity against a wide range of enveloped and non-enveloped viruses. Examples of enveloped viruses include, but are not limited to, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), herpes simplex viruses (HSV-1 and HSV-2), and other herpes viruses, for example, varicella-zoster virus (VZV), EBV, equine herpes virus (EHV), influenza virus and human cytomegalovirus (HCMV). Examples of non-enveloped viruses include, but are not limited to, papilloma virus (PV) and adenoviruses (AV).The peptide inhibits HSV-1 by blocking entry(IC50=15-26 m). DRAVPa0985$LTWQEWDREINNYTSLIYSLIEESQNQQEENEQELL&Sequence 114 from Patent US 7556813 B2 US 7556813 B2 2009-07-07CA 2497767 A1##WO 2004/029073 A2##AU 2003/278937 A1##US 2004/0122214 A1##WO 2004/029073 A3##KR 20050046780 A##MX PA05003036 A##EP 1554306 A2##BR 0314707 A##RU 2005112729 A##CN 1684972 A##RU 2317997 C2Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptidesProvided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer. DRAVPa0984SLEQIWNNMTWMEWEREIDNYTSLIYSLI%Sequence 99 from Patent US 7556813 B2 DRAVPa0983EWEREIDNYTSLIYSLIEESQNQQEKNEQE%Sequence 98 from Patent US 7556813 B2 DRAVPa0982$NNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE%Sequence 97 from Patent US 7556813 B2 DRAVPa0981+KSLEQIWNNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE%Sequence 96 from Patent US 7556813 B2 DRAVPa0980$LIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT%Sequence 95 from Patent US 7556813 B2 DRAVPa0979$SLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNI%Sequence 94 from Patent US 7556813 B2 DRAVPa0978$TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFN%Sequence 93 from Patent US 7556813 B2 DRAVPa0977$NYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW%Sequence 92 from Patent US 7556813 B2 DRAVPa0976$WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKW%Sequence 91 from Patent US 7556813 B2 DRAVPa0975$EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK%Sequence 90 from Patent US 7556813 B2 DRAVPa0974#MEWDREINNYTSLIHSLIEESQNQQEKNEQELLED%Sequence 89 from Patent US 7556813 B2 DRAVPa0973%Sequence 88 from Patent US 7556813 B2 DRAVPa0972$TWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLE%Sequence 87 from Patent US 7556813 B2 DRAVPa0971%Sequence 86 from Patent US 7556813 B2 DRAVPa0970$NMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQEL%Sequence 85 from Patent US 7556813 B2 DRAVPa0969$NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQE%Sequence 84 from Patent US 7556813 B2 DRAVPa0968$WNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQ%Sequence 83 from Patent US 7556813 B2 DRAVPa0967$IWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNE%Sequence 82 from Patent US 7556813 B2 DRAVPa0966$QIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKN%Sequence 81 from Patent US 7556813 B2 DRAV< Pa0965$EQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEK%Sequence 80 from Patent US 7556813 B2 DRAVPa0964$LEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQE%Sequence 79 from Patent US 7556813 B2 DRAVPa0963$SLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQ%Sequence 78 from Patent US 7556813 B2 DRAVPa0962$KSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQ%Sequence 77 from Patent US 7556813 B2 DRAVPa0961$NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQN%Sequence 76 from Patent US 7556813 B2 DRAVPa0960$NASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLI%Sequence 75 from Patent US 7556813 B2 DRAVPa0959%Sequence 74 from Patent US 7556813 B2 DRAVPa0958%Sequence 73 from Patent US 7556813 B2 DRAVPa0957%Sequence 72 from Patent US 7556813 B2 DRAVPa0956%Sequence 71 from Patent US 7556813 B2 DRAVPa0955%Sequence 70 from Patent US 7556813 B2 DRAVPa0954%Sequence 69 from Patent US 7556813 B2 DRAVPa0953%Sequence 68 from Patent US 7556813 B2 DRAVPa0952%Sequence 67 from Patent US 7556813 B2 DRAVPa0951%Sequence 66 from Patent US 7556813 B2 DRAVPa0950%Sequence 65 from Patent US 7556813 B2 DRAVPa0949%Sequence 64 from Patent US 7556813 B2 DRAVPa0948%Sequence 63 from Patent US 7556813 B2 DRAVPa0947%Sequence 62 from Patent US 7556813 B2 DRAVPa0946%Sequence 61 from Patent US 7556813 B2 DRAVPa0945#WQEWEQKITALLEQAQIQQEKIEYELQKLIEWEWF%Sequence 60 from Patent US 7556813 B2 DRAVPa0944'WQEWEQKITALLEQAQIQQEKNEYELQKLAEWAGLWAWF%Sequence 59 from Patent US 7556813 B2 DRAVPa0943'WQEWEQKITALLEQAQIQQEKNEYELQKLDKWAGLWEWF%Sequence 58 from Patent US 7556813 B2 DRAVPa0942'WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWNWF%Sequence 57 from Patent US 7556813 B2 DRAVPa0941#WQEWEREITALLEQAQIQQEKIEYELQKLDEWEWF%Sequence 56 from Patent US 7556813 B2 DRAVPa0940#WQEWEREITALLEQAQIQQEKNEYELQKLIEWEWF%Sequence 55 from Patent US 7556813 B2 DRAVPa0939#WQEWEREITALLEQAQIQQEKIEYELQKLIEWEWF%Sequence 54 from Patent US 7556813 B2 DRAVPa0938#WQEWDREITALLEQAQIQQEKNEYELQKLDEWEWF%Sequence 53 from Patent US 7556813 B2 DRAVPa0937'WQEWDREITALLEQAQIQQEKNEYELQKLDEWASLWEWF%Sequence 52 from Patent US 7556813 B2 DRAVPa0936'WQEWDREITALLEQAQIQQEKNEYELQKLDKWASLWNWF%Sequence 51 from Patent US 7556813 B2 DRAVPa0935(WQEWEREISAYTSLITALLEQAQIQQEKIEYELQKLEWEW%Sequence 50 from Patent US 7556813 B2 DRAVPa0934.WQEWDREISNYTSLITALLEQAQIQQEKNEYELQKLDEWASLWEWF%Sequence 49 from Patent US 7556813 B2 DRAVPa0933$WNWFITALLEQAQIQQEKNEYELQKLDKWASLWNWF%Sequence 48 from Patent US 7556813 B2 DRAVPa09322NNMTWQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF%Sequence 47 from Patent US 7556813 B2 DRAVPa0931.WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF%Sequence 46 from Patent US 7556813 B2 DRAVPa0930*NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK%Sequence 45 from Patent US 7556813 B2 DRAVPa09290MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF%Sequence 44 from Patent US 7556813 B2 DRAVPa0928*DREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF%Sequence 43 from Patent US 7556813 B2 DRAVPa0927$WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKL%Sequence 42 from Patent US 7556813 B2 DRAVPa0926%Sequence 41 from Patent US 7556813 B2 DRAVPa0925$YTSLIYSLLEKSQIQQEKNEQELLELDKWASLWNWF%Sequence 40 from Patent US 7556813 B2 DRAVPa0924%Sequence 39 from Patent US 7556813 B2 DRAVPa0923%Sequence 38 from Patent US 7556813 B2 DRAVPa0922'LSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAV%Sequence 37 from Patent US 7556813 B2 DRAVPa0921,CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC%Sequence 36 from Patent US 7556813 B2 DRAVPa0920)NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC%Sequence 35 from Patent US 7556813 B2 DRAVPa0919NNLLRAIEAQQHLLQLTVWGIKQLQARILAV%Sequence 34 from Patent US 7556813 B2 DRAVPa0918%Sequence 33 from Patent US 7556813 B2 DRAVPa0917%Sequence 32 from Patent US 7556813 B2 DRAVPa0916%Sequence 31 from Patent US 7556813 B2 DRAVPa0915%Sequence 30 from Patent US 7556813 B2 DRAVPa0914%Sequence 29 from Patent US 7556813 B2 DRAVPa0913%Sequence 28 from Patent US 7556813 B2 DRAVPa0912%Sequence 27 from Patent US 7556813 B2 DRAVPa0911%Sequence 26 from Patent US 7556813 B2 DRAVPa0910%Sequence 25 from Patent US 7556813 B2 DRAVPa0909%Sequence 24 from Patent US 7556813 B2 DRAVPa0908%Sequence 23 from Patent US 7556813 B2 DRAVPa0< 907%Sequence 22 from Patent US 7556813 B2 DRAVPa0906%Sequence 21 from Patent US 7556813 B2 DRAVPa0905%Sequence 20 from Patent US 7556813 B2 DRAVPa0904%Sequence 19 from Patent US 7556813 B2 DRAVPa0903%Sequence 18 from Patent US 7556813 B2 DRAVPa0902%Sequence 17 from Patent US 7556813 B2 DRAVPa0901%Sequence 16 from Patent US 7556813 B2 DRAVPa0900%Sequence 15 from Patent US 7556813 B2 DRAVPa0899%Sequence 14 from Patent US 7556813 B2 DRAVPa0898%Sequence 13 from Patent US 7556813 B2 DRAVPa0897%Sequence 12 from Patent US 7556813 B2 DRAVPa0896%Sequence 11 from Patent US 7556813 B2 DRAVPa0895%Sequence 10 from Patent US 7556813 B2 DRAVPa0894$Sequence 9 from Patent US 7556813 B2 DRAVPa0893$Sequence 8 from Patent US 7556813 B2 DRAVPa0892$Sequence 7 from Patent US 7556813 B2 DRAVPa0891$Sequence 6 from Patent US 7556813 B2 DRAVPa0890$Sequence 5 from Patent US 7556813 B2 DRAVPa0889$Sequence 4 from Patent US 7556813 B2 DRAVPa0888$Sequence 3 from Patent US 7556813 B2 DRAVPa0887$Sequence 2 from Patent US 7556813 B2 DRAVPa0886<TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGI$Sequence 1 from Patent US 7556813 B2 DRAVPa0885#WEEWDREINNYTKLIHELIEESQNQQEENEQELLX%Sequence 15 from Patent US 7575750 B2HIV, SIV US 7575750 B2 2009-08-18WO 2004/029201 A2##CA 2500248 A1##AU 2003/275116 A1##WO 2004/029201 A3##US 2005/0089840 A1##EP 1542718 A2##AP 2005003291 A0##BR 0314657 A##CN 1668330 A##EA 200500533 A1## JP 2006505536 A##ZA 200503118kHuman immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity,The 'X' at position 35 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.Anti-HIV, Anti-SIV DRAVPa0884"WEEWDREINNYTXLIHELIEESQNQQEENEQELL%Sequence 14 from Patent US 7575750 B2,The 'X' at position 13 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection. DRAVPa0883(WQEWEQKITALIEQAQIQQEKNEYELQKLDKWASLWEWFX%Sequence 13 from Patent US 7575750 B2gThe 'X' at position 40 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=15.7 nM against HIV-1 and TC50>25000 nM against PBMC) DRAVPa0882'WQEWEQKITALLXQAQIQQEKNEYELQKLDKWASLWEWF%Sequence 12 from Patent US 7575750 B2gThe 'X' at position 13 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=7.78 nM against HIV-1 and TC50>25000 nM against PBMC) DRAVPa0881#WEEWDREINNYTELIHELIEESQNQQEKNEQELLX%Sequence 11 from Patent US 7575750 B2gThe 'X' at position 35 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=9.09 nM against HIV-1 and TC50>25000 nM against PBMC) DRAVPa0880"WEEWDREINNYTXLIHELIEESQNQQEKNEWELL%Sequence 10 from Patent US 7575750 B2gThe<  'X' at position 13 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=3.94 nM against HIV-1 and TC50>25000 nM against PBMC) DRAVPa0879-SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELLX$Sequence 9 from Patent US 7575750 B2,The 'X' at position 45 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection. DRAVPa0878,SLEQIWNNMTWEEWDREINNYTXLIHELIEESQNQQEKNEQELL$Sequence 8 from Patent US 7575750 B2,The 'X' at position 23 represents a Lysine residue derivatized with a maleimide moiety.The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection. DRAVPa0877"WEEWDREINNYTKLIHELIEESQNQQEENEQELL$Sequence 7 from Patent US 7575750 B2The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection. DRAVPa0876"WQEWERKVDFLEENITALLEEAQIQQEKNMYELQ$Sequence 6 from Patent US 7575750 B2 DRAVPa0875"WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL$Sequence 5 from Patent US 7575750 B2 DRAVPe00519 DRAVPa0874$Sequence 4 from Patent US 7575750 B2 DRAVPa0873$Sequence 3 from Patent US 7575750 B2 DRAVPa0872"WEEWDREINNYTKLIHELIEESQNQQEKNEQELL$Sequence 2 from Patent US 7575750 B2The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=1.41 nM against HIV-1 and TC50=15900 nM against PBMC) DRAVPa0871,SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELL$Sequence 1 from Patent US 7575750 B2The peptide was modified with acetyl N-terminus and amide C-terminus, which exihibits antiviral activity by inhibiting viral infection of cells, for example, by inhibiting cell-cell fusion or free virus infection.(IC50=0.93 nM against HIV-1 and TC50=14300 nM against PBMC) DRAVPa0870&NNLLRAIEAQQHMLQLTVWQIKQLQARILAVERYLKDQ&Sequence 545 from Patent US 7582301 B1 US 7582301 B1 2009-09-01CA 2372338 A1##WO 2000/069902 A1##AU 2000/050271 A##EP 1179012 A1##BR 0010757 A##CN 1351611 A##EP 1179012 B1##AT 226593 T##DE 60000665 D1##EP 1264840 A1##JP 2002544287 A##ES 2185595 T3##AU 761591 B2##}Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptidesrPeptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component. DRAVPa0869&NNLLRAIQAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 544 from Patent US 7582301 B1 DRAVPa0868&NNLLRAIDAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 543 from Patent US 7582301 B1 DRAVPa0867&SNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 542 from Patent US 7582301 B1 DRAVPa0866$YTSLIHSLLEESQNQQEKNEQELLELDKWASLWNWF&Sequence 541 from Patent US 7582301 B1 DRAVPa0865$YTSLIHTLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 540 from Patent US 7582301 B1 DRAVPa0864$YTSLIHNLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 539 from Patent US 7582301 B1 DRAVPa0863$YTSLIHRLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 538 from Patent US 7582301 B1 DRAVPa0862$YTSLIYSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 537 from Patent US 7582301 B1 DRAVPa0861$YTSIIHSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 536 from Patent US 7582301 B1 DRAVPa0860$YTNLIHSLIEESQNQQEKNEQELLEL< DKWASLWNWF&Sequence 535 from Patent US 7582301 B1 DRAVPa0859$YTGLIHSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 534 from Patent US 7582301 B1 DRAVPa0858KEAIRD&Sequence 533 from Patent US 7582301 B1HPV 3 Anti-HPV 3 DRAVPa0857LKEAIRD&Sequence 532 from Patent US 7582301 B1 DRAVPa0856KLKEAIRD&Sequence 531 from Patent US 7582301 B1 DRAVPa0855 EKLKEAIRD&Sequence 530 from Patent US 7582301 B1 DRAVPa0854 IEKLKEAIRD&Sequence 529 from Patent US 7582301 B1 DRAVPa0853 DIEKLKEAIRD&Sequence 528 from Patent US 7582301 B1 DRAVPa0852 SDIEKLKEAIRD&Sequence 527 from Patent US 7582301 B1 DRAVPa0851 RSDIEKLKEAIRD&Sequence 526 from Patent US 7582301 B1 DRAVPa0850ARSDIEKLKEAIRD&Sequence 525 from Patent US 7582301 B1 DRAVPa0849QARSDIEKLKEAIRD&Sequence 524 from Patent US 7582301 B1 DRAVPa0848KQARSDIEKLKEAIRD&Sequence 523 from Patent US 7582301 B1 DRAVPa0847AKQARSDIEKLKEAIRD&Sequence 522 from Patent US 7582301 B1 DRAVPa0846EAKQARSDIEKLKEAIRD&Sequence 521 from Patent US 7582301 B1 DRAVPa0845VEAKQARSDIEKLKEAIRD&Sequence 520 from Patent US 7582301 B1 DRAVPa0844LVEAKQARSDIEKLKEAIRD&Sequence 519 from Patent US 7582301 B1 DRAVPa0843ALVEAKQARSDIEKLKEAIRD&Sequence 518 from Patent US 7582301 B1 DRAVPa0842VALVEAKQARSDIEKLKEAIRD&Sequence 517 from Patent US 7582301 B1 DRAVPa0841AVALVEAKQARSDIEKLKEAIRD&Sequence 516 from Patent US 7582301 B1 DRAVPa0840AAVALVEAKQARSDIEKLKEAIRD&Sequence 515 from Patent US 7582301 B1 DRAVPa0839TAAVALVEAKQARSDIEKLKEAIRD&Sequence 514 from Patent US 7582301 B1 DRAVPa0838ITAAVALVEAKQARSDIEKLKEAIRD&Sequence 513 from Patent US 7582301 B1 DRAVPa0837QITAAVALVEAKQARSDIEKLKEAIRD&Sequence 512 from Patent US 7582301 B1 DRAVPa0836AQITAAVALVEAKQARSDIEKLKEAIRD&Sequence 511 from Patent US 7582301 B1 DRAVPa0835SAQITAAVALVEAKQARSDIEKLKEAIRD&Sequence 510 from Patent US 7582301 B1 DRAVPa0834TSAQITAAVALVEAKQARSDIEKLKEAIRD&Sequence 509 from Patent US 7582301 B1 DRAVPa0833ATSAQITAAVALVEAKQARSDIEKLKEAIRD&Sequence 508 from Patent US 7582301 B1 DRAVPa0832 VATSAQITAAVALVEAKQARSDIEKLKEAIRD&Sequence 507 from Patent US 7582301 B1 DRAVPa0831!GVATSAQITAAVALVEAKQARSDIEKLKEAIRD&Sequence 506 from Patent US 7582301 B1 DRAVPa0830"LGVATSAQITAAVALVEAKQARSDIEKLKEAIRD&Sequence 505 from Patent US 7582301 B1 DRAVPa0829ALGVAT&Sequence 504 from Patent US 7582301 B1 DRAVPa0828ALGVATS&Sequence 503 from Patent US 7582301 B1 DRAVPa0827ALGVATSA&Sequence 502 from Patent US 7582301 B1 DRAVPa0826 ALGVATSAQ&Sequence 501 from Patent US 7582301 B1 DRAVPa0825 ALGVATSAQI&Sequence 500 from Patent US 7582301 B1 DRAVPa0824 ALGVATSAQIT&Sequence 499 from Patent US 7582301 B1 DRAVPa0823 ALGVATSAQITA&Sequence 498 from Patent US 7582301 B1 DRAVPa0822 ALGVATSAQITAA&Sequence 497 from Patent US 7582301 B1 DRAVPa0821ALGVATSAQITAAV&Sequence 496 from Patent US 7582301 B1 DRAVPa0820ALGVATSAQITAAVA&Sequence 495 from Patent US 7582301 B1 DRAVPa0819ALGVATSAQITAAVAL&Sequence 494 from Patent US 7582301 B1 DRAVPa0818ALGVATSAQITAAVALV&Sequence 493 from Patent US 7582301 B1 DRAVPa0817ALGVATSAQITAAVALVE&Sequence 492 from Patent US 7582301 B1 DRAVPa0816ALGVATSAQITAAVALVEA&Sequence 491 from Patent US 7582301 B1 DRAVPa0815ALGVATSAQITAAVALVEAK&Sequence 490 from Patent US 7582301 B1 DRAVPa0814ALGVATSAQITAAVALVEAKQ&Sequence 489 from Patent US 7582301 B1 DRAVPa0813ALGVATSAQITAAVALVEAKQA&Sequence 488 from Patent US 7582301 B1 DRAVPa0812ALGVATSAQITAAVALVEAKQAR&Sequence 487 from Patent US 7582301 B1 DRAVPa0811ALGVATSAQITAAVALVEAKQARS&Sequence 486 from Patent US 7582301 B1 DRAVPa0810ALGVATSAQITAAVALVEAKQARSD&Sequence 485 from Patent US 7582301 B1 DRAVPa0809ALGVATSAQITAAVALVEAKQARSDI&Sequence 484 from Patent US 7582301 B1 DRAVPa0808ALGVATSAQITAAVALVEAKQARSDIE&Sequence 483 from Patent US 7582301 B1 DRAVPa0807ALGVATSAQITAAVALVEAKQARSDIEK&Sequence 482 from Patent US 7582301 B1 DRAVPa0806ALGVATSAQITAAVALVEAKQARSDIEKL&Sequence 481 from Patent US 7582301 B1 DRAVPa0805ALGVATSAQITAAVALVEAKQARSDIEKLK&Sequence 480 from Patent US 7582301 B1 DRAVPa0804ALGVATSAQITAAVALVEAKQARSDIEKLKE&Sequence 479 from Patent US 7582301 B1 DRAVP< a0803 ALGVATSAQITAAVALVEAKQARSDIEKLKEA&Sequence 478 from Patent US 7582301 B1 DRAVPa0802!ALGVATSAQITAAVALVEAKQARSDIEKLKEAI&Sequence 477 from Patent US 7582301 B1 DRAVPa0801&Sequence 476 from Patent US 7582301 B1 DRAVPa0799KEWIRRS&Sequence 474 from Patent US 7582301 B1 DRAVPa0800EWIRRS&Sequence 475 from Patent US 7582301 B1 DRAVPa0798SKEWIRRS&Sequence 473 from Patent US 7582301 B1 DRAVPa0797 ESKEWIRRS&Sequence 472 from Patent US 7582301 B1 DRAVPa0796 EESKEWIRRS&Sequence 471 from Patent US 7582301 B1 DRAVPa0795 LEESKEWIRRS&Sequence 470 from Patent US 7582301 B1 DRAVPa0793 SDLEESKEWIRRS&Sequence 468 from Patent US 7582301 B1 DRAVPa0794 DLEESKEWIRRS&Sequence 469 from Patent US 7582301 B1 DRAVPa0792KSDLEESKEWIRRS&Sequence 467 from Patent US 7582301 B1 DRAVPa0790KAKSDLEESKEWIRRS&Sequence 465 from Patent US 7582301 B1 DRAVPa0791AKSDLEESKEWIRRS&Sequence 466 from Patent US 7582301 B1 DRAVPa0789NKAKSDLEESKEWIRRS&Sequence 464 from Patent US 7582301 B1 DRAVPa0788LNKAKSDLEESKEWIRRS&Sequence 463 from Patent US 7582301 B1 DRAVPa0786IELNKAKSDLEESKEWIRRS&Sequence 461 from Patent US 7582301 B1 DRAVPa0787ELNKAKSDLEESKEWIRRS&Sequence 462 from Patent US 7582301 B1 DRAVPa0785SIELNKAKSDLEESKEWIRRS&Sequence 460 from Patent US 7582301 B1 DRAVPa0784ISIELNKAKSDLEESKEWIRRS&Sequence 459 from Patent US 7582301 B1 DRAVPa0783DISIELNKAKSDLEESKEWIRRS&Sequence 458 from Patent US 7582301 B1 DRAVPa0782IDISIELNKAKSDLEESKEWIRRS&Sequence 457 from Patent US 7582301 B1 DRAVPa0781PIDISIELNKAKSDLEESKEWIRRS&Sequence 456 from Patent US 7582301 B1 DRAVPa0780DPIDISIELNKAKSDLEESKEWIRRS&Sequence 455 from Patent US 7582301 B1 DRAVPa0779LDPIDISIELNKAKSDLEESKEWIRRS&Sequence 454 from Patent US 7582301 B1 DRAVPa0778ALDPIDISIELNKAKSDLEESKEWIRRS&Sequence 453 from Patent US 7582301 B1 DRAVPa0776SVALDPIDISIELNKAKSDLEESKEWIRRS&Sequence 451 from Patent US 7582301 B1 DRAVPa0777VALDPIDISIELNKAKSDLEESKEWIRRS&Sequence 452 from Patent US 7582301 B1 DRAVPa0775NSVALDPIDISIELNKAKSDLEESKEWIRRS&Sequence 450 from Patent US 7582301 B1 DRAVPa0774 NNSVALDPIDISIELNKAKSDLEESKEWIRRS&Sequence 449 from Patent US 7582301 B1 DRAVPa0773!LNNSVALDPIDISIELNKAKSDLEESKEWIRRS&Sequence 448 from Patent US 7582301 B1 DRAVPa0772"TLNNSVALDPIDISIELNKAKSDLEESKEWIRRS&Sequence 447 from Patent US 7582301 B1 DRAVPa0771ITLNNS&Sequence 446 from Patent US 7582301 B1 DRAVPa0770ITLNNSV&Sequence 445 from Patent US 7582301 B1 DRAVPa0769ITLNNSVA&Sequence 444 from Patent US 7582301 B1 DRAVPa0768 ITLNNSVAL&Sequence 443 from Patent US 7582301 B1 DRAVPa0767 ITLNNSVALD&Sequence 442 from Patent US 7582301 B1 DRAVPa0766 ITLNNSVALDP&Sequence 441 from Patent US 7582301 B1 DRAVPa0764 ITLNNSVALDPID&Sequence 439 from Patent US 7582301 B1 DRAVPa0765 ITLNNSVALDPI&Sequence 440 from Patent US 7582301 B1 DRAVPa0763ITLNNSVALDPIDI&Sequence 438 from Patent US 7582301 B1 DRAVPa0762ITLNNSVALDPIDIS&Sequence 437 from Patent US 7582301 B1 DRAVPa0761ITLNNSVALDPIDISI&Sequence 436 from Patent US 7582301 B1 DRAVPa0760ITLNNSVALDPIDISIE&Sequence 435 from Patent US 7582301 B1 DRAVPa0759ITLNNSVALDPIDISIEL&Sequence 434 from Patent US 7582301 B1 DRAVPa0758ITLNNSVALDPIDISIELN&Sequence 433 from Patent US 7582301 B1 DRAVPa0757ITLNNSVALDPIDISIELNK&Sequence 432 from Patent US 7582301 B1 DRAVPa0756ITLNNSVALDPIDISIELNKA&Sequence 431 from Patent US 7582301 B1 DRAVPa0755ITLNNSVALDPIDISIELNKAK&Sequence 430 from Patent US 7582301 B1 DRAVPa0754ITLNNSVALDPIDISIELNKAKS&Sequence 429 from Patent US 7582301 B1 DRAVPa0752ITLNNSVALDPIDISIELNKAKSDL&Sequence 427 from Patent US 7582301 B1 DRAVPa0753ITLNNSVALDPIDISIELNKAKSD&Sequence 428 from Patent US 7582301 B1 DRAVPa0751ITLNNSVALDPIDISIELNKAKSDLE&Sequence 426 from Patent US 7582301 B1 DRAVPa0750ITLNNSVALDPIDISIELNKAKSDLEE&Sequence 425 from Patent US 7582301 B1 DRAVPa0749ITLNNSVALDPIDISIELNKAKSDLEES&Sequence 424 from Patent US 7582301 B1 DRAVPa0748ITLNNSVALDPIDISIELNKAKSDLEESK&Sequence 423 from Patent US 7582301 B1 DRAVPa0747ITLNNSVALDPIDISIELNKAKSDLEESKE&Sequence 422 from Patent US 7582301 B1 DRAVPa0746ITLNNSVALDPIDISIEL< NKAKSDLEESKEW&Sequence 421 from Patent US 7582301 B1 DRAVPa0745 ITLNNSVALDPIDISIELNKAKSDLEESKEWI&Sequence 420 from Patent US 7582301 B1 DRAVPa0744!ITLNNSVALDPIDISIELNKAKSDLEESKEWIR&Sequence 419 from Patent US 7582301 B1 DRAVPa0743"ITLNNSVALDPIDISIELNKAKSDLEESKEWIRR&Sequence 418 from Patent US 7582301 B1 DRAVPa0742&Sequence 417 from Patent US 7582301 B1 DRAVPa0741KSDELL&Sequence 416 from Patent US 7582301 B1 DRAVPa0740RKSDELL&Sequence 415 from Patent US 7582301 B1 DRAVPa0738 FIRKSDELL&Sequence 413 from Patent US 7582301 B1 DRAVPa0739IRKSDELL&Sequence 414 from Patent US 7582301 B1 DRAVPa0737 AFIRKSDELL&Sequence 412 from Patent US 7582301 B1 DRAVPa0736 LAFIRKSDELL&Sequence 411 from Patent US 7582301 B1 DRAVPa0735 SLAFIRKSDELL&Sequence 410 from Patent US 7582301 B1 DRAVPa0734 QSLAFIRKSDELL&Sequence 409 from Patent US 7582301 B1 DRAVPa0733NQSLAFIRKSDELL&Sequence 408 from Patent US 7582301 B1 DRAVPa0732INQSLAFIRKSDELL&Sequence 407 from Patent US 7582301 B1 DRAVPa0731KINQSLAFIRKSDELL&Sequence 406 from Patent US 7582301 B1 DRAVPa0730EKINQSLAFIRKSDELL&Sequence 405 from Patent US 7582301 B1 DRAVPa0729NEKINQSLAFIRKSDELL&Sequence 404 from Patent US 7582301 B1 DRAVPa0727QVNEKINQSLAFIRKSDELL&Sequence 402 from Patent US 7582301 B1 DRAVPa0728VNEKINQSLAFIRKSDELL&Sequence 403 from Patent US 7582301 B1 DRAVPa0726SQVNEKINQSLAFIRKSDELL&Sequence 401 from Patent US 7582301 B1 DRAVPa0725ISQVNEKINQSLAFIRKSDELL&Sequence 400 from Patent US 7582301 B1 DRAVPa0724SISQVNEKINQSLAFIRKSDELL&Sequence 399 from Patent US 7582301 B1 DRAVPa0723ASISQVNEKINQSLAFIRKSDELL&Sequence 398 from Patent US 7582301 B1 DRAVPa0722DASISQVNEKINQSLAFIRKSDELL&Sequence 397 from Patent US 7582301 B1 DRAVPa0721FDASISQVNEKINQSLAFIRKSDELL&Sequence 396 from Patent US 7582301 B1 DRAVPa0720EFDASISQVNEKINQSLAFIRKSDELL&Sequence 395 from Patent US 7582301 B1 DRAVPa0719&Sequence 394 from Patent US 7582301 B1 DRAVPa0718SDEFDASISQVNEKINQSLAFIRKSDELL&Sequence 393 from Patent US 7582301 B1 DRAVPa0717PSDEFDASISQVNEKINQSLAFIRKSDELL&Sequence 392 from Patent US 7582301 B1 DRAVPa0716FPSDEFDASISQVNEKINQSLAFIRKSDELL&Sequence 391 from Patent US 7582301 B1 DRAVPa0714!LVFPSDEFDASISQVNEKINQSLAFIRKSDELL&Sequence 389 from Patent US 7582301 B1 DRAVPa0715 VFPSDEFDASISQVNEKINQSLAFIRKSDELL&Sequence 390 from Patent US 7582301 B1 DRAVPa0713"PLVFPSDEFDASISQVNEKINQSLAFIRKSDELL&Sequence 388 from Patent US 7582301 B1 DRAVPa0712&Sequence 387 from Patent US 7582301 B1 DRAVPa0711$YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL&Sequence 386 from Patent US 7582301 B1 DRAVPa0710FYDPLV&Sequence 385 from Patent US 7582301 B1 DRAVPa0709FYDPLVF&Sequence 384 from Patent US 7582301 B1 DRAVPa0708FYDPLVFP&Sequence 383 from Patent US 7582301 B1 DRAVPa0707 FYDPLVFPS&Sequence 382 from Patent US 7582301 B1 DRAVPa0706 FYDPLVFPSD&Sequence 381 from Patent US 7582301 B1 DRAVPa0705 FYDPLVFPSDE&Sequence 380 from Patent US 7582301 B1 DRAVPa0703 FYDPLVFPSDEFD&Sequence 378 from Patent US 7582301 B1 DRAVPa0704 FYDPLVFPSDEF&Sequence 379 from Patent US 7582301 B1 DRAVPa0702FYDPLVFPSDEFDA&Sequence 377 from Patent US 7582301 B1 DRAVPa0701FYDPLVFPSDEFDAS&Sequence 376 from Patent US 7582301 B1 DRAVPa0700FYDPLVFPSDEFDASI&Sequence 375 from Patent US 7582301 B1 DRAVPa0699FYDPLVFPSDEFDASIS&Sequence 374 from Patent US 7582301 B1 DRAVPa0698FYDPLVFPSDEFDASISQ&Sequence 373 from Patent US 7582301 B1 DRAVPa0697FYDPLVFPSDEFDASISQV&Sequence 372 from Patent US 7582301 B1 DRAVPa0696FYDPLVFPSDEFDASISQVN&Sequence 371 from Patent US 7582301 B1 DRAVPa0695FYDPLVFPSDEFDASISQVNE&Sequence 370 from Patent US 7582301 B1 DRAVPa0694FYDPLVFPSDEFDASISQVNEK&Sequence 369 from Patent US 7582301 B1 DRAVPa0693FYDPLVFPSDEFDASISQVNEKI&Sequence 368 from Patent US 7582301 B1 DRAVPa0691FYDPLVFPSDEFDASISQVNEKINQ&Sequence 366 from Patent US 7582301 B1 DRAVPa0692FYDPLVFPSDEFDASISQVNEKIN&Sequence 367 from Patent US 7582301 B1 DRAVPa0690FYDPLVFPSDEFDASISQVNEKINQS&Sequence 365 from Patent US 7582301 B1 DRAVPa0689FYDPLVFPSDEFDASISQVNEKINQSL&Sequence 364 from Patent US 7582301 B1 DRAVPa0688FYDPLVF< PSDEFDASISQVNEKINQSLA&Sequence 363 from Patent US 7582301 B1 DRAVPa0687FYDPLVFPSDEFDASISQVNEKINQSLAF&Sequence 362 from Patent US 7582301 B1 DRAVPa0686FYDPLVFPSDEFDASISQVNEKINQSLAFI&Sequence 361 from Patent US 7582301 B1 DRAVPa0685FYDPLVFPSDEFDASISQVNEKINQSLAFIR&Sequence 360 from Patent US 7582301 B1 DRAVPa0684 FYDPLVFPSDEFDASISQVNEKINQSLAFIRK&Sequence 359 from Patent US 7582301 B1 DRAVPa0683!FYDPLVFPSDEFDASISQVNEKINQSLAFIRKS&Sequence 358 from Patent US 7582301 B1 DRAVPa0682"FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSD&Sequence 357 from Patent US 7582301 B1 DRAVPa0681&Sequence 356 from Patent US 7582301 B1 DRAVPa0680$FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL&Sequence 355 from Patent US 7582301 B1 DRAVPa0679&Sequence 354 from Patent US 7582301 B1 DRAVPa0678LLMQST&Sequence 353 from Patent US 7582301 B1 DRAVPa0676LQLLMQST&Sequence 351 from Patent US 7582301 B1 DRAVPa0677QLLMQST&Sequence 352 from Patent US 7582301 B1 DRAVPa0675 ELQLLMQST&Sequence 350 from Patent US 7582301 B1 DRAVPa0673 VTELQLLMQST&Sequence 348 from Patent US 7582301 B1 DRAVPa0674 TELQLLMQST&Sequence 349 from Patent US 7582301 B1 DRAVPa0672 AVTELQLLMQST&Sequence 347 from Patent US 7582301 B1 DRAVPa0671 NAVTELQLLMQST&Sequence 346 from Patent US 7582301 B1 DRAVPa0669YKNAVTELQLLMQST&Sequence 344 from Patent US 7582301 B1 DRAVPa0670KNAVTELQLLMQST&Sequence 345 from Patent US 7582301 B1 DRAVPa0668KYKNAVTELQLLMQST&Sequence 343 from Patent US 7582301 B1 DRAVPa0666LDKYKNAVTELQLLMQST&Sequence 341 from Patent US 7582301 B1 DRAVPa0667DKYKNAVTELQLLMQST&Sequence 342 from Patent US 7582301 B1 DRAVPa0665ELDKYKNAVTELQLLMQST&Sequence 340 from Patent US 7582301 B1 DRAVPa0663KQELDKYKNAVTELQLLMQST&Sequence 338 from Patent US 7582301 B1 DRAVPa0664QELDKYKNAVTELQLLMQST&Sequence 339 from Patent US 7582301 B1 DRAVPa0661LIKQELDKYKNAVTELQLLMQST&Sequence 336 from Patent US 7582301 B1 DRAVPa0662IKQELDKYKNAVTELQLLMQST&Sequence 337 from Patent US 7582301 B1 DRAVPa0660KLIKQELDKYKNAVTELQLLMQST&Sequence 335 from Patent US 7582301 B1 DRAVPa0659VKLIKQELDKYKNAVTELQLLMQST&Sequence 334 from Patent US 7582301 B1 DRAVPa0657AKVKLIKQELDKYKNAVTELQLLMQST&Sequence 332 from Patent US 7582301 B1 DRAVPa0658KVKLIKQELDKYKNAVTELQLLMQST&Sequence 333 from Patent US 7582301 B1 DRAVPa0656DAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 331 from Patent US 7582301 B1 DRAVPa0654GTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 329 from Patent US 7582301 B1 DRAVPa0655TDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 330 from Patent US 7582301 B1 DRAVPa0653NGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 328 from Patent US 7582301 B1 DRAVPa0652 CNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 327 from Patent US 7582301 B1 DRAVPa0650"NKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 325 from Patent US 7582301 B1 DRAVPa0651!KCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 326 from Patent US 7582301 B1 DRAVPa0649$KENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 324 from Patent US 7582301 B1 DRAVPa0647&NIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 322 from Patent US 7582301 B1 DRAVPa0648%IKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 323 from Patent US 7582301 B1 DRAVPa0646'SNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 321 from Patent US 7582301 B1 DRAVPa0645(LSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 320 from Patent US 7582301 B1 DRAVPa0643&Sequence 318 from Patent US 7582301 B1 DRAVPa0644)ELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 319 from Patent US 7582301 B1 DRAVPa0642+TIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 317 from Patent US 7582301 B1 DRAVPa0641,ITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 316 from Patent US 7582301 B1 DRAVPa0639.SVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 314 from Patent US 7582301 B1 DRAVPa0640-VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 315 from Patent US 7582301 B1 DRAVPa0638/TSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST&Sequence 313 from Patent US 7582301 B1 DRAVPa0636YTSVITI&Sequence 311 from Patent US 7582301 B1 DRAVPa0637YTSVIT&Sequence 312 from Patent US 7582301 B1 DRAVPa0635YTSVITIE&Sequence 310 from Patent US < 7582301 B1 DRAVPa0634 YTSVITIEL&Sequence 309 from Patent US 7582301 B1 DRAVPa0632 YTSVITIELSN&Sequence 307 from Patent US 7582301 B1 DRAVPa0633 YTSVITIELS&Sequence 308 from Patent US 7582301 B1 DRAVPa0631 YTSVITIELSNI&Sequence 306 from Patent US 7582301 B1 DRAVPa0629YTSVITIELSNIKE&Sequence 304 from Patent US 7582301 B1 DRAVPa0630 YTSVITIELSNIK&Sequence 305 from Patent US 7582301 B1 DRAVPa0628YTSVITIELSNIKEN&Sequence 303 from Patent US 7582301 B1 DRAVPa0626YTSVITIELSNIKENKC&Sequence 301 from Patent US 7582301 B1 DRAVPa0627YTSVITIELSNIKENK&Sequence 302 from Patent US 7582301 B1 DRAVPa0625YTSVITIELSNIKENKCN&Sequence 300 from Patent US 7582301 B1 DRAVPa0624YTSVITIELSNIKENKCNG&Sequence 299 from Patent US 7582301 B1 DRAVPa0622YTSVITIELSNIKENKCNGTD&Sequence 297 from Patent US 7582301 B1 DRAVPa0623YTSVITIELSNIKENKCNGT&Sequence 298 from Patent US 7582301 B1 DRAVPa0621YTSVITIELSNIKENKCNGTDA&Sequence 296 from Patent US 7582301 B1 DRAVPa0619YTSVITIELSNIKENKCNGTDAKV&Sequence 294 from Patent US 7582301 B1 DRAVPa0620YTSVITIELSNIKENKCNGTDAK&Sequence 295 from Patent US 7582301 B1 DRAVPa0618YTSVITIELSNIKENKCNGTDAKVK&Sequence 293 from Patent US 7582301 B1 DRAVPa0617YTSVITIELSNIKENKCNGTDAKVKL&Sequence 292 from Patent US 7582301 B1 DRAVPa0615YTSVITIELSNIKENKCNGTDAKVKLIK&Sequence 290 from Patent US 7582301 B1 DRAVPa0616YTSVITIELSNIKENKCNGTDAKVKLI&Sequence 291 from Patent US 7582301 B1 DRAVPa0614YTSVITIELSNIKENKCNGTDAKVKLIKQ&Sequence 289 from Patent US 7582301 B1 DRAVPa0613YTSVITIELSNIKENKCNGTDAKVKLIKQE&Sequence 288 from Patent US 7582301 B1 DRAVPa0612YTSVITIELSNIKENKCNGTDAKVKLIKQEL&Sequence 287 from Patent US 7582301 B1 DRAVPa0611 YTSVITIELSNIKENKCNGTDAKVKLIKQELD&Sequence 286 from Patent US 7582301 B1 DRAVPa0610!YTSVITIELSNIKENKCNGTDAKVKLIKQELDK&Sequence 285 from Patent US 7582301 B1 DRAVPa0609"YTSVITIELSNIKENKCNGTDAKVKLIKQELDKY&Sequence 284 from Patent US 7582301 B1 DRAVPa0608#YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYK&Sequence 283 from Patent US 7582301 B1 DRAVPa0607$YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKN&Sequence 282 from Patent US 7582301 B1 DRAVPa0606%YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNA&Sequence 281 from Patent US 7582301 B1 DRAVPa0605&YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV&Sequence 280 from Patent US 7582301 B1 DRAVPa0604'YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVT&Sequence 279 from Patent US 7582301 B1 DRAVPa0602)YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTEL&Sequence 277 from Patent US 7582301 B1 DRAVPa0603(YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTE&Sequence 278 from Patent US 7582301 B1 DRAVPa0601*YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQ&Sequence 276 from Patent US 7582301 B1 DRAVPa0600+YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQL&Sequence 275 from Patent US 7582301 B1 DRAVPa0599,YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLL&Sequence 274 from Patent US 7582301 B1 DRAVPa0597.YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQ&Sequence 272 from Patent US 7582301 B1 DRAVPa0598-YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLM&Sequence 273 from Patent US 7582301 B1 DRAVPa0596/YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQS&Sequence 271 from Patent US 7582301 B1 DRAVPa0595VFTNWL&Sequence 270 from Patent US 7582301 B1pThe peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP178. DRAVPa0593WDVFTNWL&Sequence 268 from Patent US 7582301 B1 DRAVPa0594DVFTNWL&Sequence 269 from Patent US 7582301 B1 DRAVPa0592 SWDVFTNWL&Sequence 267 from Patent US 7582301 B1 DRAVPa0591 NSWDVFTNWL&Sequence 266 from Patent US 7582301 B1 DRAVPa0590 LNSWDVFTNWL&Sequence 265 from Patent US 7582301 B1 DRAVPa0589 KLNSWDVFTNWL&Sequence 264 from Patent US 7582301 B1 DRAVPa0587LQKLNSWDVFTNWL&Sequence 262 from Patent US 7582301 B1 DRAVPa0588 QKLNSWDVFTNWL&Sequence 263 from Patent US 7582301 B1 DRAVPa0586ELQKLNSWDVFTNWL&Sequence 261 from Patent US 7582301 B1 DRAVPa0585YELQKLNSWDVFTNWL&Sequence 260 from Patent US 7582301 B1 DRAVPa0584MYELQKLNSWDVFTNWL&Sequence 259 from Patent US 7582301 B1 DRAVPa0582KNMYELQKLNSWDVFTNWL&Sequence 257 from Patent US 7582301 B1 DRAVPa0< 583NMYELQKLNSWDVFTNWL&Sequence 258 from Patent US 7582301 B1 DRAVPa0581EKNMYELQKLNSWDVFTNWL&Sequence 256 from Patent US 7582301 B1 DRAVPa0580QEKNMYELQKLNSWDVFTNWL&Sequence 255 from Patent US 7582301 B1 DRAVPa0579QQEKNMYELQKLNSWDVFTNWL&Sequence 254 from Patent US 7582301 B1 DRAVPa0578IQQEKNMYELQKLNSWDVFTNWL&Sequence 253 from Patent US 7582301 B1 DRAVPa0576AQIQQEKNMYELQKLNSWDVFTNWL&Sequence 251 from Patent US 7582301 B1 DRAVPa0577QIQQEKNMYELQKLNSWDVFTNWL&Sequence 252 from Patent US 7582301 B1 DRAVPa0575QAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 250 from Patent US 7582301 B1 DRAVPa0574EQAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 249 from Patent US 7582301 B1 DRAVPa0573LEQAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 248 from Patent US 7582301 B1 DRAVPa0572SLEQAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 247 from Patent US 7582301 B1 DRAVPa0570SQSLEQAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 245 from Patent US 7582301 B1 DRAVPa0571QSLEQAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 246 from Patent US 7582301 B1 DRAVPa0569 ISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 244 from Patent US 7582301 B1 DRAVPa0568!NISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 243 from Patent US 7582301 B1 DRAVPa0567"ANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 242 from Patent US 7582301 B1 DRAVPa0565LEANIS&Sequence 240 from Patent US 7582301 B1 DRAVPa0566#EANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL&Sequence 241 from Patent US 7582301 B1 DRAVPa0564LEANISQ&Sequence 239 from Patent US 7582301 B1 DRAVPa0563LEANISQS&Sequence 238 from Patent US 7582301 B1 DRAVPa0562 LEANISQSL&Sequence 237 from Patent US 7582301 B1 DRAVPa0561 LEANISQSLE&Sequence 236 from Patent US 7582301 B1 DRAVPa0559 LEANISQSLEQA&Sequence 234 from Patent US 7582301 B1 DRAVPa0560 LEANISQSLEQ&Sequence 235 from Patent US 7582301 B1 DRAVPa0558 LEANISQSLEQAQ&Sequence 233 from Patent US 7582301 B1 DRAVPa0557LEANISQSLEQAQI&Sequence 232 from Patent US 7582301 B1 DRAVPa0556LEANISQSLEQAQIQ&Sequence 231 from Patent US 7582301 B1 DRAVPa0554LEANISQSLEQAQIQQE&Sequence 229 from Patent US 7582301 B1 DRAVPa0555LEANISQSLEQAQIQQ&Sequence 230 from Patent US 7582301 B1 DRAVPa0553LEANISQSLEQAQIQQEK&Sequence 228 from Patent US 7582301 B1 DRAVPa0552LEANISQSLEQAQIQQEKN&Sequence 227 from Patent US 7582301 B1 DRAVPa0551LEANISQSLEQAQIQQEKNM&Sequence 226 from Patent US 7582301 B1 DRAVPa0550LEANISQSLEQAQIQQEKNMY&Sequence 225 from Patent US 7582301 B1 DRAVPa0548LEANISQSLEQAQIQQEKNMYEL&Sequence 223 from Patent US 7582301 B1 DRAVPa0549LEANISQSLEQAQIQQEKNMYE&Sequence 224 from Patent US 7582301 B1 DRAVPa0547LEANISQSLEQAQIQQEKNMYELQ&Sequence 222 from Patent US 7582301 B1 DRAVPa0546LEANISQSLEQAQIQQEKNMYELQK&Sequence 221 from Patent US 7582301 B1 DRAVPa0545LEANISQSLEQAQIQQEKNMYELQKL&Sequence 220 from Patent US 7582301 B1 DRAVPa0544LEANISQSLEQAQIQQEKNMYELQKLN&Sequence 219 from Patent US 7582301 B1 DRAVPa0542LEANISQSLEQAQIQQEKNMYELQKLNSW&Sequence 217 from Patent US 7582301 B1 DRAVPa0543LEANISQSLEQAQIQQEKNMYELQKLNS&Sequence 218 from Patent US 7582301 B1 DRAVPa0541LEANISQSLEQAQIQQEKNMYELQKLNSWD&Sequence 216 from Patent US 7582301 B1 DRAVPa0540LEANISQSLEQAQIQQEKNMYELQKLNSWDV&Sequence 215 from Patent US 7582301 B1 DRAVPa0539 LEANISQSLEQAQIQQEKNMYELQKLNSWDVF&Sequence 214 from Patent US 7582301 B1 DRAVPa0538!LEANISQSLEQAQIQQEKNMYELQKLNSWDVFT&Sequence 213 from Patent US 7582301 B1 DRAVPa0536#LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNW&Sequence 211 from Patent US 7582301 B1 DRAVPa0537"LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTN&Sequence 212 from Patent US 7582301 B1 DRAVPa0535RYLKDQ&Sequence 210 from Patent US 7582301 B1pThe peptide was potent inhibitors of HIV-1 infection and HIV induced cell-cell fusion, which derived from DP107. DRAVPa0534ERYLKDQ&Sequence 209 from Patent US 7582301 B1 DRAVPa0533VERYLKDQ&Sequence 208 from Patent US 7582301 B1 DRAVPa0531 LAVERYLKDQ&Sequence 206 from Patent US 7582301 B1 DRAVPa0532 AVERYLKDQ&Sequence 207 from Patent US 7582301 B1 DRAVPa0530 ILAVERYLKDQ&Sequence 205 from Patent US 7582301 B1 DRAVPa0529 RILAVERYLKDQ&Sequence 204 from Patent US 7582301 B1 DRAVPa0528 ARILAVERYLKDQ&Sequenc< e 203 from Patent US 7582301 B1 DRAVPa0526LQARILAVERYLKDQ&Sequence 201 from Patent US 7582301 B1 DRAVPa0527QARILAVERYLKDQ&Sequence 202 from Patent US 7582301 B1 DRAVPa0525QLQARILAVERYLKDQ&Sequence 200 from Patent US 7582301 B1 DRAVPa0524KQLQARILAVERYLKDQ&Sequence 199 from Patent US 7582301 B1 DRAVPa0523IKQLQARILAVERYLKDQ&Sequence 198 from Patent US 7582301 B1 DRAVPa0522QIKQLQARILAVERYLKDQ&Sequence 197 from Patent US 7582301 B1 DRAVPa0520VWQIKQLQARILAVERYLKDQ&Sequence 195 from Patent US 7582301 B1 DRAVPa0521WQIKQLQARILAVERYLKDQ&Sequence 196 from Patent US 7582301 B1 DRAVPa0519TVWQIKQLQARILAVERYLKDQ&Sequence 194 from Patent US 7582301 B1 DRAVPa0518LTVWQIKQLQARILAVERYLKDQ&Sequence 193 from Patent US 7582301 B1 DRAVPa0517QLTVWQIKQLQARILAVERYLKDQ&Sequence 192 from Patent US 7582301 B1 DRAVPa0516LQLTVWQIKQLQARILAVERYLKDQ&Sequence 191 from Patent US 7582301 B1 DRAVPa0514HLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 189 from Patent US 7582301 B1 DRAVPa0515LLQLTVWQIKQLQARILAVERYLKDQ&Sequence 190 from Patent US 7582301 B1 DRAVPa0513QHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 188 from Patent US 7582301 B1 DRAVPa0512QQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 187 from Patent US 7582301 B1 DRAVPa0511AQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 186 from Patent US 7582301 B1 DRAVPa0509 IEAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 184 from Patent US 7582301 B1 DRAVPa0510EAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 185 from Patent US 7582301 B1 DRAVPa0508!AIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 183 from Patent US 7582301 B1 DRAVPa0507"RAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 182 from Patent US 7582301 B1 DRAVPa0506#LRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 181 from Patent US 7582301 B1 DRAVPa0505$LLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 180 from Patent US 7582301 B1 DRAVPa0503NNLLRA&Sequence 178 from Patent US 7582301 B1 DRAVPa0504%NLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ&Sequence 179 from Patent US 7582301 B1 DRAVPa0502NNLLRAI&Sequence 177 from Patent US 7582301 B1 DRAVPa0500 NNLLRAIEA&Sequence 175 from Patent US 7582301 B1 DRAVPa0501NNLLRAIE&Sequence 176 from Patent US 7582301 B1 DRAVPa0499 NNLLRAIEAQ&Sequence 174 from Patent US 7582301 B1 DRAVPa0498 NNLLRAIEAQQ&Sequence 173 from Patent US 7582301 B1 DRAVPa0496 NNLLRAIEAQQHL&Sequence 171 from Patent US 7582301 B1 DRAVPa0497 NNLLRAIEAQQH&Sequence 172 from Patent US 7582301 B1 DRAVPa0495NNLLRAIEAQQHLL&Sequence 170 from Patent US 7582301 B1 DRAVPa0493NNLLRAIEAQQHLLQL&Sequence 168 from Patent US 7582301 B1 DRAVPa0494NNLLRAIEAQQHLLQ&Sequence 169 from Patent US 7582301 B1 DRAVPa0492NNLLRAIEAQQHLLQLT&Sequence 167 from Patent US 7582301 B1 DRAVPa0491NNLLRAIEAQQHLLQLTV&Sequence 166 from Patent US 7582301 B1 DRAVPa0489NNLLRAIEAQQHLLQLTVWQ&Sequence 164 from Patent US 7582301 B1 DRAVPa0490NNLLRAIEAQQHLLQLTVW&Sequence 165 from Patent US 7582301 B1 DRAVPa0488NNLLRAIEAQQHLLQLTVWQI&Sequence 163 from Patent US 7582301 B1 DRAVPa0486NNLLRAIEAQQHLLQLTVWQIKQ&Sequence 161 from Patent US 7582301 B1 DRAVPa0487NNLLRAIEAQQHLLQLTVWQIK&Sequence 162 from Patent US 7582301 B1 DRAVPa0485NNLLRAIEAQQHLLQLTVWQIKQL&Sequence 160 from Patent US 7582301 B1 DRAVPa0484NNLLRAIEAQQHLLQLTVWQIKQLQ&Sequence 159 from Patent US 7582301 B1 DRAVPa0482NNLLRAIEAQQHLLQLTVWQIKQLQAR&Sequence 157 from Patent US 7582301 B1 DRAVPa0483NNLLRAIEAQQHLLQLTVWQIKQLQA&Sequence 158 from Patent US 7582301 B1 DRAVPa0481NNLLRAIEAQQHLLQLTVWQIKQLQARI&Sequence 156 from Patent US 7582301 B1 DRAVPa0480NNLLRAIEAQQHLLQLTVWQIKQLQARIL&Sequence 155 from Patent US 7582301 B1 DRAVPa0478NNLLRAIEAQQHLLQLTVWQIKQLQARILAV&Sequence 153 from Patent US 7582301 B1 DRAVPa0479NNLLRAIEAQQHLLQLTVWQIKQLQARILA&Sequence 154 from Patent US 7582301 B1 DRAVPa0477 NNLLRAIEAQQHLLQLTVWQIKQLQARILAVE&Sequence 152 from Patent US 7582301 B1 DRAVPa0476!NNLLRAIEAQQHLLQLTVWQIKQLQARILAVER&Sequence 151 from Patent US 7582301 B1 DRAVPa0474#NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYL&Sequence 149 from Patent US 7582301 B1 DRAVPa0475"NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERY&Sequence 150 from Patent US 7582301 B1 DRAVPa0473$NNLLR< AIEAQQHLLQLTVWQIKQLQARILAVERYLK&Sequence 148 from Patent US 7582301 B1 DRAVPa0472%NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKD&Sequence 147 from Patent US 7582301 B1 DRAVPa0470ASLWNWF&Sequence 145 from Patent US 7582301 B1 DRAVPa0471SLWNWF&Sequence 146 from Patent US 7582301 B1 DRAVPa0469WASLWNWF&Sequence 144 from Patent US 7582301 B1 DRAVPa0468 KWASLWNWF&Sequence 143 from Patent US 7582301 B1 DRAVPa0466 LDKWASLWNWF&Sequence 141 from Patent US 7582301 B1 DRAVPa0467 DKWASLWNWF&Sequence 142 from Patent US 7582301 B1 DRAVPa0465 ELDKWASLWNWF&Sequence 140 from Patent US 7582301 B1 DRAVPa0464 LELDKWASLWNWF&Sequence 139 from Patent US 7582301 B1 DRAVPa0462ELLELDKWASLWNWF&Sequence 137 from Patent US 7582301 B1 DRAVPa0463LLELDKWASLWNWF&Sequence 138 from Patent US 7582301 B1 DRAVPa0461QELLELDKWASLWNWF&Sequence 136 from Patent US 7582301 B1 DRAVPa0460EQELLELDKWASLWNWF&Sequence 135 from Patent US 7582301 B1 DRAVPa0458KNEQELLELDKWASLWNWF&Sequence 133 from Patent US 7582301 B1 DRAVPa0459NEQELLELDKWASLWNWF&Sequence 134 from Patent US 7582301 B1 DRAVPa0457EKNEQELLELDKWASLWNWF&Sequence 132 from Patent US 7582301 B1 DRAVPa0456QEKNEQELLELDKWASLWNWF&Sequence 131 from Patent US 7582301 B1 DRAVPa0454NQQEKNEQELLELDKWASLWNWF&Sequence 129 from Patent US 7582301 B1 DRAVPa0455QQEKNEQELLELDKWASLWNWF&Sequence 130 from Patent US 7582301 B1 DRAVPa0453QNQQEKNEQELLELDKWASLWNWF&Sequence 128 from Patent US 7582301 B1 DRAVPa0452SQNQQEKNEQELLELDKWASLWNWF&Sequence 127 from Patent US 7582301 B1 DRAVPa0450EESQNQQEKNEQELLELDKWASLWNWF&Sequence 125 from Patent US 7582301 B1 DRAVPa0451ESQNQQEKNEQELLELDKWASLWNWF&Sequence 126 from Patent US 7582301 B1 DRAVPa0449IEESQNQQEKNEQELLELDKWASLWNWF&Sequence 124 from Patent US 7582301 B1 DRAVPa0448LIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 123 from Patent US 7582301 B1 DRAVPa0446HSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 121 from Patent US 7582301 B1 DRAVPa0447SLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 122 from Patent US 7582301 B1 DRAVPa0445 IHSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 120 from Patent US 7582301 B1 DRAVPa0444!LIHSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 119 from Patent US 7582301 B1 DRAVPa0442#TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 117 from Patent US 7582301 B1 DRAVPa0443"SLIHSLIEESQNQQEKNEQELLELDKWASLWNWF&Sequence 118 from Patent US 7582301 B1 DRAVPa0441YTSLIH&Sequence 116 from Patent US 7582301 B1 DRAVPa0440YTSLIHS&Sequence 115 from Patent US 7582301 B1 DRAVPa0438 YTSLIHSLI&Sequence 113 from Patent US 7582301 B1 DRAVPa0439YTSLIHSL&Sequence 114 from Patent US 7582301 B1 DRAVPa0437 YTSLIHSLIE&Sequence 112 from Patent US 7582301 B1 DRAVPa0436 YTSLIHSLIEE&Sequence 111 from Patent US 7582301 B1 DRAVPa0434 YTSLIHSLIEESQ&Sequence 109 from Patent US 7582301 B1 DRAVPa0435 YTSLIHSLIEES&Sequence 110 from Patent US 7582301 B1 DRAVPa0433YTSLIHSLIEESQN&Sequence 108 from Patent US 7582301 B1 DRAVPa0432YTSLIHSLIEESQNQ&Sequence 107 from Patent US 7582301 B1 DRAVPa0431YTSLIHSLIEESQNQQ&Sequence 106 from Patent US 7582301 B1 DRAVPa0429YTSLIHSLIEESQNQQEK&Sequence 104 from Patent US 7582301 B1 DRAVPa0430YTSLIHSLIEESQNQQE&Sequence 105 from Patent US 7582301 B1 DRAVPa0428YTSLIHSLIEESQNQQEKN&Sequence 103 from Patent US 7582301 B1 DRAVPa0427YTSLIHSLIEESQNQQEKNE&Sequence 102 from Patent US 7582301 B1 DRAVPa0425YTSLIHSLIEESQNQQEKNEQE&Sequence 100 from Patent US 7582301 B1 DRAVPa0426YTSLIHSLIEESQNQQEKNEQ&Sequence 101 from Patent US 7582301 B1 DRAVPa0424YTSLIHSLIEESQNQQEKNEQEL%Sequence 99 from Patent US 7582301 B1 DRAVPa0423YTSLIHSLIEESQNQQEKNEQELL%Sequence 98 from Patent US 7582301 B1 DRAVPa0421YTSLIHSLIEESQNQQEKNEQELLEL%Sequence 96 from Patent US 7582301 B1 DRAVPa0422YTSLIHSLIEESQNQQEKNEQELLE%Sequence 97 from Patent US 7582301 B1 DRAVPa0420YTSLIHSLIEESQNQQEKNEQELLELD%Sequence 95 from Patent US 7582301 B1 DRAVPa0419YTSLIHSLIEESQNQQEKNEQELLELDK%Sequence 94 from Patent US 7582301 B1 DRAVPe00675 DRAVPa0417YTSLIHSLIEESQNQQEKNEQELLELDKWA%Sequence 92 from Patent US 7582301 B1 DRAVPa0418YTSLIHSLIEESQNQQEKNEQELLELDKW%Sequence 93 from Patent US 7582< 301 B1 DRAVPa0416YTSLIHSLIEESQNQQEKNEQELLELDKWAS%Sequence 91 from Patent US 7582301 B1 DRAVPa0415 YTSLIHSLIEESQNQQEKNEQELLELDKWASL%Sequence 90 from Patent US 7582301 B1 DRAVPa0413"YTSLIHSLIEESQNQQEKNEQELLELDKWASLWN%Sequence 88 from Patent US 7582301 B1 DRAVPa0414!YTSLIHSLIEESQNQQEKNEQELLELDKWASLW%Sequence 89 from Patent US 7582301 B1 DRAVPa0412#YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW%Sequence 87 from Patent US 7582301 B1 DRAVPa0411%Sequence 86 from Patent US 7582301 B1 DRAVPa0409%Sequence 84 from Patent US 7582301 B1 DRAVPa0410%Sequence 85 from Patent US 7582301 B1 DRAVPa0408%Sequence 83 from Patent US 7582301 B1 DRAVPa0407%Sequence 82 from Patent US 7582301 B1 DRAVPa0405%Sequence 80 from Patent US 7582301 B1 DRAVPa0406%Sequence 81 from Patent US 7582301 B1 DRAVPa0404%Sequence 79 from Patent US 7582301 B1 DRAVPa0403%Sequence 78 from Patent US 7582301 B1 DRAVPa0401%Sequence 76 from Patent US 7582301 B1 DRAVPa0402%Sequence 77 from Patent US 7582301 B1 DRAVPa0400%Sequence 75 from Patent US 7582301 B1 DRAVPa0399%Sequence 74 from Patent US 7582301 B1 DRAVPa0397%Sequence 72 from Patent US 7582301 B1 DRAVPa0398%Sequence 73 from Patent US 7582301 B1 DRAVPa0396%Sequence 71 from Patent US 7582301 B1 DRAVPa0395%Sequence 70 from Patent US 7582301 B1 DRAVPa0393%Sequence 68 from Patent US 7582301 B1 DRAVPa0394%Sequence 69 from Patent US 7582301 B1 DRAVPa0392%Sequence 67 from Patent US 7582301 B1 DRAVPa0391%Sequence 66 from Patent US 7582301 B1 DRAVPa0390%Sequence 65 from Patent US 7582301 B1 DRAVPa0388%Sequence 63 from Patent US 7582301 B1 DRAVPa0389%Sequence 64 from Patent US 7582301 B1 DRAVPa0387%Sequence 62 from Patent US 7582301 B1 DRAVPa0386%Sequence 61 from Patent US 7582301 B1 DRAVPa0384%Sequence 59 from Patent US 7582301 B1 DRAVPa0385%Sequence 60 from Patent US 7582301 B1 DRAVPa0383%Sequence 58 from Patent US 7582301 B1 DRAVPa0382%Sequence 57 from Patent US 7582301 B1 DRAVPa0380%Sequence 55 from Patent US 7582301 B1 DRAVPa0381%Sequence 56 from Patent US 7582301 B1 DRAVPa0379%Sequence 54 from Patent US 7582301 B1 DRAVPa0378%Sequence 53 from Patent US 7582301 B1 DRAVPa0376%Sequence 51 from Patent US 7582301 B1 DRAVPa0377%Sequence 52 from Patent US 7582301 B1 DRAVPa0375%Sequence 50 from Patent US 7582301 B1 DRAVPa0374%Sequence 49 from Patent US 7582301 B1 DRAVPa0372%Sequence 47 from Patent US 7582301 B1 DRAVPa0373%Sequence 48 from Patent US 7582301 B1 DRAVPa0371%Sequence 46 from Patent US 7582301 B1 DRAVPa0370%Sequence 45 from Patent US 7582301 B1 DRAVPa0368%Sequence 43 from Patent US 7582301 B1 DRAVPa0369%Sequence 44 from Patent US 7582301 B1 DRAVPa0367%Sequence 42 from Patent US 7582301 B1 DRAVPa0366%Sequence 41 from Patent US 7582301 B1 DRAVPa0365%Sequence 40 from Patent US 7582301 B1 DRAVPa0363%Sequence 38 from Patent US 7582301 B1 DRAVPa0364%Sequence 39 from Patent US 7582301 B1 DRAVPa0362%Sequence 37 from Patent US 7582301 B1 DRAVPa0361%Sequence 36 from Patent US 7582301 B1 DRAVPa0359%Sequence 34 from Patent US 7582301 B1 DRAVPa0360%Sequence 35 from Patent US 7582301 B1 DRAVPa0358%Sequence 33 from Patent US 7582301 B1 DRAVPa0357%Sequence 32 from Patent US 7582301 B1 DRAVPa0356%Sequence 31 from Patent US 7582301 B1 DRAVPa0355%Sequence 30 from Patent US 7582301 B1 DRAVPa0354%Sequence 29 from Patent US 7582301 B1 DRAVPa0353%Sequence 28 from Patent US 7582301 B1 DRAVPa0352%Sequence 27 from Patent US 7582301 B1 DRAVPa0351%Sequence 26 from Patent US 7582301 B1 DRAVPa0350%Sequence 25 from Patent US 7582301 B1 DRAVPa0349%Sequence 24 from Patent US 7582301 B1 DRAVPa0348%Sequence 23 from Patent US 7582301 B1 DRAVPa0347%Sequence 22 from Patent US 7582301 B1 DRAVPa0346%Sequence 21 from Patent US 7582301 B1 DRAVPa0345%Sequence 20 from Patent US 7582301 B1 DRAVPa0344%Sequence 19 from Patent US 7582301 B1 DRAVPa0343%Sequence 18 from Patent US 7582301 B1 DRAVPa0342"VITIELSNIKENKMNGDAKVKLIKQELDKYKNAV%Sequence 17 from Patent US 7582301 B1 DRAVPa0341"VITIELSNIKENKCNGDAKVKLIKQELDKYKNAV%Sequence 16 from Patent US 7582301 B1 DRAVPa0340"TSVITIELSNIKENKCNGDAKVKLIKQELDKYKN%Sequence 15 f< rom Patent US 7582301 B1 DRAVPa0339"YTSVITIELSNIKENKCNGDAKVKLIKQELDKYK%Sequence 14 from Patent US 7582301 B1 DRAVPa0338%Sequence 13 from Patent US 7582301 B1 DRAVPa0337%Sequence 12 from Patent US 7582301 B1 DRAVPa0336%Sequence 11 from Patent US 7582301 B1 DRAVPa0335%Sequence 10 from Patent US 7582301 B1 DRAVPa0334$Sequence 9 from Patent US 7582301 B1 DRAVPa0333$Sequence 8 from Patent US 7582301 B1 DRAVPa0332$Sequence 7 from Patent US 7582301 B1 DRAVPa0331$Sequence 6 from Patent US 7582301 B1 DRAVPa0330$Sequence 5 from Patent US 7582301 B1 DRAVPa0329$Sequence 4 from Patent US 7582301 B1 DRAVPa0328$Sequence 3 from Patent US 7582301 B1 DRAVPa0327&NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ$Sequence 2 from Patent US 7582301 B1 DRAVPa0326$Sequence 1 from Patent US 7582301 B1 DRAVPa0325 RXXWEQWWDX%Sequence 20 from Patent US 7790171 B1 US 7790171 B1 2010-09-07WO 2002/015661 A2##AU 2001/092153 A##WO 2002/015661 A8##WO 2002/015661 A3##EP 1311538 A2##EP 1311538 B1##AT 420103 T##DE 60137340 D1##US 7790171 B1##US 2011/0064793 A1kAntiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptaseThe 'X' at position 3 indicates Thr,Val or Ile, the 'X' at position 2 indicates Glu or Asp,and the 'X' at position 10 indicates Asn or Asp.The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections. DRAVPa0324 RETWETWWAD%Sequence 19 from Patent US 7790171 B1 DRAVPa0323 KETWEVWWTE%Sequence 18 from Patent US 7790171 B1 DRAVPa0322 KETWDTWWTE%Sequence 17 from Patent US 7790171 B1 DRAVPa0321 KETWEXWWXX%Sequence 16 from Patent US 7790171 B1The 'X' at position 6 indicates Thr or Ala, the 'X' at position 10 indicates Glu or Asp,and the 'X' at position 9 indicates Thr,Ala,Val or Ile. DRAVPa0320 KETWEAWWTD%Sequence 15 from Patent US 7790171 B1 DRAVPa0319 KETWEXWWME%Sequence 14 from Patent US 7790171 B1+The 'X' at position 6 indicates Thr or Ala. DRAVPa0318 KETWEXWWTX%Sequence 13 from Patent US 7790171 B1\The 'X' at position 6 indicates Thr or Ala, and the 'X' at position 10 indicates Glu or Asp. DRAVPa0317 RETWDQWWTD%Sequence 12 from Patent US 7790171 B1 DRAVPa0316 REIWEQWWDN%Sequence 11 from Patent US 7790171 B1 DRAVPa0315 KETWETWWAE%Sequence 10 from Patent US 7790171 B1 DRAVPa0314 KETWETWWIE$Sequence 9 from Patent US 7790171 B1 DRAVPa0313 KETWEAWWME$Sequence 8 from Patent US 7790171 B1 DRAVPa0312 KETWEAWWTE$Sequence 7 from Patent US 7790171 B1 DRAVPa0311GALFLGFLGAAKETWETWWTE$Sequence 6 from Patent US 7790171 B1 DRAVPa0310RGTKALTEVIPLTED$Sequence 5 from Patent US 7790171 B1 DRAVPa0309GFLGAAGSTMGAWSQKETWETWWTE$Sequence 4 from Patent US 7790171 B1 DRAVPa0308GFLGAA$Sequence 3 from Patent US 7790171 B1 DRAVPa0307GALFLGFLGAAGSTMGAWSQPKSKRKV$Sequence 2 from Patent US 7790171 B1 DRAVPa0306 KETWETWWTE$Sequence 1 from Patent US 7790171 B12Synthetic construct(residues 395-404 of HIV-1 BH10 DRAVPa0305'CCCGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL&Sequence 126 from Patent US 7811577 B2 US 7811577 B2 2010-12-12WO 2005/118886 A2##AU 2005/250430 A1##CA 2567030 A1##WO 2005/118886 A3##EP 1755667 A2##CN 1968710 A##US 2007/0224212 A1##JP 2008501028 A##EP 1755667 A4##US 7811577 B2##EP 2354153 A2##AU 2005/250430 B2_Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activityMethods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HI< V gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process. DRAVPa0304%GGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL&Sequence 125 from Patent US 7811577 B2 DRAVPa0303'CCCGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL&Sequence 124 from Patent US 7811577 B2 DRAVPa0302%GGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL&Sequence 123 from Patent US 7811577 B2 DRAVPa0301.CCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL&Sequence 122 from Patent US 7811577 B2 DRAVPa0300,GGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL&Sequence 121 from Patent US 7811577 B2 DRAVPa0299&CCGGIEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL&Sequence 120 from Patent US 7811577 B2 DRAVPa0298IEKKIEEIEEKIEEIEK&Sequence 119 from Patent US 7811577 B2 DRAVPa0297"IEKKIEEIEEKIEEIEKLLQLTVWGIKQLQARIL&Sequence 118 from Patent US 7811577 B2 DRAVPa0296&IEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARILGGCC&Sequence 117 from Patent US 7811577 B2 DRAVPa0295&CCGGIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL&Sequence 116 from Patent US 7811577 B2 DRAVPa0294"IEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL&Sequence 115 from Patent US 7811577 B2 DRAVPa0293IEKKIEEIEKKIEEIEK&Sequence 114 from Patent US 7811577 B2 DRAVPa0292 IEKKIEAIEK&Sequence 113 from Patent US 7811577 B2 DRAVPa0291IEKKIEAIEKKIEAIEKKIEAIEK&Sequence 112 from Patent US 7811577 B2 DRAVPa0290 CCCGGIEEKIEEIEELLQLTVWGIKQLQARIL&Sequence 111 from Patent US 7811577 B2 DRAVPa0289GGGIEEKIEEIEELLQLTVWGIKQLQARIL&Sequence 110 from Patent US 7811577 B2 DRAVPa0288CCGGIEEKIEEIEELLQLTVWGIKQLQARIL&Sequence 109 from Patent US 7811577 B2 DRAVPa0287IEEKIEEIEELLQLTVWGIKQLQARIL&Sequence 108 from Patent US 7811577 B2 DRAVPa0286 IEEKIEEIEE&Sequence 107 from Patent US 7811577 B2 DRAVPa0285%GGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL&Sequence 106 from Patent US 7811577 B2 DRAVPa0284'CCCGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL&Sequence 105 from Patent US 7811577 B2 DRAVPa0283,GGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL&Sequence 104 from Patent US 7811577 B2 DRAVPa0282.CCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL&Sequence 103 from Patent US 7811577 B2 DRAVPa0281CCGGIEKKIEAIEKLLQLTVWGIKQLQARIL&Sequence 102 from Patent US 7811577 B2 DRAVPa0280IEKKIEAIEKLLQLTVWGIKQLQARIL&Sequence 101 from Patent US 7811577 B2 DRAVPa0279&CCGGIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL&Sequence 100 from Patent US 7811577 B2 DRAVPa0278"IEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL%Sequence 99 from Patent US 7811577 B2 DRAVPa0277-CCGGIEKKIEAIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL%Sequence 98 from Patent US 7811577 B2 DRAVPa0276)IEKKIEAIEKKIEAIEKKIEAIEKLLQLTVWGIKQLQARIL%Sequence 97 from Patent US 7811577 B2 DRAVPa0275/CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQIKKEIEAI%Sequence 96 from Patent US 7811577 B2 DRAVPa0274)CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQ%Sequence 95 from Patent US 7811577 B2 DRAVPa0273(LLQLTVWGIKQLQARILAIKKEIEAIKKEQEAIKKKIEAI%Sequence 94 from Patent US 7811577 B2 DRAVPa0272,CCGGLLQLTVWGIKQLQARILAIKKEIEAIKKEQEAIKKKIEAI%Sequence 93 from Patent US 7811577 B2 DRAVPa0271"IKKKIEAIEKLLQLTVWGIKQLQARILAVERYLK%Sequence 92 from Patent US 7811577 B2 DRAVPa0270&IKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARILGGCC%Sequence 91 from Patent US 7811577 B2 DRAVPa0269&CCGGIKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARIL%Sequence 90 from Patent US 7811577 B2 DRAVPa0268"IKKEIEAIKKEQEAIKKLIQLIVWGIKQIQARIL%Sequence 89 from Patent US 7811577 B2 DRAVPa0267IKKKIEAIEKLIQLIVWGIKQIQARILGGCC%Sequence 88 from Patent US 7811577 B2 DRAVPa0266CCGGIKKKIEAIEKLIQLIVWGIKQIQARIL%Sequence 87 fro< m Patent US 7811577 B2 DRAVPa0265IKKKIEAIEKLIQLIVWGIKQIQARIL%Sequence 86 from Patent US 7811577 B2 DRAVPa0264LIQLIVWGIKQIQARIL%Sequence 85 from Patent US 7811577 B2 DRAVPa0263ASQLL%Sequence 84 from Patent US 7811577 B2 DRAVPa0262IKKKIEAIEKLLQLTVWGIKQLQARILGGCC%Sequence 83 from Patent US 7811577 B2 DRAVPa0261GGCC%Sequence 82 from Patent US 7811577 B2 DRAVPa0260)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIA%Sequence 81 from Patent US 7811577 B2 DRAVPa0259)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQAAIL%Sequence 80 from Patent US 7811577 B2 DRAVPa0258)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLAARIL%Sequence 79 from Patent US 7811577 B2 DRAVPa0257)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALQARIL%Sequence 78 from Patent US 7811577 B2 DRAVPa0256)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIAQLQARIL%Sequence 77 from Patent US 7811577 B2 DRAVPa0255)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVAGIKQLQARIL%Sequence 76 from Patent US 7811577 B2 DRAVPa0254)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTAWGIKQLQARIL%Sequence 75 from Patent US 7811577 B2 DRAVPa0253)IKKEIEAIKKEQEAIKKKIEAIEKLLQATVWGIKQLQARIL%Sequence 74 from Patent US 7811577 B2 DRAVPa0252)IKKEIEAIKKEQEAIKKKIEAIEKLLALTVWGIKQLQARIL%Sequence 73 from Patent US 7811577 B2 DRAVPa0251)IKKEIEAIKKEQEAIKKKIEAIEKALQLTVWGIKQLQARIL%Sequence 72 from Patent US 7811577 B2 DRAVPa0250.GCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA%Sequence 71 from Patent US 7811577 B2 DRAVPa0249.GCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA%Sequence 70 from Patent US 7811577 B2 DRAVPa0248.GCCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL%Sequence 69 from Patent US 7811577 B2 DRAVPa0247.GCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL%Sequence 68 from Patent US 7811577 B2 DRAVPa0246$ERVVQNVSYIAQTQDQFTHLFRNINNRLNVLHRRVS%Sequence 67 from Patent US 7811577 B2 DRAVPa0245$NHTFEVENSTLNGMDLIERQIKILYAMILQTHADVQ%Sequence 66 from Patent US 7811577 B2 DRAVPa0244$ATHQETIEKVTEALKINNLRLVTLEHQVLVIGLKVE%Sequence 65 from Patent US 7811577 B2 DRAVPa0243$QTLANATAAQQDALEATYAMVQHVAKGVRILEARVA%Sequence 64 from Patent US 7811577 B2 DRAVPa0242$QSLANATAAQQNVLEATYAMVQHVAKGVRILEARVA%Sequence 63 from Patent US 7811577 B2 DRAVPa0241$AGIVQQQQQLLDVVKRQQELLRLTVWGTKNLQTRVS%Sequence 62 from Patent US 7811577 B2 DRAVPa0240&CCGGIKKEIEAIKKEQEAIKKLLQLTVWGIKALAAAIA%Sequence 61 from Patent US 7811577 B2 DRAVPa0239LLQLTVWGIKALAAAIA%Sequence 60 from Patent US 7811577 B2 DRAVPa0238)IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARILAVERYLK%Sequence 59 from Patent US 7811577 B2 DRAVPa02377IKKEIEAIKKEQEAIKKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL%Sequence 58 from Patent US 7811577 B2 DRAVPa0236)IKKEIEAIKKEQEAIKKEIEAQQHLLQLTVWGIKQLQARIL%Sequence 57 from Patent US 7811577 B2 DRAVPa02354RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARILAVERYLK%Sequence 56 from Patent US 7811577 B2 DRAVPa02341IEKKIEEIEKKIEEIEKKIEEIEEKLLQLTVWGIKQLQARILAVERYLK%Sequence 55 from Patent US 7811577 B2 DRAVPa02330IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARILAVERYLK%Sequence 54 from Patent US 7811577 B2 DRAVPa02320ARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK%Sequence 53 from Patent US 7811577 B2 DRAVPa0231+SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK%Sequence 52 from Patent US 7811577 B2 DRAVPa0230IEAQQHLLQLTVWGIKQLQARILAVERYLK%Sequence 51 from Patent US 7811577 B2 DRAVPa0229LLQLTVWGIKQLQARILAVERYLK%Sequence 50 from Patent US 7811577 B2 DRAVPa0228AVERYLK%Sequence 49 from Patent US 7811577 B2 DRAVPa0227IEAQQHLLQLTVWGIKQLQARIL%Sequence 48 from Patent US 7811577 B2 DRAVPa0226 IKKKIEAIEK%Sequence 45 from Patent US 7811577 B2 DRAVPa0225LLQLTVWGIKQLQARIL%Sequence 44 from Patent US 7811577 B2 DRAVPa0224&IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARILGGCC%Sequence 43 from Patent US 7811577 B2 DRAVPa0223&CCGGIKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARIL%Sequence 42 from Patent US 7811577 B2 DRAVPa0222"IKKEIEAIKKEQEAIKKLLQLTVWGIKQLQARIL%Sequence 41 from Patent US 7811577 B2 DRAVPa0221IKKEIEAIKKEQEAIKK%Sequence 40 from Patent US 7811577 B2 DRAVPa0220KIEEIESKIKKIENEIARIKK%Sequence 39 from Patent US 7811577 B2 DRAVPa0219KIEEIESKQKKIENEIARIKKL%Sequence 38 from Patent US 7811577 B2 DRAVPa0218KIKKIENEIARIKKL%Sequence 37 from Patent US 78115< 77 B2 DRAVPa0217KQKKIENEIAAIKKL%Sequence 36 from Patent US 7811577 B2 DRAVPa0216RMKQIEDKIEEIESKQKKIENEIARIKKL%Sequence 35 from Patent US 7811577 B2 DRAVPa0215IEKKIEE%Sequence 34 from Patent US 7811577 B2 DRAVPa0214IEKKIEA%Sequence 33 from Patent US 7811577 B2 DRAVPa0213IEKKIEEIEKKIEEIEKKIEEIEK%Sequence 32 from Patent US 7811577 B2 DRAVPa0212IKKEIEAIKKEQEAIKKKIEAIEK%Sequence 31 from Patent US 7811577 B2 DRAVPa0211!RMKQIEDKIEEILSKQYHIENEIARIKKLIGER%Sequence 30 from Patent US 7811577 B2 DRAVPa0210YGGIEKKIEAIEKKIEAIEKKIEAIEKKIEA%Sequence 29 from Patent US 7811577 B2 DRAVPa0209CCGG%Sequence 28 from Patent US 7811577 B2 DRAVPa02081CCGGRMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKALAAAIA%Sequence 27 from Patent US 7811577 B2 DRAVPa02071CCGGRMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL%Sequence 26 from Patent US 7811577 B2 DRAVPa0206BRMKQIEDKIEEIESKQKKIENEIARIKKLISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL%Sequence 25 from Patent US 7811577 B2 DRAVPe00815 DRAVPa02054RMKQIEDKIEEIESKQKKIENEIARIKKLIEAQQHLLQLTVWGIKQLQARIL%Sequence 24 from Patent US 7811577 B2 DRAVPe00814 DRAVPa0204-RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL%Sequence 23 from Patent US 7811577 B2 DRAVPe00812 DRAVPa0203)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWDIKQLQARIL%Sequence 22 from Patent US 7811577 B2 DRAVPa02020SGGCCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL%Sequence 21 from Patent US 7811577 B2 DRAVPa0201CCGGIKKKIEAIEKLLQLTVWGIKQLQARIL%Sequence 20 from Patent US 7811577 B2 DRAVPa0200>IEKKIEEIEKKIEEIEKKIEEIEEKISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL%Sequence 19 from Patent US 7811577 B2 DRAVPa0199BCCGGIKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL%Sequence 18 from Patent US 7811577 B2 DRAVPa0198AGKGIKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL%Sequence 17 from Patent US 7811577 B2 DRAVPa0197>IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL%Sequence 16 from Patent US 7811577 B2 DRAVPe00818 DRAVPa01964CCGGIEKKIEEIEKKIEEIEKKIEEIEEKIEAQQHLLQLTVWGIKQLQARIL%Sequence 15 from Patent US 7811577 B2 DRAVPa01950IEKKIEEIEKKIEEIEKKIEEIEEKIEAQQHLLQLTVWGIKQLQARIL%Sequence 14 from Patent US 7811577 B2 DRAVPa01944CCGGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL%Sequence 13 from Patent US 7811577 B2 DRAVPa01935GCCGGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL%Sequence 12 from Patent US 7811577 B2WThe peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=0.316 nM). DRAVPa01922GGIKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL%Sequence 11 from Patent US 7811577 B2WThe peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=2.173 nM). DRAVPa01910IKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL%Sequence 10 from Patent US 7811577 B2 DRAVPe00817 DRAVPa0190)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL'Sequence 1 from Patent US 7811577 B2 B2The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=1.7 nM; HIV Bal:IC50=3.2 nM).The peptide was modified with acetyl N-terminus and amide C-terminus. DRAVPe00816 DRAVPa0188KNIYRPDKFLQCVKNPEDSSCTSEI"Sequence 22 from Patent US 8080633 US 8080633 B2 2011-12-20WO 2003/091275 A2##AU 2003/241103 A8##AU 2003/241103 A1##US 2004/0116653 A1##US 8030444 B2##US 2009/0170764 A1##US 7553926 B2##US 2009/0088381 A1Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptidesPeptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID NO:18) for topical application to inhibit or prevent transmission of the HIV virus. DRAVPa0189,GKGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL$Sequence 3 from Patent US 7811577 B2 DRAVPa0187SGPGTTKRFPETVLACVKYTEIH"Sequence 21 from Patent US 8080633 DRAVPa0186NTRKSIIGPGRAFYTTGQIIGDIRQAH"Sequence 20 from Patent US 80806332Human immunodeficiency virus(HIV-1 subtype B gp120 DRAVPa0185RWRQQWS< GPGTTKRFPETVLARCVKYTEIH"Sequence 19 from Patent US 8080633 DRAVPa0184GPGTTK"Sequence 18 from Patent US 8080633 DRAVPa0182"Sequence 16 from Patent US 8080633 DRAVPa0183RQQWSGPGTTKRFPETVLARCVKYTEIH"Sequence 17 from Patent US 8080633 DRAVPa0181SGPGTTKRFPETVLARCVKYTEIH"Sequence 15 from Patent US 8080633 DRAVPa0180 RWRQTWSGPGTTK"Sequence 14 from Patent US 8080633 DRAVPa0179RQTWSGPGTTKRFPETVLARCVKYTEIH"Sequence 13 from Patent US 8080633 DRAVPa0178RWRQTWSGPGTTKRFPETVLARCVKYTEIH"Sequence 12 from Patent US 8080633 DRAVPa0177KRPGNKTVVPITLMSGLVFHSQPINRPRQAW"Sequence 11 from Patent US 8080633#Human immunodeficiency virus(HIV-2) DRAVPa0175RPGVQEIIGPMAWYSMGLNNSRAY!Sequence 9 from Patent US 8080633,Human immunodeficiency virus(HIV subgroup O) DRAVPa0176RPGNNTRGQIGPGMTFYNIENIVGDTRA"Sequence 10 from Patent US 8080633&Simian immunodeficiency virus(SIV cpz) DRAVPa0174 TRPGNNTGGQVQIGPAMTFYNIEKIVGDRQAY!Sequence 8 from Patent US 8080633,Human immunodeficiency virus(HIV subgroup N) DRAVPa0173 TRPSNNTRTSRIGPGRVFYKTGDIIGDIRKAY!Sequence 7 from Patent US 8080633'Human immunodeficiency virus(HIV sub E) DRAVPa0172TRPYNRQRTPIGLGQALYTTRYTTRIIGQAY!Sequence 6 from Patent US 8080633'Human immunodeficiency virus(HIV sub D) DRAVPa0171!TRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAH!Sequence 5 from Patent US 8080633'Human immunodeficiency virus(HIV sub C) DRAVPa0170!TRPNNNTRRSIRIGPGQAFYATGDIIGDIRQAH!Sequence 4 from Patent US 8080633'Human immunodeficiency virus(HIV sub A) DRAVPa0169 TRPNNNTRKSIIGPGRAFYTTGQIIGDIRQAH!Sequence 3 from Patent US 8080633'Human immunodeficiency virus(HIV sub B) DRAVPa0167!Sequence 1 from Patent US 8080633 DRAVPa0168NTRKSHIGPGRAFYTTGIIGDIRQAH!Sequence 2 from Patent US 8080633/Human immunodeficiency virus(HIV gp120 299-324) DRAVPa0166GICRCICGRRICRCICGR,Sequence 140 from Patent US 2009/0264344 A1HIV-1,HSV-1,HSV-2US 2009/0264344 A1 2009-10-22WUS 2005/0272645 A1##WO 2006/052637 A1##US 7314858 B2##US 2009/0264344 A1##US 7718610 B22Retrocyclins: Antiviral and Antimicrobial PeptidesThe peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity.Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens. DRAVPe01560 Anti-HIV-1,Anti-HSV-1,Anti-HSV-2 DRAVPa0165RYICRCICGRGICRCICG,Sequence 139 from Patent US 2009/0264344 A1 DRAVPe01563 DRAVPa0164GICRCICGRYICRCICGR,Sequence 138 from Patent US 2009/0264344 A1 DRAVPe01562 DRAVPa0163GICYCICGKGICRCICGR,Sequence 137 from Patent US 2009/0264344 A1 DRAVPa0162 RXICGXXIC,Sequence 136 from Patent US 2009/0264344 A1The 'X' at position 2 and 6 indicates Arg or Lys, and the 'X' at position 7 indicates Arg, Lys or Gly.The peptide has potent activity against viruses, e.g. enveloped viruses such as retroviruses.It is nonhemolytic and generally exhibits little or no in vitro cytotoxicity. DRAVPa0161GVCRCICGRGVCRCICGR,Sequence 135 from Patent US 2009/0264344 A1 Orangutan DRAVPa0160GVCRCICGRGVCRCICRR,Sequence 134 from Patent US 2009/0264344 A1 DRAVPa0159GICRCICGRRICRCICGK<Sequence 133 from Patent US 2009/0264344 A1(Retrocyclin 2F) DRAVPa0158GICKCICGRRICRCICGR<Sequence 132 from Patent US 2009/0264344 A1(Retrocyclin 2E) DRAVPa0157GICRCICGRRICKCICGR<Sequence 131 from Patent US 2009/0264344 A1(Retrocyclin 2D) DRAVPa0156GICRCICGRKICRCICGR<Sequence 130 from Patent US 2009/0264344 A1(Retrocyclin 2C) DRAVPa0155GICRCICGKKICRCICGR<Sequence 129 from Patent US 2009/0264344 A1(Retrocyclin 2B) DRAVPa0154GICRCICGKRICRCICGR<Sequence 128 from Patent US 2009/0264344 A1(Retrocyclin 2A) DRAVPa0153GICKCICGKGICKCICGR=Sequen< ce 127 from Patent US 2009/0264344 A1(K Retrocyclin-1) DRAVPa0152GICRCICGKGICRCYCGR>Sequence 126 from Patent US 2009/0264344 A1(RC101/103 hybrid) DRAVPa0151-CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL$Sequence 2 from Patent US 7811577 B2The peptide exihibits antiviral activity as a fusion inhibitor(HIV HXB2:IC50=0.04 nM; HIV Bal:IC50=0.34 nM;HIV 89.6:IC50=8 nM;HIV SHIV89.6p:IC50=6.9 Nm;HIV MN-1:IC50=0.9 nM;HIV NL43:IC50=0.1 nM).The peptide was modified with acetyl N-terminus and amide C-terminus. DRAVPa0150 RCLCVLRIC,Sequence 119 from Patent US 2009/0264344 A1 DRAVPa0149 RCLCVLRVC,Sequence 118 from Patent US 2009/0264344 A1 DRAVPa0148 RCLCTLRIC,Sequence 117 from Patent US 2009/0264344 A1 DRAVPa0147 RCLCTLRVC,Sequence 116 from Patent US 2009/0264344 A1 DRAVPa0146 RCLCGLRIC,Sequence 115 from Patent US 2009/0264344 A1 DRAVPa0145 RCLCGLRVC,Sequence 114 from Patent US 2009/0264344 A1 DRAVPa0144 RCICVLRFC,Sequence 113 from Patent US 2009/0264344 A1 DRAVPa0143 RCICVLRVC,Sequence 112 from Patent US 2009/0264344 A1 DRAVPa0142 RCICTLRFC,Sequence 111 from Patent US 2009/0264344 A1 DRAVPa0141 RCICTLRVC,Sequence 110 from Patent US 2009/0264344 A1 DRAVPa0140 RCICRLRFC,Sequence 109 from Patent US 2009/0264344 A1 DRAVPa0139 RCICRLRVC,Sequence 108 from Patent US 2009/0264344 A1 DRAVPa0138 RCICGRRIC,Sequence 107 from Patent US 2009/0264344 A1 DRAVPa0137 RCLCVRRVC,Sequence 106 from Patent US 2009/0264344 A1 DRAVPa0136,Sequence 105 from Patent US 2009/0264344 A1 DRAVPa0135 RCLCTRRFC,Sequence 104 from Patent US 2009/0264344 A1 DRAVPa0134 RCLCGRRVC,Sequence 103 from Patent US 2009/0264344 A1 DRAVPa0133,Sequence 102 from Patent US 2009/0264344 A1 DRAVPa0132 RCLCRRRFC,Sequence 101 from Patent US 2009/0264344 A1 DRAVPa0131 RCLCRRRVC,Sequence 100 from Patent US 2009/0264344 A1 DRAVPa0130 RCLCRLRIC+Sequence 99 from Patent US 2009/0264344 A1 DRAVPa0129 RCICGLRVC+Sequence 98 from Patent US 2009/0264344 A1 DRAVPa0128 RCICGLRFC+Sequence 97 from Patent US 2009/0264344 A1 DRAVPa0127 RCICGRRFC+Sequence 96 from Patent US 2009/0264344 A1 DRAVPa0126 RCICVRRVC+Sequence 95 from Patent US 2009/0264344 A1 DRAVPa0125 RCICRLRIC+Sequence 94 from Patent US 2009/0264344 A1 DRAVPa0124+Sequence 93 from Patent US 2009/0264344 A1 DRAVPa0123 RCICTLRIC+Sequence 92 from Patent US 2009/0264344 A1 DRAVPa0122 RCICTRRFC+Sequence 91 from Patent US 2009/0264344 A1 DRAVPa0121 RCICTRRVC+Sequence 90 from Patent US 2009/0264344 A1 DRAVPa0120 RCICRRRFC+Sequence 89 from Patent US 2009/0264344 A1 DRAVPa0119 RCICRRRVC+Sequence 88 from Patent US 2009/0264344 A1 DRAVPa0118 RCLCGRRFC+Sequence 87 from Patent US 2009/0264344 A1 DRAVPa0117+Sequence 86 from Patent US 2009/0264344 A1 DRAVPa0116+Sequence 85 from Patent US 2009/0264344 A1 DRAVPa0115 RCLCVRRIC+Sequence 84 from Patent US 2009/0264344 A1 DRAVPa0114 RCLCTRRIC+Sequence 83 from Patent US 2009/0264344 A1 DRAVPa0113+Sequence 82 from Patent US 2009/0264344 A1 DRAVPa0112+Sequence 81 from Patent US 2009/0264344 A1 DRAVPa0111 RCICGRRVC+Sequence 80 from Patent US 2009/0264344 A1 DRAVPa0110 RCICGLRIC+Sequence 79 from Patent US 2009/0264344 A1 DRAVPa0109 RCICVRRIC+Sequence 78 from Patent US 2009/0264344 A1 DRAVPa0108 RCICTRRIC+Sequence 77 from Patent US 2009/0264344 A1 DRAVPa0107 RCICRRRIC+Sequence 76 from Patent US 2009/0264344 A1 DRAVPa0106 RCLCGRRIC+Sequence 75 from Patent US 2009/0264344 A1 DRAVPa0105+Sequence 74 from Patent US 2009/0264344 A1 DRAVPa0104)IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA$Sequence 4 from Patent US 7811577 B2 DRAVPa0103-CCGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKALAAAIA$Sequence 5 from Patent US 7811577 B2 DRAVPa0102)IEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL$Sequence 6 from Patent US 7811577 B2 DRAVPa0101-CCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKQLQARIL$Sequence 7 from Patent US 7811577 B2 DRAVPa0100)IEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA$Sequence 8 from Patent US 7811577 B2 DRAVPa0099-CCGGIEKKIEEIEKKIEEIEKKIEEIEKLLQLTVWGIKALAAAIA$Sequence 9 from Patent US 7811577 B2 DRAVPa0098 RCLCVLGIC+Sequence 64 from Pate< nt US 2009/0264344 A1 DRAVPa0097 RCLCVLGVC+Sequence 63 from Patent US 2009/0264344 A1 DRAVPa0096 RCLCTLGIC+Sequence 62 from Patent US 2009/0264344 A1 DRAVPa0095 RCLCTLGVC+Sequence 61 from Patent US 2009/0264344 A1 DRAVPa0094 RCLCGLGIC+Sequence 60 from Patent US 2009/0264344 A1 DRAVPa0093 RCLCGLGVC+Sequence 59 from Patent US 2009/0264344 A1 DRAVPa0092 RCICVLGFC+Sequence 58 from Patent US 2009/0264344 A1 DRAVPa0091 RCICVLGVC+Sequence 57 from Patent US 2009/0264344 A1 DRAVPa0090 RCICTLGFC+Sequence 56 from Patent US 2009/0264344 A1 DRAVPa0089 RCICTLGVC+Sequence 55 from Patent US 2009/0264344 A1 DRAVPa0088 RCICRLGFC+Sequence 54 from Patent US 2009/0264344 A1 DRAVPa0087 RCICRLGVC+Sequence 53 from Patent US 2009/0264344 A1 DRAVPa0086 RCICGRGIC+Sequence 52 from Patent US 2009/0264344 A1 DRAVPa0085 RCLCVRGVC+Sequence 51 from Patent US 2009/0264344 A1 DRAVPa0084+Sequence 50 from Patent US 2009/0264344 A1 DRAVPa0083 RCLCTRGFC+Sequence 49 from Patent US 2009/0264344 A1 DRAVPa0082 RCLCTRGVC+Sequence 48 from Patent US 2009/0264344 A1 DRAVPa0081+Sequence 47 from Patent US 2009/0264344 A1 DRAVPa0080 RCLCRRGFC+Sequence 46 from Patent US 2009/0264344 A1 DRAVPa0079 RCLCRRGVC+Sequence 45 from Patent US 2009/0264344 A1 DRAVPa0078 RCLCRLGIC+Sequence 44 from Patent US 2009/0264344 A1 DRAVPa0077 RCICGLGVC+Sequence 43 from Patent US 2009/0264344 A1 DRAVPa0076 RCICGLGFC+Sequence 42 from Patent US 2009/0264344 A1 DRAVPa0075 RCICGRGFC+Sequence 41 from Patent US 2009/0264344 A1 DRAVPa0074 RCICVRGVC+Sequence 40 from Patent US 2009/0264344 A1 DRAVPa0073 RCICRLGIC+Sequence 39 from Patent US 2009/0264344 A1 DRAVPa0072+Sequence 38 from Patent US 2009/0264344 A1 DRAVPa0071 RCICTLGIC+Sequence 37 from Patent US 2009/0264344 A1 DRAVPa0070 RCICTRGFC+Sequence 36 from Patent US 2009/0264344 A1 DRAVPa0069 RCICTRGVC+Sequence 35 from Patent US 2009/0264344 A1 DRAVPa0068 RCICRRGFC+Sequence 34 from Patent US 2009/0264344 A1 DRAVPa0067 RCICRRGVC+Sequence 33 from Patent US 2009/0264344 A1 DRAVPa0066 RCLCGRGFC+Sequence 32 from Patent US 2009/0264344 A1 DRAVPa0065 RCLCGRGVC+Sequence 31 from Patent US 2009/0264344 A1 DRAVPa0064+Sequence 30 from Patent US 2009/0264344 A1 DRAVPa0063 RCLCVRGIC+Sequence 29 from Patent US 2009/0264344 A1 DRAVPa0062 RCLCTRGIC+Sequence 28 from Patent US 2009/0264344 A1 DRAVPa0061+Sequence 27 from Patent US 2009/0264344 A1 DRAVPa0060+Sequence 26 from Patent US 2009/0264344 A1 DRAVPa0059 RCICGRGVC+Sequence 25 from Patent US 2009/0264344 A1 DRAVPa0058 RCICGLGIC+Sequence 24 from Patent US 2009/0264344 A1 DRAVPa0057 RCICVRGIC+Sequence 23 from Patent US 2009/0264344 A1 DRAVPa0056 RCICTRGIC+Sequence 22 from Patent US 2009/0264344 A1 DRAVPa0055 RCICRRGIC+Sequence 21 from Patent US 2009/0264344 A1 DRAVPa0054 RCLCGRGIC+Sequence 20 from Patent US 2009/0264344 A1 DRAVPa0053+Sequence 19 from Patent US 2009/0264344 A1 DRAVPa0052LMRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGADDQGMAHSFTRPENAALPLSESARGLRCLCRRGVCQLL+Sequence 17 from Patent US 2009/0264344 A1Macaca mulatta DRAVPa0051LMRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGTDDQGMAHSFTWPENAALPLSESAKGLRCICTRGFCRLL+Sequence 15 from Patent US 2009/0264344 A1 DRAVPa0050aMRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD=Sequence 13 from Patent US 2009/0264344 A1(human defensin 4) DRAVPa0049;AQAEPLQARADEAAAQEQPGADDQEMAHAFTWHESAALPLSDSARGLRCICGRGICRLL+Sequence 12 from Patent US 2009/0264344 A1 DRAVPa0048RGCICRCIGRGCICRCIG+Sequence 10 from Patent US 2009/0264344 A1gThe peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. DRAVPa0047GICICICGRGICYCICGR*Sequence 9 from Patent US 2009/0264344 A1 DRAVPa0046GICICICGYGICRCICGR*Sequence 8 from Patent US 2009/0264344 A1 DRAVPa0045GICYCICGRGICRCICGR*Sequence 7 from Patent US 2009/0264344 A1 DRAVPa0044GICRCICGRGYCRCICGR*Sequence 6 from Patent US 2009/0264344 A1 DRAVPa0043GYCRCICGRGICRCICGR*Sequence 5 from Patent US 2009/0264344 A1 DRAVPa0042GICRCICGRGICRCYCGR*Sequence 4 fr< om Patent US 2009/0264344 A1 DRAVPa0041GICRCYCGRGICRCICGR*Sequence 3 from Patent US 2009/0264344 A1 DRAVPa0040GICRCICGKGICRCICGR2Sequence 2 from Patent US 2009/0264344 A1(RC-101) DRAVPe01561 DRAVPa0039GICRCICGRGICRCICGR*Sequence 1 from Patent US 2009/0264344 A1The peptide is potently active against both X4 and R5 strains of HIV-1 by inhibiting virus replication. The mean IC50 value of RC-101 for the seven subtype B strains was <1.25 g/ml (<660 nM). DRAVPe01559 DRAVPa0038MEHFRWG/Sequence 1 from Patent US 7244710(-MSH [4-10])Herpesvirus,HIV US 7244710 B2 2007-07-17(FR 1456903 A##ES 323291 A1##SU 622426 A3?Treatment Of Ophthalmic Infections Using Antimicrobial PeptidesThe peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription.The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (-MSH) include -MSH (1 13) which is SYSMEHFRWGKPV, -MSH (4 10) which is MEHFRWG, -MSH (6 13) which is HFRWGKPV, -MSH (11 13) which is KPV, and a KPV dimer. The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral property and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter.Herpesvirus,Anti-HIV DRAVPa0037HFRWGKPV/Sequence 2 from Patent US 7244710(-MSH [6-13]) DRAVPa0036 SYSMEHFRWGKPV/Sequence 3 from Patent US 7244710(-MSH [1-13]) DRAVPa0035VPKCCKPV!Sequence 4 from Patent US 7244710,The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5).The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription. DRAVPa0034CKPV!Sequence 5 from Patent US 7244710 DRAVPa0033VPKXCKPV!Sequence 6 from Patent US 7244710[The peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5), the 'X' at position 4 indicates Penicillamine.The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription. DRAVPa0032VPKXXKPV!Sequence 7 from Patent US 7244710aThe peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5), the 'X' at position 4 and 5 indicates Penicillamine.The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, H< erpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription. DRAVPa0031!Sequence 8 from Patent US 7244710cThe peptide is formed by two PKV peptides which linked by a linker(disulfide bond between residues 4 and 5), and the Cys at position 4 and 5 refers to Omocysteine.The peptide could treat viral ophthalmic infection of the invention caused by Poxvirus, Herpesvirus, Adenovirus, Paramyxovirus and Human Immunodeficiency virus, especially Herpesvirus and Human Immunodedeficiency virus(HIV), the key species in Herpesvirus are Herpes simplex virus, Herpes zoster virus, Epstein-Barr virus, Cytomegalovirus.The possible mechanism of action is inhibiting HIV-p24 expression in HIV infected cells or HIV transcription. DRAVPa0030!Sequence 9 from Patent US 7244710 DRAVPa0029VPKCXKPV"Sequence 10 from Patent US 7244710 DRAVPa0028"Sequence 11 from Patent US 7244710 DRAVPa0027IPLRGAFINGRWDSQCHRFSNGAIAAA&Sequence 27 from Patent US 20190367567H1N1US 2019/0367567 A1 2019-12-05CWO 2018/102753 A1##EP 3548056 A1##US 2019/0367567 A1##EP 3548056 A4/Peptides and Uses for Managing Viral InfectionsThe peptide is useful for the prevention or treatment of viral infections such as influenza infections and exhibits no toxicity to human red blood cells.It has been discovered that certain peptides are useful for managing certain viral infections. Thus, this disclosure relates to the use of peptides reported herein for the prevention or treatment of viral infections such as influenza infections. In certain embodiments, this disclosure relates to peptides, variants, or derivatives having sequences disclosed herein and pharmaceutical compositions comprising the same. DRAVPa0026IPLRGAFINGRWDSQCHRFSNGAAACA&Sequence 26 from Patent US 20190367567 DRAVPa0025IPLRGAFINGRWDSQCHRFSNAAIACA&Sequence 25 from Patent US 20190367567 DRAVPa0024IPLRGAFINGRWDSQCHRFSAGAIACA&Sequence 24 from Patent US 20190367567 DRAVPa0023IPLRGAFINGRWDSQCHRFANGAIACA&Sequence 23 from Patent US 20190367567 DRAVPa0022IPLRGAFINGRWDSQCHRASNGAIACA&Sequence 22 from Patent US 20190367567 DRAVPa0021IPLRGAFINGRWDSQCHAFSNGAIACA&Sequence 21 from Patent US 20190367567 DRAVPa0020IPLRGAFINGRWDSQCARFSNGAIACA&Sequence 20 from Patent US 20190367567 DRAVPa0019IPLRGAFINGRWDSQAHRFSNGAIACA&Sequence 19 from Patent US 20190367567 DRAVPa0018IPLRGAFINGRWDSACHRFSNGAIACA&Sequence 18 from Patent US 20190367567 DRAVPa0017IPLRGAFINGRWDAQCHRFSNGAIACA&Sequence 17 from Patent US 20190367567 DRAVPa0016IPLRGAFINGRWASQCHRFSNGAIACA&Sequence 16 from Patent US 20190367567 DRAVPa0015IPLRGAFINGRADSQCHRFSNGAIACA&Sequence 15 from Patent US 20190367567 DRAVPa0014IPLRGAFINGAWDSQCHRFSNGAIACA&Sequence 14 from Patent US 20190367567 DRAVPa0013IPLRGAFINARWDSQCHRFSNGAIACA&Sequence 13 from Patent US 20190367567 DRAVPa0012IPLRGAFIAGRWDSQCHRFSNGAIACA&Sequence 12 from Patent US 20190367567 DRAVPa0011IPLRGAFANGRWDSQCHRFSNGAIACA&Sequence 11 from Patent US 20190367567 DRAVPa0010IPLRGAAINGRWDSQCHRFSNGAIACA&Sequence 10 from Patent US 20190367567 DRAVPa0009IPLRAAFINGRWDSQCHRFSNGAIACA%Sequence 9 from Patent US 20190367567 DRAVPa0008IPLAGAFINGRWDSQCHRFSNGAIACA%Sequence 8 from Patent US 20190367567 DRAVPa0007IPARGAFINGRWDSQCHRFSNGAIACA%Sequence 7 from Patent US 20190367567 DRAVPa0006IALRGAFINGRWDSQCHRFSNGAIACA%Sequence 6 from Patent US 20190367567 DRAVPa0005APLRGAFINGRWDSQCHRFSNGAIACA%Sequence 5 from Patent US 20190367567 DRAVPa0004"SFITKLKDVAIGVAKGAGLGILKTLTCKLDNSCA%Sequence 4 from Patent US 20190367567 DRAVPa0003"SFVTKLKDVAIGVAKGAGLGILKTLTCKLDNSCA%Sequence 3 from Patent US 20190367567 DRAVPa0002%SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC%Sequence 2 from Patent US 20190367567 DRAVPa0001IPLRGAFINGRWDSQCHRFSNGAIACA-Sequence 1 from Patent US 20190367567(Urumin) H1N1,H1N2The peptide exhibits no toxicity to human red blood cells.IC50=2.5-5 M tested by graded concentrations of Urumin (0.6-320 M) against PR8 virus by plaque assay. DRAVPa1674AQEVKXWMTXTLLVA%Sequence 4 from Patent US 20090281041< The peptide shows antiviral activity against HIV-1 IIIB(IC50=4.29 0.62 M) and exhibits cytotoxicity against MT-2 cells(CC50>116 M).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling. DRAVPa1675AQAVKXWMTXTLLVA%Sequence 5 from Patent US 20090281041 The peptide shows antiviral activity against HIV-1 IIIB(IC50=2.36 0.33 M) and exhibits cytotoxicity against MT-2 cells(CC50=30.2 4.32 M).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling. DRAVPa1676AQEVKXWMTXTLLVAKKK%Sequence 6 from Patent US 20090281041 The peptide shows antiviral activity against HIV-1 IIIB(IC50=6.29 0.54 M) and exhibits cytotoxicity against MT-2 cells(CC50=13.24 0.5 M).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling. DRAVPa1677AQKVEXWMTXTLLVA%Sequence 7 from Patent US 20090281041The peptide shows antiviral activity against HIV-1 IIIB(IC50=5.15 0.76 M) and exhibits cytotoxicity against MT-2 cells(CC50>112 M).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling. DRAVPa1678AQAVKXWMTXTLLVENA%Sequence 8 from Patent US 20090281041The peptide shows antiviral activity against HIV-1 IIIB(IC50=2.95 0.33 M) and exhibits cytotoxicity against MT-2 cells(CC50>102 M).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling. DRAVPa1679AQAVKXWMTXTLLKANAE%Sequence 9 from Patent US 20090281041The peptide shows antiviral activity against HIV-1 IIIB(IC50=17.4 0.90 M) and exhibits cytotoxicity against MT-2 cells(CC50>48 M).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling. DRAVPa1680EQLVWXKMTXALAVT&Sequence 10 from Patent US 20090281041The peptide shows antiviral activity against HIV-1 IIIB(IC50>56 M) and exhibits cytotoxicity against MT-2 cells(CC50>112 M).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling. DRAVPa1681AQEVKNWMTE TLLVA&Sequence 11 from Patent US 20090281041 DRAVPa1682AQAVKNWMTXTLLXA&Sequence 12 from Patent US 20090281041 The peptide shows antiviral activity against HIV-1 IIIB(IC50=4.6 0.40 M) and exhibits cytotoxicity against MT-2 cells(CC50=67.3 4.4 M).The 'X' at position 10 and 14 indicates (S)-a-2-(2'-pentenyl)alanine, X(10) and X(14) are cross-linked by hydrocarbon stapling. DRAVPa1683AQAWKXWATXTLLVAE&Sequence 13 from Patent US 20090281041The peptide shows antiviral activity against HIV-1 IIIB(IC50=3.7 0.06 M) and exhibits cytotoxicity against MT-2 cells(CC50>106 M).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling. DRAVPa1684AQAVKXWMEXTLKVAE&Sequence 14 from Patent US 20090281041The peptide shows antiviral activity against HIV-1 IIIB(IC50>52.7 M) and exhibits cytotoxicity against MT-2 cells(CC50>105.4 M).The 'X' at position 6 and 10 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(10) are cross-linked by hydrocarbon stapling. DRAVPa1685AQAVKXWMTETLXVA&Sequence 15 from Patent US 20090281041The peptide shows antiviral activity against HIV-1 IIIB(IC50=7.97 1.03 M) and exhibits cytotoxicity against MT-2 cells(CC50>140.4 M).The 'X' at position 6 and 13 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(13) are cross-linked by hydrocarbon stapling. DRAVPa1686AQAWKXWATETLXVAN&Sequence 16 from Patent US 20090281041The peptide shows antiviral activity against HIV-1 IIIB(IC50=9.3 1.6 M) and exhibits cytotoxicity against MT-2 cells(CC50>130 M).The 'X' at position 6 and 13 indicates (S)-a-2-(2'-pentenyl)alanine, X(6) and X(13) are cross-linked by hydrocarbon stapling. DRAVPa1687IAQAKVEXWMTXTLLVAN&Sequence 17 from Patent US 20090281041The peptide shows antiviral activity against HIV-1 IIIB(IC50=7.2 1.2 M) an< d exhibits cytotoxicity against MT-2 cells(CC50>124.4 M).The 'X' at position 8 and 12 indicates (S)-a-2-(2'-pentenyl)alanine, X(8) and X(12) are cross-linked by hydrocarbon stapling. DRAVPa1688AQAVKNWMTETLLVA&Sequence 19 from Patent US 20090281041 DRAVPa1689%Sequence 1 from Patent US 20100041604Influenza VirusUS 2010/0041604 A1 2010-02-18CA 2727898 A1##WO 2009/152519 A2##US 2010/0041604 A1##WO 2009/152519 A3##EP 2310030 A2##JP 2011524373 A##US 8129499 B2##US 2013/0190228 A1##EP 2310030 A4##US 9221874 B20Novel Antiviral Peptides Against Influenza VirusH95 2% inhibition against influenza virus at 10 M.(EC50= 2.6 1.0 M)FThe present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections. DRAVPa1690RRKKAAVALLPAVLLALLA%Sequence 2 from Patent US 20100041604G94 2% inhibition against influenza virus at 10 M.(EC50=0.5 0.3 M) DRAVPe01186 DRAVPa1691RRKKAAVALLPAVLLALL%Sequence 3 from Patent US 20100041604H95 2% inhibition against influenza virus at 10 M.(EC50= 0.6 0.3 M) DRAVPe01187 DRAVPa1692%Sequence 4 from Patent US 20100041604H89 3% inhibition against influenza virus at 10 M.(EC50= 3.8 1.9 M) DRAVPa1693RRKKAAVALLPAVLLA%Sequence 5 from Patent US 20100041604H96 3% inhibition against influenza virus at 10 M.(EC50= 2.8 1.1 M) DRAVPe01189 DRAVPa1694RRKKAAVALLPAVLL%Sequence 6 from Patent US 20100041604/0% inhibition against influenza virus at 10 M. DRAVPa1695RRKKAAVALLPAVL%Sequence 7 from Patent US 20100041604 DRAVPa1696 RRKKAAVALLPAV%Sequence 8 from Patent US 20100041604 DRAVPa1697 RRKKAAVALLPA%Sequence 9 from Patent US 20100041604 DRAVPa1698&Sequence 10 from Patent US 2010004160434 8% inhibition against influenza virus at 10 M. DRAVPa1699 RRKKAAVALL&Sequence 11 from Patent US 20100041604 DRAVPa1700 RRKKAAVAL&Sequence 12 from Patent US 20100041604 DRAVPa1701&Sequence 13 from Patent US 20100041604 DRAVPa1702RRKKAAV&Sequence 14 from Patent US 20100041604 DRAVPa1703RRKKAA&Sequence 15 from Patent US 20100041604 DRAVPa1704RRKKA&Sequence 16 from Patent US 20100041604 DRAVPa1705&Sequence 17 from Patent US 20100041604 DRAVPa1706RRKKAVALLPAVLLALLAP&Sequence 18 from Patent US 20100041604H94 6% inhibition against influenza virus at 10 M.(EC50= 0.8 0.3 M) DRAVPe01191 DRAVPa1707RRKKVALLPAVLLALLAP&Sequence 19 from Patent US 20100041604H94 4% inhibition against influenza virus at 10 M.(EC50= 0.5 0.4 M) DRAVPe01192 DRAVPa1708&Sequence 20 from Patent US 20100041604G94 3% inhibition against influenza virus at 10 M.(EC50= 0.7 0.3 M) DRAVPa1709RRKKLLPAVLLALLAP&Sequence 21 from Patent US 20100041604F94 4% inhibition against influenza virus at 10 M.(EC50=0.8 0.3 M) DRAVPe01194 DRAVPa1710RRKKLPAVLLALLAP&Sequence 22 from Patent US 20100041604H94 4% inhibition against influenza virus at 10 M.(EC50= 0.9 0.3 M) DRAVPe01195 DRAVPa1711 RRKKVLLALLAP&Sequence 23 from Patent US 20100041604G90 4% inhibition against influenza virus at 10 M.(EC50=4.0 0.8 M) DRAVPe01198 DRAVPa1712&Sequence 24 from Patent US 20100041604 DRAVPa1713 RRKKALLAP&Sequence 25 from Patent US 20100041604 DRAVPa1714&Sequence 26 from Patent US 20100041604 DRAVPa1715RRKKLAP&Sequence 27 from Patent US 20100041604 DRAVPa1716RRKKAP&Sequence 28 from Patent US 20100041604 DRAVPa1717RRKKP&Sequence 29 from Patent US 20100041604 DRAVPa1718RRKKAALLVLAALAVLA&Sequence 30 from Patent US 20100041604 DRAVPa1719&Sequence 31 from Patent US 20100041604 DRAVPa1720RRKKVALLAVLLALLA&Sequence 32 from Patent US 20100041604H94 4% inhibition against influenza virus at 10 M.(EC50= 0.5 0.5 M) DRAVPe01200 DRAVPa1721RRKKAAVALLAVLLALLA&Sequence 43 from Patent US 20100041604G95 2% inhibition against influenza virus at 10 M.(EC50=1.6 1.2 M) DRAVPe01199 DRAVPa1722RRKKLLAVLLALLA&Sequence 44 from Patent US 20100041604@95 2% inh< ibition against influenza virus at 10 M.(EC50= 3 M) DRAVPe01202 DRAVPa1723 RRKKLAVLLALLA&Sequence 45 from Patent US 20100041604@94 0% inhibition against influenza virus at 10 M.(EC50= 3 M) DRAVPe01203 DRAVPa1724 RRKKAAAAAAAAA&Sequence 49 from Patent US 20100041604=87.5% inhibition against influenza virus at 10 M.(EC50~7 M) DRAVPa1725 RKKLAVLLALLA&Sequence 50 from Patent US 20100041604;75% inhibition against influenza virus at 10 M.(EC50=8 M) DRAVPa1726 RKAVLLALLA&Sequence 51 from Patent US 20100041604050% inhibition against influenza virus at 10 M. DRAVPa1727 KLAVLLALLA&Sequence 52 from Patent US 20100041604025% inhibition against influenza virus at 10 M. DRAVPa1728 KKLAVLLALLA&Sequence 53 from Patent US 20100041604 DRAVPa1729 EEDDLAVLLALLA&Sequence 54 from Patent US 20100041604 DRAVPa1730 RRKKLAVAAALLA&Sequence 55 from Patent US 20100041604 DRAVPa1731 RRKKLAVLLAAAA&Sequence 56 from Patent US 20100041604 DRAVPa1732EEDD&Sequence 61 from Patent US 20100041604 DRAVPa1733CVHAYRS$Sequence 1 from Patent US 7476649 B2Sos scrofus(pig)!Infuenza Virus,Vaccinia Virus,HIV US 7476649 B2 2009-01-13UWO/2000/001402,EP1091753,EP1652529,AU1999047282,DE000069937998,AT383866,US200400439365Antiproliferative and antiviral proteins and peptidesfThe present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. lt is based, at least in part, on the discovery of peptides and pro-teins isolated from embryonic tissue which have been foundto exhibit an antiproliferative efect on a variety of cancercells andfor to act as broad-spectrum antiviral agents.1Anti-influenza virus,Anti-vaccinia virus,Anti-HIV DRAVPa1734CVHAYRA$Sequence 2 from Patent US 7476649 B2 DRAVPa1735CVHAFRS$Sequence 3 from Patent US 7476649 B2 DRAVPa1736CVHAFRA$Sequence 4 from Patent US 7476649 B2 DRAVPa1737CVHSYRS$Sequence 5 from Patent US 7476649 B2 DRAVPa1738CVHSYRA$Sequence 6 from Patent US 7476649 B2 DRAVPa1739CVHSFRS$Sequence 7 from Patent US 7476649 B2 DRAVPa1740CVHSFRA$Sequence 8 from Patent US 7476649 B2 DRAVPa1741CVHTYRS$Sequence 9 from Patent US 7476649 B2 DRAVPa1742CVHTYRA%Sequence 10 from Patent US 7476649 B2 DRAVPa1743CVHTFRS%Sequence 11 from Patent US 7476649 B2 DRAVPa1744CVHTFRA%Sequence 12 from Patent US 7476649 B2 DRAVPa1745NGAICWGPCPTAFRQIGNCGHFKVRCCKIRP9 SARS-CoV-2US20230165936 A1 2023-06-01$WO/2021/185071 CN115379849 EP4121087>Compositions of anti-viral peptides and methods of use thereofKBroad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus. DRAVPe01761Anti-SARS-CoV-2 DRAVPa1746NGAICWGPCPTAFRQIGNCGRFRVRCCRIRP9R DRAVPe01763 DRAVPa1747PAEPYTTVTTQNTASQTMSPS19ASFV US 8592552 B2 2013-11-26WO/2009/053340,PT2203468,ES2313848,SG160760,EP2203468,ES2373258,RU0002503686,CN101835795,CA2703368,KR1020100109543,AU2008314669,JP2011502110,AT523521,ZA2010/01710,IL205260,MXMX/a/2010/004424,IN2830/DEaAntiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the < first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8. Anti-ASFV DRAVPa1748RRRRRRRRPAEPYTTVTTQNTASQTMSRS27 DRAVPa1749SLVSSDESSSGSSHSSGEHSSS20 DRAVPa1750RRRRRRRRSLVSSDESSSGSSHSSGEHSRS28 DRAVPa1751RRRRRRRRHPAEPGSTVTTQNTASQTMSCOVA1 DRAVPa1752RRRRRRRRHPTESGSTVTTQNSAAQTMSPEP1New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC10. DRAVPa1753KYKETDLLILFKDDYFAKKNEERK'Sequence 1 from Patent US20090233868 A1Human La protein HCVUS20090233868 A1 2009-09-17?WO/2006/117805 IN520/CHE/2005 EP1877431 US20110091966 CA26066682Small antiviral peptides against hepatitis C virus Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication. DRAVPa1754KYKETDL'Sequence 2 from Patent US20090233868 A1HCV DRAVPa1755KIKRWR%Sequence 10 from Patent CN104072579 B CN104072579 B 2017-01-25jSmall molecule peptide with antibacterial antiviral activity and active modifier of small molecule peptideThe invention discloses a small molecule peptide with antibacterial antiviral activity and an active modifier of the small molecule peptide. An amino acid sequence of the small molecule peptide is formed by 3-7 amino acids; a general formula of the amino acid sequence is X[0-3](R/K/O/D[ab])X[0-1]W[1-2](R/K/O/D[ab])[0-1]X[0-1], wherein X is one of the amino acids R, K, W and I; X[0-3] is any 0-3 of R, K, W and I; X[0-1] is any 0-1 of R, K, W and I; W[1-2] represents one or two Ws; (R/K/O/D[ab])[0-1] represents zero or one amino acid R or K or O or Dab; D[ab] is a 2,4-diamido-butyric acid. The experiment proves that the small molecule peptide or the active modifier thereof disclosed by the invention has good antibacterial antiviral effects, and has important application value in preparation of a drug, a sanitizer, a detergent, a corrosion remover or a packaging material for removing bacteria, fungi or viruses. DRAVPa1756KIWWK$Sequence 2 from Patent CN104072579 B DRAVPa1757KKWK%Sequence 13 from Patent CN104072579 BH5N1 Anti-H5N1 DRAVPa1758KWK%Sequence 12 from Patent CN104072579 B DRAVPa1759 CNDFRSKTC'Sequence 1 from Patent US20110135676 B2AIVUS20110135676 B2 2014-11-11=WO/2009/151313,JP2011522561,DK2300492,EP2300492,MYPI 200820614Antiviral peptide against avian influenza virus H9N2The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'thera< peutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.Anti-AIV DRAVPa1760NDFRSKT'Sequence 2 from Patent US20110135676 B24Antiviral peptide against avian influenza virus H9N3 DRAVPa1761QHSTKWF'Sequence 3 from Patent US20110135676 B24Antiviral peptide against avian influenza virus H9N4 DRAVPa1762LPYAAKH'Sequence 4 from Patent US20110135676 B24Antiviral peptide against avian influenza virus H9N5 DRAVPa1763ILGDKVG'Sequence 5 from Patent US20110135676 B24Antiviral peptide against avian influenza virus H9N6 DRAVPa1764LPYGSKH'Sequence 6 from Patent US20110135676 B24Antiviral peptide against avian influenza virus H9N7 DRAVPa1765ILGYKVG'Sequence 7 from Patent US20110135676 B24Antiviral peptide against avian influenza virus H9N8 DRAVPa1766HPQFLSL'Sequence 8 from Patent US20110135676 B24Antiviral peptide against avian influenza virus H9N9 DRAVPa1767GLYNHPQ'Sequence 9 from Patent US20110135676 B25Antiviral peptide against avian influenza virus H9N10 DRAVPa1768'Sequence 1 from Patent US20110064793 A1US20110064793 A1 2011-03-178WO/2002/015661,US7790171,EP1311538,AU2001292153,AT420103GINHIBITORS OF HIV REPLICATION AND METHOD OF TREATMENT OF HIV INFECTIONS DRAVPa1769SPMLVAYD'Sequence 2 from Patent US20110064793 A1 US11304989 B2 2022-04-19$WO/2019/069307,EP3691672,CN1111637925Peptides for use in the treatment of viral infections Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent. DRAVPa1770 HVKGKHLCP'Sequence 3 from Patent US20110064793 A1 US11304989 B3 DRAVPa1771HKGLDSAV'Sequence 4 from Patent US20110064793 A1 US11304989 B4 DRAVPa1772YVNQTDIY'Sequence 5 from Patent US20110064793 A1 US11304989 B5 DRAVPa1773 SNGTIIHVK'Sequence 6 from Patent US20110064793 A1 US11304989 B6 DRAVPa1774WNFFDWFSGLMSWFGGPLKLY'Sequence 5 from Patent US20150337015 B2RVFVUS20150337015 B2 2017-01-31WO/2014/123614>Antiviral rift valley fever virus peptides and methods of use[The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus. Anti-RVFV DRAVPa1775WNFFDWFSGLMSWFGGPLK'Sequence 6 from Patent US20150337015 B2 DRAVPa1776WNFFDWFSGLMSWFGGPLKTI'Sequence 7 from Patent US20150337015 B2 DRAVPa1777SWNFFDWFSGLMSWFGGPLK'Sequence 8 from Patent US20150337015 B2 DRAVPa1778SGSWNFFDWFSGLMSWFGG'Sequence 9 from Patent US20150337015 B2 DRAVPa1779SGSWNFFDWFSGLMSWFGGPL(Sequence 10 from Patent US20150337015 B2 DRAVPa1780CYQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFESIENSQALVDQSNKILNSAEKGNTGF'Sequence 1 from Patent US20040229219 A1Human metapneumovirusSARSUS20040229219 A1 2004-11-18WO/2005/007078Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus. Anti-SARS DRAVPa1781NPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGF'Sequence 2 from Patent U< S20040229219 A1Human coronavirus DRAVPa1782"YQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNV'Sequence 3 from Patent US20040229219 A1 DRAVPa1783!PVSSSFDPIKFPEDQFNVALDQVFESIENSQAL'Sequence 4 from Patent US20040229219 A1 DRAVPa1784!ALDQVFESIENSQALVDQSNKILNSAEKGNTGF'Sequence 5 from Patent US20040229219 A1 DRAVPa1785YQLSKVEGEQHVIKGRPVSSSFDPIKFP'Sequence 6 from Patent US20040229219 A1 DRAVPa1786'EDQFNVALDQVFESIEEDQFNVALDQVFESIEEKGNTGF'Sequence 7 from Patent US20040229219 A1 DRAVPa1787%KFPEDQFNVALDQVFESIENSQALVDQSNKILNSAEK'Sequence 8 from Patent US20040229219 A1 DRAVPa1788"EDQFNVALDQVFESIENSQALVDQSNKILNSAEK'Sequence 9 from Patent US20040229219 A1 DRAVPa1789$PELDSFKEELDKYFKNHTSPDVDLGDISGINASVVN(Sequence 10 from Patent US20040229219 A1 DRAVPa1790%DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLID(Sequence 11 from Patent US20040229219 A1 DRAVPa1791$RLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGF(Sequence 12 from Patent US20040229219 A1 DRAVPa1792NIQKEIDRLNEVAKNLNESLIDLQEL(Sequence 13 from Patent US20040229219 A1 DRAVPa1793LNESLIDLQELGKYEQYIKWPWYVWLGF(Sequence 14 from Patent US20040229219 A1 DRAVPa1794QELGKYEQYIKWPWYVWLGF(Sequence 15 from Patent US20040229219 A1 DRAVPa1795YEQYIKWPWYVWLGF(Sequence 16 from Patent US20040229219 A1 DRAVPa1796YEQYIKWPWYVWLG(Sequence 17 from Patent US20040229219 A1 DRAVPa1797 YIKWPWYVWL(Sequence 18 from Patent US20040229219 A1 DRAVPa1798PELDSFKEELDKYFKNHTSP(Sequence 19 from Patent US20040229219 A1 DRAVPa1799IPNLPDFKEELDQWFKNQTSVAPDLSLDYINVTLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKWPWYVW(Sequence 20 from Patent US20040229219 A1 DRAVPa1800PNLPDFKEELDQWFKNQTSVAPDLSLD(Sequence 21 from Patent US20040229219 A1 DRAVPa1801*YINVTFLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKW(Sequence 22 from Patent US20040229219 A1 DRAVPa1802!QVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKW(Sequence 23 from Patent US20040229219 A1 DRAVPa1803QEAIKVLNQSYINLKDIGTYEYYVKWPW(Sequence 24 from Patent US20040229219 A1 DRAVPa1804QSYINLKDIGTYEYYVKWPW(Sequence 25 from Patent US20040229219 A1 DRAVPa1805 YEYYVKWPWYVW(Sequence 26 from Patent US20040229219 A1 DRAVPa1806QDAIKKLNESYINLKEVGTYEMYVKWPWYVW(Sequence 27 from Patent US20040229219 A1Mouse hepatitis virus DRAVPa1807FLGFLG(Sequence 28 from Patent US20040229219 A1#Human immunodeficiency virus type 1 DRAVPa1808TTTS(Sequence 29 from Patent US20040229219 A1 DRAVPa1809ELDKY(Sequence 30 from Patent US20040229219 A1 DRAVPa1810ELDKW(Sequence 31 from Patent US20040229219 A1 DRAVPa1811PEL(Sequence 32 from Patent US20040229219 A1 DRAVPa1812PDFKE(Sequence 33 from Patent US20040229219 A1 DRAVPa1813FKEELDK(Sequence 34 from Patent US20040229219 A1 DRAVPa1814KWPWYVWL(Sequence 35 from Patent US20040229219 A1 DRAVPa1815QALVDQ(Sequence 36 from Patent US20040229219 A1 DRAVPa1816 GRKKRRQRRRP(Sequence 38 from Patent US20040229219 A1 DRAVPa1817ELRVRLASHLRKLRKRLLRDADD(Sequence 39 from Patent US20040229219 A1 DRAVPa1818RIQDAIK(Sequence 40 from Patent US20040229219 A1 DRAVPa1819RLNEVAK(Sequence 41 from Patent US20040229219 A1 DRAVPa1820ENQKQIANQFNKAISQIQESL(Sequence 42 from Patent US20040229219 A1 DRAVPa1821KVQDVVNQNAQALNTLVKQL(Sequence 43 from Patent US20040229219 A1 DRAVPa1822 KYEQYIKWPWYVW(Sequence 44 from Patent US20040229219 A1 DRAVPa1823 TYEMYVKWPWYVW(Sequence 45 from Patent US20040229219 A1 DRAVPa1824 TYEYYVKWPWYVW(Sequence 46 from Patent US20040229219 A1 DRAVPa1825 YEWKWIYWYPVKQ(Sequence 47 from Patent US20040229219 A1 DRAVPa1826SPNLPDFKEELDQWFKNQTSVAPDLSLDYINVTFLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKWPWYVWLLICLAGVA(Sequence 48 from Patent US20040229219 A1 DRAVPa1827UPNPPDFKEELDKWFKNQTSIAPDLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKEVGTYEMYVKWPWYVWLLIGLAGVA(Sequence 49 from Patent US20040229219 A1 DRAVPa1828TPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIA(Sequence 50 from Patent US20040229219 A1 DRAVPa1829WTFGAGAALQIPFAMQMAY(Sequence 51 from Patent US20040229219 A1 DRAVPa1830$RIQDAIKKLNESYINLKEVGTYEMYVKWPWYVWLLI(Sequence 52 from Patent US20040229219 A1 DRAVPa1831 HGVSGHGQHGVHG'Sequence 1 from Patent US20170058000 B2H3N2US20170058000 B2 2018-11-13mWO/2013/1< 76563,EP2853535,EA201401148,CN104507958,KR1020150002842,US20150299257,JP2015519342,IN6296/CHENP/2014Bioactive peptide complexestThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 3 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. Anti-H3N2 DRAVPa1832 GVSGHGQHGVHG(Sequence 12 from Patent US20170058000 B2tThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 4 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1833 VSGHGQHGVH(Sequence 14 from Patent US20170058000 B2tThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 5 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1834SGHGQHGV(Sequence 15 from Patent US20170058000 B2tThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 6 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1835 PSLTGHGFHGVYD(Sequence 16 from Patent US20170058000 B2tThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-< dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 7 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1836 FIVSAHGDHGV(Sequence 17 from Patent US20170058000 B2tThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 8 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1837THGQHGV(Sequence 18 from Patent US20170058000 B2tThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 9 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1838HGHGVHG(Sequence 19 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 10 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1839 LASLHGQHGV(Sequence 20 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino<  acid residues or is not present and R2 contains up to 11 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1840 CVVTGHGSHGVFV'Sequence 2 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 12 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1841 ISGHGQHGVP'Sequence 3 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 13 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1842 CGHGNHGVH'Sequence 4 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 14 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1843 IVARIHGQNHGL'Sequence 5 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 15 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to < design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1844 HGSDGHGVQHG'Sequence 6 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 16 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1845FGHGHGV'Sequence 7 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 17 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1846HGNHGVLA'Sequence 8 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 18 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1847 HGDSGHGQHGVD'Sequence 9 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 19 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1848HGHGVPL(Sequence 10 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes < have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 20 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1849 SGHGAVHGVM(Sequence 11 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 21 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1850 YAMSGHGHGVFI(Sequence 13 from Patent US20170058000 B2uThe proposed invention relates to proteins and biologically active peptides with immuno-modulating and antiviral activity. The proposed peptide complexes have a three-dimensional structure and are described by the following structural formula: wherein X1 is either not present or contains no less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys capable of interacting with ions of transition metals, wherein R1 contains up to 5 amino acid residues or is not present and R2 contains up to 22 amino acid residues or is not present. Complexes of peptides enriched with histidine, especially peptides of the alloferon family with Zn ions, will enable the creation of preparations with targeted mechanisms of action and will make it possible to design such preparations according to an understanding of the structure of the medicinal target. DRAVPa1851GEKKRRETVEREGG'Sequence 1 from Patent US20160346383 B2encephalomyocarditis virusUS20160346383 B2 2017-06-20WO/2016/193285,CA2931875,SG10201604401U,KR1020160141673,AU2016203656,MX2016007122,GB2546439,MYPI2016001022,CN106188267,IN201614018787,PT3191504,JP2017025055,LT3191504,BR102016012501,EP3191504,ES266089>Ezrin-derived peptides and pharmaceutical compositions thereofLThe present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1}EKKRRETVERE X2X3, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof.Anti-encephalomyocarditis virus DRAVPa1852TEKKRRETVEREKE'Sequence 2 from Patent US20160346383 B2human ezrin proteinLThe present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical indus< try and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1}EKKRRETVERE X2X4, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof. DRAVPa1853TEKKR'Sequence 3 from Patent US20160346383 B2LThe present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1}EKKRRETVERE X2X5, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof. DRAVPa1854 RETVEREKE'Sequence 4 from Patent US20160346383 B2LThe present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1}EKKRRETVERE X2X6, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof. DRAVPa1855DKEWILQKIYEIMRRLDEEG'Sequence 1 from Patent US20240309059 A1 SARS-COV-2US20240309059 A1 2024-09-19'WO/2023/282281,JPWO2023282281,EP4368631|PEPTIDE HAVING ANTI-VIRAL ACTIVITY, ANTI-VIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTI-VIRAL AGENTProvided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-19. DRAVPa1856DKEWILQKIYEIMRLLDELG'Sequence 4 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-20. DRAVPa1857DKEWILQKIYEIMRKLDEDG'Sequence 6 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-21. DRAVPa1858'DKEWILQKIYEIMRRLDEEGHAEASMRVSDLIYEFMKKD(Sequence 53 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution<  and a high possibility of being put to practical use as a therapeutic drug for COVID-22. DRAVPa1859'DKEWILQKIYEIMRRLDEEGHGEASLRVSDLIYEFMKKD(Sequence 54 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-23. DRAVPa1860'DKEWILQKIYEIMRKLDEDGHAEASMRVSDLIYEFMKKD(Sequence 52 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-24. DRAVPa1861'DKEWILQKIYEIMRRLDEEGHGEASLRVSDLIYEFMKRD(Sequence 55 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-25. DRAVPa1862'DKEWILQKIYEIMQRLDEEGHGEASLMVSDLIYEFMKRD(Sequence 58 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-26. DRAVPa1863'DKLWILQKIYEIMVRLDEEGHGEASLMVSDLIYEFMKRD(Sequence 60 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-27. DRAVPa1864'DKEWILYKIYEIMVRLDEEGHGEASLMVSDLIYEFMKRD(Sequence 62 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-28. DRAVPa1865'DKLWILQKIYEIMQRLDEEGHGEASLMVSDLIYEFMKRD(Sequence 64 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-29. DRAVPa1866'DKEWILYKIYEIMQRLDEEGHGEASLMVSDLIYEFMKRD(Sequence 66 from Patent US20240309059 A1Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2. chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-30. DRAVPa1867WEEWDKKIEEYTKKIEELIKKSONOOIDL CN106543273A 2017-03-29JPolypeptide for inhibiting HIV infection and medicinal application thereofThe invention belongs to the field of biological medicine and relates to an anti-HIV infection peptide, in particular to a polypeptide shown by a formula 1 CP_I(L)_D_I (L), its derivatives, its stereoisomers, or its salts free of physiological toxicity. CP in the formula represents a C-terminal polypeptide derived from HIV-1 gp41 and having HIV-1 inhibiting activity, L represents leucine, I represents isoleucine, and D represents aspartic acid. Variable amino acid is added to the carbon terminal of the C-terminal polypeptide having the HIV-1 inhibiting activity to obtain a longer polypeptide, so that the polypeptide has remarkable strengthened antiviral activity. The invention further relates to a drug composition containing the polypeptide shown by the formula 1, its derivatives, its stereoisomers or its salts free of physiological < toxicity and application in preparation of drugs for treating or preventing related diseases caused by HIV infection, especially acquired immune deficiency syndrome. DRAVPa1868MTWEEWDKKIEEYTKKIEELIKKSONOOIDL DRAVPa1869RVTQMNLNDRLASLYDKV$Sequence 1 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N1 CN116964073 A 2023-10-27vWO/2022/135622,CU2020000110,AU2021406354,CA3203026,BRCU2021050015,KR1020230124613,EP42688403,JP2024500731,MX2023007603BPeptides for treating respiratory tract infections of viral origin0A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 20 and an antiviral drug.1Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N1 DRAVPa1870RATQMNLNDRLASLYDKV$Sequence 6 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N20A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 21 and an antiviral drug.1Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N2 DRAVPa1871RVTAMNLNDRLASLYDKV$Sequence 7 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N30A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 22 and an antiviral drug.1Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N3 DRAVPa1872RVTQANLNDRLASLYDKV$Sequence 8 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N40A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a < combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 23 and an antiviral drug.1Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N4 DRAVPa1873RVTQMNANDRLASLYDKV$Sequence 9 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N50A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 24 and an antiviral drug.1Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N5 DRAVPa1874RVTQMNLNARLASLYDKV%Sequence 10 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N60A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 25 and an antiviral drug.1Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N6 DRAVPa1875RVTQMNLNDRLVSLYDKV%Sequence 11 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N70A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 26 and an antiviral drug.1Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N7 DRAVPa1876RVTQMNLNDRLASLYAKV%Sequence 12 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N80A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 27 and an antiviral drug.1Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N8 DRAVPa1877RVTQMNLNDRLASLYDAV%Sequence 13 from Patent CN11< 6964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N90A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 28 and an antiviral drug.1Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N9 DRAVPa1878 NDRLASLYDKV%Sequence 14 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N100A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 29 and an antiviral drug.2Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N10 DRAVPa1879 NLNDRLASLYDKV%Sequence 15 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N110A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 30 and an antiviral drug.2Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N11 DRAVPa1880RVTQMNLADRLASLYDKV%Sequence 16 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N120A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 31 and an antiviral drug.2Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N12 DRAVPa1881RVTQMNLNDALASLYDKV%Sequence 17 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N130A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for trea< ting or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 32 and an antiviral drug.2Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N13 DRAVPa1882RVTQMNLNDRLAALYDKV%Sequence 18 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N140A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 33 and an antiviral drug.2Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N14 DRAVPa1883%Sequence 19 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N150A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 34 and an antiviral drug.2Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N15 DRAVPa1884RVTQMNLNDRAASLYDKV%Sequence 21 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N160A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 35 and an antiviral drug.2Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N16 DRAVPa1885RVTQMNLNDRLASLADKV%Sequence 22 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N170A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid seque< nce identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 36 and an antiviral drug.2Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N17 DRAVPa1886GRKKRRQRRRPPQACWMSPRHLGTC%Sequence 23 from Patent CN116964073 ASARS-CoV-2,MERS-CoV,BCoV,H1N180A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 20, and a pharmaceutical composition comprising the peptide. A pharmaceutical composition for treating or preventing infections caused by viruses infecting respiratory epithelial cells of mammals, comprising a peptide having the amino acid sequence identified as SEQ ID NO: 1. The invention comprises the use of a peptide having an amino acid sequence identified as SEQ ID NO: 1 to SEQ ID NO: 20 for the preparation of a medicament for the treatment or prevention of infections caused by viruses infecting epithelial cells of the respiratory system of a mammal. Also disclosed is a combination of at least one peptide identified as the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 37 and an antiviral drug.2Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-BCoV,Anti-H1N18 DRAVPa1887DIFCDWWRWVISVLDSVK'Sequence 1 from Patent WO2024054009A1 dengue virusWO2024054009A1 2024-03-14KR20220114326A, KR2023013277WNOVEL ANTIVIRAL PEPTIDEThe present disclosure relates to an antiviral peptide and a use thereof. More specifically, the present disclosure pertains to a composition and method for treating viral diseases using an antiviral peptide.Anti-dengue virus DRAVPa1888DVVSIWFKWIDCLWDSVR%Sequence 2 from Patent WO2024054009A1 DRAVPa1889RLVKSIWDWFCIVVDSWD%Sequence 3 from Patent WO2024054009A1 DRAVPa1890DVWCSWVSWVIKLFRDID%Sequence 4 from Patent WO2024054009A1 DRAVPa1891DWVDCFWSWLIKVIDRVS%Sequence 5 from Patent WO2024054009A1 DRAVPa1892SVVCDWWDVIIKWFDRLS%Sequence 6 from Patent WO2024054009A1 DRAVPa1893DWVSKFWRILICVWDSVD%Sequence 7 from Patent WO2024054009A1 DRAVPa1894DVVDDWWSVLCKWFRIIS&Sequence 8 from Patent WO2024054009A1 DRAVPa1895RVFCIVWDWVKSWIDDLS%Sequence 9 from Patent WO2024054009A1 DRAVPa1896SWVDSFWDWLIRVIKCVD&Sequence 10 from Patent WO2024054009A1 DRAVPa1897DVVDIVLRWICSWWSDFK&Sequence 11 from Patent WO2024054009A1 DRAVPa1898RVIDCWVDWWSIVFKSLD&Sequence 12 from Patent WO2024054009A1 DRAVPa1899SVFCSLWRWVIDWVDDIK&Sequence 13 from Patent WO2024054009A1 DRAVPa1900KLVDSIWSWFICVVRDWD&Sequence 14 from Patent WO2024054009A1 DRAVPa1901DVFCIWIDWVKSLWRDVS&Sequence 15 from Patent WO2024054009A1 DRAVPa1902DWLRIIWWWVCSVVSDFK&Sequence 16 from Patent WO2024054009A1 DRAVPa1903#Sequence 1 from Patent US10538554B2Influenza viruses US10538554B2 2020-01-21gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088370A.Peptides and uses therefor as antiviral agentsPeptides with anti-influenza properties are disclosed herein. The peptides include dextro (D) or a mixture of dextro/levo (L)-amino acids, possess anti-influenza properties against multiple types of human influenza viruses along with the types which infect animals and birds and are useful as pharmaceutical compositions for the treatment or prevention of influenza virus infections. DRAVPa1904TKSRFDN#Sequence 2 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088371A DRAVPa1905$Sequence 3 from Patent US10538554B2 gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088372A DRAVPe00458 DRAVPa1906 CTKSRFDNC$Sequence 4 from Patent US10538554B2 gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088373A DRAVPa1907 RRKKCTWARFINC$Sequence 17 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113< A JP2022088374A DRAVPa1908 RRKKCTWCRFINC$Sequence 18 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088375A DRAVPa1909 RRKKCTWDRFINC%Sequence 19 from Patent US10538554B2 gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088376A DRAVPa1910 RRKKCTWERFINC$Sequence 20 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088377A DRAVPa1911 RRKKCTWFRFINC$Sequence 21 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088378A DRAVPa1912 RRKKCTWGRFINC$Sequence 22 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088379A DRAVPa1913 RRKKCTWHRFINC$Sequence 23 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088380A DRAVPa1914 RRKKCTWIRFINC$Sequence 24 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088381A DRAVPa1915 RRKKCTWKRFINC$Sequence 25 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088382A DRAVPa1916 RRKKCTWLRFINC$Sequence 26 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088383A DRAVPa1917 RRKKCTWMRFINC$Sequence 27 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088384A DRAVPa1918 RRKKCTWNRFINC$Sequence 28 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088385A DRAVPa1919 RRKKCTWPRFINC$Sequence 29 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088386A DRAVPa1920 RRKKCTWQRFINC$Sequence 30 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088387A DRAVPa1921 RRKKCTWRRFINC$Sequence 31 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088388A DRAVPa1922 RRKKCTWSRFINC$Sequence 32 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088389A DRAVPa1923 RRKKCTWTRFINC$Sequence 33 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088390A DRAVPa1924 RRKKCTWVRFINC$Sequence 34 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088391A DRAVPa1925 RRKKCTWWRFINC$Sequence 35 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088392A DRAVPa1926 RRKKCTWYRFINC$Sequence 36 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088393A DRAVPa1927 RRKKCTWFAFINC$Sequence 37 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088394A DRAVPa1928 RRKKCTWFCFINC$Sequence 38 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088395A DRAVPa1929 RRKKCTWFDFINC$Sequence 39 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088396A DRAVPa1930 RRKKCTWFEFINC$Sequence 40 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088397A DRAVPa1931 RRKKCTWFFFINC$Sequence 41 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088398A DRAVPa1932 RRKKCTWFGFINC$Sequence 42 from Patent US10538554B< 2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088399A DRAVPa1933 RRKKCTWFHFINC$Sequence 43 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088400A DRAVPa1934 RRKKCTWFIFINC$Sequence 44 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088401A DRAVPa1935 RRKKCTWFKFINC$Sequence 45 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088402A DRAVPa1936 RRKKCTWFLFINC$Sequence 46 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088403A DRAVPa1937 RRKKCTWFMFINC$Sequence 47 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088404A DRAVPa1938 RRKKCTWFNFINC$Sequence 48 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088405A DRAVPa1939 RRKKCTWFPFINC$Sequence 49 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088406A DRAVPa1940 RRKKCTWFQFINC$Sequence 50 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088407A DRAVPa1941 RRKKCWWFTWIAC$Sequence 51 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088408A DRAVPa1942 RRKKCTWFSFINC$Sequence 52 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088409A DRAVPa1943 RRKKCTWFTFINC$Sequence 53 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088410A DRAVPa1944 RRKKCTWFVFINC$Sequence 54 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088411A DRAVPa1945 RRKKCTWFWFINC$Sequence 55 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088412A DRAVPa1946 RRKKCTWFYFINC$Sequence 56 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088413A DRAVPa1947 RRKKCWWFTYIAC$Sequence 57 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088414A DRAVPa1948 RRKKCAWFTFINC$Sequence 58 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088415A DRAVPa1949 RRKKCCWFTFINC$Sequence 59 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088416A DRAVPa1950 RRKKCDWFTFINC$Sequence 60 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088417A DRAVPa1951 RRKKCEWFTFINC$Sequence 61 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088418A DRAVPa1952 RRKKCFWFTFINC$Sequence 62 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088419A DRAVPa1953 RRKKCGWFTFINC$Sequence 63 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088420A DRAVPa1954 RRKKCHWFTFINC$Sequence 64 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088421A DRAVPa1955 RRKKCIWFTFINC$Sequence 65 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088422A DRAVPa1956 RRKKCKWFTFINC$Sequence 66 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 < ,CN108699113A JP2022088423A DRAVPa1957 RRKKCLWFTFINC$Sequence 67 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088424A DRAVPa1958 RRKKCMWFTFINC$Sequence 68 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088425A DRAVPa1959 RRKKCNWFTFINC$Sequence 69 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088426A DRAVPa1960 RRKKCPWFTFINC$Sequence 70 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088427A DRAVPa1961 RRKKCQWFTFINC$Sequence 71 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088428A DRAVPa1962 RRKKCRWFTFINC$Sequence 72 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088429A DRAVPa1963 RRKKCSWFTFINC$Sequence 73 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088430A DRAVPa1964$Sequence 74 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088431A DRAVPa1965 RRKKCVWFTFINC$Sequence 75 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088432A DRAVPa1966 RRKKCWWFTFINC$Sequence 76 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088433A DRAVPa1967 RRKKCYWFTFINC$Sequence 77 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088434A DRAVPa1968 RRKKCWWFTFIAC$Sequence 78 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088435A DRAVPa1969 RRKKCWWFTFICC$Sequence 79 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088436A DRAVPa1970 RRKKCWWFTFIDC$Sequence 80 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088437A DRAVPa1971 RRKKCWWFTFIEC$Sequence 81 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088438A DRAVPa1972 RRKKCWWFTFIFC$Sequence 82 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088439A DRAVPa1973 RRKKCWWFTFIGC$Sequence 83 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088440A DRAVPa1974 RRKKCWWFTFIHC$Sequence 84 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088441A DRAVPa1975 RRKKCWWFTFIIC$Sequence 85 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088442A DRAVPa1976 RRKKCWWFTFIKC$Sequence 86 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088443A DRAVPa1977 RRKKCWWFTFILC$Sequence 87 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088444A DRAVPa1978 RRKKCWWFTFIMC$Sequence 88 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088445A DRAVPa1979 RRKKCWWFTFIPC$Sequence 89 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088446A DRAVPa1980 RRKKCWWFTFIQC$Sequence 90 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088447A DRAVPa1981 RRKKCWWFTFIRC$Sequence 91 from Patent US10538554B2< gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088448A DRAVPa1982 RRKKCWWFTFISC$Sequence 92 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088449A DRAVPa1983 RRKKCWWFTFITC$Sequence 93 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088450A DRAVPa1984 RRKKCWWFTFIVC$Sequence 94 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088451A DRAVPa1985 RRKKCWWFTFIWC$Sequence 95 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088452A DRAVPa1986 RRKKCWWFTFIYC$Sequence 96 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088453A DRAVPa1987 CTKSRFANC$Sequence 97 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088454A DRAVPa1988 CTKSRFCNC$Sequence 98 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088455A DRAVPa1989 CTKSRFENC$Sequence 99 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088456A DRAVPa1990 CTKSRFFNC%Sequence 100 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088457A DRAVPa1991 CTKSRFGNC%Sequence 101 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088458A DRAVPa1992 CTKSRFHNC%Sequence 102 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088459A DRAVPa1993 CTKSRFINC%Sequence 103 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088460A DRAVPa1994 CTKSRFKNC%Sequence 104 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088461A DRAVPa1995 CTKSRFLNC%Sequence 105 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088462A DRAVPa1996 CTKSRFMNC%Sequence 106 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088463A DRAVPa1997 CTKSRFNNC%Sequence 107 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088464A DRAVPa1998 CTKSRFPNC%Sequence 108 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088465A DRAVPa1999 CTKSRFQNC%Sequence 109 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088466A DRAVPa2000 CTKSRFRNC%Sequence 110 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088467A DRAVPa2001 CTKSRFTNC%Sequence 111 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088468A DRAVPa2002%Sequence 112 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088469A DRAVPa2003 CTKSRFVNC%Sequence 113 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088470A DRAVPa2004 CTKSRFWNC%Sequence 114 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088471A DRAVPa2005 CTKSRFYNC%Sequence 115 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088472A DRAVPa2006 RRKKCTASRFINC%Sequence 116 from < Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088473A DRAVPa2007 RRKKCTCSRFINC%Sequence 117 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088474A DRAVPa2008 RRKKCTDSRFINC%Sequence 118 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088475A DRAVPa2009 RRKKCTESRFINC%Sequence 119 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088476A DRAVPa2010 RRKKCTFSRFINC%Sequence 120 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088477A DRAVPa2011 RRKKCTGSRFINC%Sequence 121 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088478A DRAVPa2012 RRKKCTHSRFINC%Sequence 122 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088479A DRAVPa2013 RRKKCTISRFINC%Sequence 123 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088480A DRAVPa2014 RRKKCTKSRFINC%Sequence 124 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088481A DRAVPa2015 RRKKCTLSRFINC%Sequence 125 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088482A DRAVPa2016 RRKKCTMSRFINC%Sequence 126 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088483A DRAVPa2017 RRKKCTNSRFINC%Sequence 127 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088484A DRAVPa2018 RRKKCTPSRFINC%Sequence 128 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088485A DRAVPa2019 RRKKCTQSRFINC%Sequence 129 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088486A DRAVPa2020 RRKKCTRSRFINC%Sequence 130 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088487A DRAVPa2021 RRKKCTSSRFINC%Sequence 131 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088488A DRAVPa2022 RRKKCTTSRFINC%Sequence 132 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088489A DRAVPa2023 RRKKCTVSRFINC%Sequence 133 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088490A DRAVPa2024%Sequence 134 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088491A DRAVPa2025%Sequence 136 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088492A DRAVPa2026 RRKKCWWFTAIAC%Sequence 137 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088493A DRAVPa2027 RRKKCWWFTCIAC%Sequence 138 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088494A DRAVPa2028 RRKKCWWFTDIAC%Sequence 139 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088495A DRAVPa2029 RRKKCWWFTEIAC%Sequence 140 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088496A DRAVPa2030 RRKKCWWFTGIAC%Sequence 141 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A< ,EP3380493A4 ,CN108699113A JP2022088497A DRAVPa2031 RRKKCWWFTHIAC%Sequence 142 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088498A DRAVPa2032 RRKKCWWFTIIAC%Sequence 143 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088499A DRAVPa2033 RRKKCWWFTKIAC%Sequence 144 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088500A DRAVPa2034 RRKKCWWFTLIAC%Sequence 145 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088501A DRAVPa2035 RRKKCWWFTMIAC%Sequence 146 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088502A DRAVPa2036 RRKKCWWFTNIAC%Sequence 147 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088503A DRAVPa2037 RRKKCWWFTPIAC%Sequence 148 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088504A DRAVPa2038 RRKKCWWFTQIAC%Sequence 149 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088505A DRAVPa2039 RRKKCWWFTRIAC%Sequence 150 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088506A DRAVPa2040 RRKKCWWFTSIAC%Sequence 151 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088507A DRAVPa2041 RRKKCWWFTTIAC%Sequence 152 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088508A DRAVPa2042 RRKKCWWFTVIAC%Sequence 153 from Patent US10538554B2gWO2017090010A1,MY184269A,AU2016359545B2,JP2019506840A,MY189021A,EP3380493A4 ,CN108699113A JP2022088509A DRAVPa2043MLSYLIFALAVSPILG#Sequence 1 from Patent US10745448B2Vesicular stomatitis virus VSV US10745448B2 2020-08-18 JP6994714B2"Antiviral peptide and use thereforAn antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (2) an amino acid sequence that functions as a cell penetrating peptide (CPP).  Anti-VSV DRAVPa2044MKTIIALSYIFCLALG#Sequence 2 from Patent US10745448B2Influenza A virusAn antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (3) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2045MKAIIVLLMVVTSNA#Sequence 3 from Patent US10745448B2Influenza B virusAn antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (4) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2046MKCLLYLAFLFIGVNC#Sequence 4 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by t< he G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (5) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2047MKTIIALSYIFCQVLA#Sequence 5 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (6) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2048MKTIIALSYIFCLVFA#Sequence 6 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (7) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2049MKTIIALSYIFCLVLG#Sequence 7 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (8) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2050RSRKYTSWYVALKR#Sequence 8 from Patent US10745448B2Synthetic peptideAn antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (9) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2051MAKSIRSKHRRQMRMM#Sequence 9 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (10) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2052MARRRRHRGPRRPRPP$Sequence 10 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (11) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2053GRCRRLANFGPRKRRRRRR$Sequence 11 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene < of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (12) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2054RRRKRNRDARRRRRKQ$Sequence 12 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (13) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2055MQRKPTIRRKNLRLRRK$Sequence 13 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (14) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2056IMRRRGL$Sequence 14 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (15) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2057KKLKKRNK$Sequence 15 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (16) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2058 RRRANNRRR$Sequence 16 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (17) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2059RKKRKKK$Sequence 17 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (18) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2060KRKGKLKNKGSKRKK$Sequence 18 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these s< ignal sequences; and (19) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2061SKRLSSRARKRAAKRRLG$Sequence 19 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (20) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2062KRPRRRPSRPFRKP$Sequence 20 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (21) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2063 KKRTLRKNDRKKR$Sequence 21 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (22) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2064WRRQARFK$Sequence 22 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (23) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2065$Sequence 23 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (24) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2066 YARAAARQARA$Sequence 24 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (25) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2067KGRQVKVWFQNRRMKWKK$Sequence 25 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (26) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2068MLSYLIFALAVSPILGKKRTLRKNDRKKR$Sequence 26 from<  Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (27) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2069MKTIIALSYIFCLALGKKRTLRKNDRKKR$Sequence 27 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (28) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2070MKAIIVLLMVVTSNAKKRTLRKNDRKKR$Sequence 28 from Patent US10745448B2An antiviral peptide provided by the present invention includes:(1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (29) an amino acid sequence that functions as a cell penetrating peptide (CPP). DRAVPa2071SGSWLRDVWTWLQSKL#Sequence 1 from Patent US10351604B2DENV,CHIKV,YFV,JEV US10351604B2 2019-07-16hWO2016209173A1,JP6768012B2,CN107922461A,MX2017016227A,EP3313862B9,HK1248248A1,JP2020040950A,US11866460B2&Broad-spectrum anti-infective peptidesProvided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.&Anti-DENV,Anti-CHIKV,Anti-YFV,Anti-JEV DRAVPa2072GSSWLRDVWTWLQSKL#Sequence 2 from Patent US10351604B2 DENV,YFV,JEVAnti-DENV,Anti-YFV,Anti-JEV DRAVPa2073GSSWLRDVWTWLQSAL#Sequence 3 from Patent US10351604B2DENV,CHIKV,YFV,Anti-DENV,Anti-CHIKV,Anti-YFV DRAVPa2074GSSWLRDVWTKLQSWL#Sequence 4 from Patent US10351604B2 DRAVPa2075GSSWLRDIWTALQSWI#Sequence 6 from Patent US10351604B2 DENV,,YFV,JEV DRAVPa2076RRKKAAWALLPAWLLALLAP"Sequence 1 from Patent US9221874B2 US9221874B2 2015-12-29UWO2009152519A2##US20120165249A1##US8129499B2##CA2727898A1##JP2011524373A##EP2310030A4*Antiviral peptides against influenza virus DRAVPa2077RRKKAAVALIPAWLLALLA"Sequence 2 from Patent US9221874B2 DRAVPa2078RRKKAAWALLPAWLLALL"Sequence 3 from Patent US9221874B2 DRAVPa2079RRKKAAWALLPAWLLAL"Sequence 4 from Patent US9221874B2 DRAVPa2080RRKKAAWALLPAWLLA"Sequence 5 from Patent US9221874B2 DRAVPa2081RRKKAWALLPAWLLALLAP#Sequence 18 from Patent US9221874B2 DRAVPa2082RRKKWALLPAWLLALLAP#Sequence 19 from Patent US9221874B2 DRAVPa2083RRKKALLPAWLLALLAP#Sequence 20 from Patent US9221874B2 DRAVPa2084RRKKLLPAWLLALLAP#Sequence 21 from Patent US9221874B2 DRAVPa2085RRKKLPAWLLALLAP#Sequence 22 from Patent US9221874B2 DRAVPa2086 RRKKWLLALLAP#Sequence 23 from Patent US9221874B2 DRAVPa2087RRKKWALLAWLLALLA#Sequence 32 from Patent US9221874B2 DRAVPa2088RRKKAAWALLAWLLALLA#Sequence 43 from Patent US9221874B2 DRAVPa2089RRKKLLAWLLALLA#Sequence 44 from Patent US9221874B2 DRAVPa2090RRKKLAVILLALLA#Sequence 45 from Patent US9221874B2 DRAVPa2091 RKKLAWLLALLA#Sequence 50 from Patent US9221874B2 DRAVPa2092 RKAWLLALLA#Sequence 51 from Patent US9221874B2 DRAVPa2093 KLAVILALLA#Sequence 52 from Patent US9221874B2 DRAVPa2094"Sequence 1 from Patent US8883480B2H9N2 US8883480B2@WO2009151313A1##MY160435A##JP5647111B2##DK2300492T3##EP2300492B1 Anti-H9N2 DRAVPa2095"Sequence 2 from Patent US8883480B2 DRAVPa2096"Sequence 4 from Patent US8883480< B2 DRAVPa2097"Sequence 5 from Patent US8883480B2 DRAVPa2098"Sequence 6 from Patent US8883480B2 DRAVPa2099"Sequence 7 from Patent US8883480B2 DRAVPa2100HPOFLSL"Sequence 8 from Patent US8883480B2 DRAVPa2101"Sequence 9 from Patent US8883480B2 DRAVPa2102EVKLLEQSGAELVKPGASVRLSCTAS"Sequence 3 from Patent US9880167B2 Dengue Virus US9880167B2 2018-01-30US9499607B2##CN104768574B##KR20200102524A##BR112015002605B1##ES2859574T3##CA2879994C##KR102165384B1##WO2014025546A2##EP2882453B1##AU2013299986B2##JP6297560B2##MX2019008736A##HK1210054A1##JP6605643B2##-Anti-dengue virus antibodies and uses thereofWThe present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV. DRAVPa2103YMSWVKQRPEQGLEWIGRI"Sequence 4 from Patent US9880167B2 DRAVPa2104)TKYDPKFOGKATITADTSSNTAYLHLSSLTSGDTAVYYCSR"Sequence 5 from Patent US9880167B2 DRAVPa2105 WGQGTLVTVSA"Sequence 6 from Patent US9880167B2 DRAVPa2106GFNIKDT"Sequence 7 from Patent US9880167B2 DRAVPa2107DPANGD "Sequence 8 from Patent US9880167B2 DRAVPa2108GWEGFAY "Sequence 9 from Patent US9880167B2 DRAVPa2109ELVMTQTPASLAVSLGQRATISC#Sequence 10 from Patent US9880167B2 DRAVPa2110WYQQKAGQPPKLLIY#Sequence 11 from Patent US9880167B2 DRAVPa2111 GIPARFSGSGSRTDFTLTINPVEADDVATYFC#Sequence 12 from Patent US9880167B2 DRAVPa2112 FGGGTKLEIKR#Sequence 13 from Patent US9880167B2 DRAVPa2113RASENVDRYGNSFMH#Sequence 14 from Patent US9880167B2 DRAVPa2114RASNLES#Sequence 15 from Patent US9880167B2 DRAVPa2115 QRSNEVPWT#Sequence 16 from Patent US9880167B2 DRAVPa2116LRTRKRGRKLRTRKRGRK#Sequence 48 from Patent US8017579B2HIV,HSV US8017579B2 2011-09-137JP2007536910A##WO2005061539A2##CA2548740A1##EP1711526B1Treatment of viral infections8The present invention relates to polypeptides, and derivatives or analogues thereof, comprising a tandem repeat of apolipoprotein B, or a truncation thereof, derived from an HSPG receptor binding region of apolipoprotein B. Such peptides are useful for treating or preventing the development of viral infections.Anti-HIV,Anti-HSV DRAVPa2117RTRKRGRKRTRKRGRK"Sequence 3 from Patent US8017579B2 DRAVPa2118RTRKRGRRTRKRGR"Sequence 4 from Patent US8017579B2 DRAVPa2119LRKRKRLLRKRKRL"Sequence 5 from Patent US8017579B2 DRAVPa2120LRKRKRLRKLRKRKRLRK"Sequence 6 from Patent US8017579B2 DRAVPa2121WRWRKRWRKWRWRKRWRK"Sequence 7 from Patent US8017579B2 DRAVPa2122RRWRKRWRKWRWRKRWRK#Sequence 34 from Patent US8017579B2 DRAVPa2123KRWRKRWRKWRWRKRWRK#Sequence 35 from Patent US8017579B2 DRAVPa2124LRWRKRWRKWRWRKRWRK#Sequence 36 from Patent US8017579B2 DRAVPa2125HRWRKRWRKWRWRKRWRK#Sequence 37 from Patent US8017579B2 DRAVPa2126RWRKRWRKWRWRKRWRK#Sequence 38 from Patent US8017579B2 DRAVPa2127RRWRKRWRKRRWRKRWRK#Sequence 39 from Patent US8017579B2 DRAVPa2128KRWRKRWRKKRWRKRWRK#Sequence 40 from Patent US8017579B2 DRAVPa2129LRWRKRWRKLRWRKRWRK#Sequence 41 from Patent US8017579B2 DRAVPa2130HRWRKRWRKHRWRKRWRK#Sequence 42 from Patent US8017579B2 DRAVPa2131RWRKRWRKRWRKRWRK#Sequence 43 from Patent US8017579B2 DRAVPa2132RWRKRGRKRWRKRGRK#Sequence 44 from Patent US8017579B2 DRAVPa2133RTRKRWRKRTRKRGRK#Sequence 45 from Patent US8017579B2 DRAVPa2134#Sequence 46 from Patent US8017579B2 DRAVPa2135RWRKRWRWRKRWRWRKRW#Sequence 47 from Patent US8017579B2 DRAVPa2136NFRHTHR#Sequence 1 from Patent CN111499692B CN111499692B 2020-12-04KPolypeptide of targeting novel coronavirus COVID-19 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an ami< no acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-19, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2137FNRHTHR$Sequence 2 from Patent CN111499692B KPolypeptide of targeting novel coronavirus COVID-20 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-20, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2138IGVRGGW#Sequence 3 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-21 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-21, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2139KWPYKKS#Sequence 4 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-22 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-22, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2140KTYHTHR#Sequence 5 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-23 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obt< ained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-23, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2141IRQFFKK#Sequence 6 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-24 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-24, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2142FYIKINH#Sequence 7 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-25 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-25, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2143KSPPYHK#Sequence 8 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-26 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-26, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2144WVHFYHF#Sequence 9 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-27 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon<  chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-27, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2145KPYIWKS$Sequence 10 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-28 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-28, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2146KWPFKKS$Sequence 11 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-29 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-29, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2147IGHVPGT $Sequence 12 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-30 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-30, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2148WIGVRNW $Sequence 13 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-31 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of ta< rgeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-31, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2149QGTHTAH$Sequence 14 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-32 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-32, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2150NSGGSVH$Sequence 15 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-33 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-33, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2151AAARFST$Sequence 16 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-34 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-34, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2152PIGVPHT $Sequence 17 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-35 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) co< mbinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-35, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2153QVAVLYQ$Sequence 18 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-36 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-36, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2154FLGVYYH$Sequence 19 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-37 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-37, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2155ALTGIAV$Sequence 20 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-38 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-38, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2156FVFLVLL$Sequence 21 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-39 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polype< ptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-39, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2157VVIGIVN$Sequence 22 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-40 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-40, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2158NFTISVTT$Sequence 23 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-41 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-41, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2159RVVVLSFE$Sequence 24 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-42 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-42, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2160AAYYVGYL$Sequence 25 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-43 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the s< creened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-43, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2161 SIIAYTMSLG$Sequence 26 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-44 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-44, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2162 GVVFLHVTYV$Sequence 27 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-45 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-45, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2163 FTGCVIAWNR$Sequence 28 from Patent CN111499692BKPolypeptide of targeting novel coronavirus COVID-46 and application thereofgThe invention provides a polypeptide of a targeted novel coronavirus COVID-19 and application thereof, wherein the polypeptide comprises an amino acid sequence shown as SEQ ID NO. 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and/or conjugated connecting carbon chains to the N end and/or the C end of SEQ ID NO. 1-28 and has the activity of targeting coronavirus COVID-19. The invention adopts a one-bead-one-compound (OBOC) combinatorial chemistry method to synthesize a polypeptide library, utilizes the polypeptide library and the S protein on the surface of the novel coronavirus, and the screened polypeptide has strong binding capacity with the S protein of the coronavirus COVID-46, thereby providing a basis for the research and development of novel coronavirus detection reagents and therapeutic drugs. DRAVPa2164%SWETWEREIENYTROIYRILEESOEOODRNERDLLE."Sequence 1 from Patent US8603965B2 homo sapiens US8603965B2 2013-12-10WO2007143934A1##CN101088557AYPharmaceutical composition for the prophylaxis and treatment of HIV infection and its usePharmaceutical compositions for the prophylaxis and treatment of HIV infection and its use are provided. Particularly, the present invention provides a pharmaceutical composition comprising anti-virus peptides, use of said composition for manufacturing a medicament for the prophylaxis and treatment of HIV infection, and method for preventing and treating HIV infection by using said composition. DRAVPa2165NGAICWGPCPTAFRQIGNCGHFKVRCCNIR#Sequence 13 from Patent US9822155B2Influenza A virus US9822155B2 2017-11-21PWO2014180180A1##HK1190738A1##KR101800951B1##MX346160B##RU2639559C2##CN103554244BeMethod of preventi< vely treating a subject at the risk of developing infections of a respiratory virusA method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of apeptidesynthesized through a chemical route or by a genetic engineering process, characterized in that thepeptidehas a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein thepeptidehas 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of thepeptide; and wherein thepeptideconsists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 15. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrumantiviralactivities.Anti-Influenza A virus DRAVPa2166NGAICWGPCPTAFRQIGNCGHFKVRCCNID#Sequence 14 from Patent US9822155B2A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of apeptidesynthesized through a chemical route or by a genetic engineering process, characterized in that thepeptidehas a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein thepeptidehas 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of thepeptide; and wherein thepeptideconsists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 16. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrumantiviralactivities. DRAVPa2167NGAICWGPCPTAFRQIGNCGHFKVTCCNID#Sequence 15 from Patent US9822155B2A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of apeptidesynthesized through a chemical route or by a genetic engineering process, characterized in that thepeptidehas a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein thepeptidehas 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of thepeptide; and wherein thepeptideconsists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 17. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrumantiviralactivities. DRAVPa2168!DEDNGAICWGPCPTAFRQIGNCGHFKVRCCKIR#Sequence 16 from Patent US9822155B2A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of apeptidesynthesized through a chemical route or by a genetic engineering process, characterized in that thepeptidehas a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein thepeptidehas 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of thepeptide; and wherein thepeptideconsists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 18. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing n< ew prophylactic/therapeutic agents with broad-spectrumantiviralactivities. DRAVPa2169!KHRNGAICWGPCPTAFRQIGNCGHFKVRCCKIR#Sequence 17 from Patent US9822155B2A method of preventively treating a subject at the risk of developing infections of a respiratory virus is disclosed. The method includes a step of administering to the subject an effective amount of apeptidesynthesized through a chemical route or by a genetic engineering process, characterized in that thepeptidehas a functional domain capable of binding to a surface glycoprotein of a respiratory virus and has an activity of inhibiting infection of the respiratory virus, wherein thepeptidehas 5 or more basic amino acids, among which 2 or more basic amino acids are in N-terminal region or C-terminal region of thepeptide; and wherein thepeptideconsists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 19. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrumantiviralactivities. DRAVPa2170SWLRDIWDWICEVLSDFK&Sequence 1 from Patent US20230256049A1US20230256049A1 2023-08-17(WO2022020766A1##EP4171746A4##CA3186948A1TMaterials and methods for the prevention and treatment of viral respiratory diseasesThis disclosure is related totheuseofa peptide with antimicrobial properties.Thepeptide is administered topically via nasal or pulmonary delivery to prevent or treat respiratorydiseasescaused by viruses. A varietyofformulations and uses are described as well asmethodsofmanufacture thereof.Theformulations are safe and useful in patients both humans and animals forthedeliveryofappropriate bioactive substance(s) totherespiratory system. DRAVPa2171&Sequence 2 from Patent US20230256049A1 DRAVPa2172GSWLRDIWDWICEVLSDFK&Sequence 3 from Patent US20230256049A1 DRAVPa2173SWLRDIWDWICEVLSDFKTW&Sequence 4 from Patent US20230256049A1 DRAVPa2174KFDSLVECIWDWIDRLWS&Sequence 5 from Patent US20230256049A1 DRAVPa2175KWLCRIWSWISDVLDDFE&Sequence 6 from Patent US20230256049A1 DRAVPa2176SIWRDWVDLICEFLSDWK&Sequence 7 from Patent US20230256049A1 DRAVPa2177DWLRIIWDWVCSVVSDFK&Sequence 8 from Patent US20230256049A1 DRAVPa2178PLKPTKRSFIKDLLFNKV&Sequence 9 from Patent US20230256049A1 DRAVPa2179SWLRDIWDWISEVLSDFK'Sequence 10 from Patent US20230256049A1 DRAVPa2180'Sequence 11 from Patent US20230256049A1 DRAVPa2181SWLRDIWDWICEVLSDFR'Sequence 12 from Patent US20230256049A1 DRAVPa2182SYLRDIWDYICEVLSDFK'Sequence 13 from Patent US20230256049A1 DRAVPa2183SYLRDIWDYISEVLSDFK'Sequence 14 from Patent US20230256049A1 DRAVPa2184SYLREIWDYISEVLSDFR'Sequence 15 from Patent US20230256049A1 DRAVPa2185SWLREIWDWICEVLSDFK'Sequence 16 from Patent US20230256049A1 DRAVPa2186SWLRDIWDWISEVLSDFR'Sequence 32 from Patent US20230256049A1 DRAVPa2187SWLRDIWDYISEVLSDFR'Sequence 33 from Patent US20230256049A1 DRAVPa2188'Sequence 34 from Patent US20230256049A1 DRAVPa2189SWLRDIWDYICEVLSDFR'Sequence 35 from Patent US20230256049A1 DRAVPa2190AWLRDIWDWICEVLSDFK'Sequence 40 from Patent US20230256049A1 DRAVPa2191SALRDIWDWICEVLSDFK'Sequence 41 from Patent US20230256049A1 DRAVPa2192SWARDIWDWICEVLSDFK'Sequence 42 from Patent US20230256049A1 DRAVPa2193SWLADIWDWICEVLSDFK'Sequence 43 from Patent US20230256049A1 DRAVPa2194SWLRAIWDWICEVLSDFK'Sequence 44 from Patent US20230256049A1 DRAVPa2195SWLRDAWDWICEVLSDFK'Sequence 45 from Patent US20230256049A1 DRAVPa2196SWLRDIADWICEVLSDFK'Sequence 46 from Patent US20230256049A1 DRAVPa2197SWLRDIWAWICEVLSDFK'Sequence 47 from Patent US20230256049A1 DRAVPa2198SWLRDIWDAICEVLSDFK'Sequence 48 from Patent US20230256049A1 DRAVPa2199SWLRDIWDWACEVLSDFK'Sequence 49 from Patent US20230256049A1 DRAVPa2200SWLRDIWDWIAEVLSDFK'Sequence 50 from Patent US20230256049A1 DRAVPa2201SWLRDIWDWICAVLSDFK'Sequence 51 from Patent US20230256049A1 DRAVPa2202SWLRDIWDWICEALSDFK'Sequence 52 from Patent US20230256049A1 DRAVPa2203SWLRDIWDWICEVASDFK'Sequence 53 from Patent US20230256049A1 DRAVPa2204< SWLRDIWDWICEVLADFK'Sequence 54 from Patent US20230256049A1 DRAVPa2205SWLRDIWDWICEVLSAFK'Sequence 55 from Patent US20230256049A1 DRAVPa2206SWLRDIWDWICEVLSDAK'Sequence 56 from Patent US20230256049A1 DRAVPa2207SWLRDIWDWICEVLSDFA'Sequence 57 from Patent US20230256049A1 DRAVPa2208WRCKVRAP19GAstV CN115894614A 2023-04-04sAntiviral affinity peptide of targeted goose astrovirus Spike protein and application of antiviral affinity peptideThe invention relates to anantiviralaffinitypeptideof a targeted goose astrovirus Spike protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis WRCKVR, WKHKRR or WKHWYK. According to the method, a molecular docking virtual screening technology is adopted, a crystal structure of TAstV-2Spike protein is taken as a template, and SWISS-MODEL software is used for homologous modeling, so that a three-dimensional structure of the GAstV Spike protein is obtained. The method comprises the following steps: selecting a C-terminal partial region of a Spike protein structure as an active pocket by using SYBYL software, carrying out molecular docking on polypeptide ligands in a library and the selected pocket by using a Surflex-Dock/SYBYL function, comprehensively evaluating a docking result according to Cscore, screening out the affinitypeptidefor specifically identifying the GAstV Spike protein, and laying a foundation for subsequent research onantiviralpolypeptide drugs Anti-GAstV DRAVPa2209WKHKRRAP21The invention relates to anantiviralaffinitypeptideof a targeted goose astrovirus Spike protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis WRCKVR, WKHKRR or WKHWYK. According to the method, a molecular docking virtual screening technology is adopted, a crystal structure of TAstV-3Spike protein is taken as a template, and SWISS-MODEL software is used for homologous modeling, so that a three-dimensional structure of the GAstV Spike protein is obtained. The method comprises the following steps: selecting a C-terminal partial region of a Spike protein structure as an active pocket by using SYBYL software, carrying out molecular docking on polypeptide ligands in a library and the selected pocket by using a Surflex-Dock/SYBYL function, comprehensively evaluating a docking result according to Cscore, screening out the affinitypeptidefor specifically identifying the GAstV Spike protein, and laying a foundation for subsequent research onantiviralpolypeptide drugs DRAVPa2210WKHWYKAP30The invention relates to anantiviralaffinitypeptideof a targeted goose astrovirus Spike protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis WRCKVR, WKHKRR or WKHWYK. According to the method, a molecular docking virtual screening technology is adopted, a crystal structure of TAstV-4Spike protein is taken as a template, and SWISS-MODEL software is used for homologous modeling, so that a three-dimensional structure of the GAstV Spike protein is obtained. The method comprises the following steps: selecting a C-terminal partial region of a Spike protein structure as an active pocket by using SYBYL software, carrying out molecular docking on polypeptide ligands in a library and the selected pocket by using a Surflex-Dock/SYBYL function, comprehensively evaluating a docking result according to Cscore, screening out the affinitypeptidefor specifically identifying the GAstV Spike protein, and laying a foundation for subsequent research onantiviralpolypeptide drugs DRAVPa2211KYWQRE#Sequence 8 from Patent CN116874560AFAdV-4 CN116874560A 2023-10-13bAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application thereofJThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structu< ral domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-4 infection in the future. Anti-FAdV-4 DRAVPa2212KYWGRN$Sequence 11 from Patent CN116874560AbAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber2 protein and application thereofJThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-5 infection in the future. DRAVPa2213YMKKYA$Sequence 14 from Patent CN116874560AbAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber3 protein and application thereofJThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-6 infection in the future. DRAVPa2214YMKHSD$Sequence 16 from Patent CN116874560AbAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber4 protein and application thereofJThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-7 infection in the future. DRAVPa2215YMKHSR$Sequence 20 from Patent CN116874560AbAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber5 protein and application thereofJThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the presen< t invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-8 infection in the future. DRAVPa2216YMKHRH$Sequence 21 from Patent CN116874560AbAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber6 protein and application thereofJThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-9 infection in the future. DRAVPa2217YMKHRV$Sequence 22 from Patent CN116874560AbAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber7 protein and application thereofKThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-10 infection in the future. DRAVPa2218KQWKEH$Sequence 24 from Patent CN116874560AbAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber8 protein and application thereofKThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-11 infection in the future. DRAVPa2219KQWYRT$Sequence 25 from Patent CN116874560AbAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber9 protein and application thereofKThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain th< e optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-12 infection in the future. DRAVPa2220KQWGHR$Sequence 27 from Patent CN116874560AcAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber10 protein and application thereofKThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-13 infection in the future. DRAVPa2221KQWCQW$Sequence 32 from Patent CN116874560AcAntiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber11 protein and application thereofKThe invention provides anantiviralaffinitypeptidetargeting fowl adenovirus 4 type Fiber1 protein and application of theantiviralaffinitypeptide. The sequence of the affinitypeptideis YMKHRV. According to a three-dimensional structure of a spike protein Knob structural domain, the affinitypeptidetargeting the Fiber1Knob structural domain is designed by utilizing a computer virtual screening technology. According to the present invention, the active pocket docking range is selected, the in vitro test screening is performed to obtain the optimalpeptidehaving theantiviralactivity on FAdV-4, the clue and the theoretical support are provided for the further research on the virus receptor and theantiviraldrug design, and the new thought is provided for the prevention and the control of the FAdV-14 infection in the future. DRAVPa2222 VTFLVGLNQYLV'Sequence 47 from Patent US20140294942A1vsvUS20140294942A1 2014-10-02WO/2013/0366227ANTIVIRALPEPTIDES EFFECTIVE AGAINST HEPATITIS C VIRUS_In certain embodiments this invention provides novelantiviralpeptide(s) that are effective against positive sense RNA viruses that have an internal ribosome entry site (IRES). Thepeptide(s) can be used to inhibit propagation of such viruses and thereby provide a effective modality for the treatment of infections such as hepatitis C, and the like.Anti-vsv DRAVPa2223 VSFRVGLHEYPV'Sequence 48 from Patent US20140294942A1 DRAVPa2224-SDWGVLTNLG ILLLLSIAVL IALSCICGSGKKRTLRKNDRKKR'Sequence 29 from Patent US20210380642B2Ebolavirus Marburg virus US20210380642B2 2023-09-26 JP2021187810!Antiviral peptide and use thereofThe synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 100 amino acid residues.$Anti-Ebola virus Anti-Marburg virus DRAVPa2225+RQWIPAGIGVTGVIIAVIALFCICKFVGSGKKRTLRKNDRKKR'Sequence 30 from Patent US20210380642B2The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 101 amino acid residues. DRAVPa2226< +RQWIPAGIGITGIIIAIIALLCVCKLLGSGKKRTLRKNDRKKR'Sequence 31 from Patent US20210380642B2The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 102 amino acid residues. DRAVPa22270MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSGSGKKRTLRKNDRKKR'Sequence 32 from Patent US20210380642B2The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 103 amino acid residues. DRAVPa22280MEGLSLLQLPRDKFRKSSFFVWVIILFQKAFSGSGKKRTLRKNDRKKR'Sequence 33 from Patent US20210380642B2The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 104 amino acid residues. DRAVPa2229!MKTTCFLISLILQGTKNGSGKKRTLRKNDRKKR'Sequence 34 from Patent US20210380642B2The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 105 amino acid residues. DRAVPa2230 MKTTCLLISLIQGCKTGSGKKRTLRKNDRKKR'Sequence 35 from Patent US20210380642B2Ebola virus Marburg virus The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 106 amino acid residues. DRAVPa2231 NAIVGIVLLIVVTFLAIKTKKRTLRKNDRKKR'Sequence 36 from Patent US20210380642B2The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 107 amino acid residues. DRAVPa2232"FFFIIGLIIGLFLVLRVGIHLKKRTLRKNDRKKR'Sequence 37 from Patent US20210380642B2The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 108 amino acid residues. DRAVPa2233"VLAVIIGFVILMFLIKLIGVLKKRTLRKNDRKKR'Sequence 38 from Patent US20210380642B2The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that < functions as a cell penetrating peptide (CPP), and consists of a total of not more than 109 amino acid residues. DRAVPa2234'Sequence 43 from Patent US20070073039A1Hepatitis C VirusHCV Dengue viralUS20070073039A1 2007-03-29@EP1931699##CA2624153##AU2006299550##WO/2007/041487##JP2009510122&Peptidesthatinhibitviralinfections,Inhibit HCV infection by more than ten-fold.The present application is directed topeptidesthatinhibitinfection of a virus from the Flaviviridae family, methods of using thesepeptidestoinhibitviralinfections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising thesepeptides. DRAVPa2235'Sequence 92 from Patent US20070073039A1 Dengue viral DRAVPa2236LRDIWDWICEVLSDFK(Sequence 107 from Patent US20070073039A1 DRAVPa2237LYGNEGCGWAGWLLSPRG&Sequence 6 from Patent US20070073039A1 DRAVPa2238IFLLALLSCLTVPASAYQ&Sequence 8 from Patent US20070073039A1 DRAVPa2239GSATLCSALYVGDLCGSV'Sequence 12 from Patent US20070073039A1 DRAVPa2240ALYVGDLCGSVFLVGQLF'Sequence 13 from Patent US20070073039A1 DRAVPa2241IMDMIAGAHWGVLAGIAY'Sequence 14 from Patent US20070073039A1 DRAVPa2242YLYGVGSSIASWAIKWEY'Sequence 24 from Patent US20070073039A1 DRAVPa2243WMMLLISQAEAALENLVI'Sequence 27 from Patent US20070073039A1 DRAVPa2244TLVFDITKLLLAIFGPLW'Sequence 30 from Patent US20070073039A1 DRAVPa2245ATQTFLATCINGVCWTVY'Sequence 32 from Patent US20070073039A1 DRAVPa2246DWICEVLSDFKTWLKAKL'Sequence 44 from Patent US20070073039A1 DRAVPa2247DTEDVVCCSMSYSW'Sequence 47 from Patent US20070073039A1 DRAVPa2248SSGADTEDVVCCSMSYSW'Sequence 48 from Patent US20070073039A1 DRAVPa2249CTMLVCGDDLVVICESAG'Sequence 53 from Patent US20070073039A1 DRAVPa2250WMNSTGFTKVCGAPPCVI'Sequence 21 from Patent US20070073039A1/Inhibit HCV infection by five-fold to ten-fold. DRAVPa2251MYVGGVEHRLEAACNWTR'Sequence 23 from Patent US20070073039A1 DRAVPa2252GAVYAFYGMWPLLLLLLA'Sequence 28 from Patent US20070073039A1 DRAVPa2253TSTWVLVGGVLAAT'Sequence 37 from Patent US20070073039A1 DRAVPa2254QIVGGVYLLPRRGPRLGW&Sequence 4 from Patent US20070073039A1/Inhibit HCV infection by two-fold to five-fold. DRAVPa2255QPGYPWPLYGNEGCGWAG&Sequence 5 from Patent US20070073039A1 DRAVPa2256GWAGWLLSPRGSRPSWGP&Sequence 7 from Patent US20070073039A1 DRAVPa2257DAILHTPGCVPCVREGNA&Sequence 9 from Patent US20070073039A1 DRAVPa2258LPTTQLRRHIDLLVGSAT'Sequence 10 from Patent US20070073039A1 DRAVPa2259RHIDLLVGSATLCSALYV'Sequence 11 from Patent US20070073039A1 DRAVPa2260HINSTALINCNESLNTGWL'Sequence 15 from Patent US20070073039A1 DRAVPa2261NCNESLNTGWLAGLFYQH'Sequence 16 from Patent US20070073039A1 DRAVPa2262LASCRRLTDFAQGWGPIS'Sequence 17 from Patent US20070073039A1 DRAVPa2263TDFAQGWGPISYANGSGL'Sequence 18 from Patent US20070073039A1 DRAVPa2264GPISYANGSGLDERPYCW'Sequence 19 from Patent US20070073039A1 DRAVPa2265GSGLDERPYCWHYPPRPC'Sequence 20 from Patent US20070073039A1 DRAVPa2266PCVIGGVGNNTLLCPTDC'Sequence 22 from Patent US20070073039A1 DRAVPa2267ASWAIKWEYVVLLFLL'Sequence 25 from Patent US20070073039A1 DRAVPa2268KWEYVVLLFLLLADARVC'Sequence 26 from Patent US20070073039A1 DRAVPa2269GMWPLLLLLLALPQRAYA'Sequence 29 from Patent US20070073039A1 DRAVPa2270VSTATQTFLATCIN'Sequence 31 from Patent US20070073039A1 DRAVPa2271DSSVLCECYDAGCAWYEL'Sequence 33 from Patent US20070073039A1 DRAVPa2272AYMNTPGLPVCQDHLEFW'Sequence 34 from Patent US20070073039A1 DRAVPa2273LEFWEGVFTGLTHIDAHF'Sequence 35 from Patent US20070073039A1 DRAVPa2274HPITKYIMTCMSADLEVV'Sequence 36 from Patent US20070073039A1 DRAVPa2275WVLVGGVLAALAAYCLST'Sequence 38 from Patent US20070073039A1 DRAVPa2276LAALAAYCLSTGCVV'Sequence 39 from Patent US20070073039A1 DRAVPa2277EVFWAKHMWNFISGIQYL'Sequence 40 from Patent US20070073039A1 DRAVPa2278MWNFISGIQYLAGLSTLP'Sequence 41 from Patent US20070073039A1 DRAVPa2279PAILSPGALVVGVVCAAI'Sequence 42 from Patent US20070073039A1 DRAVPa2280YVSGMTTDNLKCPCQIPS'Sequence 45 from Patent US20070073039A1 DRAVPa2281SSGADTEDVVCCSMS'Sequence 46 from Patent US20070073039A1 DRAVPa2282DVVCCSMS< YSWTGAL'Sequence 49 from Patent US20070073039A1 DRAVPa2283TVTESDIRTEEAIYQCCD'Sequence 50 from Patent US20070073039A1 DRAVPa2284GNTILTCYIKARAACRAAG'Sequence 51 from Patent US20070073039A1 DRAVPa2285RAAGLQDCTMLVCGDDLV'Sequence 52 from Patent US20070073039A1 DRAVPa2286DDLVVICESAGVQEDAAS'Sequence 54 from Patent US20070073039A1 DRAVPa2287LELITSCSSNVSVAHDGA'Sequence 55 from Patent US20070073039A1 DRAVPa2288HTPVNSWLGNIIMFAPTL'Sequence 56 from Patent US20070073039A1 DRAVPa2289APTLWARMILMTHFFSVL'Sequence 57 from Patent US20070073039A1 DRAVPa2290DQLEQALNCEIYGACYSI'Sequence 58 from Patent US20070073039A1 DRAVPa2291GVPPLRAWRHRARSVRAR'Sequence 59 from Patent US20070073039A1 DRAVPa2292WRHRARSVRARLLSRGGR'Sequence 60 from Patent US20070073039A1 DRAVPa2293GWFTAGYSGGDIYHSVSH'Sequence 61 from Patent US20070073039A1 DRAVPa2294ELSTTDDAGTICANIGVC#Sequence 1 from Patent CN113754750BSVCV CN113754750B 2023-08-25<Antibacterialpeptideand application thereof in aquaculturewThe invention discloses an antibacterialpeptideand application thereof in aquaculture. The amino acid sequence of the antibacterialpeptideis as shown in SEQ ID NO.1. A section of micromolecule polypeptide caNKL2102-119 with the length of 18aa is selected and artificially synthesized through bioinformatics analysis and fitting of a three-dimensional space structure of a crucian carp NK-lysin protein, and research finds that the micromolecule polypeptide has excellent antibacterial andantiviralactivity, does not easily generate drug resistance, is short in synthesis sequence, small in molecular weight, small in chemical synthesis difficulty, and high in bioactivity, can greatly save the cost of large-scale production on the basis of killing pathogenic bacteria in organisms, is expected to become an effective substitute of antibiotics in aquaculture, has high economic value and production and application value, and can inhibit replication of spring viremia virus (SVCV) of carp, a new thought is provided for preparation of aquaticantiviraldrugs, and prevention and control of related aquatic viral diseases are facilitated. DRAVPa2295REYNNRSAIGNTIEALFQ#Sequence 1 from Patent CN113999286B Enterovirus CN113999286B 2024-08-02WO/2022/021902##JP2023535570Broad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 2C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitorThe invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 2C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs. DRAVPa2296 YGRKKRRQRRRGSGREYNNRSAIGNTIEALFQ#Sequence 2 from Patent CN113999286BBroad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 3C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitorThe invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 3C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromo< lecular drugs. DRAVPa2297"YGRKKRRQRRRGSGLIREYNNRSAIGNTIEALFQ#Sequence 3 from Patent CN113999286BBroad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 4C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitorThe invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 4C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs. DRAVPa2298$YGRKKRRQRRRGSGSELIREYNNRSAIGNTIEALFQ#Sequence 4 from Patent CN113999286BBroad-spectrum anti-enterovirus polypeptide inhibitor of targeted enterovirus 5C protein and application of broad-spectrum anti-enterovirus polypeptide inhibitorThe invention belongs to the field of biological medicine, and particularly relates to a polypeptide inhibitor targeting enterovirus 2C protein and an application thereof. The core sequence of the polypeptide inhibitor provided by the invention is shown as SEQ ID NO.1, and the sequence of the cell-penetrating peptide is shown as SEQ ID NO.2. Compared with other inhibitors of targeting enterovirus 5C protein, the polypeptide provided by the invention is higher in inhibition efficiency and good in safety, provides a new strategy for prevention and control of enteroviruses, and also provides a new theoretical basis for accelerating research and development of anti-human enterovirus polypeptide micromolecular drugs. DRAVPa2299 YPFDDKMSFLFA"Sequence 1 from Patent US6337074B1 Herpesviruses US6337074B1 2002-01-086EP0918866##AU1997037013##WO/1998/004707##US20050164163Anti-herpesviral agentAn antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL8 (or homologues thereof) is also described. DRAVPa2300AGVWGEGGKFVYPFDDKMSFLFA"Sequence 2 from Patent US6337074B1An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL9 (or homologues thereof) is also described. DRAVPa2301VLAGVWGEGGKFVYPFDDKMSFLFA"Sequence 3 from Patent US6337074B1An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also sui< table anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL10 (or homologues thereof) is also described. DRAVPa2302TGVLAGVWGEGGKFVYPFDDKMSFLFA"Sequence 4 from Patent US6337074B1An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL11 (or homologues thereof) is also described. DRAVPa2303VFTGVLAGVWGEGGKFVYPFDDKMSFLFA"Sequence 5 from Patent US6337074B1An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL12 (or homologues thereof) is also described. DRAVPa2304TGVLAGVWGEGGKFV"Sequence 6 from Patent US6337074B1An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL13 (or homologues thereof) is also described. DRAVPa2305IELVFTGVLAGVWGEGGKFV"Sequence 7 from Patent US6337074B1An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL14 (or homologues thereof) is also described. DRAVPa2306EILREIELVFTGVLA"Sequence 8 from Patent US6337074B1An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL15 (or homologues thereof) is also described. DRAVPa2307IVEFLKVGFGTEGGVWLVAG"Sequence 9 from Patent US6337074B1An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these protein< s in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL16 (or homologues thereof) is also described. DRAVPa2308VKLWYQLEKEPIVGA#Sequence 10 from Patent US6337074B1An antiviral agent capable of disrupting the association of two viral proteins required for DNA replication in herpesviruses. The agents disrupt the association of UL8 and POL in HSV-1 or the association of equivalent homologues of these proteins in other herpesviruses (for example UL 102 and UL54 in HCMV). Suitable agents are peptides which mimic the C-terminal or C-proximal portion of UL8 (or its homologues) for example the peptide IELVFTGVLAGVWGEGGKFV. Peptidomimetic compounds of such peptides are also suitable anti-viral agents. An assay to test for agents capable of disrupting association of POL and UL17 (or homologues thereof) is also described. DRAVPa2309KHGHHRH&Sequence 1 from Patent US20210040153A1DENVUS20210040153A1 2021-02-11CN108395470##WO/2019/137247XOLIGOPEPTIDE HAVING DENGUE VIRUS REPLICATION INHIBITION FUNCTION AND APPLICATION THEREOFThe present invention relates to the field of virology, and specifically discloses a short peptide having a dengue virus replication inhibition function and an application thereof. The amino acid sequence of the short peptide provided in the present invention is KHGHHRH, i.e. Lys-His-Gly-His-His-Arg-His (SEQ ID NO. 1). The short peptide has a high specificity affinity with NS5 and has the function of efficiently inhibiting dengue virus replication, the anti-viral effect thereof not been limited to DENV-2, but also having a significant inhibitory effect on the replication of type 1, type 3, and type 4 dengue virus. One cysteine is added to the two ends of the short peptide sequence, the short peptide being cyclised by means of the cysteines at the two ends to form a cyclic peptide. The obtained cyclic peptide strengthens the dengue virus replication inhibition function, and can be used for specific treatment of dengue virus infection. DRAVPa2310 CKHGHHRHC&Sequence 2 from Patent US20210040153A1The present invention relates to the field of virology, and specifically discloses a short peptide having a dengue virus replication inhibition function and an application thereof. The amino acid sequence of the short peptide provided in the present invention is KHGHHRH, i.e. Lys-His-Gly-His-His-Arg-His (SEQ ID NO. 1). The short peptide has a high specificity affinity with NS5 and has the function of efficiently inhibiting dengue virus replication, the anti-viral effect thereof not been limited to DENV-2, but also having a significant inhibitory effect on the replication of type 1, type 3, and type 5 dengue virus. One cysteine is added to the two ends of the short peptide sequence, the short peptide being cyclised by means of the cysteines at the two ends to form a cyclic peptide. The obtained cyclic peptide strengthens the dengue virus replication inhibition function, and can be used for specific treatment of dengue virus infection. DRAVPa2311CHPVFCPRRYKQIGTCGLPGTKC#Sequence 2 from Patent CN118451094A CN118451094A 2024-08-06WO/2023/125432##EP4457237-Antiviral peptides and methods of use thereofAntiviral peptides and formulations thereof for treating or preventing one or more symptoms of coronavirus infection are described. Peptides derived from human beta defensin 2 have been demonstrated to have antiviral properties against different coronavirus variants, including cross-linking viral particles, blocking intercellular fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via an intranasal route to prevent or alleviate one or more symptoms of coronavirus infection, such as red< ucing syncytial formation and lung injury. DRAVPa2312CHPVFCPRRYKQIGTCGLPGTKCCKK#Sequence 3 from Patent CN118451094AAntiviral peptides and formulations thereof for treating or preventing one or more symptoms of coronavirus infection are described. Peptides derived from human beta defensin 3 have been demonstrated to have antiviral properties against different coronavirus variants, including cross-linking viral particles, blocking intercellular fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via an intranasal route to prevent or alleviate one or more symptoms of coronavirus infection, such as reducing syncytial formation and lung injury. DRAVPa2313GAICHPVFCPRRYKQIGTCGLPGTKCCKKP#Sequence 4 from Patent CN118451094AAntiviral peptides and formulations thereof for treating or preventing one or more symptoms of coronavirus infection are described. Peptides derived from human beta defensin 4 have been demonstrated to have antiviral properties against different coronavirus variants, including cross-linking viral particles, blocking intercellular fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via an intranasal route to prevent or alleviate one or more symptoms of coronavirus infection, such as reducing syncytial formation and lung injury. DRAVPa2314QPSVQIQVYQGEREIAAHAAAKLPDLCTEL#Sequence 1 from Patent CN108409866AHPV CN108409866A 2018-08-17WO/2019/144607sMulti-epitope combined peptide used for treating and preventing human papillomavirus infection and related diseases The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E7, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa2315QPSVQIQVYQGEREIAAHAAATLHEYMLDL#Sequence 2 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E8, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa2316QPSVQIQVYQGEREIAAHAAAYMLDLQPET#Sequence 3 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing<  human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E9, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa2317QPSVQIQVYQGEREIAAHAAARAHYNIVTF#Sequence 4 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E10, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa2318QPSVQIQVYQGEREIAAHAAACDSTLRLCV#Sequence 5 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E11, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa2319QPSVQIQVYQGEREIAAHAAARLCVQSTHV#Sequence 6 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E12, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating an< d preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa2320QPSVQIQVYQGEREIAAHAAALIMGTLGIV#Sequence 7 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E13, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa2321QPSVQIQVYQGEREIAAHAAATLGIVCPI#Sequence 8 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E14, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa23223QPSVQIQVYQGEREIAAHAAAYKLPDLCTELNTSLQDIEITCVYCKTVLEL#Sequence 9 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E15, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa23230QPSVQIQVYQGEREIAAHAAASVYGDTLEKLTNTGLYNLLIRCLRCQK$Sequence 10 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E16, and the multi-epitope combined peptide is in linear arrangement < through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients.3 DRAVPa2324*QPSVQIQVYQGEREIAAHAAAATLQDIVLHLEPQNEIPVDLL$Sequence 11 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E17, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa23253QPSVQIQVYQGEREIAAHAAAGVNHQHLPARRAEPQRHTMLCMCCKCEARI$Sequence 12 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E18, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa23261QPSVQIQVYQGEREIAAHAAAVVESSADDLRAFQQLFLSTLSFVCPWCA$Sequence 13 from Patent CN108409866A The invention relates to a multi-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E19, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa2327QPSVQIQVYQGEREIAAHAAAFQQLFLNTL$Sequence 14 from Patent CN108409866A The invention relates to a m< ulti-epitope combined peptide used for treating and preventing human papillomavirus (HPV) infection and related diseases. The multi-epitope combined peptide consists of a binding domain and a hinge domain of carboxyl-terminated peptide of mycobacterium tuberculosis heat shock protein 70 (HSP70), and antigen epitope peptides of T cells of HPV E6 and E20, and the multi-epitope combined peptide is in linear arrangement through the arrangement mode of HSP stimulated epitope peptide-hinge area-HPV CTL epitope. The multi-epitope combined peptide provided by the invention can be used as a vaccine to induce the immune response mediated by specific T lymphocytes through injection of intradermal, hypodermic, focus or mucosal tissues, and can induce effective antiviral effect in tissues and local tissues for treating and preventing HPV infection and related diseases. The multi-epitope combined peptide provided by the invention has the advantages of low use dose and no need of adding artificial excipients. DRAVPa2328FLKHIKSFWRGAKAIFRGARQGWREHRSequence 1 from CN119326871AMSRV CN119326871A 2025-01-21CN 119326871 A%Ms-Piscidinb̃(W6RY'YSў9_rukb6RBRbluoir-Nv^(u,gSflQ_NMs Piscidinb̃(W6RY'YSў9_rukb6RBRbluoir-Nv^(u yrp/fcOMs Piscidinb̃(W6RY'YSў9_rukb6RBR-Nv^(uNSMs Piscidinb̃(W6RY'YSў9_rukagluoir-Nv^(u Ms Piscidinb̃v(lWx^R:NSEQ ID NO.1@b:y:FLKHIKSFWRGAKAIFRGARQGWREHR Op/fMs Piscidinb̃Yb6RMSRVXk0cؚMSRVagv'YSўvX[;ms S\O:N2lMSRVaguuv\o(Woir0 Anti-MSRV DRAVPa2329 KYGPTPVRDGFKSequence 1 from CN 118767104 APEDVCN 118767104 A 2024-10-15lApplication of pea active peptide in inhibition of porcine epidemic diarrhea virus replication and apoptosisThe invention discloses an application of pea active peptide in inhibition of porcine epidemic diarrhea virus replication and apoptosis, and relates to the technical field of antiviral biologica.According to the application, synthesized pea active peptide is utilized, toxicity of peptides with different concentrations to Vero cells is determined by adopting a CCK-8 test, and the application of the pea active peptide in inhibition of porcine epidemic diarrhea virus replication and apoptosis is achieved. The inhibition effect of the pea active peptide KYGPTPVRDGFK on the porcine epidemic diarrhea virus in Vero cells is determined through indirect immunofluorescence, virus copy number, immunoblotting and half tissue infection amount, and the inhibition effect of the KYGPTPVRDGFK on Vero cell apoptosis induced by the porcine epidemic diarrhea virus is verified through immunoblotting. Results show that the pea bioactive peptide can significantly inhibit the replication of the porcine epidemic diarrhea virus and significantly reduce the Vero cell apoptosis level induced by the porcine epidemic diarrhea virus, thereby providing a new idea and method for the prevention and treatment of the PEDV. Anti-PEDV DRAVPa2330 VSIPWTHKVSequence 124 from CN118620040AhumanHBV CN118620040A 2024-09-10aCN 114478711 A## CN 118580321 A3## CN 118580322 A##CN 118620040 A##CN 114478711 B##CN 119039403 A+Antigen peptide aiming at hepatitis B virusPThe invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-124. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV< -related liver cancer immunotherapy through large-scale synthesis.Anti-HBV DRAVPa2331 FLLAQFTSAISequence 3 from CN118620041AaCN 114478711 A## CN 118580321 A,##CN 118580322 A,##CN 118620040 A##CN 114478711 B##CN 119039403 APThe invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-125. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis. DRAVPa2332 FLPDFFPSISequence 6 from CN118620042AaCN 114478711 A##CN 118580321 A## CN 118580322 A## CN 118620040 A## CN 114478711 B##CN 119039403 APThe invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-126. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis. DRAVPa2333 RVRALYFPASequence 84 from CN118620043A_CN 114478711 A##CN 118580321 A##CN 118580322 A## CN 118620040 A##CN 114478711 B##CN 119039403 APThe invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-127. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis. DRAVPa2334GWKDFKKTIKKLLRGASRLLKFSequence 1 from CN117024530B Hantaan virus, Chikungunya virus CN117024530B 2024-03-19CN 117024530 A## CN 117024530 B$b_uirPerceptide-TJ-2SvQ(W6RY^1bukoir-Nv(u,gSfmSoir6RYb/gW wQSOlQ_NeWb_uirPerceptide TJ 2SvQ(W6RY^1bukoir-Nv(u0,gSfcOveWb_uirPer< ceptide TJ 2/fWNN]zfelhQe0g^v^Tb wQ g^1bukag;m'` ؚHeb6RIlnuk0WT[Ŗuk01WUS~uuukT2W{viuk Og'`uSSO gHeMNOuk}ϑ :N_SeNN^1bukoircOOncTW@x :NON{|eP^cOhQevb/gKbk0*Anti-Hantaan virus, Anti-Chikungunya virus DRAVPa2335MGVKVLFALICIAVAEASequence 1 from CN119390792AMonkeypox virus M1R CN116024265B 2025-02-07CN 116024265 A##CN 116024265 B6RY4suukM1rbSRlˆ}vvelSvQ@b(u8hxRP[,gSflQ_NNy6RY4suukM1RbSRlˆ}vvelSvQ@b(u8hxRP[0,gSfmSuirb/gW wQSOmSNy6RY4suukM1RbSRlˆ}vvelSvQ@b(u8hxRP[0,gSfcOvelSbY Nek(A1)\8hxRP[[eQ[;N~ހ _0R͑~~ހ8hxRP[xTˆ}v Tˆ}v:N\Y((lWx^R/fSEQ ID No.1)TN4suukM1RbSvNz_0Rvˆ}v((A2)W{Q͑~~ހ NW{Q Nn-N_4suukM1RbSRlˆ}v0Ǒ(ugIQ }vOSGa_[4suukM1Rw8h~ހRlh4ls^>fWON}vˆ}vOSAlTbSO{OSLc f(uN'Yĉ!j]NSuN MNOuNb,g0Anti-Monkeypox virus M1R DRAVPa2336APAICHDGKAHFPRESequence 1 from CN119320428ACOVID-19 CN119320428A 2025-01-17CN 119320428 AeWQruk^1MQuORCd4+t~ހhMOSvQ^(u,gSfmSuir;Sf[b/gW lQ_NeWQruk^1MQuORCD4+T~ހhMO Sb[eWQrukSY*hSvQS_*hqQ gvThhMO ؏Sb[eYyKQbS_*hyr gvMQuORzSThhMO؏lQ_NThhMO MHCVZSOS^(u0,gSf_vhMOk&{T)Y6qr` NHLA II{|RP[~TcHTvĉ_ [ThhMOvhQsؚ NYMNOVRKNNv~Nmb,g)R(u,gSfvhMO6RYvThhMO MHCVZSOwQ g:_pv:RoCD4+T~ހ;mSvHe^,gSfvhMOTThhMO MHCVZSOS6R\ObՋBRv0 Anti-COVID-19 DRAVPa2337EGVFVSNGTHWFVTQSequence 2 from CN119320428A DRAVPa2338AGLIAIVMVTIMLCCMSequence 3 from CN119320428A DRAVPa2339KFNGLTVLPPLLTDESequence 4 from CN119320428A DRAVPa2340GTHWFVTQRNFYEPQISequence 5 from CN119320428A DRAVPa2341EDLLFNKVTLADAGSequence 6 from CN119320428A DRAVPa2342TFEYVSQPFLMDLEGSequence 7 from CN119320428A DRAVPa2343 NDDTPVDEALGRVLTPTAVDEALVDLAPDADPSequence 1 from CN119285713ASeneca virus type A CN119285713A 2025-01-10CN 119285713 AAW^XQaSuk3aˆ}vbShMO0USKQbSOSvQ^(u ,gSf^\Nuir;Sob/gW wQSOlQ_NNyAW^XQaSuk3Aˆ}vbShMObvQx8hx NAW^XQaSuk3Aˆ}vbShMOyr_'`~TvUSKQbSO RlUSKQbSOvBgN$v~ހ*hSvQ(W6RY2T/bluAW^XQaSukagvoir0bhKmT/bʋeAW^XQaSukagvՋBR-Nv^(u0,gSfcOvUSKQbSO1uOυS:NCCTCC NOC202466vBgN$v~ހ*hSVA 3A 5A7RlNu USbYyr_'`~TAW^XQaSuk3Aˆ}vbShMOMON3Aˆ}vހY~gW,{5 36MO(lWx S(uN6RY2T/bluAW^XQaSukagvoir bhKmT/bʋeAW^XQaSukagvՋBR0Anti-Seneca virus type A DRAVPa2344 SPTVWLSVISequence 1 from CN119241665ACN 119241665 A 2025-01-03YNWpukvzOV'`m]~ހbShMOSvQ^(u=,gSflQ_NYNWpukbSvzOV'`m]~ހbShMOS^(u ^\N;Sf[MQuf[Taguf[W0YNWpukbSvzOV'`m]~ހbShMO @bhMOv(lWx^RSbN NNaNybYySPTVWLSVILPLLPIFFCLCPTVQASKLLPSDFFPSI N(lWx^RUS*N(lWxvSdbfbcTv(lWx^R0,g3uvhMOSNyr_'`0WN~ހk'`zOV'`m]~ހ~T :RoT;mS0XkTRS N S%cbYNWpukvMQuHe^\O(uُNbSSN(ueg6RYYNWpukagvlu'`T2'`uׂ _NSN(ueg6RYhKmYNWpukyr_'`~ހkWzOV'`m]~ހvhKmՋBR (WYNWpv20luTʋe-N g@w\o(Wv^(uNCN 112028978 A##CN 112028978 B##CN 116375822 A##CN 116375822 BeQukyr_'`Cd8+t~ހhMOSvQ^(u,gSf^\NMQuf[b/gW wQSOlQ_NeQukyr_'`CD8+T~ހhMO (lWx^R:NSEQ ID NO:180,gSf؏lQ_N NeQukyr_'`CD8+T~ހhMOv^(u0,gSf@bcOveQukyr_'`CD8+T~ހhMOYNu:_pv~ހMQu^T{ Rlؚ4ls^IFN  [NeWQrukagv204N^luTuׂvxSGWwQ g͑vyf[aINT^(uMRof0 DRAVPa2424 NYNYLYRLF#Sequence 9 from Patent CN116375822B DRAVPa2425NATRFASVYAWNRKR$Sequence 16 from Patent CN116375822B DRAVPa2426FASVYAWNRKRISNC$Sequence 17 from Patent CN116375822B DRAVPa2427RKRISNCVADYSVLY$Sequence 18 from Patent CN116375822B DRAVPa2428SNCVADYSVLYNSAS$Sequence 19 from Patent CN116375822B DRAVPa2429FHDMVGHHILGACH#Sequence 1 from Patent CN118221784A CN118221784A 2024-06-21CN 118221784 AtAfrican swine fever virus p72 protein antigen epitope peptide as well as monoclonal antibody and application thereofnThe invention discloses an antigen epitope peptide of an African swine fever virus p72 protein, which is a peptide fragment 102 to 114 or/and a peptide fragment 239 to 248 of the African swine fever virus p72 protein, and the amino acid sequence of the antigen epitope peptide is 102FHDMVGHHILGACH114 or/and 239GPLLCNIHDL248. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of g< ood specificity and high accuracy, and provide a new tool for immunological detection of the African swine fever virus p72 protein. DRAVPa2430 GPLLCNIHDL#Sequence 2 from Patent CN118221784A DRAVPa2431MSILEKITSSPSECAEHLTNKDSCL#Sequence 1 from Patent CN118184749A CN118184749A 2024-06-14CN 118184749 AwAfrican swine fever virus pS273R protein antigen epitope peptide as well as monoclonal antibody and application thereofThe invention discloses an antigen epitope peptide of an African swine fever virus pS273R protein and a monoclonal antibody aiming at the antigen epitope, the antigen epitope peptide is 1-25 peptide fragments of the African swine fever virus pS273R protein, and the amino acid sequence of the antigen epitope peptide is 1MSILEKITSSPSECAEHLTNKDSCL25. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the African swine fever virus, have the characteristics of good specificity and high accuracy, and provide a new tool for researching the biological function of the African swine fever virus pS273R protein. DRAVPa2432DAEFRHDSGYEVHHQK#Sequence 1 from Patent CN118161592A CN118161592A 2024-06-11CN 118161592 AWGlycopeptide compound for inhibiting SARS-CoV-2 virus infection and application thereofThe invention relates to the field of biological medicine, in particular to a glycopeptide compound for inhibiting SARS-CoV-2 virus infection. The glycopeptide compound disclosed by the invention comprises polypeptide and polysaccharide, wherein the polypeptide comprises a polypeptide P1 or a polypeptide P2, and the amino acid sequence of the polypeptide P1 is as shown in SEQ ID NO.1; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.1 through amino acid substitution, deletion or increase; the amino acid sequence of the polypeptide P2 is as shown in SEQ ID NO. 2; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.2 through amino acid substitution, deletion or increase; the structural fragment of the polysaccharide comprises any one or more than two of xFuc-N1Gal-N1 (xFuc-N1) GlcNAc structural units, x is equal to 0 or 1, and N1 is equal to 1, 2, 3, 4 or 6. The glycopeptide compound can be combined with S protein of the novel coronavirus and heparin molecules on the surface of human cells, and host cells are protected from invasion of the novel coronavirus through competitive inhibition. DRAVPa2433*DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA#Sequence 2 from Patent CN118161592A DRAVPa2434 NMLSTVLGV#Sequence 1 from Patent CN117430665B CN117430665B 2024-06-04CN 117430665 A##CN 117430665 B2uWAmaukT~ހbShMOSvQ^(u ,gSf^\NMQulub/gW wQSOmS2uWAmaukT~ހbShMOSvQ^(u0,gSf㉳Qvb/g/fvMR(W2uWAmaukW\l g_SNy(uN2uWAmauk(uuׂvT~ހbShMO0,gSfvb/geHh2uWAmaukT~ހbShMO vQ(lWx^RYSEQ ID No.10@b:y0,gSfcONvbShMOwQ g_:_vMQuS'` [bSyr_'`vCD8+T~ހvQSNTHLA A2͑THLA A2{2mˆ}v~ňbpMHC YTirbvcw0RbSHT~ހ ;mST~ހ gHe[T~ހMQu S(uN2uWAmauk(uuׂxS06RYToirxS04N^lu0 DRAVPa2435 FMYSDFHFI#Sequence 2 from Patent CN117430665B DRAVPa2436 STICFFMQI#Sequence 3 from Patent CN117430665B DRAVPa2437 CLPACVYGL#Sequence 4 from Patent CN117430665B DRAVPa2438 AMDSNTLEL#Sequence 5 from Patent CN117430665B DRAVPa2439 MQIAILITT#Sequence 6 from Patent CN117430665B DRAVPa2440 FQGRGVFEL#Sequence 7 from Patent CN117430665B DRAVPa2441 AIMDKNIIL#Sequence 8 from Patent CN117430665B DRAVPa2442 CVNGSCFTV#Sequence 9 from Patent CN117430665B DRAVPa2443 KADTKILFI$Sequence 10 from Patent CN117430665B DRAVPa2444 IVLEANFSV$Sequence 11 from Patent CN117430665B DRAVPa2445+AEQRASPLTSIVSAVVGILLVVVLGVVFGILIKRRQQKIRKYT#Sequence 1 from Patent CN116574685BZIKV CN116574685B 2024-05-31CN 116574685 A##CN 116574685 BNyň}b̃Ll-37vYlSOSvQ(Wb[aSuk-Nv^(u,gSflQ_NNyň}b̃LL 37vYlSOSvQ(Wb[aSuk-Nv^(u vQ-N b̃LL 37ǏOp(WvQNzbCzv荜ˆ}vň}NYlSO N 6RY_0RvNT[hQ'`}Y @n3z['`_N'Y'Ycؚ e(WSOQ؏/fSOY g>fWvbuk\O(u $\vQ/fLL 37 TM exo (W[ZIKVagv2Tlu NGW gg:NO_vHeg SN\O:N2l[aSukagoirv gRY 0 Anti-ZIKV DRAVPa2446KFLNPDREYDFRDLR#Sequence 1 from Patent CN107033225BPPRV CN107033225B 2024-05-14CN 107033225 A##CN 107033225 BNy\S R}QuukHnˆ}vbShMOSvQnx[06RYelT^(u ,gSfmSNy\S R}QuukHNˆ}vbShMO bShMOv(lW< x^R:NH123123KFLNPDREYDFRDLR137,b/TH185185GTGCLGRTVTRA196,b/TH487487IRGPRGRCH495,b/TH569569ECFPWYHKVWCYHDCLI585,gSfO(uYyMQuOo`f[oN[vhˆ}vۏLB~ހhMOۏLKm 6qT[Kmv N ThMOR+RۏLN]Tb ^(ucELISAelۏLvQS^S'` N TvYS(lWSvhg hKmNHNˆ}vvbSOvS^S'` N t[QPPRV HNˆ}vvB~ހhMO0 Anti-PPRV DRAVPa2447 GTGCLGRTVTRA#Sequence 2 from Patent CN107033225B DRAVPa2448 IRGPRGRCH#Sequence 3 from Patent CN107033225B DRAVPa2449ECFPWYHKVWCYHDCLI#Sequence 4 from Patent CN107033225B DRAVPa2450EGLYILEPHEGLYALAILEALAGLYPHEILEGLUASNGLYTRPGLUGLYMETVALASPGLYTRPTYRGLY#Sequence 1 from Patent CN116947982BInfluenza virus CN116947982BCN 116947982 A##CN 116947982 B NagORhMO^RSvQ(WAmaukuׂv^(u,gSfmSMQuf[b/gW mSS+T(uN2TluAmaukN[vuuvMQuSv~Tir lQ_N NagAmaukHA2vORhMO^RSvQ(WAmaukuׂxSv^(u0,gSfv NagORhMOv(lWx^RYSEQ ID NO:1 3@b:y0,gSfǏ[AmaukHA2ۏLMQuOo`f[KmTRir[v~T[{ Q NagwQ gMQuS'`vORhMO ُ NagORhMOwQ gT/B~ހhMO Y[~ހMQuTSOmMQu\O:N;QuׂvMQuSY[:_HevϞMQu S[[Amaukvؚn^vsIgA0vk T7h[勗bS:SvvQNY ,gSfvORhMOwQ gؚHeNTؚO['` S\O:NAmauׂvP MQuS0Anti-Influenza virus DRAVPa2451<ARGLEUILEGLYLYSTHRASNGLULYSPHEHISGLNILEGLULYSGLUPHESERGLUVAL#Sequence 2 from Patent CN116947982B DRAVPa2452<GLYSERILEARGASNGLYTHRTYRASPHISASPVALTYRARGASPGLUALALEUASNASN#Sequence 3 from Patent CN116947982B DRAVPa2453ENNVPVTHAKELLHTEHNGM#Sequence 3 from Patent CN118027159A CN118027159ACN 118027159 ABroad-spectrum B cell epitope peptide of HA1 protein of H9 subtype avian influenza virus and application of broad-spectrum B cell epitope peptide5The invention belongs to the technical field of biology, and particularly relates to an H9 subtype avian influenza virus HA1 protein broad-spectrum B cell epitope peptide and application thereof, two sections of H9 subtype AIV HA1-derived B cell epitopes of an aa 39-59 polypeptide (ENNVPVTHAKELLHTEHNGM) and an aa 309-329 polypeptide (YAFGNCPKYIGVKSLKLAVG) are screened and identified, the B cell epitopes have high conservative property, besides the 320 < th > amino acid of the aa 309-329 polypeptide, the B cell epitopes of the aa 39-59 polypeptide and the YAFGNCPKYIGVKSLKLAVG are added into the B cell epitopes of the aa 309-329 polypeptide, and The conservative rates of other sites of the two polypeptides in the H9 AIV subtype are both greater than 96%. Serological experiments find that the two polypeptides can be specifically combined with different branch strains in the H9 AIV subtype and do not react with other subtype avian influenza viruses; meanwhile, the aa 309-329 polypeptide immune serum can also be specifically combined with different branched strains. DRAVPa2454YAFGNCPKYIGVKSLKLAVG$Sequence 30 from Patent CN118027159A DRAVPa2455dQVQLQQPGAELVKPGASVKLSCKSSGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTKYNEKFKTKATLTADKSSSTAYMQLSSLTSEDSAVYYCARAF#Sequence 1 from Patent CN116903709B CN116903709B 2024-05-07CN 116903709 A##CN 116903709 BNy^2m*svukpK205Rˆ}vbShMOSvQUSKQbSON^(u,gSflQ_NNy^2m*svuk(African swine fever virus,ASFV)pK205Rˆ}vbShMO @bbShMOv(lWx^RYSEQ ID NO3@b:y ,gSf؏lQ_NNyb@bbShMOvUSKQbSOSvQ6RYelT^(u ^\NRP[uirf[W0,gSfcOvbShMOTUSKQbSO(uN^2m*svukvhKm wQ gyr_'`}YQnx^ؚI{Op :Nxvz^2m*svukpK205Rˆ}vvuirf[RS_ShKmelcON gN?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                                                                                                       ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                                                                                                         ~ 5@                 ~ .@                 !~  @ "  #  $ %  &  '    ( ) * +~ "@ ,  #  $ %  &  '    ( ) - .~  @ /  #  $ %  &  '    ( ) 0 1~ @ 2 3 #  $ %  &  '    ( ) 4 5~ @ 6 3 #  $ %  &  '    ( ) 7 8~ $@ 9 3 #  $ %  &  '    ( ) : ;~ "@ <  #  $ % & '  ( ) = >~ @ ?  #  $ % & '  ( ) @ A~  @ B  #  $ % & '  ( ) C D~  @ E  #  $ % & '  ( ) F G~ (@ H I #  $ % & '  ( ) J K~ @ L M #  $ %  &  '    ( ) N O~  @ P M #  $ %  &  '    ( ) Q R~ @ S I #  $ %  &  '    ( ) T U~ @ V I #  $ %  &  '    ( ) W X~ *@ Y 3 #  $ %  &  '    ( ) Z [~ 1@ \  #  $ %  &  '    ( ) ] ^~ "@ _  #  $ %  &  '    ( ) ` a~ .@ b  #  $ %  &  '    ( ) c d~ 2@ e f #  $ %  &  '    ( ) g h~ 0@ i j #  $ %  &  '    ( ) k l~ &@ m n #  $ %  &  '    ( ) o p~ 4@ q n #  $ %  &  '    ( ) r s~ ,@ t u #  $ %  &  '    ( ) v w~ 1@ x  #  $ %  &  '    ( ) y z~ 5@ { | #  $ %  &  '    ( ) } ~~ @  u #  $ %  &  '    ( )  ~ &@   #  $ %  &  '    ( )  ~ >@   #  $ %  &  '    ( )  ~ *@   #  $ % & '  ( ) ! !~ !@ ! ! !# ! !$ !% ! & ! ' !  ! ( !) " "~ "@ " " "# " "$ "% " & " ' "  " ( ") # #~ #@ # # ## # #$ #% # & # ' #  # ( #) $ $~ $*@ $ $ $# $ $$ $% $ & $ ' $  $ ( $) % %~ %*@ % % %# % %$ %% % & % ' %  % ( %) & &~ &*@ & & &# & &$ &% & & & ' &  & ( &) ' '~ ' @ ' ' '# ' '$ '% ' & ' ' '  ' ( ') ( (~ (@ ( ( (# ( ($ (% ( & ( ' (  ( ( () ) )~ )2@ ) ) )# ) )$ )% ) & ) ' )  ) ( )) * *~ *1@ * * *# * *$ *% * & * ' *  * ( *) + +~ +7@ + + +# + +$ +% + & + ' +  + ( +) , ,~ ,1@ , , ,# , ,$ ,% , & , ' ,  , ( ,) - -~ -1@ - - -# - -$ -% - & - ' -  - ( -) . .~ .1@ . . .# . .$ .% . & . ' .  . ( .) / /~ /1@ / / /# / /$ /% / & / ' /  / ( /) 0 0~ 01@ 0 0 0# 0 0$ 0% 0 & 0 ' 0  0 ( 0) 1 1~ 11@ 1 1 1# 1 1$ 1% 1 & 1 ' 1  1 ( 1) 2 2~ 2$@ 2 2 2# 2 2$ 2% 2 & 2 ' 2  2 ( 2) 3 3~ 3@ 3 3 3# 3 3$ 3% 3 & 3 ' 3  3 ( 3) 4 4~ 4@ 4 43 4# 4 4$ 4% 4 & 4 ' 4  4 ( 4) 5 5~ 5@ 5 5 5# 5 5$ 5% 5 & 5 ' 5  5 ( 5) 6 6~ 6*@ 6 6 6# 6 6$ 6% 6 & 6 ' 6  6 ( 6) 7 7~ 7*@ 7 7 7# 7 7$ 7% 7 & 7 ' 7  7 ( 7) 8 8~ 8"@ 8 8u 8# 8 8$ 8% 8 & 8 ' 8  8 ( 8) 9 9~ 9@ 9 9 9# 9 9$ 9% 9 & 9 ' 9  9 ( 9) : :~ :@ : : :# : :$ :% : & : ' :  : ( :) ; ;~ ;1@ ; ; ;# ; ;$ ;% ; & ; ' ;  ; ( ;) < <~ <@ < < <# < <$ <% < & < ' <  < ( <) = =~ =1@ = = =# = =$ =% = & = ' =  = ( =) > >~ >2@ > > ># > >$ >% > & > ' >  > ( >) ? ?~ ?(@ ? ? ?# ? ?$ ?% ? & ? ' ?  ? ( ?) @ @~ @"@ @ @ @# @ @$ @% @ & @ ' @  @ ( @) A A~ A&@ A AI A# A A$ A% A & A ' A  A ( A) B B~ B4@ B B B# B B$ B% B & B ' B  B ( B) C C~ C*@ C C C# C C$ C% C & C ' C  C ( C) D D~ D @ D D D# D D$ D% D & D ' D  D ( D) E E~ E,@ E E| E# E E$ E% E & E ' E  E ( E) F F~ F2@ F F F# F F$ F% F & F ' F  F ( F) G G~ G"@ G G G# G G$ G% G & G ' G  G ( G) H H ~ H"@ H  H H# H H$ H% H & H ' H  H ( H) I  I ~ I1@ I  I I# I I$ I% I & I ' I  I ( I) J J~ J$@ J J3 J# J J$ J% J & J ' J  J ( J) K K~ K"@ K K K# K K$ K% K & K ' K  K ( K) L L~ L@ L L| L# L L$ L% L & L ' L  L ( L) M M~ M @ M M| M# M M$ M% M & M ' M  M ( M) N N~ N@ N N N# N N$ N% N & N ' N  N ( N) O O~ O@ O  O3 O# O O$ O% O & O ' O  O ( O) P! P"~ P@ P# P$ P# P P$ P% P & P ' P  P ( P) Q% Q&~ Q8@ Q' Q Q# Q Q$ Q% Q & Q ' Q  Q ( Q) R( R)~ R@ R* R R# R R$ R% R & R ' R  R ( R) S+ S,~ S@ S- S S# S S$ S% S & S ' S  S ( S) T. T/~ T0@ T0 T T# T T$ T% T & T ' T  T ( T) U1 U2~ U5@ U3 U U# U U$ U% U & U ' U  U ( U) V4 V5~ V6@ V6 V V# V V$ V% V & V ' V  V ( V) W7 W8~ W6@ W9 W W# W W$ W% W & W ' W  W ( W) X: X;~ X(@ X< X= X# X X$ X% X & X ' X  X ( X) Y> Y?~ Y$@ Y@ YA Y# Y Y$ Y% Y & Y ' Y  Y ( Y) ZB ZC~ Z$@ ZD Z Z# Z Z$ Z% Z & Z ' Z  Z ( Z) [E [F~ [$@ [G [A [# [ [$ [% [ & [ ' [  [ ( [) \H \I~ \&@ \J \A \# \ \$ \% \ & \ ' \  \ ( \) ]K ]L~ ]@ ]M ] ]# ] ]$ ]% ] & ] ' ]  ] ( ]) ^N ^"~ ^@ ^O ^M ^# ^ ^$ ^% ^ & ^ ' ^  ^ ( ^) _P _~ _"@ _Q _A _# _ _$ _% _ & _ ' _  _ ( _) `R `~ `(@ `S `A `# ` `$ `% ` & ` ' `  ` ( `) aT aU~ a$@ aV a a a aW aX a Y a Z a  a [ a b\ b]~ b$@ b^ b b b bW bX b Y b Z b  b [ b c_ c`~ c$@ ca c c c cW cX c Y c Z c  c [ c db dc~ d$@ dd d d d dW dX d Y d Z d  d [ d ee ef~ e$@ eg e e e eW eX e Y e Z e  e [ e fh fi~ f$@ fj f f f fW fX f Y f Z f  f [ f gk gl~ g$@ gm g g g gW gX g Y g Z g  g [ g hn ho~ h$@ hp h h h hW hX h Y h Z h  h [ h iq ir~ i$@ is i i i iW iX i Y i Z i  i [ i jt ju~ j$@ jv j j j jW jX j Y j Z j  j [ j kw kx~ k$@ ky k k k kW kX k Y k Z k  k [ k lz l{~ l$@ l| l l l lW lX l Y l Z l  l [ l m} m~~ m$@ m m m m mW mX m Y m Z m  m [ m n n~ n$@ n n n n nW nX n Y n Z n  n [ n o o~ o$@ o o o o oW oX o Y o Z o  o [ o p p~ p$@ p p p p pW pX p Y p Z p  p [ p q q~ q$@ q q q q qW qX q Y q Z q  q [ q r r~ r$@ r r r r rW rX r Y r Z r  r [ r s s~ s$@ s s s s sW sX s Y s Z s  s [ s t t~ t$@ t t t t tW tX t Y t Z t  t [ t u u~ u$@ u u u u uW uX u Y u Z u  u [ u v v~ v$@ v v v v vW vX v Y v Z v  v [ v w w~ w$@ w w w w wW wX w Y w Z w  w [ w x x~ x$@ x x x x xW xX x Y x Z x  x [ x y y~ y$@ y y y y yW yX y Y y Z y  y [ y z z~ z;@ z zu z z z z z  z  z  z  z { {~ {?@ { {u { { { { {  {  {  {  { | |~ |?@ | |u | | | | |  |  |  |  | } }~ }6@ } }u } } } } }  }  }  }  } ~ ~~ ~<@ ~ ~u ~ ~ ~ ~ ~  ~  ~  ~  ~  ~ &@  u               ~ (@  u           ~ $@  u           ~ 1@  u           ~ <@  u           ~ 3@  u           ~ 7@  u           ~ >@  u           ~ 1@  u           ~ 1@  u           ~ 1@  u           ~ 1@  u           ~ 1@  u           ~ 1@  u           ~ 1@  u           ~ 1@  u           ~ 1@  u           ~ 0@  u           ~ 0@   u              ~ 0@   u           ~ 0@  u           ~ 0@  u           ~ 0@  u           ~ 0@  u            ~ 0@ ! u       "   # $~ 0@ % u       &   ' (~ .@ ) u       *   + ,~ .@ - u       .   / 0~ .@ 1 u       2   3 4~ .@ 5 u       6   7 8~ .@ 9 u       :   ; <~ .@ = u       >   ? @~ .@ A u       B   C D~ .@ E u       F   G H~ .@ I u       J   K L~ :@ M u       N   O P~ :@ Q u       R   S T~ :@ U u       V   W X~ :@ Y u       Z   [ \~ :@ ] u       ^   _ `~ 9@ a u       b   c d~ :@ e u       f   g h~ :@ i u       j   k l~ :@ m u       n   o p~ ;@ q u       r   s t~ ;@ u u       v   w x~ ;@ y u       z   { |~ ;@ } u       ~    ~ ;@  u           ~ :@  u           ~ ;@  u           ~ ;@  u           ~ ;@  u           ~ 8@  u           ~ 9@  u           ~ 9@  u           ~ 9@  u           ~ 9@  u           ~ 9@  u           ~ 8@  u           ~ 9@  u           ~ 9@  u           ~ 9@  u           ~ 8@  u           ~ 8@  u           ~ 8@  u           ~ 8@  u           ~ 8@  u           ~ 8@  u           ~ 8@  u           ~ 8@  u           ~ 8@  u           ~ 5@  u           ~ ,@  u            ~ ,@  u           ~ ,@  u           ~ ,@  u           ~ ,@  u           ~ ,@  u           ~ ,@  u           ~ ,@  u           ~ ,@  u            ~ ,@   u              ~ &@             ~  @             ~ &@             ~ &@              !~ ,@ "           # $~  @ %           & '~ 1@ (          )  * +~ &@ ,           - .~ ,@ /          0  1 2~ 1@ 3          4  5 6~ $@ 7           8 9~ 0@ :           ; <~ 4@ =           > ?~ &@ @          A  B C~ @ D           E F~ 4@ G           H I~ :@ J           K L~ ;@ M           N O~ 6@ P        Q   R S~ 6@ T        U   V W~ 0@ X        Y   Z [~ 0@ \        ]   ^ _~ ;@ `        a   b c~ 2@ d        e   f g~ *@ h           i j~ 4@ k           l m~ D@ n    o p o q r s  t u~ 4@ v        w  x  y z~ I@ {    o p o q | s  } ~~ D@     o p o q  s   ~ D@     o p o q  s   ~ D@     o p o q  s   ~ D@     o p o q  s   ~ H@     o p o q  s   ~ H@     o p o q  s   ~ I@     o p o q  s   ~ I@     o p o q  s   ~ I@     o p o q  s   ~ H@     o p o q  s   ~ H@     o p o q  s   ~ I@     o p o q  s   ~ H@     o p o q  s   ~ B@     o p o q  s    ~ H@     o p o q  s   ~ H@     o p o q  s   ~ D@     o p o q  s   ~ D@     o p  o  q    s   ~ D@     o p  o  q    s   ~ A@     o p  o  q    s   ~ F@     o p  o  q    s   ~ I@     o p  o  q    s   ~ B@     o p  o  q    s   ~ H@     o p  o  q    s   ~ E@     o p  o  q    s   ~ G@     o p  o  q    s   ~ B@     o p  o  q    s   ~ C@     o p  o  q    s   ~ F@     o p  o  q    s   ~ B@     o p  o  q    s   ~ A@     o p  o  q    s   ~ B@     o p  o  q    s   ~ A@     o p  o  q    s   ~ A@     o p  o  q    s   ~ B@     o p  o  q    s   ~ B@     o p  o  q    s   ~ B@     o p  o  q    s   ~ I@     o p  o  q    s   ~ B@     o p  o  q    s   ~ D@     o p  o  q    s   ~ B@      o p  o  q    s     ~ C@      o p  o  q    s    ~ K@     o p  o  q    s   ~ C@     o p  o  q    s   ~ E@     o p  o  q    s   ~ B@                 ~ M@   A   o p  o  q    s  ! "~ "@ #               $ %~ C@ &               '  ( )~ C@ *               !+ !,~ !*@ !- ! ! ! ! ! !  !  !  !  ! ". "/~ "(@ "0 " " " " " "  "  "  "  " #1 #2~ #&@ #3 # # # # # #  #  #  #  # $4 $5~ $,@ $6 $ $ $ $ $ $  $  $  $  $ %7 %8~ %*@ %9 % % % % % %  %  %  %  % &: &;~ &@ &< & & & & & &  &  &  &  & '= '>~ '1@ '? ' ' ' ' ' '  '  '  '  ' (@ (A~ (0@ (B ( ( ( ( ( (  (  (  (  ( )C )D~ ).@ )E ) ) ) ) ) )  )  )  )  ) *F *G~ *6@ *H * * * * * *  *  *  *  * +I +J~ +5@ +K + + + + + +  +  +  +  + ,L ,M~ ,3@ ,N , , , , , ,  ,  ,  ,  , -O -P~ -*@ -Q - - - - - -  -  -  -  - .R .S~ .9@ .T . . . . . .  .  .  .  . /U /V~ /8@ /W / / / / / /  /  /  /  / 0X 0Y~ 06@ 0Z 0 0 0 0 0 0  0  0  0  0 1[ 1\~ 1,@ 1] 1 1 1 1 1 1  1  1  1  1 2^ 2_~ 2.@ 2` 2 2 2 2 2 2  2  2  2  2 3a 3b~ 3>@ 3c 3 3 3 3 3 3  3  3  3  3 4d 4e~ 4B@ 4f 4 4 4 4 4 4  4  4  4  4 5g 5h~ 58@ 5i 5 5 5 5 5 5  5  5  5  5 6j 6k~ 6;@ 6l 6 6 6 6 6 6  6  6  6  6 7m 7n~ 7<@ 7o 7 7 7 7 7 7  7  7  7  7 8p 8q~ 8=@ 8r 8 8 8 8 8 8  8  8  8  8 9s 9t~ 93@ 9u 9 9 9 9 9 9  9  9  9  9 :v :w~ :4@ :x : : : : : :  :  : y :  : ;z ;{~ ;:@ ;| ; ; ; ; ; ;  ;  ;  ;  ; <} <~~ <1@ < < < < < < <  <  <  <  < = =~ =3@ = = = = = = =  =  = y =  = > >~ >0@ > > > > > > >  >  >  >  > ? ?~ ?1@ ? ? ? ? ? ? ?  ?  ?  ?  ? @ @~ @2@ @ @ @ @ @ @ @  @  @  @  @ A A~ A&@ A A A A A A A  A  A  A  A B B~ B(@ B B B B B B B  B  B y B  B C C~ C.@ C C C C C C C  C  C  C  C D D~ D>@ D D D D D D D  D  D  D  D E E~ E:@ E E E E E E E  E  E  E  E F F~ F,@ F F F F F F F  F  F  F  F G G~ G;@ G G G G G G G  G  G  G  G H H~ H<@ H H H H H H H  H  H  H  H I I~ I=@ I I I I I I I  I  I  I  I J J~ J3@ J J J J J J J  J  J  J  J K K~ K4@ K K K K K K K  K  K y K  K L L~ L:@ L L L L L L L  L  L  L  L M M~ M1@ M M M M M M M  M  M  M  M N N~ N2@ N N N N N N N  N  N y N  N O O~ O2@ O O O O O O O  O  O  O  O P P~ P @ P P P P P P P  P  P  P  P Q Q~ Q2@ Q Q Q Q Q Q Q  Q  Q  Q  Q R R~ R4@ R R R R R R R  R  R  R  R S S~ S0@ S S S S S S S  S  S  S  S T T~ T"@ T T T T T T T  T  T  T  T U U~ U1@ U U U U U U U  U  U  U  U V V~ V&@ V V V V V V V  V  V  V  V W W~ W.@ W W W W W W W  W  W  W  W X X~ X$@ X X X X X X X  X  X  X  X Y Y~ Y,@ Y Y Y Y Y Y Y  Y  Y  Y  Y Z Z~ Z&@ Z Z Z Z Z Z Z  Z  Z  Z  Z [ [~ [(@ [ [ [ [ [ [ [  [  [ y [  [ \ \~ \C@ \ \ \ \ \ \ \  \  \  \  \ ] ]~ ](@ ] ] ] ] ] ] ]  ]  ]  ]  ] ^ ^~ ^C@ ^ ^ ^ ^ ^ ^ ^  ^  ^  ^  ^ _ _~ _C@ _ _ _ _ _ _ _  _  _  _  _ ` `~ `C@ ` ` ` ` ` ` `  `  `  `  ` a a~ aC@ a a a a a a a  a  a  a  a b b~ bC@ b b b b b b b  b  b  b  b c c~ cC@ c c c c c c c  c  c  c  c d d~ dC@ d d d d d d d  d  d  d  d  d e e~ eC@ e e e e e e e  e  e  e  e  e f f~ fC@ f f f f f f f  f  f  f  f g g~ gB@ g g g g g g g  g  g  g  g  g h h~ hC@ h h h h h h h  h  h  h  h   h i  i ~ iP@ i  i i i i i i  i  i  i  i j  j~ jB@ j j j j j j j  j  j  j  j  j k k~ kB@ k k k k k k k  k  k  k  k  k l l~ l(@ l l l l l l l  l  l  l  l m m~ m@ m  m m m m m m  m  m ! m  m n" n#~ n3@ n$ n n n n n n  n  n  n  n o% o&~ o2@ o' o o o o o o  o  o  o  o p( p)~ p2@ p* p p p p p p  p  p  p  p q+ q,~ q>@ q- q q q q q q  q  q  q  q . q r/ r0~ r2@ r1 r r r r r r  r  r  r  r 2 r s3 s4~ s @ s5 s s s s s s  s  s  s  s t6 t7~ t @ t8 t t t t t t  t  t  t  t u9 u:~ u @ u; u u u u u u  u  u  u  u v< v=~ v1@ v> v v? v v@ vA v B v C v  v D vE wF wG~ w @ wH w w w w w w  w  w  w  w xI xJ~ x.@ xK x x? x x@ xA x B x C x  x D xE yL yM~ y.@ yN y y? y y@ yA y B y C y  y D yE zO zP~ z*@ zQ z z? z z@ zA z B z C z  z D zE {R {S~ {2@ {T { {? { {@ {A { B { C {  { D {E |U |V~ |3@ |W | |? | |@ |A | B | C | X | D |E }Y }Z~ }3@ }[ } }? } }@ }A } B } C } \ } D }E ~] ~^~ ~3@ ~_ ~ ~? ~ ~@ ~A ~ B ~ C ~ ` ~ D ~E a b~ 3@ c  ?  @ A  B  C  d  D E e Z~ 3@ f  ?  @ A  B  C  g  D E h i~ 3@ j  ?  @ A  B  C  k  D E l V~ 3@ m  ?  @ A  B  C  n  D E o ^~ 3@ p  ?  @ A  B  C  q  D E r b~ 3@ s  ?  @ A  B  C  t  D E u v~ 3@ w  ?  @ A  B  C    D E x i~ 3@ y  ?  @ A  B  C  z  D E { |~ 3@ }  ?  @ A  B  C    D E ~ ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 2@   ?  @ A  B  C    D E  ~ 2@   ?  @ A  B  C    D E  ~ 2@   ?  @ A  B  C    D E  ~ 2@   ?  @ A  B  C    D E  ~ 0@   ?  @ A  B  C    D E  ~ 1@   ?  @ A  B  C    D E  ~ 2@   ?  @ A  B  C    D E  ~ .@   ?  @ A  B  C    D E  ~ 0@   ?  @ A  B  C    D E  ~ 1@   ?  @ A  B  C    D E  ~ 2@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ 3@   ?  @ A  B  C    D E  ~ "@                 ~ .@                 ~ "@                 ~  @                     ~ $@                  ~ $@                 ~ &@                 ~ $@                 ~ "@                 ~ $@             !    " #~ =@ $    % &  '  (  )  *  + ,~ ?@ -    % &  '  (  )  *  . /~ 9@ 0    % &  '  (  )  *  1 2~ ;@ 3    % &  '  (  )  *  4 5~ =@ 6    % &  '  (  )  *  7 8~ ?@ 9    % &  '  (  )  *  : ;~ A@ <    % &  '  (  )  *  =  > ?~ A@ @    % &  '  (  )  *  A  B C~ A@ D    % &  '  (  )  *  E  F G~ A@ H    % &  '  (  )  *  I  J K~ A@ L    % &  '  (  )  *  M  N O~ A@ P    % &  '  (  )  *  Q  R S~ A@ T    % &  '  (  )  *  U  V W~ A@ X    % &  '  (  )  *  Y  Z [~ A@ \    % &  '  (  )  *  ]  ^ _~ A@ `    % &  '  (  )  *  a  b c~ A@ d    % &  '  (  )  *  e  f g~ A@ h    % &  '  (  )  *  i  j k~ A@ l    % &  '  (  )  *  m  n o~ A@ p    % &  '  (  )  *  q  r s~ A@ t    % &  '  (  )  *  u  v w~ <@ x    % &  '  (  )  *  y z~ A@ {    % &  '  (  )  *  | }~ L@ ~    % &  '  (  )  *   ~ G@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ A@     % &  '  (  )  *   ~ F@     % &  '  (  )  *   ~ A@     % &  '  (  )  *   ~ F@     % &  '  (  )  *   ~ F@     % &  '  (  )  *   ~ O@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ C@     % &  '  (  )  *   ~ *@     % &  '  (  )  *   ~ *@     % &  '  (  )  *   ~ *@     % &  '  (  )  *   ~ *@     % &  '  (  )  *   ~ *@     % &  '  (  )  *   ~ *@     % &  '  (  )  *   ~ *@     % &  '  (  )  *   ~ *@     % &  '  (  )  *   ~ .@     % &  '  (  )  *   ~ .@     % &  '  (  )  *   ~ .@     % &  '  (  )  *   ~ >@     % &  '  (  )  *   ~ A@     % &  '  (  )  *   ~ <@     % &  '  (  )  *    ~ <@      % &  '  (  )  *     ~ <@      % &  '  (  )  *   ~ H@     % &  '  (  )  *   ~ A@     % &  '  (  )  *   ~ L@     % &  '  (  )  *   ~ B@     % &  '  (  )  *   ~ B@     % &  '  (  )  *    ~ A@ !    % &  '  (  )  *  " #~ =@ $    % &  '  (  )  *  % &~ A@ '    % &  '  (  )  *  ( )~ *@ *    % &  '  (  )  *  + ,~ <@ -    % &  '  (  )  *  . /~ <@ 0    % &  '  (  )  *  1 2~ <@ 3    % &  '  (  )  *  4 5~ A@ 6    % &  '  (  )  *  7 8~ A@ 9    % &  '  (  )  *  : ;~ <@ <    % &  '  (  )  *  = ?~ A@ >    % &  '  (  )  *  A  ? @~ @@ A    % &  '  (  )  *  B C~ @@ D    % &  '  (  )  *  E F~ 5@ G    % &  '  (  )  *  H I~ 3@ J    % &  '  (  )  *  K L~ 3@ M    % &  '  (  )  *  N O~ =@ P    % &  '  (  )  *  Q R~ A@ S    % &  '  (  )  *  T U~ B@ V  W  % &  '  (  X  * Y Z [~ <@ \  W  % &  '  (  ]  * Y ^ _~ A@ `  W  % &  '  (  a  * Y b c~ B@ d  W  % &  '  (  ]  * Y e f~ <@ g  W  % &  '  (  ]  * Y h i~ <@ j  W  % &  '  (  ]  * Y k f~ <@ l  W  % &  '  (  ]  * Y !m !n~ !;@ !o ! !W ! !% !& ! ' ! ( ! ] ! * !Y "p "q~ "B@ "r " "W " "% "& " ' " ( " s " * "Y #t #u~ #A@ #v # #W # #% #& # ' # ( # s # * #Y $w $x~ $A@ $y $ $W $ $% $& $ ' $ ( $ s $ * $Y %z %{~ %A@ %| % %W % %% %& % ' % ( % s % * %Y &} &~~ &A@ & & &W & &% && & ' & ( & s & * &Y ' '~ 'A@ ' ' 'W ' '% '& ' ' ' ( ' s ' * 'Y ( (~ (*@ ( ( (W ( (% (& ( ' ( ( (  ( * (Y ) )~ );@ ) ) )W ) )% )& ) ' ) ( )  ) * )Y * *~ *E@ * * *W * *% *& * ' * ( *  * * *Y + +~ +G@ + + + + +% +& + ' + ( + ) + * + , ,~ ,A@ , , , , ,% ,& , ' , ( , ) , * , - -~ -A@ - - - - -% -& - ' - ( - ) - * -  - . .~ .L@ . . . . .% .& . ' . ( . ) . * . / /~ /Q@ / / / / /% /& / ' / ( / ) / * / 0 0~ 0J@ 0 0 0W 0 0% 0& 0 ' 0 ( 0 ) 0 * 0Y 1 1~ 1K@ 1 1 1 1 1% 1& 1 ' 1 ( 1 ) 1 * 1 2 2~ 2G@ 2 2 2W 2 2% 2& 2 ' 2 ( 2 ) 2 * 2Y 3 3~ 3C@ 3 3 3 3 3% 3& 3 ' 3 ( 3 ) 3 * 3 4 4~ 4<@ 4 4 4 4 4% 4& 4 ' 4 ( 4 ) 4 * 4 5 5~ 5<@ 5 5 5 5 5% 5& 5 ' 5 ( 5 ) 5 * 5 6 6~ 6<@ 6 6 6 6 6% 6& 6 ' 6 ( 6 ) 6 * 6 7 7~ 7<@ 7 7 7 7 7% 7& 7 ' 7 ( 7 ) 7 * 7 8 8~ 8<@ 8 8 8 8 8% 8& 8 ' 8 ( 8 ) 8 * 8 9 9~ 9A@ 9 9 9 9 9% 9& 9 ' 9 ( 9 ) 9 * 9 : :~ :A@ : : : : :% :& : ' : ( : ) : * : ; ;~ ;A@ ; ; ; ; ;% ;& ; ' ; ( ; ) ; * ; < <~ <A@ < < < < <% <& < ' < ( < ) < * < = =~ =A@ = = = = =% =& = ' = ( = ) = * = > >~ >A@ > > > > >% >& > ' > ( > ) > * > ? ?~ ?A@ ? ? ? ? ?% ?& ? ' ? ( ? ) ? * ? @ @~ @A@ @ @ @ @ @% @& @ ' @ ( @ ) @ * @ A A~ AA@ A A A A A% A& A ' A ( A ) A * A B B~ BA@ B B B B B% B& B ' B ( B ) B * B C C~ CA@ C C C C C% C& C ' C ( C ) C * C D D~ DA@ D D D D D% D& D ' D ( D ) D * D E E~ EA@ E E E E E% E& E ' E ( E ) E * E F F~ FA@ F F F F F% F& F ' F ( F ) F * F G G~ GA@ G G G G G% G& G ' G ( G ) G * G H H~ HA@ H H H H H% H& H ' H ( H ) H * H I I~ IA@ I I I I I% I& I ' I ( I ) I * I J J~ JA@ J J J J J% J& J ' J ( J ) J * J K K~ KA@ K K K K K% K& K ' K ( K ) K * K L L~ LA@ L L L L L% L& L ' L ( L ) L * L M M~ MA@ M M M M M% M& M ' M ( M ) M * M N N~ NA@ N N N N N% N& N ' N ( N ) N * N O O~ OA@ O O O O O% O& O ' O ( O ) O * O P P~ PA@ P P P P P% P& P ' P ( P ) P * P Q Q~ QA@ Q Q Q Q Q% Q& Q ' Q ( Q ) Q * Q R R~ RA@ R  R R R R% R& R ' R ( R ) R * R S  S ~ SA@ S  S S S S% S& S ' S ( S ) S * S T  T~ TA@ T T T T T% T& T ' T ( T ) T * T U U~ UA@ U U U U U% U& U ' U ( U ) U * U V V5~ VA@ V V V V V% V& V ' V ( V ) V * V W W~ WA@ W W W W W% W& W ' W ( W ) W * W X X~ XA@ X X X X X% X& X ' X ( X ) X * X Y Y~ YA@ Y Y Y Y Y% Y& Y ' Y ( Y ) Y * Y Z Z~ ZA@ Z  Z Z Z Z% Z& Z ' Z ( Z ) Z * Z [! ["~ [A@ [# [ [ [ [% [& [ ' [ ( [ ) [ * [ \$ \%~ \A@ \& \ \ \ \% \& \ ' \ ( \ ) \ * \ ' \ ]( ])~ ]A@ ]* ] ] ] ]% ]& ] ' ] ( ] ) ] * ] + ] ^, ^-~ ^A@ ^. ^ ^ ^ ^% ^& ^ ' ^ ( ^ ) ^ * ^ / ^ _0 _1~ _A@ _2 _ _ _ _% _& _ ' _ ( _ ) _ * _ 3 _ `4 `5~ `A@ `6 ` ` ` `% `& ` ' ` ( ` ) ` * ` 7 ` a8 a9~ aA@ a: a a a a% a& a ' a ( a ) a * a ; a b< b=~ bA@ b> b b b b% b& b ' b ( b ) b * b ? b c@ cA~ cA@ cB c c c c% c& c ' c ( c ) c * c C c dD dE~ dA@ dF d d d d% d& d ' d ( d ) d * d G d eH eI~ eA@ eJ e e e e% e& e ' e ( e ) e * e K e fL fM~ fA@ fN f f f f% f& f ' f ( f ) f * f O f gP gQ~ gA@ gR g g g g% g& g ' g ( g ) g * g S g hT hU~ hA@ hV h h h h% h& h ' h ( h ) h * h W h iX iY~ iA@ iZ i i i i% i& i ' i ( i ) i * i [ i j\ j]~ jA@ j^ j j j j% j& j ' j ( j ) j * j _ j k` ka~ kA@ kb k k k k% k& k ' k ( k ) k * k c k ld le~ l@@ lf l l l l% l& l ' l ( l ) l * l mg mh~ m@@ mi m m m m% m& m ' m ( m ) m * m nj nk~ n@@ nl n n n n% n& n ' n ( n ) n * n om on~ o@@ oo o o o o% o& o ' o ( o ) o * o pp pq~ p@@ pr p p p p% p& p ' p ( p ) p * p qs qt~ q@@ qu q q q q% q& q ' q ( q ) q * q rv rw~ r@@ rx r r r r% r& r ' r ( r ) r * r sy sz~ s@@ s{ s s s s% s& s ' s ( s ) s * s t| t}~ t@@ t~ t t t t% t& t ' t ( t ) t * t u u~ u@@ u u u u u% u& u ' u ( u ) u * u v v~ v@@ v v v v v% v& v ' v ( v ) v * v w w~ w@@ w w w w w% w& w ' w ( w ) w * w x x~ x@@ x x x x x% x& x ' x ( x ) x * x y y~ yA@ y y y y y% y& y ' y ( y ) y * y z z~ zA@ z z z z z% z& z ' z ( z ) z * z  z { {~ {B@ { { { { {% {& { ' { ( { ) { * { | |~ |H@ | | | | |% |& | ' | ( | ) | * | } }~ }C@ } } } } }% }& } ' } ( }  } * } ~ ~~ ~1@ ~ ~ ~ ~ ~% ~& ~ ' ~ ( ~  ~ * ~  ~ D@     % &  '  (    *   ~ B@     % &  '  (    *   ~ B@     % &  '  (    *   ~ B@     % &  '  (    *   ~ B@     % &  '  (    *   ~ B@     % &  '  (    *   ~ B@     % &  '  (    *   ~ B@     % &  '  (    *      ~ &@                 ~ &@                 ~ &@                 ~ &@                 ~ &@                 ~ &@                   ~ &@                   ~ $@                   ~ $@                   ~ &@                   ~ 1@                 ~ 7@                 ~ <@                 ~ <@                 ~ ;@                 ~  @                 ~ &@                 !~ ,@                 '~ 1@                )   $~  @                 +~ &@                 .~ ,@                0   2~ 1@                4   9~ 0@                 6~ $@                 <~ 4@                 ?~ &@                A   F~ 4@                 C~ @                 I~ :@                 L~ ;@                 O~ 6@                 S~ 6@                 [~ 0@                 W~ 0@                 _~ ;@                 c~ 2@                 c~ 2@                 g~ *@                 j~ 4@                ! u~ 4@ "           #    x  $ u~ 4@ %           &    x  ' ( ~ B@ )    * +  ,  -    .  / 0 ~ =@ 1    * +  ,  -    .  2 3 ~ >@ 4    * +  ,  -    .  5 6 ~ B@ 7    * +  ,  -    .  8 9 ~ E@ :    * +  ,  -    .  ; < ~ B@ =    * +  ,  -    .  > ? ~ B@ @    * +  ,  -    .  A B ~ B@ C    * +  ,  -    .  D E ~ B@ F    * +  ,  -    .  G H ~ B@ I    * +  ,  -    .  J K ~ B@ L    * +  ,  -    .  M N ~ A@ O    * +  ,  -    .  P ~ B@ Q    * +  ,  -    .    R S ~ B@ T    * +  ,  -    .  U ~ B@ V    * +  ,  -    .    W X ~ B@ Y    * +  ,  -    .  Z [ ~ B@ \    * +  ,  -    .  ] ^ ~ B@ _    * +  ,  -    .  ` a ~ B@ b    * +  ,  -    .  c d ~ B@ e    * +  ,  -    .  f g ~ B@ h    * +  ,  -    .  i j ~ B@ k    * +  ,  -    .  l m ~ B@ n    * +  ,  -    .  o p ~ B@ q    * +  ,  -    .  r s ~ B@ t    * +  ,  -    .  u v ~ B@ w    * +  ,  -    .  x m~ D@ y    * +  ,  -    .  z z~ I@ {    * +  ,  -    .  | ~ H@ }    * +  ,  -    .  ~ ~ D@     * +  ,  -    .   ~ I@     * +  ,  -    .   ~ I@     * +  ,  -    .   ~ I@     * +  ,  -    .   ~ H@     * +  ,  -    .   ~ H@     * +  ,  -    .   ~ H@     * +  ,  -    .   ~ I@     * +  ,  -    .   ~ H@     * +  ,  -    .   ~ D@     * +  ,  -    .   ~ D@     * +  ,  -    .    ~ A@     * +  ,  -    .    ~ C@     * +  ,  -    .    ~ C@     * +  ,  -    .    ~ C@     * +  ,  -    .    ~ A@     * +  ,  -    .    ~ A@     * +  ,  -    .    ~ A@     * +  ,  -    .    ~ A@     * +  ,  -    .    ~ C@     * +  ,  -    .    ~ C@     * +  ,  -    .    ~ D@     * +  ,  -    .    ~ G@     * +  ,  -    .    ~ B@     * +  ,  -    .    ~ I@     * +  ,  -    .    ~ G@     * +  ,  -    .    ~ E@     * +  ,  -    .    ~ H@     * +  ,  -    .    ~ E@     * +  ,  -    .    ~ B@     * +  ,  -    .   ~ B@     * +  ,  -    .    ~ B@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ B@     * +  ,  -    .    ~ C@     * +  ,  -    .    ~ F@     * +  ,  -    .    ~ D@     * +  ,  -    .    ~ ?@     * +  ,  -    .   ~ D@     * +  ,  -    .   ~ B@     * +  ,  -    .     ~ A@     * +  ,  -    .   ~ D@     * +  ,  -    .   ~ F@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ I@     * +  ,  -    .   ~ H@     * +  ,  -    .   ~ G@     * +  ,  -    .   ~ E@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ F@     * +  ,  -    .   ~ C@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ A@     * +  ,  -    .   ~ A@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ A@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ I@     * +  ,  -    .   ~ D@     * +  ,  -    .    ~ C@     * +  ,  -    .   ~ B@     * +  ,  -    .   ~ K@     * +  ,  -    .   ~ E@     * +  ,  -    .   %~ C@     * +  ,  -    .  '   ~ B@     * +  ,  -    .     ~ C@     * +  ,  -    .    ~ P@ !    * +  ,  -    .  " # ~ N@ $    * +  ,  -    .  % & ~ A@ '  (  ) *  +  ,  -  . / 0 1 ~ A@ 2  (  ) *  +  ,  3  . / 4 5 ~ D@ 6  (  ) *  +  ,  7  . / 8 9 ~ C@ :  (  ) *  +  ,  ;  . / < = ~ A@ >  (  ) *  +  ,  ?  . / @ A ~ A@ B  (  ) *  +  ,  C  . / D E ~ F@ F  (  ) *  +  ,  G  . / H I ~ F@ J  (  ) *  +  ,  K  . / L M ~ A@ N  (  ) *  +  ,  O  . / P Q ~ A@ R  (  ) *  +  ,  O  . / S T ~ A@ U  (  ) *  +  ,  O  .  V / W ~ B@ X  (  ) *  +  ,  O  .   / !Y !%~ !C@ !Z ! !( ! !) !* ! + ! , ! O ! . ! ' !/ "[ "\ ~ "A@ "] " "( " ") "* " + " , " ^ " . "/ #_ #` ~ #F@ #a # #( # #) #* # + # , # b # . #/ $c $d ~ $C@ $e $ $ $ $f $g $ h $ i $  $ j $ %k %l ~ %C@ %m % % % %f %g % h % i %  % j % &n &o ~ &C@ &p & & & &f &g & h & i &  & j & 'q 'r ~ 'C@ 's ' ' ' 'f 'g ' h ' i '  ' j ' (t (u ~ (B@ (v ( ( ( (f (g ( h ( i (  ( j ( )w )x ~ )B@ )y ) ) ) )f )g ) h ) i )  ) j ) *z *{ ~ *B@ *| * * * *f *g * h * i *  * j * +} +~ ~ +B@ + + + + +f +g + h + i +  + j + , , ~ ,B@ , , , , ,f ,g , h , i ,  , j , - - ~ -B@ - - - - -f -g - h - i -  - j - . . ~ .B@ . . . . .f .g . h . i .  . j . / / ~ /B@ / / / / /f /g / h / i /  / j / 0 0 ~ 0@ 0 0 0 0 0f 0g 0 h 0 i 0  0 j 0 1 1 ~ 1@ 1 1 1 1 1f 1g 1 h 1 i 1  1 j 1 2 2 ~ 2 @ 2 2 2 2 2f 2g 2 h 2 i 2  2 j 2 3 3 ~ 3"@ 3 3 3 3 3f 3g 3 h 3 i 3  3 j 3 4 4 ~ 4$@ 4 4 4 4 4f 4g 4 h 4 i 4  4 j 4 5 5 ~ 5&@ 5 5 5 5 5f 5g 5 h 5 i 5  5 j 5 6 6 ~ 6(@ 6 6 6 6 6f 6g 6 h 6 i 6  6 j 6 7 7 ~ 7*@ 7 7 7 7 7f 7g 7 h 7 i 7  7 j 7 8 8 ~ 8,@ 8 8 8 8 8f 8g 8 h 8 i 8  8 j 8 9 9 ~ 9.@ 9 9 9 9 9f 9g 9 h 9 i 9  9 j 9 : : ~ :0@ : : : : :f :g : h : i :  : j : ; ; ~ ;1@ ; ; ; ; ;f ;g ; h ; i ;  ; j ; < < ~ <2@ < < < < <f <g < h < i <  < j < = = ~ =3@ = = = = =f =g = h = i =  = j = > > ~ >4@ > > > > >f >g > h > i >  > j > ? ? ~ ?5@ ? ? ? ? ?f ?g ? h ? i ?  ? j ? @ @ ~ @6@ @ @ @ @ @f @g @ h @ i @  @ j @ A A ~ A7@ A A A A Af Ag A h A i A  A j A B B ~ B8@ B B B B Bf Bg B h B i B  B j B C C ~ C9@ C C C C Cf Cg C h C i C  C j C D D ~ D:@ D D D D Df Dg D h D i D  D j D E E ~ E;@ E E E E Ef Eg E h E i E  E j E F F ~ F<@ F F F F Ff Fg F h F i F  F j F G G ~ G=@ G G G G Gf Gg G h G i G  G j G H H ~ H>@ H H H H Hf Hg H h H i H  H j H I I ~ I?@ I I I I If Ig I h I i I  I j I J J ~ J@@ J J J J Jf Jg J h J i J  J j J K K ~ K@@ K K K K Kf Kg K h K i K  K j K L L ~ LA@ L L L L Lf Lg L h L i L  L j L M M ~ M@ M M M M Mf Mg M h M i M  M j M N N ~ N@ N N N N Nf Ng N h N i N  N j N O O ~ O @ O O O O Of Og O h O i O  O j O P P ~ P"@ P P P P Pf Pg P h P i P  P j P Q Q ~ Q$@ Q Q Q Q Qf Qg Q h Q i Q  Q j Q R R ~ R&@ R R R R Rf Rg R h R i R  R j R S S ~ S(@ S S S S Sf Sg S h S i S  S j S T T ~ T*@ T T T T Tf Tg T h T i T  T j T U U ~ U,@ U U U U Uf Ug U h U i U  U j U V V ~ V.@ V V V V Vf Vg V h V i V  V j V W W ~ W0@ W W W W Wf Wg W h W i W  W j W X X ~ X1@ X X X X Xf Xg X h X i X  X j X Y Y ~ Y2@ Y Y Y Y Yf Yg Y h Y i Y  Y j Y Z Z ~ Z3@ Z Z Z Z Zf Zg Z h Z i Z  Z j Z [ [ ~ [4@ [ [ [ [ [f [g [ h [ i [  [ j [ \ \ ~ \5@ \ \ \ \ \f \g \ h \ i \  \ j \ ] ] ~ ]6@ ] ] ] ] ]f ]g ] h ] i ]  ] j ] ^ ^ ~ ^7@ ^ ^ ^ ^ ^f ^g ^ h ^ i ^  ^ j ^ _ _ ~ _8@ _ _ _ _ _f _g _ h _ i _  _ j _ ` ` ~ `9@ ` ` ` ` `f `g ` h ` i `  ` j ` a! a" ~ a:@ a# a a a af ag a h a i a  a j a b$ b% ~ b;@ b& b b b bf bg b h b i b  b j b c' c( ~ c<@ c) c c c cf cg c h c i c  c j c d* d+ ~ d=@ d, d d d df dg d h d i d  d j d e- e. ~ e>@ e/ e e e ef eg e h e i e  e j e f0 f1 ~ f?@ f2 f f f ff fg f h f i f  f j f g3 g4 ~ g@@ g5 g g g gf gg g h g i g  g j g h6 h7 ~ h@@ h8 h h h hf hg h h h i h  h j h i9 i~ iA@ i: i i i if ig i h i i i  i j i j; j< ~ j@ j= j j j jf jg j h j i j  j j j k> k? ~ k@ k@ k k k kf kg k h k i k  k j k lA lB ~ l @ lC l l l lf lg l h l i l  l j l mD mE ~ m"@ mF m m m mf mg m h m i m  m j m nG nH ~ n$@ nI n n n nf ng n h n i n  n j n oJ oK ~ o&@ oL o o o of og o h o i o  o j o pM pN ~ p*@ pO p p p pf pg p h p i p  p j p qP qQ ~ q(@ qR q q q qf qg q h q i q  q j q rS rT ~ r,@ rU r r r rf rg r h r i r  r j r sV sW ~ s0@ sX s s s sf sg s h s i s  s j s tY tZ ~ t.@ t[ t t t tf tg t h t i t  t j t u\ u] ~ u1@ u^ u u u uf ug u h u i u  u j u v_ v` ~ v2@ va v v v vf vg v h v i v  v j v wb wc ~ w4@ wd w w w wf wg w h w i w  w j w xe xf ~ x3@ xg x x x xf xg x h x i x  x j x yh yi ~ y5@ yj y y y yf yg y h y i y  y j y zk zl ~ z6@ zm z z z zf zg z h z i z  z j z {n {o ~ {7@ {p { { { {f {g { h { i {  { j { |q |r ~ |8@ |s | | | |f |g | h | i |  | j | }t }u ~ }9@ }v } } } }f }g } h } i }  } j } ~w ~x ~ ~:@ ~y ~ ~ ~ ~f ~g ~ h ~ i ~  ~ j ~ z { ~ ;@ |    f g  h  i    j  } ~ ~ <@     f g  h  i    j    ~ >@     f g  h  i    j    ~ =@     f g  h  i    j    ~ ?@     f g  h  i    j    ~ @@     f g  h  i    j    ~ @@     f g  h  i    j    ~ A@     f g  h  i    j    ~ @     f g  h  i    j    ~ @     f g  h  i    j    ~  @     f g  h  i    j    ~ "@     f g  h  i    j    ~ $@     f g  h  i    j    ~ &@     f g  h  i    j    ~ *@     f g  h  i    j    ~ (@     f g  h  i    j    ~ ,@     f g  h  i    j    ~ .@     f g  h  i    j    ~ 0@     f g  h  i    j    ~ 1@     f g  h  i    j    ~ 2@     f g  h  i    j    ~ 3@     f g  h  i    j    ~ 4@     f g  h  i    j    ~ 5@     f g  h  i    j    ~ 6@     f g  h  i    j    ~ 7@     f g  h  i    j    ~ 9@     f g  h  i    j    ~ 8@     f g  h  i    j    ~ :@     f g  h  i    j    ~ ;@     f g  h  i    j    ~ <@     f g  h  i    j    ~ =@     f g  h  i    j    ~ >@     f g  h  i    j    ~ ?@     f g  h  i    j    ~ @@     f g  h  i    j    ~ @@     f g  h  i    j    ~ A@     f g  h  i    j   ~ A@     f g  h  i    j      ~ @   W  f g  h  i    j Y   ~ @   W  f g  h  i    j Y   ~ "@   W  f g  h  i    j Y   ~  @   W  f g  h  i    j Y   ~ $@   W  f g  h  i    j Y   ~ &@   W  f g  h  i    j Y   ~ (@   W  f g  h  i    j Y   ~ *@   W  f g  h  i    j Y   ~ ,@   W  f g  h  i    j Y   ~ .@   W  f g  h  i    j Y   ~ 0@   W  f g  h  i    j Y   ~ 1@   W  f g  h  i    j Y   ~ 2@   W  f g  h  i    j Y   ~ 4@   W  f g  h  i    j Y   ~ 3@   W  f g  h  i    j Y   ~ 5@   W  f g  h  i    j Y   ~ 6@   W  f g  h  i    j Y   ~ 7@   W  f g  h  i    j Y ! " ~ 8@ #  W  f g  h  i    j Y $ % ~ 9@ &  W  f g  h  i    j Y ' ( ~ :@ )  W  f g  h  i    j Y * + ~ ;@ ,  W  f g  h  i    j Y - w~ <@ .  W  f g  h  i    j Y / 0 ~ =@ 1  W  f g  h  i    j Y 2 3 ~ >@ 4  W  f g  h  i    j Y 5 6 ~ ?@ 7  W  f g  h  i    j Y 8 9 ~ @@ :  W  f g  h  i    j Y ; < ~ @@ =  W  f g  h  i    j Y > ? ~ A@ @  W  f g  h  i    j Y A c~ A@ B  W  f g  h  i    j  e Y C D ~ B@ E  W  f g  h  i    j Y F G ~ @ H  W  f g  h  i    j Y I J ~ @ K  W  f g  h  i    j Y L M ~  @ N  W  f g  h  i    j Y O P ~ "@ Q  W  f g  h  i    j Y R S ~ $@ T  W  f g  h  i    j Y U V ~ &@ W  W  f g  h  i    j Y X Y ~ *@ Z  W  f g  h  i    j Y [ \ ~ (@ ]  W  f g  h  i    j Y ^ _ ~ ,@ `  W  f g  h  i    j Y a b ~ .@ c  W  f g  h  i    j Y d e ~ 0@ f  W  f g  h  i    j Y g h ~ 1@ i  W  f g  h  i    j Y j k ~ 2@ l  W  f g  h  i    j Y m n ~ 3@ o  W  f g  h  i    j Y p q ~ 4@ r  W  f g  h  i    j Y s t ~ 5@ u  W  f g  h  i    j Y v w ~ 6@ x  W  f g  h  i    j Y y z ~ 7@ {  W  f g  h  i    j Y | } ~ 9@ ~  W  f g  h  i    j Y   ~ 8@   W  f g  h  i    j Y   ~ :@   W  f g  h  i    j Y   ~ ;@   W  f g  h  i    j Y   ~ <@   W  f g  h  i    j Y   ~ =@   W  f g  h  i    j Y   ~ >@   W  f g  h  i    j Y   ~ ?@   W  f g  h  i    j Y   ~ @@   W  f g  h  i    j Y   ~ @@   W  f g  h  i    j Y   ~ A@   W  f g  h  i    j Y  k~ A@   W  f g  h  i    j  m Y   ~ B@   W  f g  h  i    j Y  ~ B@   W  f g  h  i    j Y   ~ @   W  f g  h  i    j Y   ~  @   W  f g  h  i    j Y   ~ @   W  f g  h  i    j Y   ~ "@   W  f g  h  i    j Y   ~ &@   W  f g  h  i    j Y   ~ $@   W  f g  h  i    j Y   ~ (@   W  f g  h  i    j Y   ~ *@   W  f g  h  i    j Y   ~ .@   W  f g  h  i    j Y   ~ ,@   W  f g  h  i    j Y   ~ 0@   W  f g  h  i    j Y   ~ 2@   W  f g  h  i    j Y   ~ 1@   W  f g  h  i    j Y   ~ 3@   W  f g  h  i    j Y   ~ 5@   W  f g  h  i    j Y   ~ 4@   W  f g  h  i    j Y   ~ 7@   W  f g  h  i    j Y   ~ 6@   W  f g  h  i    j Y   ~ 8@   W  f g  h  i    j Y   ~ 9@   W  f g  h  i    j Y   ~ ;@   W  f g  h  i    j Y   ~ :@   W  f g  h  i    j Y   ~ <@   W  f g  h  i    j Y   ~ >@   W  f g  h  i    j Y   ~ =@   W  f g  h  i    j Y   ~ ?@   W  f g  h  i    j Y   ~ @@   W  f g  h  i    j Y   ~ A@   W  f g  h  i    j Y   ~ @@   W  f g  h  i    j Y   ~ B@   W  f g  h  i    j Y   ~ C@   W  f g  h  i    j Y   ~ B@   W  f g  h  i    j Y   ~ C@   W  f g  h  i    j Y   ~ D@   W  f g  h  i    j Y  ~ E@   W  f g  h  i    j Y   ~ D@   W  f g  h  i    j Y   ~ E@   W  f g  h  i    j Y   ~ F@   W  f g  h  i    j Y   ~ G@   W  f g  h  i    j Y   ~ F@   W  f g  h  i    j Y   ~ G@   W  f g  h  i    j Y   ~ @   W  f g  h  i    j Y ! " ~ @ #  W  f g  h  i    j Y $ % ~  @ &  W  f g  h  i    j Y ' ( ~ "@ )  W  f g  h  i    j Y * + ~ &@ ,  W  f g  h  i    j Y - . ~ $@ /  W  f g  h  i    j Y 0 1 ~ (@ 2  W  f g  h  i    j Y 3 4 ~ ,@ 5  W  f g  h  i    j Y 6 7 ~ *@ 8  W  f g  h  i    j Y 9 : ~ .@ ;  W  f g  h  i    j Y < = ~ 1@ >  W  f g  h  i    j Y ? @ ~ 0@ A  W  f g  h  i    j Y B C ~ 2@ D  W  f g  h  i    j Y E F ~ 3@ G  W  f g  h  i    j Y H I ~ 5@ J  W  f g  h  i    j Y K L ~ 4@ M  W  f g  h  i    j Y N O ~ 6@ P  W  f g  h  i    j Y Q R ~ 8@ S  W  f g  h  i    j Y T U ~ 7@ V  W  f g  h  i    j Y W X ~ 9@ Y  W  f g  h  i    j Y !Z ![ ~ !:@ !\ ! !W ! !f !g ! h ! i !  ! j !Y "] "^ ~ "<@ "_ " "W " "f "g " h " i "  " j "Y #` #a ~ #;@ #b # #W # #f #g # h # i #  # j #Y $c $d ~ $=@ $e $ $W $ $f $g $ h $ i $  $ j $Y %f %g ~ %>@ %h % %W % %f %g % h % i %  % j %Y &i &j ~ &?@ &k & &W & &f &g & h & i &  & j &Y 'l 'm ~ '@@ 'n ' 'W ' 'f 'g ' h ' i '  ' j 'Y (o (p ~ (@@ (q ( (W ( (f (g ( h ( i (  ( j (Y )r )s ~ )A@ )t ) )W ) )f )g ) h ) i )  ) j )Y *u *v ~ *A@ *w * *W * *f *g * h * i *  * j *Y +x +y ~ +B@ +z + +W + +f +g + h + i +  + j +Y ,{ ,| ~ ,B@ ,} , ,W , ,f ,g , h , i ,  , j ,Y -~ - ~ -C@ - - -W - -f -g - h - i -  - j -Y . . ~ .C@ . . .W . .f .g . h . i .  . j .Y / / ~ /D@ / / /W / /f /g / h / i /  / j /Y 0 0 ~ 0D@ 0 0 0W 0 0f 0g 0 h 0 i 0  0 j 0Y 1 1 ~ 1E@ 1 1 1W 1 1f 1g 1 h 1 i 1  1 j 1Y 2 2 ~ 2E@ 2 2 2W 2 2f 2g 2 h 2 i 2  2 j 2Y 3 3 ~ 3F@ 3 3 3W 3 3f 3g 3 h 3 i 3  3 j 3Y 4 4 ~ 4G@ 4 4 4W 4 4f 4g 4 h 4 i 4  4 j 4Y 5 5 ~ 5F@ 5 5 5W 5 5f 5g 5 h 5 i 5  5 j 5Y 6 6 ~ 6G@ 6 6 6W 6 6f 6g 6 h 6 i 6  6 j 6Y 7 7 ~ 7@ 7 7 7 7 7f 7g 7 h 7 i 7  7 j 7 8 8 ~ 8 @ 8 8 8 8 8f 8g 8 h 8 i 8  8 j 8 9 9 ~ 9@ 9 9 9 9 9f 9g 9 h 9 i 9  9 j 9 : : ~ :"@ : : : : :f :g : h : i :  : j : ; ; ~ ;$@ ; ; ; ; ;f ;g ; h ; i ;  ; j ; < < ~ <&@ < < < < <f <g < h < i <  < j < = = ~ =(@ = = = = =f =g = h = i =  = j = > > ~ >,@ > > > > >f >g > h > i >  > j > ? ? ~ ?*@ ? ? ? ? ?f ?g ? h ? i ?  ? j ? @ @ ~ @.@ @ @ @ @ @f @g @ h @ i @  @ j @ A A ~ A0@ A A A A Af Ag A h A i A  A j A B B ~ B1@ B B B B Bf Bg B h B i B  B j B C C ~ C3@ C C C C Cf Cg C h C i C  C j C D D ~ D2@ D D D D Df Dg D h D i D  D j D E E ~ E4@ E E E E Ef Eg E h E i E  E j E F F ~ F5@ F F F F Ff Fg F h F i F  F j F G G ~ G6@ G G G G Gf Gg G h G i G  G j G H H ~ H7@ H H H H Hf Hg H h H i H  H j H I I ~ I9@ I I I I If Ig I h I i I  I j I J J ~ J8@ J J J J Jf Jg J h J i J  J j J K K ~ K:@ K K K K Kf Kg K h K i K  K j K L L ~ L;@ L L L L Lf Lg L h L i L  L j L M M ~ M<@ M M M M Mf Mg M h M i M  M j M N N ~ N=@ N N N N Nf Ng N h N i N  N j N O O ~ O?@ O O O O Of Og O h O i O  O j O P P ~ P>@ P P P P Pf Pg P h P i P  P j P Q Q ~ Q@@ Q Q Q Q Qf Qg Q h Q i Q  Q j Q R R ~ R@@ R R R R Rf Rg R h R i R  R j R S S ~ SA@ S S S S Sf Sg S h S i S  S j S T T ~ T@ T T T T Tf Tg T h T i T  T j T U U ~ UA@ U U U U Uf Ug U h U i U  U j U V V ~ V@ V V V V Vf Vg V h V i V  V j V W W ~ W @ W W W W Wf Wg W h W i W  W j W X X~ X"@ X X X X Xf Xg X h X i X  X j X Y Y~ Y$@ Y Y Y Y Yf Yg Y h Y i Y  Y j Y Z Z~ Z(@ Z Z Z Z Zf Zg Z h Z i Z  Z j Z [  [ ~ [&@ [  [ [ [ [f [g [ h [ i [  [ j [ \  \ ~ \*@ \ \ \ \ \f \g \ h \ i \  \ j \ ] ]~ ],@ ] ] ] ] ]f ]g ] h ] i ]  ] j ] ^ ^~ ^.@ ^ ^ ^ ^ ^f ^g ^ h ^ i ^  ^ j ^ _ _~ _1@ _ _ _ _ _f _g _ h _ i _  _ j _ ` `~ `0@ ` ` ` ` `f `g ` h ` i `  ` j ` a a~ a2@ a a a a af ag a h a i a  a j a b b~ b3@ b  b b b bf bg b h b i b  b j b c! c"~ c4@ c# c c c cf cg c h c i c  c j c d$ d%~ d5@ d& d d d df dg d h d i d  d j d e' e(~ e7@ e) e e e ef eg e h e i e  e j e f* f+~ f6@ f, f f f ff fg f h f i f  f j f g- g.~ g8@ g/ g g g gf gg g h g i g  g j g h0 h1~ h9@ h2 h h h hf hg h h h i h  h j h i3 i4~ i:@ i5 i i i if ig i h i i i  i j i j6 j7~ j;@ j8 j j j jf jg j h j i j  j j j k9 k:~ k=@ k; k k k kf kg k h k i k  k j k l< l=~ l<@ l> l l l lf lg l h l i l  l j l m? m@~ m>@ mA m m m mf mg m h m i m  m j m nB nC~ n?@ nD n n n nf ng n h n i n  n j n oE oF~ o@@ oG o o o of og o h o i o  o j o pH pI~ p@@ pJ p p p pf pg p h p i p  p j p qK qL~ qA@ qM q q q qf qg q h q i q  q j q rN rO~ rA@ rP r r r rf rg r h r i r  r j r sQ sR~ s@ sS s s s sf sg s h s i s T s j s tU tV~ t@ tW t t t tf tg t h t i t T t j t uX uY~ u @ uZ u u u uf ug u h u i u T u j u v[ v\~ v$@ v] v v v vf vg v h v i v T v j v w^ w_~ w"@ w` w w w wf wg w h w i w T w j w xa xb~ x&@ xc x x x xf xg x h x i x T x j x yd ye~ y(@ yf y y y yf yg y h y i y T y j y zg zh~ z*@ zi z z z zf zg z h z i z T z j z {j {k~ {.@ {l { { { {f {g { h { i { T { j { |m |n~ |,@ |o | | | |f |g | h | i | T | j | }p }q~ }0@ }r } } } }f }g } h } i } T } j } ~s ~t~ ~1@ ~u ~ ~ ~ ~f ~g ~ h ~ i ~ T ~ j ~ v w~ 2@ x    f g  h  i  T  j  y z~ 3@ {    f g  h  i  T  j  | }~ 5@ ~    f g  h  i  T  j   ~ 4@     f g  h  i  T  j   ~ 6@     f g  h  i  T  j   ~ 7@     f g  h  i  T  j   ~ 8@     f g  h  i  T  j   ~ 9@     f g  h  i  T  j   ~ ;@     f g  h  i  T  j   ~ :@     f g  h  i  T  j   ~ <@     f g  h  i  T  j   ~ =@     f g  h  i  T  j   ~ >@     f g  h  i  T  j   ~ @@     f g  h  i  T  j   ~ ?@     f g  h  i  T  j   ~ @@     f g  h  i  T  j   ~ A@     f g  h  i  T  j   ~ A@     f g  h  i  T  j   ~ B@     f g  h  i  T  j   ~ @     f g  h  i    j   ~ B@     f g  h  i  T  j   ~ @     f g  h  i    j   ~ "@     f g  h  i    j   ~  @     f g  h  i    j   ~ $@     f g  h  i    j   ~ &@     f g  h  i    j   ~ *@     f g  h  i    j   ~ (@     f g  h  i    j   ~ ,@     f g  h  i    j   ~ 0@     f g  h  i    j   ~ .@     f g  h  i    j   ~ 1@     f g  h  i    j   ~ 2@     f g  h  i    j   ~ 4@     f g  h  i    j   ~ 3@     f g  h  i    j   ~ 5@     f g  h  i    j   ~ 7@     f g  h  i    j   ~ 6@     f g  h  i    j   ~ 8@     f g  h  i    j   ~ 9@     f g  h  i    j   ~ ;@     f g  h  i    j   ~ :@     f g  h  i    j   ~ <@     f g  h  i    j   ~ =@     f g  h  i    j   ~ ?@     f g  h  i    j   ~ >@     f g  h  i    j   ~ @@     f g  h  i    j   ~ @@     f g  h  i    j   ~ A@     f g  h  i    j     ~ A@      f g  h  i    j     ~ B@     f g  h  i    j   ~ B@     f g  h  i    j   ~ @     f g  h  i    j   ~ @     f g  h  i    j   ~  @     f g  h  i    j   ~ "@     f g  h  i    j   ~ &@      f g  h  i    j  ! "~ $@ #    f g  h  i    j  $ %~ (@ &    f g  h  i    j  ' (~ *@ )    f g  h  i    j  * +~ .@ ,    f g  h  i    j  - .~ ,@ /    f g  h  i    j  0 1~ 0@ 2    f g  h  i    j  3 4~ 1@ 5    f g  h  i    j  6 7~ 3@ 8    f g  h  i    j  9 :~ 2@ ;    f g  h  i    j  < =~ 4@ >    f g  h  i    j  ? @~ 5@ A    f g  h  i    j  B C~ 7@ D    f g  h  i    j  E F~ 6@ G    f g  h  i    j  H I~ 8@ J    f g  h  i    j  K L~ 9@ M    f g  h  i    j  N O~ ;@ P    f g  h  i    j  Q R~ :@ S    f g  h  i    j  T U~ <@ V    f g  h  i    j  W X~ =@ Y    f g  h  i    j  Z [~ ?@ \    f g  h  i    j  ] ^~ >@ _    f g  h  i    j  ` a~ @@ b    f g  h  i    j  c d~ @@ e    f g  h  i    j  f g~ A@ h    f g  h  i    j  i j~ A@ k    f g  h  i    j  l m~ @ n    f g  h  i    j  o p~ @ q    f g  h  i    j  r s~ "@ t    f g  h  i    j  u v~  @ w    f g  h  i    j  x y~ $@ z    f g  h  i    j  { |~ &@ }    f g  h  i    j  ~ ~ *@     f g  h  i    j   ~ (@     f g  h  i    j   ~ ,@     f g  h  i    j   ~ .@     f g  h  i    j   ~ 0@     f g  h  i    j   ~ 2@     f g  h  i    j   ~ 1@     f g  h  i    j   ~ 3@     f g  h  i    j   ~ 4@     f g  h  i    j   ~ 6@     f g  h  i    j   ~ 5@     f g  h  i    j   ~ 7@     f g  h  i    j   ~ 8@     f g  h  i    j   ~ :@     f g  h  i    j   ~ 9@     f g  h  i    j   ~ ;@     f g  h  i    j   ~ <@     f g  h  i    j     ~ >@     f g  h  i    j   ~ =@     f g  h  i    j   ~ ?@     f g  h  i    j   ~ @@     f g  h  i    j   ~ A@     f g  h  i    j   ~ @@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j     ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ G@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j    ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   5~ A@     f g  h  i    j    ~ A@      f g  h  i    j    ~ A@      f g  h  i    j    ~ A@     f g  h  i    j   ~ A@     f g  h  i    j   "~ A@     f g  h  i    j   )~ A@     f g  h  i    j  +   %~ A@     f g  h  i    j  '   -~ A@     f g  h  i    j  /   1~ A@     f g  h  i    j  3   9~ A@     f g  h  i    j  ;   5~ A@     f g  h  i    j  7   =~ A@      f g  h  i    j  ?  ! A~ A@ "    f g  h  i    j  C  # E~ A@ $    f g  h  i    j  G  % M~ A@ &    f g  h  i    j  O  ' I~ A@ (    f g  h  i    j  K  ) Q~ A@ *    f g  h  i    j  S  !+ !U~ !A@ !, ! ! ! !f !g ! h ! i !  ! j ! W ! "- "]~ "A@ ". " " " "f "g " h " i "  " j " _ " #/ #Y~ #A@ #0 # # # #f #g # h # i #  # j # [ # $1 $a~ $A@ $2 $ $ $ $f $g $ h $ i $  $ j $ c $ %3 %~ %L@ %4 % % % %f %g % h % i %  % j % &5 &~ &Q@ &6 & & & &f &g & h & i &  & j & '7 'e~ '@@ '8 ' 'W ' 'f 'g ' h ' i '  ' j 'Y (9 (h~ (@@ (: ( (W ( (f (g ( h ( i (  ( j (Y ); )k~ )@@ )< ) )W ) )f )g ) h ) i )  ) j )Y *= *n~ *@@ *> * *W * *f *g * h * i *  * j *Y +? +q~ +@@ +@ + +W + +f +g + h + i +  + j +Y ,A ,t~ ,@@ ,B , ,W , ,f ,g , h , i ,  , j ,Y -C -w~ -@@ -D - -W - -f -g - h - i -  - j -Y .E .z~ .@@ .F . .W . .f .g . h . i .  . j .Y /G /}~ /@@ /H / /W / /f /g / h / i /  / j /Y 0I 0~ 0@@ 0J 0 0W 0 0f 0g 0 h 0 i 0  0 j 0Y 1K 1~ 1@@ 1L 1 1W 1 1f 1g 1 h 1 i 1  1 j 1Y 2M 2~ 2@@ 2N 2 2W 2 2f 2g 2 h 2 i 2  2 j 2Y 3O 3~ 3@@ 3P 3 3W 3 3f 3g 3 h 3 i 3  3 j 3Y 4Q 4R~ 4A@ 4S 4 4W 4 4f 4g 4 h 4 i 4  4 j 4Y 5T 5U~ 5A@ 5V 5 5W 5 5f 5g 5 h 5 i 5  5 j 5Y 6W 6X~ 6A@ 6Y 6 6W 6 6f 6g 6 h 6 i 6  6 j 6Y 7Z 7[~ 7A@ 7\ 7 7W 7 7f 7g 7 h 7 i 7  7 j 7Y 8] 8~ 8H@ 8^ 8 8 8 8f 8g 8 h 8 i 8  8 j 8 9_ 9~ 9J@ 9` 9 9 9 9f 9g 9 h 9 i 9  9 j 9 :a :~ :K@ :b : : : :f :g : h : i :  : j : ;c ;~ ;G@ ;d ; ; ; ;f ;g ; h ; i ;  ; j ; <e <~ <C@ <f < < < <f <g < h < i <  < j < =g =~ =D@ =h = = = =f =g = h = i =  = j = >i >~ >B@ >j > > > >f >g > h > i >  > j > ?k ?~ ?B@ ?l ? ? ? ?f ?g ? h ? i ?  ? j ? @m @~ @B@ @n @ @ @ @f @g @ h @ i @  @ j @ Ao A~ AB@ Ap A A A Af Ag A h A i A  A j A Bq B~ BB@ Br B B B Bf Bg B h B i B  B j B Cs Ct~ CC@ Cu C C C Cf Cg C h C i C T C j C Dv D~ DB@ Dw D D D Df Dg D h D i D  D j D  D Ex Ey~ E$@ Ez E E E E{ E| E } E ~ E  E  E F F~ F$@ F F F F F{ F| F } F ~ F  F  F G G~ G$@ G G G G G{ G| G } G ~ G  G  G H H~ H$@ H H H H H{ H| H } H ~ H  H  H I I~ I$@ I I I I I{ I| I } I ~ I  I  I J J~ J$@ J J J J J{ J| J } J ~ J  J  J K K~ K$@ K K K K K{ K| K } K ~ K  K  K L L~ L$@ L L L L L{ L| L } L ~ L  L  L M M~ M$@ M M M M M{ M| M } M ~ M  M  M N N~ N$@ N N N N N{ N| N } N ~ N  N  N O O~ O$@ O O O O O{ O| O } O ~ O  O  O P P~ P$@ P P P P P{ P| P } P ~ P  P  P Q Q~ Q$@ Q Q Q Q Q{ Q| Q } Q ~ Q  Q  Q R R~ R$@ R R R R R{ R| R } R ~ R  R  R S S~ S5@ S S S S S{ S| S } S ~ S  S  S T T~ T.@ T T T T T{ T| T } T ~ T  T  T U U~ U9@ U U U U U{ U| U } U ~ U  U  U V V~ V@ V V V V V{ V| V } V ~ V  V  V W W~ W;@ W W W W W{ W| W } W ~ W  W  W X X~ X$@ X X X X X{ X| X } X ~ X  X  X Y Y~ YC@ Y Y Y Y Y Y Y  Y  Y  Y  Y Z Z~ ZB@ Z Z Z Z Z Z Z  Z  Z  Z  Z [ [~ [C@ [ [ [ [ [ [ [  [  [  [  [ \ \~ \B@ \ \ \ \ \ \ \  \  \  \  \ ] ]~ ]G@ ] ] ] ] ] ] ]  ]  ]  ]  ] ^ ^~ ^F@ ^ ^ ^ ^ ^ ^ ^  ^  ^  ^  ^ _ _~ _C@ _ _ _ _ _ _ _  _  _  _  _ ` `~ `1@ ` ` ` ` ` ` `  `  `  `  ` a a~ aA@ a a a a a a a  a  a  a  a b b~ bC@ b b b b b b b  b  b  b  b c c~ cC@ c c c c c c c  c  c  c  c d d~ dA@ d d d d d d d  d  d  d  d e e~ e1@ e e e e e e e  e  e  e  e f f~ f$@ f f f f f f f  f  f  f  f g g~ g8@ g g g g g g g  g  g  g  g h h~ h@@ h h h h h h h  h  h  h  h i i~ i>@ i i i i i i i  i  i  i  i j j~ j?@ j j j j j j j  j  j  j  j k k~ k;@ k k k k k k k  k  k  k  k l l~ l$@ l l l l l l l  l  l  l  l m m~ mB@ m m m m m m m  m  m  m  m n n~ nC@ n n n n n n n  n  n  n  n o o~ oF@ o o o o o o o  o  o  o  o p p ~ pG@ p  p p p p p p  p  p  p  p q  q ~ q?@ q  q q q q q q  q  q  q  q r r~ r;@ r r r r r r r  r  r  r  r s s~ sC@ s s s s s s s  s  s  s  s t t~ tA@ t t t t t t t  t  t  t  t u u~ uF@ u u u u u u u  u  u  u  u v v~ vD@ v v v v v v v  v  v  v  v w w~ wG@ w w w w w w w  w  w  w  w x  x!~ xD@ x" x x x x x x  x  x  x  x y# y$~ yD@ y% y y y y y y  y  y  y  y z& z'~ zF@ z( z z z z z z  z  z  z  z {) {*~ {A@ {+ { { { { { {  {  {  {  { |, |-~ |C@ |. | | | | | |  |  |  |  | }/ }0~ }C@ }1 } } } } } }  }  }  }  } ~2 ~3~ ~A@ ~4 ~ ~ ~ ~ ~ ~  ~  ~  ~  ~ 5 6~ ?@ 7               8 9~ ?@ :               ; <~ ;@ =               > ?~ 1@ @               A B~ @ C               D E~ ?@ F               G H~ @ I               J K~ D@ L               M N~ D@ O               P Q~ D@ R               S T~ D@ U               V W~ D@ X               Y Z~ D@ [               \ ]~ D@ ^               _ `~ D@ a               b c~ D@ d               e f~ D@ g               h i~ G@ j               k l~ G@ m               n o~ G@ p               q r~ G@ s               t u~ B@ v               w x~ B@ y               z {~ B@ |               } ~~ B@                 ~ B@                 ~ B@                 ~ C@                 ~ 1@                 ~ D@                 ~ K@                 ~ D@                 ~ J@                 ~ H@                 ~ H@                 ~ H@                 ~ E@                 ~ >@                 ~ 8@                 ~ @                 ~ 7@                 ~ $@                 ~ 1@                 ~ C@                 ~ C@                 ~ A@                 ~ 1@                 ~ 5@                 ~ 6@                 ~ .@                 ~ .@                 ~ =@                 ~ @                 ~ @                 ~ 8@                 ~ 8@                 ~ @@                 ~ ?@                 ~ @                 ~ H@                 ~ H@                 ~ P@                   ~ J@                   ~ F@                   ~ D@                 ~ H@                 ~ ?@                 ~ O@                 ~ P@                 ~ @P@                    ~ O@                     ~ J@                 ~ H@                 ~ J@                 ~ J@                 ~ I@                  ~ H@ !               "  # $~ D@ %           &    '  ( )~ 9@ *    + ,  -  .  /  0 1~ F@ 2               3 4~ 7@ 5    + ,  -  .  /  6 7~ ;@ 8 9   + ,  -  .  /  : ;~ >@ <    + ,  -  .  /  = >~ @ ?    + ,  -  .  /  @ ;~ >@ A    + ,  -  .  /  B C~ <@ D    + ,  -  .  /  E F~ 8@ G    + ,  -  .  /  H I~ *@ J    + ,  -  .  /  K L~ <@ M    + ,  -  .  /  N O~ >@ P    + ,  -  .  /  Q R~ ?@ S T   + ,  -  .  /  U V~ 8@ W X   + ,  -  .  /  Y Z~ <@ [ \   + ,  -  .  /  ] ^~ @@ _ `   + ,  -  .  /  a b~ @@ c d   + ,  -  .  /  e f~ ?@ g h   + ,  -  .  /  i j~ @@ k l   + ,  -  .  /  m n~ @@ o p   + ,  -  .  /  q r~ @@ s t   + ,  -  .  /  u O~ >@ v    + ,  -  .  /  w x~ :@ y z   + ,  -  .  /  { |~ 2@ }  ~                ~ 2@   ~                ~ 2@   ~                ~ 2@   ~              ~ "@   ~              ~ 2@   ~              ~ 2@   ~              ~ 2@   ~              ~ 2@   ~              ~ 2@   ~              ~ 2@   ~              ~ 2@   ~              ~ 2@   ~              ~ 2@   ~              ~ 2@   ~              ~ F@                 ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@    ~                ~ "@    ~               ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~              ~ "@   ~               !~ "@ "  ~             # ~ "@ $  ~             % ~ "@ &  ~             ' (~ "@ )  ~             * +~ "@ ,  ~             - .~ "@ /  ~             0 1~ "@ 2  ~             3 4~ "@ 5  ~             6 7~ "@ 8  ~             !9 !~ !"@ !: ! !~ ! ! ! !  !  !  !  ! "; "<~ "D@ "= " " " " " "  "  "  "  " #> #?~ #F@ #@ # # # # # #  #  #  #  # $A $B~ $D@ $C $ $ $ $ $ $  $  $  $  $ %D %E~ %F@ %F % % % % % %  %  %  %  % &G &H~ &D@ &I & & & & & &  &  &  &  & 'J 'K~ 'F@ 'L ' ' ' ' ' '  '  '  '  ' (M (N~ ("@ (O ( (~ ( ( ( (  (  (  (  ( )P )Q~ )"@ )R ) )~ ) ) ) )  )  )  )  ) *S *T~ *"@ *U * *~ * * * *  *  *  *  * +V +W~ +"@ +X + +~ + + + +  +  +  +  + ,Y ,Z~ ,"@ ,[ , ,~ , , , ,  ,  ,  ,  , -\ -]~ -"@ -^ - -~ - - - -  -  -  -  - ._ .`~ ."@ .a . .~ . . . .  .  .  .  . /b /c~ /"@ /d / /~ / / / /  /  /  /  / 0e 0f~ 0"@ 0g 0 0~ 0 0 0 0  0  0  0  0 1h 1i~ 1"@ 1j 1 1~ 1 1 1 1  1  1  1  1 2k 2l~ 2"@ 2m 2 2~ 2 2 2 2  2  2  2  2 3n 3o~ 3"@ 3p 3 3~ 3 3 3 3  3  3  3  3 4q 4r~ 4"@ 4s 4 4~ 4 4 4 4  4  4  4  4 5t 5u~ 5"@ 5v 5 5~ 5 5 5 5  5  5  5  5 6w 6N~ 6"@ 6x 6 6~ 6 6 6 6  6  6  6  6 7y 7z~ 7"@ 7{ 7 7~ 7 7 7 7  7  7  7  7 8| 8}~ 8"@ 8~ 8 8~ 8 8 8 8  8  8  8  8 9 9T~ 9"@ 9 9 9~ 9 9 9 9  9  9  9  9 : :~ :"@ : : :~ : : : :  :  :  :  : ; ;~ ;"@ ; ; ;~ ; ; ; ;  ;  ;  ;  ; < <~ <"@ < < <~ < < < <  <  <  <  < = =~ ="@ = = =~ = = = =  =  =  =  = > >~ >"@ > > >~ > > > >  >  >  >  > ? ?~ ?"@ ? ? ?~ ? ? ? ?  ?  ?  ?  ? @ @~ @"@ @ @ @~ @ @ @ @  @  @  @  @ A A~ A"@ A A A~ A A A A  A  A  A  A B B`~ B"@ B B B~ B B B B  B  B  B  B C C~ C"@ C C C~ C C C C  C  C  C  C D D~ D"@ D D D~ D D D D  D  D  D  D E E~ E"@ E E E~ E E E E  E  E  E  E F F~ F"@ F F F~ F F F F  F  F  F  F G G~ G"@ G G G~ G G G G  G  G  G  G H H~ H"@ H H H~ H H H H  H  H  H  H I I~ I"@ I I I~ I I I I  I  I  I  I J J]~ J"@ J J J~ J J J J  J  J  J  J K K~ K"@ K K K~ K K K K  K  K  K  K L L~ L"@ L L L~ L L L L  L  L  L  L M M~ M"@ M M M~ M M M M  M  M  M  M N N~ N"@ N N N~ N N N N  N  N  N  N O O~ O"@ O O O~ O O O O  O  O  O  O P P~ P"@ P P P~ P P P P  P  P  P  P Q Q~ Q"@ Q Q Q~ Q Q Q Q  Q  Q  Q  Q R R~ R"@ R R R~ R R R R  R  R  R  R S S~ S"@ S S S~ S S S S  S  S  S  S T T~ T"@ T T T~ T T T T  T  T  T  T U Ur~ U"@ U U U~ U U U U  U  U  U  U V V~ VS@ V V V~ V V V V  V  V  V  V W W~ WS@ W W W~ W W W W  W  W  W  W X X~ X@X@ X X X~ X X X X  X  X  X  X Y Y~ YM@ Y Y Y~ Y Y Y Y  Y  Y  Y  Y Z Z~ Z2@ Z Z Z~ Z Z Z Z  Z  Z  Z  Z [ [~ [2@ [ [ [~ [ [ [ [  [  [  [  [ \ \~ \2@ \ \ \~ \ \ \ \  \  \  \  \ ] ]~ ]2@ ] ] ]~ ] ] ] ]  ]  ]  ]  ] ^ ^~ ^2@ ^ ^ ^~ ^ ^ ^ ^  ^  ^  ^  ^ _ _~ _2@ _ _ _~ _ _ _ _  _  _  _  _ ` `~ `2@ ` ` `~ ` ` ` `  `  `  `  ` a a~ a2@ a a a~ a a a a  a  a  a  a b b~ b2@ b b b~ b b b b  b  b  b  b  b c c~ c2@ c c c~ c c c c  c  c  c  c  c d d~ d@ d d d d d d d  d  d  d  d  e  e ~ e @ e  e e e e e e  e  e  e  e  f  f~ f*@ f f f f f f f  f  f  f  f  g g~ g @ g g g g g g g  g  g  g  g  h h~ h@ h h h h h h h  h  h  h  h  i i~ i @ i i i i i i i  i  i  i  i  j j~ j @ j j j j j j j  j  j  j  j  k k~ k @ k  k k k k k k  k  k ! k  k  l" l~ l @ l# l l l l l l  l  l  l  l  m$ m%~ m @ m& m m m m m m  m  m  m  m  n' n~ n @ n( n n n n n n  n  n  n  n  o) o*~ o;@ o+ o o, o o- o. o / o 0 o 1 o 2 o, p3 p4~ p;@ p5 p p, p p- p. p / p 0 p 1 p 2 p, q6 q7~ q;@ q8 q q, q q- q. q / q 0 q 1 q 2 q, r9 r:~ r;@ r; r r, r r- r. r / r 0 r 1 r 2 r, s< s=~ s;@ s> s s, s s- s. s / s 0 s 1 s 2 s, t? t@~ t;@ tA t t, t t- t. t / t 0 t 1 t 2 t, uB uC~ u;@ uD u u, u u- u. u / u 0 u 1 u 2 u, vE vF~ v;@ vG v v, v v- v. v / v 0 v 1 v 2 v, wH wI~ w;@ wJ w w, w w- w. w / w 0 w 1 w 2 w, xK xL~ x;@ xM x x, x x- x. x / x 0 x 1 x 2 x, yN yO~ y;@ yP y y, y y- y. y / y 0 y 1 y 2 y, zQ zR~ z;@ zS z z, z z- z. z / z 0 z 1 z 2 z, {T {U~ {;@ {V { {, { {- {. { / { 0 { 1 { 2 {, |W |X~ |;@ |Y | |, | |- |. | / | 0 | 1 | 2 |, }Z }[~ };@ }\ } }, } }- }. } / } 0 } 1 } 2 }, ~] ~^~ ~;@ ~_ ~ ~, ~ ~- ~. ~ / ~ 0 ~ 1 ~ 2 ~, ` a~ ;@ b  ,  - .  /  0  1  2 , c d~ ;@ e  ,  - .  /  0  1  2 , f g~ ;@ h  ,  - .  /  0  1  2 , i j~ ;@ k  ,  - .  /  0  1  2 , l m~ ;@ n  ,  - .  /  0  1  2 , o p~ ;@ q  ,  - .  /  0  1  2 , r s~ ;@ t  ,  - .  /  0  1  2 , u v~ A@ w  ,  - .  /  0  1  2 , x y~ A@ z  ,  - .  /  0  1  2 , { |~ B@ }  ,  - .  /  0  1  2 , ~ ~ ;@     - .  /  0    2   ~ .@                 ~ .@                 ~ 2@                 ~ .@                 ~ 1@                 ~ 2@                 ~ .@                 ~ .@                 ~ .@                 ~ 0@                 ~ 0@                 ~ .@                 ~ 0@                 ~ 2@                 ~ .@                 u~ 4@                x E  ~ 3@                 E  ~ 2@                 E  '~ 1@                ) E  ~ 0@                 E  ~ .@               E  ~ ,@               E  ~ *@               E  ~ (@               E  ?~ &@                A E  ~ $@               E  ~ "@               E  ~  @               E  ~ @               E  ~ @               E  ~ @               E  C~ @               E  ~ 3@                 E  ~ 2@                 E  2~ 1@                4 E   ~ 0@                    E   ~ .@                 E  ~ (@                 E  +~ &@               E  ~ "@               E  $~  @               E  ~ @                E ! "~ @ #              E $ %~ @ &              E ' (~ 1@ )              E * F~ 4@ +              E , -~ 0@ .           /    0 E 1 2~ 2@ 3           4    5 E 6 7~ ,@ 8           9    : E ; <~ *@ =           >    ? E @ A~ *@ B           C   E D E~ (@ F           G   E H I~ $@ J           K   E L M~ $@ N           O   E P Q~ &@ R              E S T~ *@ U              E V W~ *@ X              E Y Z~ *@ [              E \ ]~ @ ^              E _ `~ @ a b c  d e  f  g  h i j k~ @ l b c  d e  f  g  h i m n~ @ o b c  d e  f  g  h i p q~ @ r b c  d e  f  g  h i s t~ @ u b c  d e  f  g  h i v w~ @ x b c  d e  f  g  h i y z~ @ { b c  d e  f  g  h i | }~ @ ~ b c  d e  f  g  h i  ~ @  b c  d e  f  g  h i  ~ @  b c  d e  f  g  h i  ~ @  b c  d e  f  g  h i  ~ @  b c  d e  f  g  h i  ~ >@                 ~ >@                 ~ 3@               ~ ;@               ~ 4@               ~ <@               ~ <@               ~ <@               ~ 8@               ~ @               ~ @               ~ @               ~ @               ~ @               ~ "@               ~ @               ~ @               ~ @               ~ @               ~ @               ~ @               ~ @               ~ @               ~ $@               ~  @   ?                E   ~ "@   ?             E  ~  @   ?             E  ~  @   ?             E  ~ "@   ?             E  ~ 5@      ! "  #  $  % & ' (~ 3@ )     ! "  #  $  % & * +~ 5@ ,     ! "  #  $  % & - .~ 4@ /     ! "  #  $  % & 0 1~ 3@ 2     ! "  #  $  % & 3 4~ 5@ 5     ! "  #  $  % & 6 7~ P@ 8 9 :  ; <  =  >  ? @ A B~ S@ C D :  ; <  =  >  ? @ E F~ A@ G 9 :  ; <  =  >  ? @ H I~ @@ J 9 :  ; <  =  >  ? @ K L~ @@ M 9 :  ; <  =  >  ? @ N O~ <@ P 9 :  ; <  =  >  ? @ Q R~ C@ S 9 :  ; <  =  >  ? @ T U~ B@ V 9 :  ; <  =  >  ? @ W X~ A@ Y 9 :  ; <  =  >  ? @ Z [~ B@ \ D :  ; <  =  >  ? @ ] ^~ B@ _ D :  ; <  =  >  ? @ ` a~ B@ b D :  ; <  =  >  ? @ c d~ :@ e D :  ; <  =  >  ? @ f g~ <@ h D :  ; <  =  >  ? @ i j~ 4@ k D :  ; <  =  >  ? @ l m~ .@ n D :  ; <  =  >  ? @ o p~ ,@ q D :  ; <  =  >  ? @ r s~ $@ t D :  ; <  =  >  ? @ u v~ 4@ w D :  ; <  =  >  ? @ x y~ @R@ z D :  ; <  =  >  ? @ { |~ ;@ } D :  ; <  =  >  ? @ ~ ~ E@  D :  ; <  =  >  ? @  ~ @@  D :  ; <  =  >  ? @  ~ <@  D :  ; <  =  >  ? @  ~ 4@  D :  ; <  =  >  ? @  ~ (@  D :  ; <  =  >  ? @  ~ ?@   :  ; <  =  >  ? @  ~ @   :  ; <  =  >  ? @  ~ @  D :  ; <  =  >  ? @  ~ @  D :  ; <  =  >  ? @  ~ @   :  ; <  =  >  ? @  ~ @  D :  ; <  =  >  ? @  ~ @   :  ; <  =  >  ? @  ~ @  D :  ; <  =  >  ? @  ~  @  D :  ; <  =  >  ? @  ~ @  9 :  ; <  =  >  ? @  ~ &@   :  ; <  =  >  ? @  ~ 7@   :  ; <  =  >  ? @  ~ @   :  ; <  =  >  ? @  ~ @  D :  ; <  =  >  ? @  ~ 5@  D :  ; <  =  >  ? @  ~ 4@  D :  ; <  =  >  ? @  ~ *@  D :  ; <  =  >  ? @  ~ *@   :  ; <  =  >  ? @  ~ *@  D :  ; <  =  >  ? @ ! !~ !*@ ! ! !: ! !; !< ! = ! > ! ? !@ " "~ "T@ " "D ": " "; "< " = " > " ? "@ # #~ #@U@ # # #: # #; #< # = # > # ? #@ $ $~ $U@ $ $D $: $ $; $< $ = $ > $ ? $@ % %~ %3@ % %D %: % %; %< % = % > % ? %@ & &~ &B@ & & &: & &; &< & = & > & ? &@ ' '~ '*@ ' ' ' ' ' ' '  '  '  ' ( (~ ((@ ( ( ( ( ( ( (  (  (  ( ) )~ )$@ ) ) ) ) ) ) )  )  )  ) * *~ * @ * * * * * * *  *  *  * + +~ +*@ + + + + + + +  +  +  + , ,~ ,&@ , , , , , , ,  ,  ,  , - -~ -@ - - - - - - -  -  -  - . .~ .@ . . . . . . .  .  .  . / /~ /$@ / / / / / / /  /  /  / 0 0~ 0*@ 0 0 0 0 0 0 0  0  0  0 1 1 ~ 1$@ 1  1 1 1 1 1 1  1  1   1 2  2 ~ 2"@ 2 2 2 2 2 2 2  2  2  2 3 3~ 3(@ 3 3 3 3 3 3 3  3  3  3 4 4~ 4&@ 4 4 4 4 4 4 4  4  4  4 5 5~ 5@ 5 5 5 5 5 5 5  5  5  5 6 6~ 6@ 6 6 6 6 6 6 6  6  6  6 7  7!~ 7(@ 7" 7 7 7 7 7 7  7  7 # 7 8$ 8%~ 8@ 8& 8 8 8 8 8 8  8  8 ' 8 9( 9)~ 9$@ 9* 9 9 9 9 9 9  9  9 + 9 :, :-~ :(@ :. : : : : : :  :  : / : ;0 ;1~ ;,@ ;2 ; ;3 ; ;4 ;5 ; 6 ; 7 ; 8 ;9 <: <;~ <,@ << <= <3 < <4 <5 < 6 < 7 < > <9 =? =@~ =@ =A == =3 = =4 =5 = 6 = 7 = B =9 >C >D~ >"@ >E >= >3 > >4 >5 > 6 > 7 > F >9 ?G ?H~ ?4@ ?I ? ?J ? ?K ?L ? M ? N ? O ? @P @Q~ @4@ @R @ @J @ @K @L @ M @ N @ S @ AT AU~ A4@ AV A AJ A AK AL A M A N A W A BX BY~ BC@ BZ B BJ B BK BL B M B N B [ B C\ C]~ CC@ C^ C CJ C CK CL C M C N C _ C D` Da~ DC@ Db D DJ D DK DL D M D N D c D Ed Ee~ EC@ Ef E EJ E EK EL E M E N E g E Fh Fi~ FC@ Fj F FJ F FK FL F M F N F k F Gl Gm~ GC@ Gn G GJ G GK GL G M G N G o G Hp Hq~ HC@ Hr H HJ H HK HL H M H N H s H It Iu~ IC@ Iv I IJ I IK IL I M I N I w I Jx Jy~ JC@ Jz J JJ J JK JL J M J N J { J K| K}~ K=@ Kz K K K K~ K K  K  K L L~ L?@ Lz L L L L~ L L  L  L M M~ M2@ M M M M M M M  M  M  M N N~ N2@ N N N N N N N  N  N  N O O~ O2@ O O O O O O O  O  O  O P P~ P2@ P P P P P P P  P  P  P Q Q~ Q2@ Q Q Q Q Q Q Q  Q  Q  Q R R~ R2@ R R R R R R R  R  R  R S S~ S2@ S S S S S S S  S  S  S T T~ T2@ T T T T T T T  T  T  T U U~ U2@ U U U U U U U  U  U  U V V~ V&@ V V V V V V V  V  V  V W W~ W*@ W W W W W W W  W  W  W X X~ X2@ X X X X X X X  X  X  X Y Y~ Y2@ Y Y Y Y Y Y Y  Y  Y  Y Z Z~ Z2@ Z Z Z Z Z Z Z  Z  Z  Z [ [~ [2@ [ [ [ [ [ [ [  [  [  [ \ \~ \2@ \ \ \ \ \ \ \  \  \  \ ] ]~ ]2@ ] ] ] ] ] ] ]  ]  ]  ] ^ ^~ ^9@ ^ ^ ^ ^ ^ ^ ^  ^  ^  ^ _ _~ _2@ _ _ _ _ _ _ _  _  _  _ ` `~ `2@ ` ` ` ` ` ` `  `  `  ` a a~ a2@ a a a a a a a  a  a  a b b~ b2@ b b b b b b b  b  b  b c c~ c2@ c c c c c c c  c  c  c d  d ~ d2@ d  d d d d d d  d  d  d e  e ~ e2@ e e e e e e e  e  e  e f f~ f2@ f f f f f f f  f  f  f g g~ g2@ g g g g g g g  g  g  g h h~ h2@ h h h h h h h  h  h  h i i~ i2@ i i i i i i i  i  i  i j j~ j2@ j j j j j j j  j  j  j k k~ k2@ k  k k k k k k  k  k  k l! l"~ l2@ l# l l l l l l  l  l  l m$ m%~ m2@ m& m m m m m m  m  m  m n' n(~ n2@ n) n n n n n n  n  n  n o* o~ o@ o+ o o, o o- o. o / o 0 o 1 oE p2 p3~ p@ p4 p p, p p- p. p 5 p 0 p 1 pE q6 q~ q"@ q7 q q, q q- q. q 8 q 0 q 1 q 9 qE r: r;~ r"@ r< r r, r r- r. r = r 0 r 1 rE s> s?~ s*@ s@ s s, s s- s. s A s 0 s 1 sE tB tC~ t*@ tD t t, t t- t. t E t 0 t 1 tE uF uG~ u*@ uH u u, u u- u. u I u 0 u 1 uE vJ vK~ v*@ vL v v, v v- v. v M v 0 v 1 vE wN wO~ w*@ wP w w, w w- w. w Q w 0 w 1 wE xR xS~ x*@ xT x x, x x- x. x U x 0 x 1 xE yV yW~ y*@ yX y y, y y- y. y Y y 0 y 1 yE zZ z[~ z*@ z\ z z, z z- z. z ] z 0 z 1 zE {^ {_~ {*@ {` { {, { {- {. { a { 0 { 1 {E |b |c~ |*@ |d | |, | |- |. | e | 0 | 1 |E }f }g~ }*@ }h } }, } }- }. } i } 0 } 1 }E ~j ~k~ ~*@ ~l ~ ~, ~ ~- ~. ~ m ~ 0 ~ 1 ~E n o~ *@ p  ,  - .  q  0  1 E r s~ *@ t  ,  - .  u  0  1 E v w~ *@ x  ,  - .  y  0  1 E z {~ *@ |  ,  - .  }  0  1 E ~ ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .     0  1 E    ~ *@    ,  - .     0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@    ,  - .  !  0  1 E " ~ *@ #  ,  - .  $  0  1 E % &~ *@ '  ,  - .  (  0  1 E ) *~ *@ +  ,  - .  ,  0  1 E - .~ *@ /  ,  - .  0  0  1 E 1 2~ *@ 3  ,  - .  4  0  1 E 5 6~ *@ 7  ,  - .  8  0  1 E 9 :~ *@ ;  ,  - .  <  0  1 E = >~ *@ ?  ,  - .  @  0  1 E A B~ *@ C  ,  - .  D  0  1 E E F~ *@ G  ,  - .  H  0  1 E I J~ *@ K  ,  - .  L  0  1 E M N~ *@ O  ,  - .  P  0  1 E Q R~ *@ S  ,  - .  T  0  1 E U V~ *@ W  ,  - .  X  0  1 E Y Z~ *@ [  ,  - .  \  0  1 E ] ^~ *@ _  ,  - .  `  0  1 E a b~ *@ c  ,  - .  d  0  1 E e f~ *@ g  ,  - .  h  0  1 E i j~ *@ k  ,  - .  l  0  1 E m n~ *@ o  ,  - .  p  0  1 E q r~ *@ s  ,  - .  t  0  1 E u v~ *@ w  ,  - .  x  0  1 E y z~ *@ {  ,  - .  |  0  1 E } ~~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ "@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E   ~ *@    ,  - .     0  1 E    ~ *@   ,  - .    0  1 E  {~ *@   ,  - .    0  1 E  {~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@   ,  - .    0  1 E  ~ *@    ,  - .  !  0  1 E " #~ *@ $  ,  - .  %  0  1 E & '~ *@ (  ,  - .  )  0  1 E * +~ *@ ,  ,  - .  -  0  1 E . /~ *@ 0  ,  - .  1  0  1 E 2 3~ *@ 4  ,  - .  5  0  1 E 6 7~ *@ 8  ,  - .  9  0  1 E : ;~ *@ <  ,  - .  =  0  1 E > ?~ *@ @  ,  - .  A  0  1 E B C~ *@ D  ,  - .  E  0  1 E F G~ *@ H  ,  - .  I  0  1 E J K~ *@ L  ,  - .  M  0  1 E N O~ *@ P  ,  - .  Q  0  1 E R S~ *@ T  ,  - .  U  0  1 E V W~ *@ X  ,  - .  Y  0  1 E Z [~ 0@ \ ] ^  _ `  a  b  c d e f~ 0@ g h ^  _ `  a  b  i d j k~ .@ l m ^  _ `  a  b  n d o p~ 0@ q ] ^  _ `  a  b  r d s t~ 0@ u h ^  _ `  a  b  v d w x~ 0@ y h ^  _ `  a  b  z d { |~ 0@ } h ^  _ `  a  b  ~ d  ~ ,@   ^  _ `  a  b   d  ~ 3@   ^  _ `  a  b   d  ~ 0@   ^  _ `  a  b   d  ~ 3@   ^  _ `  a  b   d  ~ 0@   ^  _ `  a  b   d  ~ 1@   ^  _ `  a  b   d  ~ @   ^  _ `  a  b   d  ~  @   ^  _ `  a  b   d  ~ "@   ^  _ `  a  b   d  ~ @   ^  _ `  a  b   d  ~ .@   ^  _ `  a  b   d  ~ 2@   ^  _ `  a  b   d  ~ ,@   ^  _ `  a  b   d  ~ *@   ^  _ `  a  b   d  ~  @   ^  _ `  a  b   d  ~ "@   ^  _ `  a  b   d  ~ &@   ^  _ `  a  b   d  ~ 2@   ^  _ `  a  b   d  ~ =@   ^  _ `  a  b   d  ~ =@   ^  _ `  a  b   d  ~ <@   ^  _ `  a  b   d  ~ 0@               ~ 0@               ~ 0@               ~ 0@               ~ 0@               ~ 4@   ?          E  ~ 3@   ?          E  ~ 2@   ?          E  ~ 1@   ?          E  ~ 0@   ?          E ! !~ !3@ ! ! !? ! ! ! !  !  !  !E " "~ "2@ " " "? " " " "  "  "  "E # #~ #1@ #  # #? # # # #  #  #  #E $  $ ~ $0@ $  $ $? $ $ $ $  $  $  $E %  %~ %.@ % % %? % % % %  %  %  %E & &~ &(@ & & &? & & & &  &  &  &E ' '~ '0@ ' ' '? ' ' ' '  '  '  'E ( (~ (2@ ( ( (? ( ( ( (  (  (  (E ) )~ ),@ ) ) )? ) ) ) )  )  )  )E * *~ **@ * * *? * * * *  *  *  *E + + ~ +(@ +! + +? + + + +  +  +  +E ," ,#~ ,$@ ,$ , ,? , , , ,  ,  ,  ,E -% -&~ -$@ -' - -? - - - -  -  -  -E .( .~ ."@ .) . .* . .+ . . , .  .  .- /. /~ /@ // / /* / /+ / / , /  /  /- 00 0~ 0@ 01 0 0* 0 0+ 0 0 , 0  0  0- 12 1~ 1@ 13 1 1* 1 1+ 1 1 , 1  1  1- 24 2~ 2@ 25 2 2* 2 2+ 2 2 , 2  2  2- 36 3~ 3@ 37 3 3* 3 3+ 3 3 , 3  3  3- 48 49~ 4@ 4: 4 4* 4 4+ 4 4 , 4  4  4- 5; 5~ 5@ 5< 5 5* 5 5+ 5 5 , 5  5  5- 6= 6>~ 6:@ 6? 6 6@ 6 6A 6B 6 C 6 D 6 E 6 7F 7G~ 73@ 7H 7 7@ 7 7A 7B 7 C 7 D 7 E 7 8I 8J~ 8D@ 8K 8 8@ 8 8A 8B 8 C 8 D 8 E 8 9L 9M~ 9&@ 9N 9 9@ 9 9A 9B 9 C 9 D 9 E 9 :O :P~ :@ :Q : :@ : :A :B : C : D : E : ;R ;S~ ;@ ;T ; ;@ ; ;A ;B ; C ; D ; E ; <U <V~ <@ <W < <@ < <A <B < C < D < E < =X =Y~ =7@ =Z = =@ = =A =B = C = D = E = >[ >\~ >.@ >] > >@ > >A >B > C > D > E > ?^ ?_~ ?@@ ?` ? ?@ ? ?A ?B ? C ? D ? E ? @a @b~ @&@ @c @ @@ @ @A @B @ C @ D @ E @ Ad Ae~ A.@ Af A A@ A AA AB A C A D A E A Bg Bh~ B@ Bi B B@ B BA BB B C B D B E B Cj Ck~ C"@ Cl C C@ C CA CB C C C D C E C Dm Dn~ D2@ Do D Dp D Dq Dr D s D t D u Dv Ew Ex~ E0@ Ey E Ep E Eq Er E s E t E u Ev Fz F{~ F,@ F| F Fp F Fq Fr F s F t F u Fv G} G~~ G,@ G G Gp G Gq Gr G s G t G u Gv H H~ H2@ H H Hp H Hq Hr H s H t H u Hv I I~ I2@ I I Ip I Iq Ir I s I t I u Iv J J~ J2@ J J Jp J Jq Jr J s J t J u Jv K K~ K2@ K K Kp K Kq Kr K s K t K u Kv L L~ L2@ L L Lp L Lq Lr L s L t L u Lv M M~ M2@ M M Mp M Mq Mr M s M t M u Mv N N~ N1@ N N Np N Nq Nr N s N t N u Nv O O~ O2@ O O Op O Oq Or O s O t O u Ov P P~ P2@ P P Pp P Pq Pr P s P t P u Pv Q Q~ Q2@ Q Q Qp Q Qq Qr Q s Q t Q u Qv R R~ R2@ R R Rp R Rq Rr R s R t R u Rv S S~ S0@ S S Sp S Sq Sr S s S t S u Sv T T~ T0@ T T Tp T Tq Tr T s T t T u Tv U U~ U0@ U U Up U Uq Ur U s U t U u Uv V V~ V0@ V V Vp V Vq Vr V s V t V u Vv W W~ W2@ W W Wp W Wq Wr W s W t W u Wv X X~ X@ X X X X X X X  X  X Y Y~ Y@ Y Y Y Y Y Y Y  Y  Y Z Z~ Z@ Z Z Z Z Z Z Z  Z  Z [ [~ [@ [ [ [ [ [ [ [  [  [ \ \~ \@ \ \ \ \ \ \ \  \  \ ] ]~ ]@ ] ] ] ] ] ] ]  ]  ] ^ ^~ ^@ ^ ^ ^ ^ ^ ^ ^  ^  ^ _ _~ _@ _ _ _ _ _ _ _  _  _ ` `~ `@ ` ` ` ` ` ` `  `  ` a a~ a@ a a a a a a a  a  a b b~ b@ b b b b b b b  b  b c c~ c@ c c c c c c c  c  c d d~ d@ d d d d d d d  d  d e e~ e@ e e e e e e e  e  e f f~ f@ f f f f f f f  f  f g g~ g@ g g g g g g g  g  g h h~ h@ h h h h h h h  h  h i i~ i@ i i i i i i i   i   i j  j ~ j@ j  j j j j j j  j  j k k~ k@ k k k k k k k  k  k l l~ l@ l l l l l l l  l  l m m~ m@ m m m m m m m  m  m n n ~ n @ n! n n n n n n " n # n o$ o%~ o @ o& o o o o o o ' o ( o p) p*~ p @ p+ p p p p p p , p - p q. q/~ q$@ q0 q q q q q q 1 q 2 q r3 r4~ r$@ r5 r r r r r r 6 r 7 r s8 s9~ s$@ s: s s s s s s ; s < s t= t>~ tB@ t? t@ t t tA tB t C t D t E t uF uG~ u>@ uH u uI u uJ uK u L u M u N uO vP vQ~ v>@ vR v vI v vJ vK v L v M v S vO wT wU~ w>@ wV w wI w wJ wK w L w M w W wO xX xY~ x@@ xZ x xI x xJ xK x L x M x [ xO y\ y]~ y@@ y^ y yI y yJ yK y L y M y _ yO z` za~ z2@ zb z z z zc zd z e z f z g z {h {a~ {2@ {i { { { {c {d { e { f { g { |j |k~ |3@ |l | | | |c |d | e | f | g | }m }n~ }4@ }o } } } }c }d } e } f } g } ~p ~q~ ~2@ ~r ~ ~ ~ ~c ~d ~ e ~ f ~ g ~ s t~ 2@ u    c d  e  f  g  v w~ 2@ x    c d  e  f  g  y z~ 2@ {    c d  e  f  g  | }~ 2@ ~    c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ 2@     c d  e  f  g   ~ @             ~ @             ~ @             ~ @             ~ @             ~ @             ~ @             ~ @             ~ @             ~ @                  ~ @             ~ @             ~ @             ~ @              !~ (@ "  #  $ %  &  '  ( ) * +~ (@ ,  #  $ %  &  '  ( ) - .~ E@ /  0  1 2  3  4  5 6 7 8~ E@ 9  0  1 2  3  4  : 6 ; <~ E@ =  0  1 2  3  4  > 6 ? @~ H@ A  0  1 2  3  4  B 6 C D~ H@ E  0  1 2  3  4  F 6 G H~ A@ I  0  1 2  3  4  J 6 K L~ A@ M  N  1 2  3  4  O 6 P Q~ @@ R  0  1 2  3  4  S 6 T U~ A@ V  0  1 2  3  4  W 6 X Y~ A@ Z  0  1 2  3  4  [ 6 \ a~ 2@ ] ^ _  ` a  b  c  d  e f ~ ,@ g ^ h  ` a  b  c  e i j~ 0@ k ^ h  ` a  b  c  e l m~ 2@ n ^   ` a  b  c  d  e o p~ 2@ q ^   ` a  b  c  d  e r s~ 2@ t ^   ` a  b  c  d  e u v~ 2@ w ^   ` a  b  c  d  e x y~ 2@ z ^   ` a  b  c  d  e { |~ 2@ } ^   ` a  b  c  d  e ~ ~ 2@  ^   ` a  b  c  d  e  ~ 2@  ^   ` a  b  c  d  e  ~ 2@  ^   ` a  b  c  d  e  ~ 2@  ^   ` a  b  c  d  e  ~ ,@  ^   ` a  b  c  d  e  ~ 2@  ^   ` a  b  c  d  e  ~ 2@  ^   ` a  b  c  d  e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ ,@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ .@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ .@  ^   ` a  b  c    e  ~ .@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@   ^   ` a  b  c    e    ~ 2@   ^   ` a  b  c    e   ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@  ^   ` a  b  c    e  ~ 2@            ! "~ 2@ #  $  % &  '  (  ) * +~ @@ ,  $  % &  '  -  . / 0~ A@ 1  $  % &  '  2  3 4 5~ B@ 6  $  % &  '  7  8 9 :~ (@ ;  <  = >  ?  @  A B C~ 7@ D  <  = >  ?  @  E F G~ 9@ H  <  = >  ?  @  I J K~ ;@ L  <  = >  ?  @  M N O~ =@ P  <  = >  ?  @  Q R S~ .@ T  <  = > ? @ U  V  W~  4@  X    <    =  >  ?  @  Y  Z  [~  .@  \    <    =  >  ?  @  ]  ^  _~  4@  `    <    =  >  ?  @  a  b  c~  .@  d    <    =  >  ?  @  e  f  g~  @  h    i    j  k  l  m  n  o  p~  "@  q    i    j  k  l  m  r  s  t~  7@  u        v  w  x  y  z  {  |~  :@  }        v  w  x  y  ~  ~ >@     v w x y   ~ >@           ~ >@           ~ >@           ~ >@             ~  >@                      ~  >@                      ~  >@                      ~  =@                      ~  I@                      ~  H@                        ~  E@                      ~  I@                      ~  H@                      ~  >@                      ~  ;@                        ~  (@                        ~  "@                        ~  $@                        ~  "@                        ~  "@                        ~  6@                        ~  1@                      ~ .@              !   !  ~ ! .@ !  !  !  !  !  !  !  !   !   !   "  " ~ " 0@ "  "  "  "  "  "  "  "   "   "   #  # ~ # .@ #  #  #  #  #  #  #  #   #   #   $  $ ~ $ 0@ $  $  $  $  $  $  $  $   $   $   %  % ~ % ,@ %  %  %  %  %  %  %  %   %   %   &  & ~ & .@ &  &  &  &  &  &  &  &   &   &   '  ' ~ ' @@ '   '  ' ! '  ' " ' # ' $ ' % ' & ' ' ( ( ( )~ ( "@ ( * (  (  (  ( + ( , ( + ( - ( . (  ) / ) 0~ ) $@ ) 1 )  )  )  ) + ) , ) + ) - ) . )  * 2 * 3~ * "@ * 4 *  *  *  * + * , * + * - * . *  + 5 + 6~ + "@ + 7 +  +  +  + + + , + + + - + . +  , 8 , 9~ , "@ , : ,  ,  ,  , ; , < , = , > , ? ,  - @ - A~ - @ - B -  -  -  - ; - < - = - > - ? -  . C . D~ . &@ . E .  .  .  . ; . < . = . > . ? .  / F / G~ / "@ / H /  / I /  / J / K / L / M / N / O 0 P 0 Q~ 0 "@ 0 R 0  0 I 0  0 J 0 K 0 L 0 M 0 N 0 O 1 S 1 T~ 1 "@ 1 U 1  1 I 1  1 J 1 K 1 L 1 M 1 N 1 O 2 V 2 W~ 2 "@ 2 X 2  2 I 2  2 J 2 K 2 L 2 M 2 N 2 O 3 Y 3 Z~ 3 $@ 3 [ 3  3 \ 3  3 ] 3 ^ 3 _ 3 ` 3 a 3 b 4 c 4 d~ 4 5@ 4 e 4  4 \ 4  4 ] 4 ^ 4 _ 4 ` 4 a 4 b 5 f 5 g~ 5 "@ 5 h 5  5  5  5 i 5 j 5 k 5 l 5 m 5 n 6 o 6 p~ 6 "@ 6 h 6  6  6  6 i 6 j 6 k 6 l 6 m 6 n 7 q 7 r~ 7 "@ 7 h 7  7  7  7 i 7 j 7 k 7 l 7 m 7 n 8 s 8 t~ 8 2@ 8 u 8  8  8  8 v 8 w 8 x 8 y 8 z 8  9 { 9 |~ 9 2@ 9 } 9  9  9  9 v 9 w 9 x 9 y 9 z 9  : ~ : ~ : 2@ :  :  :  :  : v : w : x : y : z :  ;  ; ~ ; 2@ ;  ;  ;  ;  ; v ; w ; x ; y ; z ;  <  < ~ < @ <  <  <  <  <  <  <  <  <  <   =  = ~ = @ =  =  =  =  =  =  =  =  =  =   >  > ~ > @ >  >  >  >  >  >  >  >  >  >   ?  ? ~ ? @ ?  ?  ?  ?  ?  ?  ?  ?  ?  ?   @  @ ~ @ .@ @  @  @  @  @  @  @  @  @  @  A  A ~ A .@ A  A  A  A  A  A  A  A  A  A  B  B ~ B .@ B  B  B  B  B  B  B  B  B  B  C  C ~ C 1@ C  C  C  C  C  C  C  C  C  C  D  D ~ D 9@ D  D  D  D  D  D  D  D  D  D  E  E ~ E 3@ E  E  E  E  E  E  E  E  E  E  F  F ~ F 8@ F  F  F  F  F  F  F  F  F  F  G  G ~ G "@ G  G  G  G  G  G  G  G - G  G  H  H ~ H "@ H  H  H  H  H  H  H  H - H  H  I  I ~ I "@ I  I  I  I  I  I  I  I - I  I  J  J ~ J "@ J  J  J  J  J  J  J  J - J  J  K  K ~ K .@ K  K  K  K  K  K  K  K  K  K  L  L ~ L .@ L  L  L  L  L  L  L  L  L  L  M  M ~ M .@ M  M  M  M  M  M  M  M  M  M  N  N ~ N .@ N  N  N  N  N  N  N  N  N  N  O  O ~ O .@ O  O  O  O  O  O  O  O  O  O  P  P ~ P .@ P  P  P  P  P  P  P  P  P  P  Q  Q ~ Q .@ Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  R  R ~ R .@ R  R  R  R  R  R  R  R  R  R  S  S ~ S .@ S  S  S  S  S  S  S  S  S  S  T  T ~ T .@ T  T  T  T  T  T  T  T  T  T  U  U ~ U .@ U  U  U  U  U  U  U  U  U  U  V  V ~ V .@ V  V  V  V  V  V  V  V  V  V  W  W ~ W .@ W  W  W  W  W  W  W  W  W  W  X  X ~ X .@ X  X  X  X  X  X  X  X  X  X  Y  Y ~ Y .@ Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Z  Z ~ Z .@ Z  Z  Z  Z  Z  Z  Z  Z  Z  Z  [  [  ~ [ .@ [  [  [  [  [  [  [  [  [  [  \  \  ~ \ .@ \  \  \  \  \  \  \  \  \  \  ]  ]  ~ ] .@ ]  ]  ]  ]  ]  ]  ]  ]  ]  ]  ^  ^  ~ ^ .@ ^  ^  ^  ^  ^  ^  ^  ^  ^  ^  _  _  ~ _ .@ _  _  _  _  _  _  _  _  _  _  `  `  ~ ` .@ `  `  `  `  `  `  `  `  `  `  a  a  ~ a .@ a  a  a  a  a  a  a  a  a  a  b  b  ~ b .@ b  b  b  b  b  b  b  b  b  b  c  c  ~ c .@ c  c  c  c  c  c  c  c  c  c  d  d  ~ d  @ d  d  d  d  d  d  d  d ! d " d # e $ e % ~ e @ e & e  e  e  e  e  e  e ! e " e # f ' f ( ~ f ,@ f ) f  f  f  f  f  f  f ! f " f # g * g + ~ g @ g , g  g  g  g  g  g  g ! g " g # h - h . ~ h $@ h / h  h  h  h  h  h  h ! h " h # i 0 i 1 ~ i 9@ i 2 i  i  i  i  i  i  i ! i " i # j 3 j 4 ~ j 1@ j 5 j  j  j  j  j  j  j ! j " j # k 6 k 7 ~ k C@ k 8 k  k  k  k  k  k  k ! k " k # l 9 l M~ l &@ l : l  l  l  l  l  l  l ! l " l # m ; m < ~ m :@ m = m  m  m  m  m  m  m ! m " m # n > n ? ~ n 1@ n @ n  n  n  n  n  n  n ! n " n # o A o B ~ o B@ o C o  o  o  o  o  o  o ! o " o # p D p E ~ p $@ p F p  p  p  p  p  p  p ! p " p # q G q H ~ q B@ q I q  q J q  q K q L q M q N q O q P r Q r R ~ r *@ r S r  r T r  r U r V r W r X r Y r Z s [ s \ ~ s W@ s ] s  s T s  s U s V s W s X s Y s Z t ^ t _ ~ t *@ t ` t  t  t  t a t b t c t d t e t  u f u g ~ u 5@ u h u  u  u  u a u b u c u d u e u  v i v j ~ v *@ v k v  v  v  v a v b v c v d v e v  w l w m ~ w "@ w n w  w  w  w o w b w p w q w r w  x s x t ~ x "@ x u x  x  x  x o x b x p x q x r x  y v y w ~ y .@ y x y  y  y  y o y b y p y q y r y  z y z z ~ z .@ z { z  z  z  z o z b z p z q z r z  { | { } ~ { .@ { ~ {  {  {  { o { b { p { q { r {  |  |  ~ | .@ |  |  |  |  | o | b | p | q | r |  }  }  ~ } ,@ }  }  }  }  }  }  }  }  }  }  ~  ~  ~ ~ $@ ~  ~  ~  ~  ~  ~  ~  ~  ~  ~      ~  9@                       ~ 0@             ~ E@             ~ "@             ~ "@             ~ "@             ~ "@             ~ "@             ~ "@             ~ "@             ~ "@             ~ "@             ~ "@             ~ "@             ~ E@             ~ .@             ~ (@             ~ "@             ~ 1@             ~ @Q@             ~ N@             ~ N@             ~ 4@             ~ 4@             ~ ]@      ! ! ! !  ! !~ Z@ !     ! ! ! !  ! !~ 3@  !     ! ! ! !   !  !~ >@  !  !   ! ! ! ! !  ! !~ "@ !  !  ! ! ! ! ! ! ! !~ "@ !    !  ! !! "! #!  $! %!~ 9@ &!    '! (! )! *! +!  ,! -!~ 9@ .!    '! (! )! *! +!  /! 0!~ 9@ 1!    '! (! )! *! +!  2! 3!~ 9@ 4!    '! (! )! *! +!  5! 6!~ .@ 7!    8! 9! :! ;! !~ @ ?!  @!  A! B! C! D! E! F! G! H!~ .@ I!    J! K! L! M! N!  O! P!~ &@ Q!    R! S! T! U! V!  W! X!~ "@ Y!    Z! S! [! \! ]!  ^! _!~ .@ `!    a! S! b! c! d!  e! f!~ .@ g!    a! S! b! c! d!  h! i!~ .@ j!    a! S! b! c! d!  k! l!~ .@ m!    a! S! b! c! d!  n! o!~ .@ p!    a! S! b! c! d!  q! r!~ .@ s!    a! S! b! c! d!  t! u!~ .@ v!    a! S! b! c! d!  w! x!~ .@ y!    a! S! b! c! d!  z! {!~ .@ |!    a! S! b! c! d!  }! ~!~ .@ !    a! S! b! c! d!  ! !~ .@ !    a! S! b! c! d!  ! !~  @ !    ! ! ! ! !  ! !~ ,@ !  !  ! ! ! ! ! ! ! !~ @ !    ! ! ! ! !  ! !~ @ !    ! ! ! ! !  ! !~ &@ !    ! ! ! ! !  ! !~ @ !    ! ! ! ! !  ! !~ @ !    ! ! ! ! !  ! !~ (@ !    ! ! ! ! !  ! !~ 3@ !  !  ! ! ! ! ! ! ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  ! !~ "@ !    ! ! ! ! !  " "~ "@ "    ! ! ! ! !  " "~ "@ "    ! ! ! ! !  " "~ "@ "    ! ! ! ! !   "  "~ .@  "   "   " " " " " " " "~ :@ "  "  " " " " " ">@7   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b Root EntryWorkbook